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Thesis summary 
 
Resolution of inflammation involves suppression of inflammatory cell infiltration, effective 
clearance of apoptotic cells and induction of an anti-inflammatory response thereby re-
establishing tissue homeostasis. Defects in this process may lead to chronic inflammatory 
diseases and tissue destruction. Periodontitis is a chronic oral inflammatory disease 
characterised by an aberrant host response to a pathogenic plaque biofilm resulting in 
local tissue damage and frustrated healing that can result in tooth loss. Cysteine 
proteases (Gingipains) from the key periodontal pathogen Porphyromonas gingivalis have 
been implicated in periodontal disease pathogenesis by inhibiting inflammation resolution 
and are linked with systemic chronic inflammatory disease e.g. rheumatoid arthritis. Given 
the importance of successful clearance of AC by the innate immune system in the 
restoration of tissue homeostasis and maintenance of healthy tissues, this project sought 
to characterise the impact of proteolytic enzymes from P.gingivalis on the innate immune 
response. The impact on AC clearance and innate immune responses was assessed.   
This project addressed the specific hypothesis that gingipains promote disease by acting 
to inhibit multiple stages of the AC clearance process. The effect of gingipains on the 
ability of macrophages to find AC, interact with and remove AC and respond appropriately 
were assessed. Gingipain treatment of macrophages was shown to reduce the ability of 
macrophages to migrate towards AC.  In addition, expression of CD14, a key receptor 
known to tether AC, was also reduced.  Together these gingipain-induced innate immune 
changes reduced effective clearance of AC at two separate points in the clearance 
process (migration and tethering) thus reducing the AC binding to phagocytes. Data 
presented here also suggest that gingipains reduced anti-inflammatory mediators (TGF-β 
and IL-10) in macrophages phagocytosing apoptotic neutrophils. Furthermore, whilst 
apoptotic neutrophils turn off the inflammation induced by lipopolysaccharide from 
P.gingivalis, they fail to turn off the novel gingipain induced inflammatory cytokine 
production. These data suggest that gingipains induce a strong and dominant pro-
inflammatory response that may be resistant to inhibition by AC.  Taken together, the work 
presented here reveals several key stages of the resolution phase of inflammation are 
inhibited.  The failure of this process will result in immune cell necrosis and release of 
inflammatory mediators into the gingival crevicular fluid to cause catastrophic 
consequences of inflammation in the periodontal region. For the first time, this work 
suggests that gingipains may be potent contributors to chronic periodontal inflammation 
via their impact on multiple stages of the AC clearance process and thus represent a 
potential therapeutic target. 
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LPS  Lipopolysaccharide 
 LP E. coli LPS Escherichia coli  
LR1 Leukocyte response integrin 
mAb  Monoclonal antibody 
MAP  Mitogen-activated protein 
MBL Mannose-binding lectin 
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mCD14 Membrane CD14 
 MCP-1 Macrophage chemokine protein 
M-CSF Macrophage colony-stimulating factor  
MFG-E8  Milk fat globule epidermal growth factor 
MIF MØ migration inhibitory factor 
MIP-1α Macrophage inflammatory protein 1 alpha   
MMPs Metalloproteinases  
MØ Macrophages  
 MPO Myeloperoxidase  
 MYD88 Myeloid differentiation primary response protein 88  
NETs Neutrophil extracellular traps  
NF-κB  Nuclear factor-κB  
 NGS  Normal goat serum 
 NHS  Normal human serum 
NØ Neutrophils  
 OD  Optical density 
 OPD  O-Phenylenediamine dihydrochloride 
P. gingivalis   Porphyromonas gingivalis  
P. gingivalis 
LPS Pg LPS 
  PAMP Pathogen-associated molecular patterns  
PARs Protease activated receptors 
PBS  Phosphate-buffered saline 
PBS-T  PBS containing tween 
PC Phospatidylcholine 
 PCR  Polymerase chain reaction 
PD Periodontal disease  
PDL Periodontal ligament  
PE  Phycoerythin 
 PECAM-1 Patelet endothelial cell adhesion molecule-1  
PGD2 Prostaglandin D2  
 PI  Propidium Iodide 
 PI  Phosphoinositide  
 PI3K Phosphatidylinositol 3-kinase  
PKC Protein kinase C 
 PMA  Phorbol 12-myristate 13-acetate 
PRRs Pattern recognition receptors 
PS  Phoshatidylserine 
 PSR  Phoshatidylserine receptor 
RgpB Arginine gingipain 
 ROS Reactive oxygen species  
S1P Sphingosine 1-phosphate  
S1PRs Sphingosine 1-phosphate receptors 
sCD14 Soluble CD14 
 SDS  Sodium dodecyl sulphate 
sfRPMI Serum-free RPMI 
 
SHP-1  
Src homology region 2 domain-containing 
phosphatase-1 
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SIRP-α Signal-regulatory protein alpha  
SLE Systemic lupus erythematosus  
SP-A  Surfactant protein A 
SP-D  Surfactant protein D 
SR-A  Class A Scavenger receptor 
TG Transglutaminase 
 TGF-β Transforming Growth Factor beta  
TIRAP TIR domain-containing adapter protein 
TLRs Toll-like receptors 
 TNF-R Tumour necrosis factor receptor  
TNF-α  Tumour-necrosis factor 
TRIF TIR-domain-containing adapter-inducing interferon-β  
Tris  Tris(hydroxymethyl)methylamine 
TSP-1  Thombospondin-1 
 TSP-1  Thrombospondin  
 TUNEL Terminal TdT-mediated dUTP-biotin nick end labelling  
Tween 20  Polysorbate 20 
 VD3  Dihydroxyvitamin D3 
VEGF Vascular endothelial growth factors 
WASP Wiskott-Aldrich syndrome protein  
α2MR α-2 macroglobulin receptors 
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Chapter 1 
Introduction 
Inflammation is a form of self-protection that defends our body from infection stimulated by 
foreign invaders, trauma and immune reactions. To combat infection or repair tissue 
damage and restore tissue homeostasis, the inflammatory cascade begins with a rapid, 
and coordinated reaction generating the cardinal signs of redness, heat, pain and swelling 
which ultimately lead to resolution and healing. The generation of inflamed tissue is 
mediated by a broad range of molecular mediators, immune cells, biochemical pathways 
and blood vessels 1. Notably, cells of the innate and adaptive immune system differ in 
their sensing of microbial infection and the innate immune system provides the first line of 
defence by triggering phagocytic cells such as neutrophils (NØ) and macrophages (MØ) 
to eliminate the microbial infection 2. However the innate immune system does not 
‘remember’ pathogens and consequently input from the adaptive immune system is 
required, which involves instructing lymphocytes to ‘remember’ the antigens of intruding 
pathogens 3. The mechanism of resolution of inflammation unfolds in several phases and 
each stage has been studied and its importance has been identified as any failures in 
repair result in tissue destruction and release of toxic mediators which lead to chronic 
inflammatory diseases 4. Traditionally, removal of pro-inflammatory mediators (e.g. 
invading bacteria) was understood to resolve inflammation in a passive manner. More 
recently, however, it has become accepted that the phases (explained in section 1.3) 
involved in resolving inflammation are active rather than passive which offers 
opportunities to design novel approaches to treat chronic inflammatory diseases. The 
restoration of tissue homeostasis occurs during acute inflammation and is normally self-
limiting resulting in tissue healing. In addition, the basal level of the MØ and lymphocyte 
counts returns to normal when the infected tissue is healed 5.   
1.1 Acute inflammation  
At a site of injury, granulocytes such as NØ, eosinophils, and basophils are recruited 
rapidly to neutralise and remove harmful agents such as bacteria or other inflammatory 
stimuli derived from the host immune system. Resolving the inflammation is a tightly-
regulated process which involves activation and production of proteins important for cell 
signalling to enable clearance of dead cell debris thereby resulting in tissue homeostasis.  
Restoration of tissue homeostasis via immune regulatory molecules such as anti-
inflammatory cytokines is a finite process which is controlled by a range of cellular and 
biochemical mechanism designed to remove the inflammatory stimuli as soon as the 
immune system is activated 6 (figure 1). 
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Figure 1: Illustration of acute inflammation pathways 
Following an infection or injury, the inflammatory process is triggered in the host immune 
system with the aim to eliminate the pathogenic insult and the damaged tissues and/or 
cell debris. In acute inflammation, upon sensing the inflammatory stimuli : 1) NØ are 
recruited from the blood to the tissue to attack and clear the pathogens, 2) NØ 
subsequently recruit monocytes from the circulating blood which become differentiated 
into MØ, 3) At this stage, the pathogens and infected cells are phagocytosed by the NØ 
and become apoptotic (AC).  4) MØ present in the tissues uptake and engulf the apoptotic 
NØ and thereby suppress inflammation via their release of anti-inflammatory mediators 
such as Transforming Growth Factor beta (TGF-β1), Interleukin 10 (IL-10) and 
prostaglandin E2 (PGE2) which ultimately leads to healing of the damaged tissue.  
1.2 Chronic inflammation 
If acute inflammation fails to resolve effectively or if inflammatory stimuli persist the 
production of pro-inflammatory cytokines are chronically triggered leading to dysregulation 
of tissue homeostasis mechanisms resulting in chronic inflammatory diseases such as 
chronic periodontitis, rheumatoid arthritis, cardiovascular diseases, atherosclerosis, 
neurodegenerative diseases and other systemic diseases 7-14. Failure of any of the phases 
(as described in figure 1), such as NØ undergoing apoptosis or alteration in apoptotic cell 
(AC) surface ligand expression required for phagocytosis or modification of chemical 
mediators misleading the recruitment of professional phagocytes, might inhibit the repair 
of inflamed tissue leading to the release of toxic cellular contents which cause further 
tissue destruction (figure 2) 15-17. Therefore, understanding the mechanisms involved in 
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the resolution of inflammation will provide important insight into the role of associated cell 
and molecular mediators involved in achieving the restoration of tissue homeostasis and 
hence may identify novel therapeutic targets for use in the treatment of chronic 
inflammatory diseases. 
 
Figure 2: Illustration of chronic inflammation pathways 
Following an infection or injury, inflammation is triggered in the host immune system which 
aims to eliminate the pathogenic insult and the damaged tissues or cell debris. Failure of 
any phases in acute inflammation might result in chronic inflammation. E.g. as shown in 
this diagram if: 1) NØ fail to sense the pathogens or infected cells or 2) MØ recognition of 
AC NØ were inhibited. Failure of either of these events might trigger the discharge of pro-
inflammatory cytokines causing further inflammatory process activation and associated 
damage to the tissues. 
1.3 Mechanisms of resolution of inflammation  
Inflammation resolution is a tightly-regulated process involving apoptosis of recruited cells 
and rapid removal of AC and clearance of activated inflammatory cells. Recognition of 
pathogenic insults by tissue-resident immune cells such as mast cells and MØ along with 
the recruitment of NØ promotes anti-inflammatory mediator release thereby leading to 
tissue homeostasis. The following phases describe the process of inflammation 
regulation. 
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Phase I: Tissue MØ alert NØ following pathogenic insult 
At a site of injury, e.g. in inflamed or infected skin, the invading foreign organisms or 
particles are sensed by specialised receptors present in the resident MØ and mast cells in 
the host. MØ are equipped with the pattern recognition receptors (PRRs) such as Toll-like 
receptors (TLRs), C-type lectin receptors and membrane-bound surface receptors which 
recognise the pathogen-associated molecular patterns (PAMPs) and damage-associated 
molecular patterns (DAMPs) 18. DAMPs result from the release of cytoplasmic and nuclear 
contents from the infected cells and these can initiate the inflammatory response by 
alarming resident phagocytes. Following this, the MØ produce TNF-α, interleukin-6 (IL-6), 
CXCL1 and CXCL2 to alert and recruit NØ present in the vasculature 19. 
Phase II: NØ attract monocytes  
NØ are the first cells recruited to the site of inflammation and they rapidly migrate from the 
blood stream to the site of infection via extravasation. NØ migration from the blood to the 
infected site is guided by various chemoattractants released by the invaded pathogens, 
e.g. N-Formylmethionine-leucyl-phenylalanine (FMLP) or by the activated resident MØ at 
the site of inflammation e.g. CXCL8 20, 21. To execute a timely recruitment of the NØ to the 
site of infection, increased blood flow and increased permeability occurs by dilation of the 
blood vessels and this promotes the release of plasma proteins together aiding the NØ 
rolling and adhesion cascade 22. 
The initial key events involved in NØ migration are weak adhesion to the inner surface of 
the endothelium allowing slow rolling along the surface of the vessel wall and firm 
adhesion and spreading to initiate intravascular crawling and finally transmigration through 
the extravascular space. To accomplish these events mediators such as selectins, 
cytokines, and integrins play a major role 23.  
NØ use two types of defence against the invaded or infected agents. Oxygen-dependent 
mechanisms, the Fc receptors present on the NØ bind to the antibodies on the pathogen 
stimulating increased oxygen usage by a process called respiratory burst 24. This influx of 
oxygen triggers the release of oxygen radicals referred to as reactive oxygen species 
(ROS) through the activation of NADPH oxidase which reduces the molecular oxygen (O2) 
to superoxide radical (O2 -) thereby producing oxygen radicals which attack the bacterial 
organism. On the other hand, singlet oxygen radicals are produced by the fusion of 
myeloperoxidase (MPO) with a phagosome resulting in the secretion of MPO into the 
phagolysosome which produces hypochlorite, a toxic agent to assist in the killing of 
pathogens 25. In the oxygen-independent mechanism, the NØ releases numerous 
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antimicrobial proteins such as cathepsin, lysozyme, lactoferrin and other hydrolytic 
enzymes required to break down the bacterial cell wall membrane and causing a 
deprivation of iron nutrients essential for the survival of the pathogens 26. Other than the 
above two methods, NØ are also armed with the ability to generate a trap around the 
microorganisms by synthesising NØ extracellular traps (NETs). NETs have recently been 
widely studied for their role in the pathogenesis of infectious and inflammatory diseases 27, 
28. Using the mechanisms described above NØ are able to combat most microbial 
infections. 
Also at this stage, NØ release LL-37, cathepsin G, azurocidin and α-defensins, molecules 
which are known to promote the inflammatory response in monocytes recruited from the 
circulating blood to the infected site 29, 30. Circulating monocytes are recruited by a CCR2-
dependent pathway which guides these cells to the site of infection and ultimately 
differentiate into MØ 31. MØ differentiation involves MØ colony-stimulating factor (M-CSF), 
granulocyte–MØ colony-stimulating factor (GM-CSF) and other cytokines which prepare 
the differentiated MØ with various receptors required for resolving the inflammation 32. 
Phase III: Viable NØ to apoptotic NØ  
The lifespan of an emigrated NØ is rather short and cells rapidly undergo apoptosis. At 
this stage, lipoxins are released by other resident cells such as platelets and endothelial 
cells to inhibit NØ influx and promote infiltration of monocytes 33. Following the activation 
of NØ by resident MØ, the NØ releases annexin I from tertiary granules to promote their 
own death by apoptosis. The expression of annexin I is followed by other AC death 
markers such as phosphatidylserine (PS), a well-known marker which reveals AC death. 
At this phase, lipoxin A4 also contributes to the enhancement of apoptotic NØ uptake by 
MØ and inhibits CXCL8 release, a NØ chemoattractant 34.  
Phase IV: Restoration of tissue homeostasis  
Clearance of AC is a vital phase in the inflammation resolution process necessary for 
regulating the restoration of the extracellular matrix. NØ undergoing apoptosis release 
‘find-me’ signals and display ‘eat-me’ signals that enable MØ receptors to recognise the 
dying cells 35. Various receptors such as phosphatidylserine receptors (PS-R), CD14, 
CD36, ICAM-3, tyrosine kinase receptor, integrins and complement receptors have been 
found to participate in recognising AC-associated molecules either directly or indirectly 
using soluble molecules 36-40. The uptake and phagocytosis of AC promotes the release of 
anti-inflammatory agents such as TGFβ, IL-10, PGE2, and vascular endothelial growth 
factors (VEGF). For the inflamed tissue to return to normal tissue homeostasis the 
mediators released by the phagocytosis process have been reported to have anti-
inflammatory and pro- resolution properties which suppress further inflammation and clear 
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the inflammatory debris 33, 41. Notably the failure of the clearance phase has been linked 
with the pathogenesis of several autoimmune and chronic inflammatory diseases (figure 
3) 42, 43. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Phases involved in acute inflammation and its resolution 
Phase I: upon tissue injury, the resident MØ are the first cells to sense the disturbance in 
tissue homeostasis. This is followed by the activation of endothelium by upregulation of 
adhesion molecules on their surface, sending signals to alert NØ by stimulating cytokines 
and chemokines. Phase II: Recruited NØ secrete granule contents such as LL-37 and 
azurocidin to promote inflammatory monocyte extravasation. Phase III: Further infiltrations 
of NØ cease however influx of monocytes continues. MØ at this point have a control over 
the life span of NØ by producing pro- or anti- apoptotic signals. Phase IV: Apoptotic NØ 
taken up by the MØ by phagocytosis and MØ release anti-inflammatory mediators leading 
to tissue healing. Adapted from 44.  
1.4 Chronic inflammatory diseases  
Considerable research has investigated the function of phagocytes in relation to their anti-
microbial ability and promoted AC clearance, leading to the production of anti-
inflammatory mediators essential to “turn off” the inflammation to enable tissue healing 45-
49. Understanding of the inflammatory mechanism provides potential therapeutic strategies 
to promote healing in chronic inflammatory diseases 42, 50. Due to the occurrence of 
numerous microorganisms in the oral cavity followed by the stimulation of inflammatory 
agents, periodontal disease (PD) serves as an excellent model to study host-pathogen 
interactions in relation to AC clearance mechanisms and inflammation.  
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1.4.1 Periodontal disease (PD) 
PD is a multifactorial disease characterised by an aberrant inflammatory immune 
response to plaque bacteria. The periodontium is composed of dentine, cementum, 
gingiva, periodontal ligament and alveolar bone (figure 4). Disease progression in the 
periodontium results in loss of these key supporting tissue structures 51. PD is highly 
prevalent affecting 90% of the worldwide population 52. Furthermore, a recent large Adult 
Dental Health Survey conducted in the United Kingdom estimated that 45 percent of 
adults are prone to PD as characterised by periodontal pocket measurement using a 
periodontal probe, an instrument used to measure the depth of the pocket space between 
the tooth and gum to detect the severity of periodontitis 53, 54. Notably a periodontal pocket 
depth exceeding 6-7mm in addition to bone loss is considered as an advanced PD (figure 
4) 53. 
 
 
 
 
 
 
 
 
Figure 4: Structure of the periodontium 
The main components include the gingiva which surrounds the tooth, cementum 
surrounding the root of the tooth, alveolar bone which provides the bony housing for the 
tooth and the periodontal ligament (PDL). The PDL enables anchoring of the tooth root to 
the alveolar bone. Adapted from 51. 
 
In the 1960’s the understanding of the epidemiology of PD highlighted that: a) the 
development of gingivitis, frequently, but not always, progressed to periodontitis leading to 
periodontal pocket formation, bone loss and subsequent loss of teeth; b) the prevalence of 
periodontitis increased with age as tooth loss occurred predominantly after the age of 35; 
and c) that almost all adults were susceptible to severe periodontitis 55, 56. However, 
advances in periodontal research have now changed our understanding of the relationship 
between gingivitis and periodontitis in regard to the role of the immune system.  
Goodson et al. (1982) developed the ‘’burst’’ theory which concluded that not all gingivitis 
cases progressed to periodontitis. Underpinning this were two models: a) contained 
gingivitis- where few inflamed gingival sites “burst” to cause severe periodontitis followed 
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by tooth loss, and b) stable gingivitis – where many inflamed gingival sites continue to be 
free of any destruction of tooth or bone for their lifespan 57. Following Goodson (1982), 
Prayitno (1993) et al. in the early 1990s conducted research into the periodontal health of 
students and tea pickers evaluating whether gingivitis always progressed to severe PD 58. 
Data indicated that gingivitis was less prevalent in students whereas chronic periodontitis 
was common in both the groups suggesting that gingivitis was a poor predictor of 
progression to periodontitis 58. Later developments in dentistry have utilised advanced 
technology such as dental X-rays and intraoral X-rays to differentiate diseased gums from 
normal healthy gums  59. 
Traditionally, the periodontal epithelium has been considered as a passive, physical 
barrier which protects underlying tissue from bacterial invasion. However, stimulating this 
tissue with bacterial components results in epithelial responses leading to rupture of the 
barrier 60. In response to inflammatory stimuli e.g. periodontal pathogens, the epithelial 
cells alter their proliferation and differentiation to facilitate restoration of tissue 
homeostasis. Research, however, indicates that while the epithelium has a barrier 
function it also plays an active role in innate host defence 61. Subsequently, further study 
on the interaction of the periodontal epithelium with the immune system will aid our 
insights into mechanisms involved in regulating oral health and disease.  
1.4.2 Pathogenic mechanisms in PD 
To begin to understand the pathogenesis of periodontitis it is important to consider how 
inflammatory responses and immune mechanisms are regulated. Since complex mixes of 
pathogens are associated with the progressive forms of the disease, it is not clear which 
specific pathogen(s) is/are responsible for pathogenesis. Furthermore, the disease is also 
the result of the host response combined with the presence of bacteria. This is highlighted 
by the fact that there have been cases where individuals have the presence of certain 
microorganisms yet have no signs of disease, suggesting that immune- inflammatory 
responses drive the disease process 8. Moreover, results from studies of twins have 
demonstrated that both environmental and genetic factors may also influence the clinical 
development of PD 62. A study by Loe demonstrated that destruction of the periodontal 
tissue occurs in two ways, via a direct mechanism and an indirect mechanism 63. The 
production of histolytic enzymes, cytotoxic agents and lethal metabolites by plaque 
bacteria affects directly the metabolism of the normal tissue which in turn activates 
inflammatory responses. It has been proposed that subsequent immunopathological 
responses, followed by the direct mechanism in addition to the endogenous enzymes 
indirectly lead to initiation and progression of periodontitis 63.  
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Whilst there has been much research concentrating on the regulation of immune 
mechanisms and inflammatory responses in the pathogenesis of periodontitis, it is 
important to consider the inflammatory mediators involved in the development of the 
disease. Upon bacterial invasion of the gingival region, lipopolysaccharide (LPS), 
proteases and other toxic components from bacteria stimulate local mast cells to produce 
TNF-α and other potent pro-inflammatory mediators such as histamine, cytokines, 
chemokines, prostaglandins and matrix metalloproteinases (MMPs). Released mediators 
recruit inflammatory phagocytic cells (e.g. NØ) and subsequently, these leukocytes 
release relatively high levels of MMPs which destroy the gingival tissues via their 
deleterious effects on connective tissue and bone metabolism 64. At this point, it is 
important for the host immune system to remove or reduce the microbes as, if this is 
unsuccessful, tissue redness, swelling and bleeding occur. Failure to resolve inflammation 
may be due to poor innate immune responses from the host or due to environmental 
modifying factors which prevent tissue repair and remodelling. This project aims to 
understand the poor inflammation resolution by scrutinising MØ phagocytosis 
mechanisms in the presence of periodontal pathogens and their products.   
MØ, and antigen-presenting cells trigger CD4 T helper cells to either reduce or increase 
the inflammatory mediators by producing cytokines. Immune mediators release 
subsequently affects prostaglandins, particularly PGE2 which plays a prominent role in the 
pathogenic mechanism of PD 65, 66. The activation of prostaglandins along with 
leukotrienes and cytokines triggers the cardinal signs of inflammation. At a later stage of 
inflammation, PGE2 and prostaglandin D2 (PGD2) promote anti-inflammatory mediator 
release by inducing the production of key factors such as lipoxins, resolvins, and 
protectins which activate homeostatic mechanisms 33.  
The nuclear factor-κB (NF-κB) ligand (RANKL), a member of TNF-α superfamily, is 
involved in activation of osteoclast differentiation and stimulation in periodontitis patients’ 
leads to degradation of alveolar bone 67. Additionally, IL-8, GM-CSF, IFN-γ are reported to 
be hyperactive in peripheral NØ of periodontitis patients indicating the type and level of 
cytokines present determine the nature of the periodontal inflammation 68. Interestingly 
Page differentiated periodontal health and disease by the production of pro- and anti-
inflammatory cytokines 69. High levels of pro- inflammatory agents, PGE2 and MMPs and 
relatively low levels of anti-inflammatory cytokines and tissue inhibitor of 
metalloproteinases (TIMPs) are indicated as causative of periodontitis while the reverse 
characterises periodontal health However, recent research reported other than pro-
inflammatory, the anti-inflammatory cytokines were also present in higher levels in 
periodontitis patients contributing to the tissue destruction due to lack of balance between 
these mediators (Table 1). 
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Cytokines present in periodontal 
disease 
References 
IL-1β 70, 71 
TNF-α 72-74 
INF-γ 75-77 
PGE2 78-80 
MMPs 81-83 
IL-6 72, 84, 85 
TGF-β 86-88 
IL-8 72, 89, 90 
IL-12 91, 92 
 
Table 1: List of inflammatory mediators reported to be in PD 
The table presents the pro-inflammatory and anti-inflammatory cytokines which if 
in excess could result in periodontal tissue damage. 
1.4.3 Oral Biology and Inflammation 
Gingivitis can be initiated by the formation of plaque (bacterial biofilm) at the gingival 
surface. Whilst bacteria appear to be a major aetiological factor in oral disease, significant 
literature suggests that it is the host inflammatory responses that drives the pathogenesis 
93-95. Subsequently, it has been proposed that the activation of the innate immune system 
due to bacteria-derived factors plays a major role in triggering inflammation in the PD 
patients 96. The significant tissue recruitment of NØ due to the production of IL-8 from the 
periodontal epithelial cells paves the way for the trafficking of immune cells 97. 
Consequently, the presence of large numbers of NØ is either primed by bacterial 
proteases or an inflammatory stimuli in the periodontal environment triggering the cells to 
produce pro-inflammatory mediators or undergo necrosis exacerbating the tissue damage. 
Furthermore, the oral microorganisms have been shown to evade MØ by inducing 
activation of protein kinase A via cyclic AMP-dependent pathway 98. Protein kinase A 
activation inhibits the secretion of nitric oxide which is essential for MØ killing of 
pathogens 99. Additionally, periodontal tissue resident cells such as gingival fibroblast, 
epithelial cells, and periodontal ligament fibroblasts have been shown to release pro-
inflammatory mediators such as IL-1β, IL-6, IL-8 and TNF-α on encountering bacteria 
agents 100.  
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Although, the above-mentioned studies suggest that aggressive inflammation is an 
important factor it is also vital to note that to initiate the inflammation the presence of 
microorganisms is essential. Hence, knowledge of the association between bacterial 
species and PD will advance our focus on virulent species that contribute to the oral 
infection. 
1.4.4 Bacterial aetiology of periodontitis 
Around 500 bacterial species have been reported as being present in plaque from 
beneath the gingival margin and this includes Gram-positive, Gram-negative, aerobic, 
anaerobic microbes along with traces of yeast 101. Certain bacteria including ones from the 
genera Bacteroides, Actinobacillus, Eikenella, Fusobacterium, Capnocytophaga, and 
Eubacterium are known to adhere to the tooth surface and their involvement is associated 
with deep periodontal pockets which eventually leads to the destruction of the tooth’s 
supporting healthy tissues. Depending on the tooth position the level of bacterial 
accumulation and retention varies. The combination of various bacterial species reports 
that Gram-negative bacteria or the anaerobic organisms are not the only microbial species 
that contribute to periodontists. Moreover, the mechanism by which gingivitis transits to 
aggressive periodontal disease is unclear. The accumulation of large numbers of bacterial 
species in the gingival region is now subsequently associated with gingivitis and gum 
inflammation 102. However, studies analysing dental plaque samples using molecular 
techniques such as 16S rRNA sequencing identified an even more diverse number of 
bacterial species in the subgingival region suggesting that a greater number of species in 
the microbial environment of the tooth are yet to be characterised 103.  
Bacterial virulence factor expression is dependent on the nature of the environment. 
Strains of pathogenic species can sense environmental cues and this, in turn, regulates 
the network of genes which modulates virulence factor production 104-106. Socransky et al. 
originally proposed that aggressive PD was strongly associated with two pathogens 
Aggregatibacter actinomycetemcomitans (in juvenile periodontitis) and Porphyromonas 
gingivalis (P. gingivalis) (adult periodontitis) 107. Later, the same study grouped the oral 
microbiota into a complex and proposed that each complex is identified with a colour 
based on their level of virulence associated with periodontal disease. In this microbiota 
complex, Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola 
showed the strongest relationship with PD based on association studies, elimination of 
lesions, host response, virulence factors and animal studies 107.  Additionally, genome 
sequencing studies of oral bacteria were applied to understand the pathogenesis of the 
subgingival microbiota. In these genome sequencing studies, 15 environmentally 
important oral microorganisms were studied and among these A.actinomycetemcomitans 
and P. gingivalis were selected for determination of their complete DNA sequence. Data 
Introduction 
28 
 
generated provided new insight into metabolic pathways and their potential virulence 
mechanisms 108. For this reason and their ability manipulate genetically quickly, P. 
gingivalis was used to study its impact on host immune cells within PD 109-111.  
1.4.5 Porphyromonas gingivalis  
P. gingivalis, a Gram-negative anaerobic rod-shaped bacterium, is a virulent pathogen 
involved in inflammatory oral infections in humans 107. Recent studies have shown that P. 
gingivalis can reside inside epithelial, endothelial and smooth muscle cells without 
inducing apoptosis for a maximum period of 48 hours however infected host cells do 
become activated 112, 113. The ability to invade host cells intracellularly demonstrates one 
of the approaches P. gingivalis uses to escape the host immunity. So far invasion of P. 
gingivalis has been demonstrated in human gingival epithelial cells, periodontal ligament, 
fibroblasts and aortic endothelial cells 60, 114-117.  
P. gingivalis components such as fimbriae, LPS, proteases, haemagglutinin adhesion 
domains, outer membrane proteins and exopolysaccharides have been reported to 
participate in disrupting the regulation of host immune responses 118-130. The proteases of 
P. gingivalis include enzymes such as collagenase, trypsin-like cysteine protease and 
gelatinase which are responsible for the destruction of periodontal tissues 95, 131. Among all 
the proteases, gingipains composed of cysteine proteases, account for 85% of the 
extracellular proteolytic activity from P. gingivalis and they significantly contribute to the 
damage of the tooth’s supporting tissues by the colonisation in the periodontal pockets 132. 
Moreover, the most commonly studied P. gingivalis components are LPS and gingipains 
due to their activity contributing to the pathogenesis of PD by eliciting inflammatory 
mediator production from immune cells and causing destruction of the inflamed 
periodontal tissue 133-135. 
1.4.5.1 P. gingivalis LPS  
Lipopolysaccharide (LPS), present in the outer membrane of Gram–negative bacteria, 
contributes to the stimulation of the host innate immune response by binding to the 
resident cells present in the periodontal tissues resulting in the synthesis of pro-
inflammatory mediators 136-138. P. gingivalis LPS has been implicated in activating human 
monocytes via CD14-dependent pathways 138. However, in non-myeloid cells such as 
human endothelial cells P. gingivalis LPS stimulates weaker expression of E-selectin and 
interleukin-8 (IL-8) secretion due to the expression of low copy numbers of membrane 
CD14 (mCD14)  compared with monocytes. Furthermore, the endothelial cells on 
treatment with Ec LPS and higher dose of P. gingivalis LPS resulting in inhibition of E-
selection expression suggesting that P. gingivalis LPS might be an antagonist for human 
endothelial cells 139. Moreover, the addition of MY4 (anti-CD14 antibody) in human 
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endothelial cell cultures resulted in inhibition of the E-selectin response indicating the 
requirement of CD14 in eliciting E-selectin expression 140. However, soluble CD14 
(sCD14) has been demonstrated to promote LPS-induced responses in human epithelial 
and endothelial cells through LPS being transferred to soluble CD14 from the LPS-
lipopolysaccharide binding protein (LBP) complex 141. Collectively, these data suggest that 
CD14 either in the membrane or soluble form is able to stimulate cytokine levels in 
myeloid and non-myeloid cells. 
Early work has suggested that the main function of CD14 is to serve as pattern 
recognition receptor (PRR) for LPS and in association with LBP it elicits a strong 
inflammatory responses as revealed by studies in heparinized human blood exposed to 
LPS  142. Furthermore, treating human blood with monoclonal antibodies (mAb) blocking 
CD14 inhibited the release and synthesis of TNF-α demonstrating that CD14 regulates 
LPS-mediated inflammation in the innate immune response to bacterial components 142. 
Upon invading the host, bacteria are sensed by the immune cells via LBP which transfers 
the LPS to CD14. The CD14 present in both forms, mCD14 anchored to the plasma 
membrane by a phosphatidylinositol linkage and the soluble form sCD14 participate in 
endotoxin recognition 143. At this stage, the CD14 divides the LPS to monomers and 
transfers the complex to Toll-like receptors, an important receptor for sensing foreign 
agents to elicit an immune response.  
1.4.5.1.1 Toll-like receptors (TLRs) 
TLRs are best characterised for recognising PAMPs along with CD14 and are located on 
the cell surface or in intracellular compartments of the cell. Based on the reported human 
and mouse TLR studies, the TLR4 intracellular signalling cascades were established: 
TLR4 signals via MD-2 (Lymphocyte antigen 96) protein through two pathways: i) the TIR 
domain-containing adapter protein (TIRAP) and myeloid differentiation primary response 
protein 88 (MyD88) pathway accelerates translocation of NF-κB inducing expression of 
pro-inflammatory cytokine genes, and ii) the TIR-domain-containing adapter-inducing 
interferon-β (TRIF) – and their adaptor molecules (TRAM) pathway regulates interferon 
regulatory factor-3 (IRF-3) or NF-κB translocation in an MYD88 independent pathway that 
effectuates the upregulation of pro-inflammatory cytokines (figure 5) 144, 145.  
Interestingly TLR4 deficient mice fail to respond to LPS from E.coli via peritoneal MØ and 
B cells indicating that TLR4 regulates endotoxin responses on phagocytic cells 146. 
However, depending on the endotoxin present on the bacteria TLR recognition might 
differ, indeed P. gingivalis LPS has been shown previously to be detected by both TLR2 
and TLR4 147.  
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Figure 5: CD14 signals LPS binding through TLR4-MD2 pathways 
Invading bacterial toxins such as LPS are sensed by the lipopolysaccharide-binding 
protein (LBP) mediated by CD14. Binding of lipid A to TLR4 associated MD2 complex 
signals through MYD88 and (TIRAP) to stimulate the release of cytokines and 
chemokines. The MYD88 –independent pathway engages the TRIF and their adaptor 
molecules TRAM to stimulates the activation of interferon (IFN)-regulatory factor (IRF3) 
resulting in the production of IFN-beta and the expression of IFN-inducible genes. 
 
Initial reports characterised the role of TLR2 as a LPS signalling molecule for P. gingivalis. 
By treating murine MØ with P. gingivalis LPS there was an upregulation of TLR2 along 
with higher levels of TNF-α secretions 148. In addition, P. gingivalis LPS activates p38 
mitogen-activated protein (MAP) kinase, a key component in intracellular signalling 
pathways in human monocytes but not in human endothelial cells or Chinese hamster 
ovary (CHO) cells transfected with TLR4 149. These findings suggest that though P. 
gingivalis LPS alerts the host immunity selective modification of the immune response 
was observed on the cellular level. On the other hand, extensive TLR4 research 
demonstrates the P. gingivalis LPS activates mouse Ba/F3 cells via the TLR4/MD2-
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MyD88-dependent pathway and it was proposed that contamination from the proteases 
present in P. gingivalis LPS might have induced cell activation mediated by TLR2 150. 
Moreover, mCD14 participates with TLR4 in activating gingival fibroblast, though both 
TLR2 and TLR4 were expressed by the fibroblasts in the gingiva 134, 151. Additionally, P. 
gingivalis LPS has been shown to be activated weakly on monocytes/MØ compared with 
E.coli LPS due to the difference in the lipid A structure of P. gingivalis LPS which is 
composed of branched fatty acids and absence of phosphate groups compared with E.coli 
LPS 121, 139, 148, 149, 152, 153. However, both molecules have been shown to induce a similar 
level of inflammatory mediators 154. 
1.4.5.2 Gingipains 
Gingipains belong to the C25 peptidase family and are classified into two types based on 
their ability to cleave proteins at particular amino acid sequences 155. Arginine gingipains 
(Rgp) cleave after the ARG-amino acid with a capacity to degrade immunoglobulin and 
complement components, integrin-fibronectin-binding and cytokines. Arginine gingipains, 
based on their structure and molecular weight, are divided into two types RgpA and RgpB. 
RgpA, sometimes referred as HrgpA is ~95kda in size and is non-covalently complexed by 
catalytic and hemagglutinin/adhesion domains (figure 6). While RgpB is ~50kda and lacks 
hemagglutinin/adhesion domains, however, it does have a catalytic domain similar to 
RgpA (figure 6). There is also a lysine gingipain (Kgp) of molecular mass ~60kDa, which 
cleaves after LYS-amino acids and contains a catalytic and hemagglutinin adhesion 
domains similar to RgpA (figure 6). Kgp has been reported to be the most potent of all the 
gingipains due to its ability to aid invasion of the host immune cells 95, 122, 156, 157. 
1.4.5.2.1 Structure and homologies of gingipains  
P. gingivalis genomic studies have revealed that RgpA, RgpB, and Kgp are encoded by 
separate gene loci and this is consistent in all P. gingivalis strains 158-162. RgpA and Kgp 
are composed of an Arg-specific or Lys-specific catalytic domain followed by a large C-
terminal hemagglutinin/adhesion (HA) region (figure 6) 158, 160. On the other hand, RgpB 
consists of an Arg-specific catalytic domain followed by a small C-terminal fragment 
(figure 6)  163. All three gingipains carry a signal peptide and an N-terminal ‘pro’-fragment 
at the beginning of their specific catalytic domains. The C-terminal HA region present in 
the RgpA and Kgp is responsible for the additional virulence factor by carrying biological 
specificities such as adhesion properties in the HA domain (figure 6)  164. RgpA and RgpB 
are 98% identical in their amino acid sequence in almost all P. gingivalis strains 165, 166. 
RgpA catalytic domains (RgpAcat) and RgpB catalytic domains (RgpBcat) share ~90% of 
amino acid sequence identity and ~75% of protein identity in the propeptide regions 164. 
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However, Kgp catalytic domains (Kgpcat) share only ~30% of amino acid sequence identity 
with RgpAcat and RgpBcat.  
Since, Kgp and RgpA contain the HA domain (figure 6) responsible for adhesion binding 
properties they have been studied for their ability to interact with host immune cells and 
cause disruption of the periodontal tissues compared with RgpB protease, which lacks the 
HA domain (figure 6) 162, 163, 167. 
 
 
 
 
 
 
Figure 6: Structure and homologies of gingipains  
Three forms of gingipain are depicted with catalytic domains (cat) (open boxes) with a 
molecular weight in kilodaltons (kDa) followed by four regions of hemagglutinin adhesion 
domains (HA) denoted in coloured boxes. The numbers found below the HA1 to HA4 
domain marks the specific peptide regions for the gingipains. The homologies shared 
between the gingipains are identified using the same colours. Adapted from 168, 169 
 
1.4.5.2.2 Hemagglutinin adhesion domains (HA) 
HA domains have been shown to be responsible for the adhesion and lysis of erythrocytes 
demonstrating the ability of HA domains to bind haemoglobin to acquire iron and 
protoporphyrin IX (PPIX) for their own survival 170, 171. Other than HA domains, fimbriae 
and outer membrane vesicles have been observed to participate in the adherence to 
erythrocytes and epithelial cells 172-174. The hemagglutinin proteins (HagA) are the primary 
reason for the black pigmentation of the colonies grown on blood agar plates 175. HagA 
proteins produced from P. gingivalis invasion on the host immune cells helps in survival of 
the bacteria by binding to erythrocytes thereby providing haem for the bacterial survival 
and resulting on haemolysis. Data also indicates that HagA proteins are involved in 
mediating the binding and arrest of immune cell functions in the initial phases of P. 
gingivalis invasion 164, 176. Both RgpA and Kgp have been described for their ability to bind 
to haemin, using purified proteins such as monomeric and heterodimeric forms 129. In 
addition, both RgpA and Kgp lose their ability to bind to haemin on denaturation through 
boiling indicating the vital role of the HA region binding affinity for destruction of tissues 
177. For both RgpA and Kgp, the specific region of haemoglobin-binding to gingipains was 
identified as the HA2 domain, more precisely the Kgp15/Rgp15 region (figure 6). Kgp has 
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been suggested as the major active haemoglobinase in P. gingivalis due to its ability to 
cleave haemoglobin with the highest efficiency, data obtained using the kgp+ rgpA– mutant 
strain in comparison to the kgp– rgpA+ mutant strain 178. 
1.4.5.3 Gingipain effects on host immune cells 
Extensive research on gingipain biology has shown that these proteases enable bacterial 
evasion of the host immune system either by degrading the chemokine IL-8 and impairing 
NØ recruitment or by activating the kallikrein/kinin pathway 179-181. The kallikrein/kinin 
pathway, a metabolic cascade releasing bradykinin, kallidin and vasodilator related 
peptides has been proposed to be involved in the pathophysiology of PD 182. Gingipains 
activate kallikrein/kinin pathways by enhancing vascular permeability and triggering blood 
coagulation at gingival sites 183. Furthermore, modulation of IL-8 on human NØ via slow 
degradation, by soluble form of gingipains, and quicker degradation by membrane-
associated gingipains, demonstrates that gingipains also target inflammatory mediators by 
regulating the cytokine networks in the host 184.  
Gingipains have also been implicated in inducing AC death in cells e.g. bovine coronary 
artery and human microvascular endothelial cells, human gingival fibroblasts and human 
gingival epithelial cells 185-187. In contrast, gingipains have been shown not to induce 
apoptosis in human NØ and THP-1 MØ 188, 189. Subsequently it has been suggested that 
the reason for the delayed or hyperactive or inhibited NØ apoptosis found frequently in the 
chronic periodontitis patients is due to gingipains attacking the immune system 190-192.  
1.4.5.4 Evasion of host immune system by gingipains 
Gingipains have been shown to cleave IL-8 precisely at the N-terminal portion of 5- and 
11-amino acid peptides by Rgp and 8-amino acid peptide at the N-terminal by Kgp 
resulting in low chemotactic activity 193. This suggests that cleavage of IL-8, a 
chemoattractant for NØ might indirectly modulate NØ chemotaxis, resulting in a poor 
immune response. Additionally, cleavage of C5a complement receptor, another potent 
chemoattractant for NØ was also reported to be cleaved by gingipains on NØ 194. In 
rheumatoid arthritis, C5a has been demonstrated to activate mast cells which in turn 
recruit NØ to the joints indicating a possible mechanistic association between periodontitis 
and rheumatoid arthritis 195, 196. CD4 T cells participate in recognising MHC-II peptide 
complexes on MØ or dendritic cells and activate antigen presentation during an infection 
to play an important role in promoting an immune response. Gingipains are also known to 
suppress this immune response promoted by T cells by cleaving CD4 and CD8 and 
weakening the immune cells in response to the bacterial invasion 197. A previous study 
also reports degradation of protease-activated receptors (PARs) by gingipains on oral 
epithelial cell lines 198. PARs have been shown to participate in keratinocyte uptake and 
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engulfment of E. coli 199. Taken together, it is clear that the gingipains evade the host 
immune system by either modulating or cleaving the receptors essential to mediate the 
AC clearance mechanism of the immune cells. The project here focus on gingipains ability 
to effect MØ migration and phagocytosis activity which may explain the prevalence of poor 
inflammation resolution in periodontitis patients.  
Subsequently studies on gingipains inhibitors might provide an insight into the role of 
gingipains contribution in the suppression of inflammation in periodontal disease. 
1.4.5.5 Inhibition of gingipains, a potential treatment for PD? 
As P. gingivalis is a major bacterium contributing to the pathogenesis of chronic 
periodontal diseases in adults, P. gingivalis surface components have been studied for 
their mechanisms in evading host immune responses which include involvement of 
gingipains and LPS 179, 180, 188, 200, 201. Subsequently several studies have proposed the 
possible use of gingipain inhibitors to prevent the virulence factor activity in host cells. 
In the late 1990’s, Potempa et al. observed that all chloromethane compounds inhibited all 
forms of gingipains (RgpA, RgpB, and Kgp) 202. P1 residues in the chloromethane 
compounds inactivated the gingipains however chloromethane-P2 residues exhibited 
some specificity in blocking gingipain protease activity. This suggests that depending on 
the peptidyl component of chloromethane compounds the degree of inhibition varied 202. 
Gingipains, named after clostripain, due to the structural similarities, were also inhibited by 
Aza-Lys and Aza-Orn derivatives of Aza-peptide Michael acceptors. Aza-peptide Michael 
acceptors were irreversible inhibitors specific for the cysteine protease family which 
inhibited Kgp gingipain and clostripain precisely 203. The commonly used cysteine 
protease inhibitor in gingipain studies is Nα-p-tosyl-l-lysine chloromethyl ketone (TLCK), 
which has been reported to inhibit caspase 3 activated apoptosis of gingipain-treated 
bovine coronary artery endothelial cells and prevents a CD31 reduction in gingipain-
treated endothelial cells 185, 204. Proteinase inhibitors such as antithrombin III and human 
alpha-2-macroglobulin (α2M) also block the activity of RgpA and RgpB while 
macroglobulin alpha-1-inhibitor 3 from rat plasma inhibited all three forms of gingipain 
proteases 205, 206. Moreover, antibacterial activities against gingipains are also observed 
with cystatin and cystatin–derivatives, cysteine protease inhibitors 207, 208.  
1.4.6 P. gingivalis virulence factors in host immune cells  
Though gingipains are essential for the colonisation of the host tissue, it is reported that 
other components of P.gingivalis such as lipoteichoic acids, haemagglutinins, fimbriae, 
capsules, LPS, outer membrane proteins, and their vesicles participate in driving the 
chronic inflammation observed in PD 95. P. gingivalis fimbriae have been reported to 
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modulate CD11b/CD18 on monocytes via TLR2 signalling 209. In addition, the same work 
demonstrated that P. gingivalis fimbriae activates the CD14-TLR2 complex on CHO cells 
suggesting that fimbriae regulates the production of pro-inflammatory cytokines via TLR2 
mediated activation of NF-κB. The lipid-A-associated protein from the haemagglutin 
domain of the gingipains has been shown to be responsible for inducing increased levels 
of IL-6 in human gingival fibroblast and human peripheral blood mononuclear cells 210. IL-6 
has been previously reported to be linked with tissue destruction in the gingival region of 
the periodontium 72. Before colonisation, the bacteria adhere to the oral cavity firmly to 
avoid any resistance from the flow of saliva. The P. gingivalis capsules have been shown 
to participate in the adherence which is mediated by adhesins within the haemagglutinins. 
Based on the level of sugar the capsule components differ in the P. gingivalis strains 211. A 
previous report suggested that capsules participate in the evasion of the host immune 
system through inhibiting phagocytosis of P. gingivalis by MØ treated with encapsulated 
components 212. Elicited IgG antibody levels were found in mice injected with the vesicles 
from the outer membrane proteins of P. gingivalis through transcutaneous immunisation 
213. Additionally, reduced alveolar bone loss was observed in IgG elicited mice suggesting 
a possible therapy for periodontal disease-associated bone degradation. While other P. 
gingivalis components, such as lipoteichoic acid, induce interleukin-1β and 
cyclooxygenase-2 in human gingival fibroblasts through activation of p38, peptidoglycan 
from P. gingivalis has been shown to induce increased IL-6 in mouse peritoneal MØ 84, 85.  
Therefore, the above studies suggest that invasion of  P. gingivalis on the immune cells 
results in aberrant or exacerbated inflammation leading to bone loss in the alveolar region 
214. If not resolved, this inflammation will drive  chronic disease 35.  
1.4.7 Periodontitis and chronic diseases: A Global burden 
The World Health Organisation (WHO) predicts that by 2020 the major chronic disease 
such as cardiovascular disorders, diabetes, rheumatoid arthritis, cancer and chronic 
obstructive pulmonary disease will rise in incidence from 40% to 60% 215. Chronic 
inflammation plays a central role in the association of periodontitis with other chronic 
inflammatory diseases. Notably, bacterial toxins from periodontitis indicate that 
periodontal inflammation enhances metabolic dysregulation in other chronic inflammatory 
disease 216. 
1.4.7.1 Periodontitis and Diabetes: Interrelationship 
Chronic inflammation of the periodontium leads to progressive destruction of tissues in 
specific organs leading to life-threatening conditions. One such association is 
demonstrated by the poor glycaemic control in the periodontitis patients showing an 
increased risk for non-insulin-dependent diabetics 217. In addition, previous work has 
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stated that inoculating type II diabetic rats with periodontal bacteria results in bone 
degradation through increased expression of caspase-3 compared with diabetic rats 
without inoculation 218. These data suggest that both diseases, i.e. periodontitis and 
diabetes, influence each other and this has been described previously by Preshaw et al. 
as a two-way ‘’relationship’’ 219. 
1.4.7.2 Periodontitis and Atherosclerosis: A Complex relationship 
Prevalence of cardiovascular problems in individuals with periodontitis is 25-50% higher 
compared with orally healthy individuals. Poor oral hygiene is a possible risk factor for 
periodontitis and the development of periodontitis is highly connected with atherosclerosis 
220. Mounting evidence indicates that periodontitis influences the process of vascular 
inflammation 181. Notably, P. gingivalis can stimulate the host to produce proteases such 
as MMPs which deactivate cytokines. MMPs activated by P. gingivalis gingipains have 
been shown to stimulate IL-1 and TNF-α at the transcriptional level 221. The initiation of the 
inflammatory response by MMP-1 (collagenase) in endothelial cells and other components 
of the artery wall is regarded as the first sign of atherosclerosis 222. Furthermore, 
epidemiological studies indicate that bacterial components such as LPS and heat shock 
proteins (HSP) in serum lead to atherosclerosis development 223. As described earlier with 
regards to the pathogenesis of periodontitis LPS stimulates monocytes or MØ by binding 
to the CD14 receptor. CD14 in myocardial infarction patients exhibits an elevated 
frequency of allele T (-260) compared with controls 224. Secondly, cross-reactivity between 
P. gingivalis and HSPs produced by the endothelium demonstrates an additional role in 
inflammation of vascular tissue and hence in causing atherosclerosis 181, 225. Finally, the 
involvement of reactive oxygen species in the periodontal lesions has been reported to 
influence tissue damage in the aorta of rats exhibiting higher levels of hexanoyl-lysine 
expression, a marker for lipid peroxidation on initiating atherosclerosis, including 
cardiovascular diseases 226, 227.  
1.4.7.3 Periodontitis and Rheumatoid arthritis: The mouth – joint connection 
Increasing evidence suggests that periodontitis and rheumatoid arthritis share a common 
pathology as a result of cytokines and MMPs. Interestingly these effector molecules and 
inflammatory cytokine profiles appear to be raised in both diseases 228. P. gingivalis 
peptidyl-arginine deiminase (PPAD), a bacterial enzyme which has the ability to transform 
arginine residues in proteins to citrulline, generates citrullinated proteins directly 
contributing to bone loss in the development of rheumatoid arthritis 229, 230. The human 
protein-arginine deiminase (PAD), an enzyme necessary for NET formation, together with 
PPAD are present in the periodontium region and mucosal oral epithelium 231. Though the 
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mechanism requires further elucidation, P. gingivalis seems to be an important factor 
likely to be associated with citrullination of autoantigens in in vivo conditions 232. 
1.5 Apoptosis – An essential death in life 
Apoptosis is a form of cell suicide and tightly-regulated programmed cell death occurs in 
the human body throughout life to support tissue development, growth and differentiation 
and pathogenic processes 233. The apoptotic machinery is proposed to remove 109 cells 
per day which comprise defective, aged or inflammatory cells in multicellular organisms 
234. A cell undergoing apoptosis goes through physical, molecular and biochemical 
transformations to help the tissue-resident professional phagocytes such as MØ, NØ, 
dendritic cells and the non-professional phagocytes such as epithelial and endothelial 
cells recognise and phagocytose 235, 236. 
Apart from developmental and aging processes, cell death also occurs during a 
pathogenic insult or during traumatic tissue damage. Not all cells undergo death on 
receiving stimuli. Indeed, corticosteroids, steroid hormones which cause thymocyte cell 
death leave other cells unaffected 233, 237. In Caenorhabditis elegans, damage in DNA fails 
to signal the P53 pathway to induce apoptosis in somatic cells due to the inactivation of 
caspase-dependent apoptosis pathways 238. This study shows that DNA damage does not 
always lead to AC death 238-241.  
When a cell undergoes death, its morphology changes. To begin with cell shrinkage 
occurs and studies using light and electron microscopy identified that pyknosis, 
condensation of chromatin and cell shrinkage, is the first noticeable characteristic feature 
of apoptosis 242, 243. Initial stages of cell death also include the appearance of blebs on the 
plasma membrane. Upon apoptosis induction, the cell gets smaller in size with the 
nucleus condensing gradually until it segregates into smaller fragments, these are termed 
apoptotic bodies (figure 7). Aggregation of ribosomes, dilation of endoplasmic reticulum 
and vacuoles in the cytoplasm are also observed. The discharged apoptotic bodies are 
later ingested by professional phagocytes and digested by lysosomal pathways. If AC 
remain uningested necrosis can occur and this is a major causative factor for chronic 
inflammatory diseases 233, 242, 243. Notably, for the above morphological changes to occur 
activation of caspases is necessary 244-247. 
Caspases are one of the important enzymes involved in regulation of apoptosis. Caspase 
activation occurs either by intrinsic or extrinsic pathways. The intrinsic pathway is 
mediated by mitochondria hence they are also termed mitochondrial pathways.  
Intracellular stress, such as oxidative stress, activates caspase enzymes by the formation 
of the ‘apoptosome’ protein complex. The apoptosome is formed by the efflux of 
cytochrome C from the permeabilized outer mitochondrial membrane which binds to an 
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adaptor molecule known as apoptotic protease activating factor 1 (APAF-1) and pro-
caspase-9 248, 249. On the other hand, extrinsic pathways are mediated by the death 
receptor pathways forming a death-inducing signalling complex (DISC). The extrinsic 
pathway is activated by death ligands such as TNF-α, FAS-L and TRAIL. The death 
ligands binds to the surface of the target cell through transmembrane death receptors (e’g 
TNF-R, Fas, Death receptors) resulting in the formation of DISC, composed of pro-
caspase 8. Upon activation of the DISC or apoptosome, the accumulation of relatively 
inactive pro-caspases results in the release of active caspase into the cytoplasm to trigger 
the caspase cascades 249, 250. Caspases play an important role in apoptosis and it is also 
argued that they play an important role in causing changes in AC morphology 243, 251-253. 
Caspase-1 has been linked with pyroptosis, a highly inflammatory form of AC death which 
occurs following infection with bacterial compounds which causes DNA damage. This 
process has been demonstrated in J774A MØ under in vivo condition 254.  
 
 
 
 
 
 
Figure 7: Stages of apoptotic cell death 
Healthy viable cells undergo programmed cell death (apoptosis). Morphological and 
biochemical changes are two characteristic features which determine the process of cell 
death. During the early stages, the first observable morphological changes are shrinkage 
of the cell membrane, resulting in dense cytoplasm due to smaller cell size appearance. 
The important characteristic features of apoptosis are condensation of chromatin followed 
by the formation of blebs. In the later stages, extensive plasma membrane blebbing 
occurs and the cell fragments in preparation to separate and form apoptotic bodies, which 
contain cytoplasm with or without the nuclear membrane fragments. The apoptotic bodies 
will later be engulfed by MØ. Phosphatidylserine, a traditional ‘’Gold standard’’ 
biochemical marker is also observed on the external leaflet of the plasma membrane, 
flipped from the internal leaflet.  
 
Of all caspases, caspase-3 (CASP3) was found to be the critical mediator of programmed 
cell death processes. Caspase-6 and -2 facilitate DNA fragmentation by triggering 
activation of DNase enzymes followed by degradation of nuclear lamina which results in 
cell shrinkage 255-257. Importantly, caspase-3 mediates the uptake of MCF7 AC by 
monocytic THP-1 and human monocyte-derived MØ (HMDM) cells by stimulating the 
release of lysophosphatidylcholine (LPC) mediated through the activation of the calcium-
independent phospholipase 258.  
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1.5.1 Apoptosis in the oral cavity 
In the oral cavity host-bacterial interactions occur at the mucosal surface and studies of 
this have facilitated our understanding of the composition of the biological fluids and 
immune cell responses involved in this process. Notably, mucosal tissues including the 
gingival tissues of the oral cavity are exposed to a wide range of microorganisms. Recent 
evidence now indicates that local tissue apoptosis drives the regulation of immune-
inflammatory responses in response to microbes, inhibiting the anti-inflammatory signals 
affecting the phagocytes at the site of infection 259. 
Caspases, Bcl-2 family proteins, tumour necrosis factor receptor (TNF-R) superfamily, 
and adaptor proteins aid in regulating the apoptotic process 260. Gamonal et al. 
demonstrated that apoptotic NØ stained with the terminal TdT-mediated dUTP-biotin nick 
end labelling TUNEL technique remained positive for active caspase-3, Fas, FasL, p53, 
and chromatin condensation in the inflammatory infiltrate from periodontitis samples and 
negative in normal healthy controls suggesting that apoptotic mechanisms play a vital role 
in the inflammatory process associated with gingival tissue destruction detected in 
periodontitis patients 261. Notably however, Bcl-2 presence was unaltered in both groups 
261. 
Other than the regulation of apoptosis-associated enzymes, a dying cell exhibits AC 
associated molecular patterns (ACAMPs) which enable recognition and uptake by the 
phagocytic receptor cells for appropriate disposal.  
1.5.2 Apoptotic-cell associated molecular patterns (ACAMPs) – ‘eat-me’ 
signals 
Over the past few decades, it has become evident that the clearance of AC by phagocytes 
is a non-inflammatory process even though innate immune receptors are involved. 
ACAMPs are specifically a subtype of ligand that binds to PRR and hence are similar to 
PAMPs 35. Additionally, Tennant et al. showed that anti-LPS Abs bind AC and so 
hypothesised that both PAMPs and ACAMPs share common epitopes 262. 
In the 1990s, the MØ vitronectin receptor (VnR), αVβ3 integrin was identified, through the 
use of antibody and peptide-mediated blockade. Data subsequently indicated that the MØ 
VnR played a significant role in recognition of AC 263. Various ‘eat-me’ markers on dying 
cells, soluble bridging molecules and their specific phagocytic receptors identified in 
recent years, highlight the remarkable complexity in efficient cell clearance. Discrimination 
of a dying/dead cell from a healthy cell requires specific markers generating a recognition 
‘synapse’ between phagocytes and their target cells 264. It is not however clear whether a 
MØ modifies their receptor levels depending on the ligands that are expressed on the 
surface of AC. Understanding the role of AC-associated ligands as ‘eat me’ signals to 
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phagocytes will provide insights into the defective AC clearance potentially linked with 
periodontitis and other persistent inflammatory disease.  
1.5.2.1 Phosphatidylserine (PS) 
The major component of the cell membrane are phospholipids. PS is located at the 
cytoplasmic side of the plasma membrane and though quantitatively relatively low in 
cellular organelles it plays a vital role within the structures of biological membranes 265. 
Most immune cells, including monocytes, mature MØ, dendritic cells and activated B cells, 
express the PS receptor (PS-R) on their surface 266-269. Activation of protein kinase C in 
the cell modifies the PS by phosphorylation via caspase enzymes and triggers PS 
movement from the inner leaflet to the outer surface membrane. This phenomenon is one 
of the major biochemical reactions which occurs during programmed cell death 270, 271.  
The translocation of PS from the inner to the outer leaflet of the plasma membrane is due 
to loss of aminophospholipid translocase activity in the inner leaflet and increased trans-
bilayer movement of phospholipids requiring calcium as a mediator 272, 273. Nevertheless, 
Bratton et al. reported that inhibition of extracellular calcium on NØ prevented the 
expression of PS on the outer surface suggesting that extracellular calcium along with the 
loss of inner leaflet of aminophospholipid translocase activity increase the expression of 
PS on the outer leaflet 274. Other than PS-R, brain angiogenesis inhibitor 1(BAI1), LDL-
receptor-related protein 1 (LRP1) and calreticulin have all been proposed to bind directly 
to PS on AC 275-278.  
PS-mediated ingestion of AC by PS-R MØ deactivates the pro-inflammatory mediators 
and thereby enhances expression of anti-inflammatory cytokines such as TGF-β1 in an 
autocrine/paracrine fashion promoting inflammation resolution 279. Notably engulfment of 
avidin-biotinylated coated erythrocytes were prevented in PS-blocked particles in MØ 280. 
Furthermore, the same study investigated that ligation of CD14, CD68, CD36, and αvβ3 
integrin resulted in adhesion of particles however the particles were substantially engulfed 
only in the presence of PS along with the non-ligated receptors. The above studies 
indicate that several receptors are involved in recognising PS on the AC to promote 
binding and engulfment by phagocytes.  
1.5.2.2 ICAM-3 
The CD50 gene encodes the intercellular adhesion molecule 3 (ICAM-3), an 
immunoglobulin superfamily member gene present in humans. The first report of AC-
associated ICAM-3 acting as an important ligand mediating recognition by MØ revealed 
that as leukocytes undergo apoptosis, surface expression of ICAM-3 reduces as it 
becomes active as an ‘eat me’ signal  281.  Moreover, membrane-distal Ig-like domains are 
the key region on apoptotic ICAM-3 for recognition by phagocytes. The distal Ig-like 
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domain of leukocyte ICAM-3  interacts with MØ leukointegrin LFA-1 to bind to viable cells 
but not for phagocytosis however adhesion/phagocytosis of AC were LFA-1 independent 
and also were not dependent on the ICAM-3 receptor αdβ2 on MØ 281. Recent research 
has shown that apoptosis stimulates release from dying leukocytes of ICAM-3 on 
extracellular vesicles in order to encourage MØ recruitment and phagocytosis of AC in 
addition to promoting a domain 1–2-dependent binding communication with phagocytes 
37. This work revealed that using anti-ICAM-3 monoclonal antibodies or the absence of 
ICAM-3 results in defective MØ chemotaxis towards apoptotic leukocytes 37. Therefore, 
next to PS, ICAM-3 is the second AC associated molecule involved in the process of MØ 
recognition and clearance of dying leukocytes.  
1.5.3 AC clearance receptors associated with phagocytes  
Phagocyte recruitment towards AC involves various receptors expressed on the surface of 
MØ, soluble mediators and the ‘find’ and ‘eat-me’ signals associated with AC. In addition, 
healthy viable cells including phagocytes can also express ‘don’t eat-me’ signals which 
can bind phagocytic receptors on MØ in order to suppress phagocytic uptake by other 
phagocytes. One of the key molecular features of the AC clearance is the expression of 
cell surface receptors expressed on the phagocytes that mediate AC binding and uptake. 
A defect in any of the receptors could lead to reduced AC clearance and hence resulting 
in disease.  However, a few studies have investigated the phenotype of mice lacking AC 
clearance receptors 282, 283.  Whilst some show no phenotype (e.g. scavenger receptor–A 
(SRA1-/-) mice) perhaps as a result of other receptors taking over the role of SRA1, others 
(e.g. CD14-/-; milk-fat-globule-EGF-factor 8, MFG-E8-/-) show defective uptake of AC by 
phagocytes but not autoimmunity 43, 284.  However defective clearance of AC and an 
autoimmune phenotype has been revealed clearly in the case of the C1q-/- mouse and the 
TG-2-/- mouse 285, 286. The glomerulonephritis mouse gene targeted to result in C1q-/- and 
TG-2-/- showed elevated number of glomerular apoptotic bodies compared to wild type. 
Also, lack of TG2 not only prevented the clearance of dying cells but also deficient in TGF-
β, associated with the development of autoantibodies.  
1.5.3.1 Scavenger receptor – CD36 
CD36 is a scavenger receptor that also acts as a receptor for wide range of ligands such 
as long chain fatty acids and thrombospondin 287. Previous research indicates that MØ 
utilise CD36 to recognise apoptotic NØ irrespective of whether their primary clearance 
mechanism utilises the PS-R or αvβ3 receptor 288. Though PS is a potential candidate in 
facilitating AC uptake by MØ, CD36 on MØ participates in ingestion by interacting with 
membrane-associated oxidised PS (OX-PS) on AC. The Mass spectrometry analysis of 
apoptotic membranes showed that OX-PS is the ligand for CD36 suggesting that CD36 
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might be another possible MØ receptor involved in engulfment of AC 289. Thrombospondin 
(TSP), a multi-functional adhesive molecule helps in mediating adhesive interactions by 
acting as a ‘’molecular bridge’’ between erythrocytes and monocytes/MØ 290-292. TSP not 
only regulates platelet-platelet interactions but it also promotes HMDM recognition of aged 
NØ by binding to Glycoprotein VI (platelet) (GPVI) associated with platelet glycoprotein 4 
and CD36 forming a trimeric complex 293, 294. CD36’s function in AC clearance was also 
demonstrated by transfecting CD36 into human Bowes melanoma cells where it improved 
the ability to ingest apoptotic NØ, lymphocytes, and fibroblasts 295. Moreover, upon 
transfecting CD36 into the monkey COS-7 cells, which naturally have a limited capacity 
for phagocytosis, these cells now showed enhanced phagocytosis of AC underscoring the 
role of CD36 in the uptake of dying cells 295. As a potential oxidized low-density lipoprotein 
(oxLDL) receptor, CD36 binds to LDL, regulated by the myeloperoxidase–hydrogen 
peroxide–nitrite system of phagocytic cells (MPO-oxLDL), enabling the synthesis of foam 
cells and regulation of plaque build-up in atherosclerosis patients 296. Following application 
of anti-CD36 mAbs, foam cell generation was downregulated by ~80% and 
monocytes/MØ deficient in CD36 exhibited reduced binding of oxLDL by 40-60% 
compared with CD36 expressing MØ. These data implicated CD36’s significance in 
uptake of oxLDL and foam cell formation 297-299.   
1.5.3.2 Low density lipoprotein receptor-related protein 1 (LRP1) CD91 
CD91 acts as a signalling partner for calreticulin which itself cannot transduce intracellular 
signals as it is a non-transmembrane protein however combined they signal the uptake 
and removal of dying/dead cells 300. The CD91-calreticulin complex regulates the collectin 
family of innate immune proteins including C1q, surfactant protein A (SP-A) and surfactant 
protein D (SP-D) to enhance the function of pulmonary murine and human alveolar MØ in 
the clearance of AC in vitro 301. SP-A and SP-D maintain tissue homeostasis in the lungs 
by binding to signal inhibitory regulatory protein α (SIRPα) through their globular head 
domains thereby downregulating Src-family kinases and p38 map kinase, suppressing 
pro-inflammatory mediator activity. On the other hand, when the globular head domains of 
SP-A and SP-D bind to pathogen-associated molecular patterns (PAMPs) or CD91-
calrecticulin complex on alveolar cells, this initiates the ingestion of AC causing pro-
inflammatory and pro-immunogenic responses, indicating that CD91 participates in 
triggering the pro-inflammatory mediators through binding to the collagenous tails of SP-A 
and SP-D in the lung environment resulting in inflammation 302. Deficiency in C1q, a 
complement component, prevents the binding of C1q to apoptotic NØ in systemic lupus 
erythematosus (SLE) with patients failing to initiate the calrecticulin-CD91 complex for the 
uptake and clearance of apoptotic NØ resulting in necrosis and tissue damage due to the 
release of noxious contents from the necrotic NØ 303. The same study also identified that 
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other than monocytes and MØ, CD91 is also expressed on NØ confirming that all 
professional phagocytes utilise the CD91-calreticulin apoptotic recognition pathway for 
engulfment processes 303. Notably as one of the α-2 macroglobulin receptors (α2MR), 
CD91 modulation affects HMDM uptake of α2-macroglobulin coated erythrocytes acting 
as an alternative ligand for CD91 301.  
1.5.3.3 CD14 
The cluster of differentiation antigen 14 (CD14), is a 55 kilodalton (kDa) glycoprotein 
expressed abundantly on monocytes and MØ but its expression is ten-fold weaker on NØ 
304, 305. Other than LPS, CD14 binds to various bacteria components such as lipoteichoic 
acid, peptidoglycan, muramyl dipeptide, Mycobacterium tuberculosis, and 
lipoarabinomannan as well as other molecules such as uronic acid polymers, and 
rhamnose-glucose polymers derived from streptococcal cell wall polysaccharides. 
Consequently CD14 is regarded as a ‘’pattern recognition receptor’’ (PRR) as it serves as 
a receptor within immune cells to detect foreign molecules to enable them to orchestrate 
the host’s immune response 306-310. Extensive studies on LPS induced TNF-α production 
on monocytes or MØ at the protein and mRNA level show that CD14 recognises a 
substantial array of ligands present on the pathogens 311-314.  
Non-myeloid cells or cells devoid of membrane bound CD14 expression utilise sCD14–
LPS complexes to interact with TLR4 to induce TNF-α expression 315. The sCD14–LPS 
complex has also been reported to activate epithelial, endothelial, vascular smooth 
muscle cells, monocytes and polymorphonuclear leukocytes 141, 316-319. Interestingly, a 
significant increase in sCD14 was observed in the saliva of periodontitis patients 
compared with healthy controls indicating that sCD14 provides a biomarker for PD 320. 
However, no difference in sCD14 levels were observed between the chronic and 
aggressive periodontitis groups 320. 
Polymorphism of CD14 has been linked with several systemic diseases. The C (-260) -->T 
nucleotide polymorphism in the promoter of the CD14 gene has been shown to affect 
myocardial infarction survival 224. In Alzheimer disease patients, CD14 expression on 
microglial cells stimulates toxic agent in the brain by binding with fibrils of Alzheimer's 
amyloid peptide causing the induction of neuroinflammatory mediators 321. Anti-CD14 
monoclonal antibodies have also been shown to inhibit bone resorption in mouse 
embryonic calvarial cells exposed to LPS indicating that CD14 might have a role to play in 
anti-resorptive therapy for bone loss 322. Since the first description of the prototypic 
monocyte/MØ immunophenotypic marker CD14 in the human immune system, research 
has come a long way 323. However it is notable that the earlier studies emphasised the 
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role of CD14 as a receptor on MØ cells vital as an essential mediator for recognition and 
phagocytosis of AC 324. 
1.5.3.3.1 Role of CD14 in AC clearance  
MØ use many receptors to recognise dying or dead cells and at least five receptors (PS-
R, vitronectin integrin with CD36- class B scavenger receptor (SR), the class A SR-A, 
ATP-binding cassette transporters (ABC1) and CD14) which are regarded as major 
molecules for the recognition and engulfment process. CD14 has been proposed as an 
important receptor in the removal of AC for cell binding and uptake by MØ highlighting 
their contribution to immunomodulatory effects of the phagocytic process 288, 325. Devitt et 
al. proposed that CD14 stimulates a distinct response in MØ upon interaction with LPS or 
AC, as LPS is pro-inflammatory and AC are regarded as being anti-inflammatory 324. This 
previous study used the anti-CD14 monoclonal antibodies 61D3 and MEM-18 to reduce 
uptake of apoptotic lymphocytes by MØ. 
Subsequently, Moffatt et al. proposed that CD14 could also bind ICAM-3; an apoptotic 
ligand which binds with MØ phagocytic receptors to enable the uptake of apoptotic Burkitt 
lymphomas (BL) cells. However to date, there has been no direct evidence that these 
molecules interact 281. CD14-dependent clearance of AC was also reported for apoptotic 
lymphocytes and apoptotic NØ demonstrating that CD14 may utilise multiple apoptosis-
associated plasma membrane structures to promote the clearance of dying cells as their 
ability is not limited to the uptake of apoptotic leukocytes. 288, 326. Also, thus far there is no 
evidence demonstrating that PS represents a ligand for CD14. 
CD14 is a molecule of significant interest as it mediates a pro-inflammatory response in 
MØ challenged with endotoxins and other bacterial components 327, 328. Notably MØ CD14, 
following binding of AC, mediates an anti-inflammatory response 329. Though 
microorganisms such as P. gingivalis are regarded as being essential to initiate 
periodontal disease, it is the host’s aggressive inflammatory response that is understood 
to exacerbate the disease. Notably P. gingivalis LPS or gingipains or poor uptake of AC 
clearance could be essential in this process and the involvement of CD14 will be 
discussed in further detail in this thesis.  
1.5.4 Soluble mediators of AC clearance: ‘bridging’ molecules 
To facilitate phagocyte binding to AC, numerous bridging molecules have been identified, 
serving as extracellular mediators which ‘decorate’ AC to enable engulfment by MØ. 
Expression of PS on the AC surface binds to milk-fat-globule-EGF-factor 8 (MFG-E8), 
growth arrest-specific 6 (Gas6), β2-glycoprotein I (β2-GPI) and protein S, all of which aid 
in additional recognition by the phagocyte for AC uptake 43, 330-332. The Arg-Gly-Asp (RGD) 
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motif present in the second epidermal growth factor (EGF) domain of MFG-E8 binds to 
αvβ3 and αvβ5 integrins and interacts with oxidised PS to a high degree and to a lesser 
degree with non-oxidized PS and phosphatidylcholine (PC) serving as an opsonin for AC 
43, 333. αvβ3 and αvβ5 integrins promote complement-dependent clearance of AC by 
associating with complement receptor 3 and 4 on MØ stimulating the attachment to C3b/bi 
activation sites on the AC 40. Gas6 mediates uptake of PS liposomes and AC by acting as 
a ligand for the tyrosine kinase family receptor Axl/Mer/Sky to facilitate the clearance of 
PS-expressing AC 330. Additionally, PS liposome clearance by MØ in in vitro phagocytosis 
was also shown to be mediate by β2GPI 331. Other than this collagenous tails from 
collectin family members and binding to calreticulin triggers LRP-1/CD91 signalling for 
their uptake by phagocytes 302. Also, TSP-1 binds to TSP-1 binding sites on the surface of 
AC triggering the MØ-associated with integrin αvβ3/CD36 for the engulfment procedure 294. 
Moreover, the modified sugars and/or lipids on the AC surface also play a role in assisting 
in tissue homeostasis by clearing dying/dead cells 334, 335. 
1.5.5 Don’t ‘eat me’ signals 
To discriminate a viable cell from a dying/dead cell, ‘eat me’ signal inhibitors might be 
present on viable cells in order to avoid accidental phagocytotic ingestion. A healthy viable 
cell declares ‘’don’t-eat me’’ by expressing ligands that cause repulsion/detachment of the 
phagocytes.  This signal will be dominant even if the viable cell also presents ‘eat-me’ 
ligands.  However during AC death, only ‘eat me’ signals are expressed so the cells are 
cleared by phagocytes 336.  
1.5.5.1 CD31 
Initial studies on CD31, also known as platelet endothelial cell adhesion molecule-1 
(PECAM-1), established that it was required for transmigration of leukocytes across 
vascular endothelial cell membranes through intracellular junctions 337. Brown et al. 
demonstrated that CD31 on a viable cell interacts with the phagocyte CD31 homotypically 
to promote a repulsion mode after initial tethering ultimately resulting in prevention of 
engulfment. However, CD31 on a AC on interaction with the phagocytes CD31 switch 
from a repulsive to an adhesion mode preparing the cells to tether prior to being engulfed 
by the phagocytes 338. 
1.5.5.2 CD47 
CD47 is expressed by many cell types and is an integrin-associated membrane protein 
which binds to signal-regulatory protein alpha (SIRP-α) and upregulates Src homology 
region 2 domain-containing phosphatase-1 (SHP-1) to prevent the uptake of AC 339-341. 
Reduced or altered CD47 expression occurs on cells undergoing apoptosis and is used as 
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a marker for ‘find and eat me’ due to the inactivation of SIRP-α signals 275. Other than 
CD31, transendothelial migration of NØ requires CD47 molecules on their surface in order 
to reach inflammatory sites across the endothelium 342. Increased CD47 expression on the 
surface of NØ correlates with increased efficiency of NØ transmigration 343. CD47-
deficient mice infected with E.coli to induce peritonitis show a delay in accumulation of NØ 
at the infected sites indicating CD47 is necessary to mediate NØ inflammatory responses 
344. Moreover, CD47-dependent NØ chemotaxis is observed in NØ stimulated with the 
RGD motif of entactin, a component of basement membranes and leukocyte response 
integrin (LRI), suggesting the interactions between NØ and entactin occur through CD47 
molecules 345. Therefore, CD47 not only aids in differentiating viable and AC but is also 
involved in NØ adhesion and migration.  
1.5.5.3 CD46 
Other than the above described receptors, CD46, a complement protection factor, is also 
involved in signalling as ‘’don’t – eat me’’. Modification or losses of CD46 are observed in 
caspase-dependent apoptotic Jurkat cells resulting in their clearance while viable cells 
expressed uniform CD46. Additionally, cleavage of caspase 3 in senescent keratinocytes 
and ionophore-treated sperm cells showed CD46 on apoptotic blebs or microparticles 
confirming the redistribution of CD46 into patches from the viable cell surface to apoptotic 
membrane bodies 346. Collectively, this shows that viable cells are tested constantly to 
prove they are alive to avoid their ingestion by phagocytes by potentially masking the 
‘eat–me’ signals. 
1.6 Phagocytosis 
Phagocytosis plays a key host defensive role against foreign species’ invasion by 
ingesting the microorganism and generating protective responses e.g. antibodies and T 
cells 347. AC clearance is essential for the maintenance of normal tissue structure and 
function and phagocytosis plays a key role in this process. The dying cell and the released 
apoptotic bodies are engulfed by the cell membrane of phagocytic cells forming a large 
fluid vesicle termed a phagosome. During this process the phagocyte e.g. a MØ, becomes 
activated and induces healing of the damaged tissues by modulating inflammation 348. 
This clearance phase is regarded as the most important process in the apoptosis 
programme as it removes dead cells associated with inflammation, infection and tissue 
homeostatic process 349. The presence of pattern recognition receptors such as Toll-like 
receptors in MØ and NØ, two major professional phagocytes, facilitates the differentiation 
between cells of the host and the pathogen. Acute inflammation, which represents the 
initial response, attracts phagocytes by generating cytokines and chemokines in addition 
to the complement peptides C3a, C4a, C5a which have the ability to kill bacteria directly 8. 
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The engulfment of AC is essential to avoid further tissue inflammation as every dead cell 
carries intracellular components that are potentially toxic and can stimulate the immune 
system 350. Invading microbes are disarmed by NØ, the first recruited line of defence in the 
innate immune system, by producing antimicrobial species to avoid spreading the 
infection in the host. Professional phagocytes have a higher degree and ability for 
phagocytosis compared with non-professional phagocytes. While there are differences in 
clearance kinetics the mechanisms involved in clearing up dead cells are similar 236. 
1.6.1 NØ 
Polymorphonuclear NØ are the predominant white blood cell and research has shown that 
NØ ‘decide’ the fate of the inflammation either by resolving it or by exacerbating it. Packed 
with an armoury of anti-microbial granules, NØ differentiate from bone marrow 
transcriptionally and translationally and they undergo a second round of transcription 
regulation referred to as the ‘’immune response programme” on entering inflamed tissue 
to promote wound healing and achieve tissue homeostasis 351, 352. Antigen peptides 
produced from digested pathogens, phagocytosed by MØ and dendritic cells, are 
presented by MHC class II molecules, presenting these cells to CD4 T-cells. Indeed 
cytokine activated NØ display an up-regulation of MHC molecules whereas resting NØ 
lack these professional antigen presenting molecules 353. The concept of NØ function as 
antigen presenters has been rejected by many researchers because of the short lifespan 
of NØ. However NØ interactions with the adaptive immune system work through NØ 
soluble mediators and cytokine production contributing to their influence on the immune 
response. 
1.6.1.1 NØ in periodontal disease 
Leukocytes from periodontitis patients triggered lymphocyte transformation, from small 
resting lymphocytes to large cells on exposure to oral bacteria resulting in cell-mediated 
immune response and this marked a significant breakthrough in the pathogenic 
understanding of PD 354. This was followed by a demonstration that NØ from localized 
juvenile periodontitis (LJP) are impaired in their chemoattractant ability and this was the 
first systemic abnormality demonstrated in patients with severe PD 355. NØ are found in 
large numbers in the gingival crevice, periodontal pockets and saliva derived from the oral 
cavity 351, 356. Granulocyte monocyte-colony stimulating factor (GM-CSF) reduces NØ 
apoptosis in gingival crevicular fluid (GCF) by regulating Bax expression exerting control 
over the lifespan of NØ in the oral cavity 190. Moreover, smoking influences the inhibition of 
NØ apoptosis in the gingival connective tissue of chronic periodontitis patients 357. These 
studies indicate that delayed apoptosis may contribute to tissue destruction in the infected 
PD patients. On the other hand, necrotic NØ (30%) are found in higher numbers 
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compared with apoptotic NØ (1%) in the gingival crevice, periodontal pockets and in the 
saliva from the oral cavity 356. These necrotic NØ might be present due to the failed 
clearance of AC and thus have been allowed to proceed to secondary necrosis though the 
nature of the defect is unknown. 
CXCL12, also known as stromal cell-derived factor-1, is increased in GCF from 
periodontitis patients along with other chemoattractants produced by immune cells, (e.g. 
IL-8, IL-1β, C5a) and exogenous chemotactic signals, (e.g. LPS, FMLP) 358. These 
attractants may be responsible for NØ trafficking at the crevicular site and if AC clearance 
is not sufficient they may become necrotic. Over recent years, peripheral NØ hyper-
responsiveness and impaired NØ function have been proposed as a major cause of tissue 
destruction in periodontitis 359-361. The Fc-γ receptor in NØ reportedly mediates hyper-
reactivity and oxygen radical release resulting in tissue damage in patients with oral 
inflammation 362. Indeed higher levels of reactive oxygen species have been shown to be 
generated by chronic periodontitis patients 363, 364. Studies on the recruitment of NØ to the 
subgingival area support either a reduction or increase in phagocytosis by NØ, 
subsequent release of NØ elastase and reactive oxygen species purportedly contributes 
to the destruction of the periodontal tissue 97, 365-369. Notably elastase from NØ has been 
reported to cleave CD14, an established AC clearance receptor on MØ resulting in 
impairment of apoptotic lymphocyte clearance 370. 
During gingivitis, the microenvironment around the tooth surface is activated by 
inflammatory infiltrates enhancing the serum level of TNF-alpha and IL-1 which affects NØ 
function 371. Decreased priming activity and chemotaxis of NØ were found towards 
gingipain-treated IL-8 from immune 72-amino-acid variants on subsequent exposure to 
FMLP. However exposure to gingipain-treated IL-8 from non-immune 77-amino-acid 
variants and exposure to FMLP resulted in enhanced oxidative burst activation and 
chemotactic activity of NØ suggesting that, depending on the cellular source of the 
chemokine, gingipains regulate their effects differentially by modulating NØ activation and 
chemotaxis 193. 
NØ in their activated form also utilise a defence mechanism, NETs that ensnare and kill 
pathogens in the human body. These NETs are composed of DNA, histones and anti-
microbial granules which entrap microbes and degrade their virulence factors 372. The 
formation of NETs was initially observed in humans by Brinkmann 27. NETs can be 
generated within 10 minutes, depending on the dose and nature of stimuli. Virulence 
factors and exposure to LPS, IL-8 or phorbol myristate acetate (PMA) showed flat 
membrane protrusions with smooth fibres and globular domains together with granule 
proteins and chromatin forming an anti-microbial extracellular structure 27. The 
mechanisms by which NØ produce NETs remains to be fully understood. Recently NETs 
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have been found to be abundant on the gingival surface during periodontitis progression 
in the GCF and are flushed out of the gingival pocket by the crevicular exudate 373. 
Inflammatory exudate samples from periodontitis patients, analysed using scanning 
electron microscopy and immuno-staining for confocal laser scanning microscopy, 
demonstrated the abundance of NETs in GCF and periodontal pockets 28, 373, 374. 
Atherothrombosis patient samples have also been shown to contain P. gingivalis DNA in 
increased levels along with the presence of NETs suggesting that periodontal bacteria 
may impact via NET stimulation on other systemic diseases 375. The influence of NETs in 
modulating the host-pathogen interaction through immune cells and protection against the 
inflammatory environment in PD are yet to be fully elucidated.  
1.6.1.2 NØ elastase in periodontitis  
The activation of NØ results in NØ elastase release, which is a serine protease that is 
secreted in azurophilic granules to destroy bacteria. Notably NØ elastase-deficient mice 
have shown susceptibility to Gram-positive and Gram-negative bacteria 376. However, 
increased NØ elastase activity along with MMP-9 has been found in chronic periodontitis 
patients compared with healthy controls 377. Moreover, NØ elastase has been reported to 
cause tissue destruction in the periodontium region by digesting the non-collagenous 
proteins which protect the collagen fibrils involved in the maintenance of supporting 
vasculature of the gums 378. The previous report also stated that NØ were hyperactive in 
chronic and aggressive periodontitis patients in terms of NØ elastase levels found in the 
gingival crevicular fluid 368. Also, phagocytosis of P. gingivalis by NØ has been shown to 
lead to increased levels of NØ elastase and reactive oxygen species release which attack 
not only the pathogens but also the host cells indicating the ability of periodontal bacteria 
to modulate the host response 368.  
NØ elastase has also been shown to play a role in migrational activities. NØ elastase-
deficient mice exhibit reduced adhesion and transmigration towards zymosan particles 
indicating a non-redundant role of NØ elastase in this process 379. In contrast, another 
recent study showed that the CD14 receptor was cleaved by NØ elastase on MØ resulting 
in prevention of phagocytosis of apoptotic lymphocytes 370. These findings are also further 
supported by work from Nemoto et al. who demonstrated the cleavage of platelet-derived 
growth factor receptor (PDGF) by NØ elastase on periodontal ligament cells 380. Taken 
together, data indicates that increased levels of NØ elastase such as in periodontitis 
patients might result in cleavage of receptors essential for cell clearance and growth factor 
induction and thereby resulting in compromised bacterial invasion at the periodontal sites.  
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1.6.2 MØ 
MØ are a phagocytic cell activated in response to an infection and they differentiate from 
circulating blood monocytes as they enter tissues 381. Notably an inflammatory stimulus 
(e.g. microbial components) can trigger infiltration of immune cells comprising NØ, MØ, 
and lymphocytes. LPS is an important outer membrane component of Gram-negative 
bacteria, which activates MØ at the site of infection to elaborate pro-inflammatory 
cytokines such as IL-1 and TNF-α 36, 382.  These molecules, in association with PGE2 and 
hydrolytic enzymes, generate strong pro-inflammatory gradients leading to the destruction 
of the primary human periodontal epithelium and bone resorption 383 (figure 8).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8:  Illustration of activation of MØ challenged with LPS in PD 
LPS in association with lipopolysaccharide-binding protein (LBP) associates with MØ and 
mediates production of pro-inflammatory mediators resulting in activation of fibroblasts. 
This activation leads to the production of PGE2 and MMPs which resorb alveolar bone 
and damage the connective tissue in periodontal disease. Adapted from 69. 
 
Clearance of dead cells and activation of anti-inflammatory responses is a major role 
performed by MØ phagocytosis 324, 384. Earlier studies have reported that MØ attraction 
towards AC followed by cell corpse clearance is an essential phase in the phagocytosis 
process necessary to achieve tissue homeostasis 37. Failure of AC clearance has been 
demonstrated in both the C1q-/- and the transglutaminase TG-2-/- knock out mice and 
underlines their association with an autoimmune mechanism 285, 286. 
Notably monocytes and MØ are activated by oral pathogens, such as A.  
actinomycetemcomitans and P. gingivalis leading to secretion of pro-inflammatory and 
Activation of 
MØ 
PGE2 IL-1 TNF-α MMPs 
Activation of 
resident 
fibroblast 
Production of 
inflammatory 
mediators 
PGE2 
MMP 
  MØ Modulation by 
genetic factors 
Extracellular 
matrix 
destruction 
Alveolar 
bone 
resorption 
TLR4 LPS CD14 
LBP 
Introduction 
51 
 
tissue-destructive mediators 385. Reports demonstrate that, compared with minimally-
inflamed tissues, chronic periodontitis comprises no increase in MØ recruitment however 
failure of the activation process may underlie the pathological process of PD 386. 
Moreover, this premise has been supported by a recent report indicating that periodontal 
pathogens can modify MØ migration and activation by preventing the production of 
monocyte chemoattractant protein-1 (MCP-1), a key chemokine which regulates infiltration 
and migration of MØ 387.  The project presented here also focused on the migratory role of 
MØ towards apoptotic NØ and determined whether P. gingivalis components effect the 
MØ phagocytosis function. Findings might shed further light on the inflammatory 
mediators involved with the periodontal environment. 
MØ play an indispensable role in the initiation, maintenance, and resolution of 
inflammation by controlling the release of pro- and anti-inflammatory mediators in 
responses to different immune challenges. MØ can be classified into two polar types, by 
their specific function in inflammation, as M1 or M2. M1 have been identified as having a 
pro-inflammatory role contributing to driving disease whilst M2 aid in resolving 
inflammation via production of anti-inflammatory cytokines. MØ that clear AC are skewed 
towards an M2 phenotype by producing anti-inflammatory cytokines aiding AC clearance 
and restoring tissue homeostasis 388. A strong M1 host response potentially plays an 
important role in chronic adult periodontitis progression along with the causative bacteria. 
Indeed, the host response is considered to be protective however tissue destruction is 
known to take place when there is a hypo-responsiveness or hyper-responsiveness by the 
host immune system 389. Furthermore, increased severity of periodontitis can be 
associated with diseases caused by impairment of the immune system e.g 
agranulocytosis, leucocyte adhesion deficiency, leukaemia, cyclic neutropenia and 
thrombocytopenia 52. Indeed, chronic periodontitis serves as an experimental model for 
the understanding of systemic diseases that are triggered by inflammatory pathways 390. 
Although the host immune response impacts on periodontal inflammatory disease it is 
also the environmental factors that regulate immune-inflammatory mechanisms 
contributing to the manifestations of the disease (Table 2).  
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Risk Factors Association with periodontitis Cell defect Reference 
Smoking 
Upregulation of TLR4 mRNA expression was 
found in periodontitis patients who smoked 
compared with non-smoking periodontitis 
patients. 
Reduced NØ count and NØ elastase 
activity have been reported. Additionally, 
increased Th2 response was found in 
smoking periodontitis patients which 
have been linked with autoimmune 
disease. 
391-393 
Psychological 
factors 
Activation of hypothalamus secretes mediators 
due to chronic stress stimulating the release of 
glucocorticoid hormones which in turn 
activates interleukins.  Increased production of 
IL-6 in response to psychological stress has 
been associated with depression and negative 
thoughts thereby having an impact on oral 
hygiene. 
The release of glucocorticoid from the 
adrenal cortex reduced the recruitment of 
immune cells and inhibited the immune 
response by inhibiting MØ antigen 
presentation. 
394-396 
Genetic factors 
Studies of identical twins indicate that genetic 
predisposition plays a role in causing 
periodontitis. 
A study in the Turkish population 
indicated gene variation in 
myeloperoxidase (MPO) and nitric oxide 
synthase contributes towards aggressive 
periodontitis. 
397-399 
Ageing 
Butyric acid, a secondary metabolite released 
by the periodontopathogenic bacteria, has 
been reported to associate with oxidative 
stress induction. Subsequently, studies show 
that oxidative stress has a potential impact on 
age-related disease. 
NØ function declines with age notably 
affecting phagocytosis process and 
higher gene expression of pro-
inflammatory cytokines in NØ has also 
been reported. 
400, 401 
                                                              
Introduction 
53 
 
Pre term delivery 
Research indicates that premature labour and 
low-birth-weight (PLBW) babies may be 
affected by the inflammation triggered by 
bacteria which can travel to the blood stream 
and affect the foetus. It is also indicated that 
pre-term delivery may be an independent risk 
factor associated with periodontitis but not 
directly causative. 
Unknown 402, 403 
Other systemic 
disease 
Agranulocytosis and leukocyte adhesion 
deficiency were related to impairment in NØ 
function though they are not proven to have a 
definitive association with periodontitis. 
NØ dysfunction diseases 404, 405 
 
Table 2: List of risk factors associated with PD 
The table shows the environmental risk factors associated with PD and their involvement in modulation of specific cell types via their receptors. 
The table also presents information as to how the modulation of cytokine production might provide a further factor that contributes to 
periodontitis. 
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1.6.2.1 Chemotaxis of MØ in periodontal environment 
Recruitment of monocytes and MØ to the gingival sites in response to bacterial infection is 
a key factor involved in inflammation of periodontal sites 406. The continuous influx of 
phagocytes indicates the challenge to stabilise wound healing by resolution pathways. 
Initiation of systemic diseases linked with oral disease underlines the potential importance 
of immune cell migration to carry bacterial toxins or impaired immune cell responses in 
causing tissue destruction at sites other than the primary site of infection. Both MØ and 
endothelial cells recruit inflammatory monocytes via CCR2 to the inflamed tissue 31, 407. 
However, increased amounts of chemokines can result in the tissue damage observed in 
periodontal tissue. MØ chemokine protein (MCP-1), another chemokine involved in the 
recruitment of monocytes/MØ has been reported to be expressed in greater amounts in 
periodontal gingival tissues resulting in increased infiltration of monocytes and increased 
severity of disease 408. In addition, MØ inflammatory protein 1 alpha (MIP-1α), IFN-
gamma-inducible protein-10, CCR3, and CCR5 have been reported to be elevated in 
inflamed human gingival tissue compared with healthy controls. These data suggest that 
these active chemokines might be responsible for the accumulation of immune cells at the 
infected sites in the periodontitis patients 409, 410. Moreover, MØ migration inhibitory factor 
(MIF) deficient mice exhibited reduced bone resorption by inhibiting differentiation and 
activity of osteoclasts and also decreased infiltration of NØ along with increased 
production of IL-10 411.  
During inflammation the immigrated monocytes from the blood differentiate into classical 
MØ which are equipped with TLRs and receptors to enable cell clearance. Impairment of 
MØ phagocytosis by A. actinomycetemcomitans, a periodontal pathogenic bacterium, has 
been reported causing significantly less phagocytosis activity compared with wild-type MØ 
and the underlying reason for this has been associated with higher TNF-α in periodontitis 
patients 411. Also, the type and the level of cytokines in GCF indicates the coordination of 
MØ in achieving tissue homeostasis 412-414. Overall, these data indicate that the regulation 
of immune-inflammatory mechanisms in PD is largely governed by the aggressive 
inflammatory mediators initiated by the oral microorganisms 214.  
Once the MØ have cleared the pathogens and AC, it is important for the MØ to emigrate 
the inflamed tissue and enter the lymph nodes. At the lymph nodes, the MØ stimulate T 
cells in order to activate the adaptive immune system 415. This process has been shown to 
be inhibited in PD due to the infiltration of CD4+ and CD25+ T cells in the periodontal 
lesions suggesting that regulatory T cells might play an important role in regulating PD 416. 
However, the reason for this T cell infiltration is yet to be determined.  
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While the above studies indicate that the infiltration of phagocytes or other immune cells 
are an underlying problem in the periodontal environment, in this thesis the reasons for 
the persistence of the AC were examined by studying the role of MØ migration on 
exposure to bacteria or their components. Given the previous lack of knowledge, this 
study examined the efficiency of MØ migration following exposure to gingipains from P. 
gingivalis using quantitative and qualitative measurements in various chemotaxis models.  
1.7 Aims and objectives 
Gingipains, proteolytic enzymes from a major aetiologic agent P. gingivalis, are 
associated with PD and reportedly are a major cause of evasion of the host immune 
system and tissue destruction in the inflamed oral region. A growing body of research 
suggests failure to restore homeostasis may be a major factor involved in the 
pathogenesis of chronic inflammatory periodontal diseases and the main toxic agent is 
gingipains which act by “confusing” phagocytic cells’ recognition and phagocytosing ability 
of AC. While previous studies have established AC clearance mechanisms underlying the 
non-inflammatory physiological clearance of dying cells, there is minimal work that has 
studied how these mechanisms are affected by pathogens in disease. This project seeks 
to address why there appears to be poor inflammation resolution in PD and whether this 
results from defective AC clearance. Though inflammatory NØ have been identified widely 
as a major cause for aberrant inflammation in periodontitis patients, to date there has 
been no study aimed at the ability of MØ phagocytosis in the gingipain-exposed 
environment. Therefore this project aims to analyse for the first time the AC clearance 
mechanisms involved in PD by scrutinising MØ receptors associated with clearance and 
MØ migratory and phagocytosing ability in addition to the inflammatory mediators 
associated with apoptotic human NØ (figure 9). This research may open up new 
strategies for intervention in the disease process. 
The hypothesis underlying this project is that MØ lose their ability to find, recognise and 
phagocytose AC due to their cleavage of AC clearance receptors by factors released from 
P. gingivalis prompting a dominant inflammatory response causing the tissue destruction 
observed in periodontal disease.  
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Figure 9: Possible scenarios involved in the AC clearance mechanism within PD 
1) MØ receptors essential for AC clearance bind to ‘eat-me’ ligands expressed on the 
surface of an AC for the uptake and phagocytosis resulting in an anti-inflammatory 
response. 2) The ability of MØ receptor on exposure to bacterial virulence such as LPS or 
gingipains from P. gingivalis, might be dysregulated by cleaving essential AC clearance 
receptors. 3) Failure of uptake of AC due to the cleaved receptors on the phagocytes 
results in inflammation. 4) If the AC were taken up by the non-cleaved MØ receptors this 
might produce a dominant inflammatory response by suppressing anti-inflammatory 
mediators in the host immune system.   
 
In order to address this hypothesis, the specific aims and objectives of this project are 
1) To establish an in vitro model for AC clearance using THP-1 MØ and primary 
apoptotic NØ. 
2) To purify and characterise the ~50 kDa and ~60kDa RgpB and Kgp respectively 
from P. gingivalis. 
3) To determine MØ migrational and phagocytosis ability towards AC human NØ in 
the gingipain environment. 
4) To quantify the capacity of AC NØ in inhibiting the inflammation induced by 
gingipains and LPS by measuring the pro- and anti-inflammatory mediators at 
protein and gene expression levels. 
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Chapter 2 
Materials and Methods 
2.1 Equipment and software 
 Anaerobic chamber (Don Whitley Scientific, UK) 
 Avanti J-E centrifuge (Beckman Coulter, UK) 
 Benchtop centrifuge (Sigma, Germany) 
 Biosafety cabinet (Thermo Fisher Scientific, UK) 
 Cell-IQ Analyser™ software (CM Technologies, UK) 
 Cell-IQ tracking system device (CM Technologies, UK) 
 Chemotaxis Dunn CTG chamber, DCC100 (Hawksley and Sons Ltd, UK) 
 Chromata-Vue C71 light box and UVX radiometer (UV-P Inc, USA) 
 Cryo-freezing container NALGENE (Fisher, UK) 
 Eppendorf Centrifuge 5810R (DJB Lab care Ltd, UK)  
 Flow cytometer cytomics FC 500 (Beckmann Coulter, UK) 
 FlowJO Version 10 software (FlowJo INK, USA) 
 Gel imaging for fluorescence and chemiluminescence G: BOX Chemi XRQ 
(Syngene, UK) 
 Gyro-rocker (SSL3, UK) 
 Haemocytometer double cell standard (Camlab Ltd, UK) 
 Ibidi web tool for Chemotaxis and Migration 
(http://ibidi.com/xtproducts/en/Software-and-Image-Analysis/Manual-Image-
Analysis/Chemotaxis-and-Migration-Tool) 
 Image J web tool (https://imagej.nih.gov/ij/) 
 Incubator (Sanyo Biomedical, Europe) 
 Inverted fluorescence microscope Zeiss Axiovert 200M (Zeiss, UK) 
 Inverted microscope (Nikon Eclipse, Europe) 
 Minigel Vertical Electrophoresis Apparatus and Western Blot wet transfer system 
(Bio-Rad, UK)  
 Nanodrop 1000 spectrophotometer (Thermo Scientific, UK) 
 Optima L-look Ultracentrifuge (Beckman Coulter, UK) 
 Orbital shaker (Thermo Fisher Scientific, UK) 
 Plate reader EL800 (BioTek Potton, UK) 
 Plate spinner, Perfect spin (Peqlab, Germany) 
 qPCR software MxPro-Mx3000P SYBR Green software (Thermo Fisher Scientific, 
UK) 
 Spectrophotometer Model DU-7 (Beckman Instrument (UK) Ltd, UK) 
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 Stratagene Mx3000P (Thermo Fisher Scientific, UK) 
 70Ti rotor (Beckman Coulter, UK) 
2.2 Antibodies 
Mouse (Affymetrix eBioscience, UK) 
 Mouse IgG1 K Isotype control PE (clone P3.6.2.8.1) 
 Mouse IgG1 K Isotype control FITC (clone: P3.6.2.8.1) 
 Mouse IgM Isotype Control FITC (clone: 11E10) 
Anti-mouse (Sigma-Aldrich, UK) 
 Anti-Mouse IgG (whole molecule) – FITC antibody produced in goat  
 
 Anti-human IgG (Fc specific)-FITC, mouse IgG1 (MOPC 21) 
 
Anti-Human (Affymetrix eBioscience, UK) 
 Anti-Human CD47-FITC (clone: B6H12) 
 Anti-Human CD31, PE (clone WM-59)  
 Anti-Human CD36, FITC (clone: eBioNL07)  
 Anti-Human CD91, PE (clone A2MR-92) 
Biotin binding protein (Life technologies, UK) 
 Streptavidin HRP  
2.3 Cell culture 
2.3.1 Materials and reagents for cell culture 
All reagents for this study were supplied by Sigma - Aldrich, UK unless otherwise stated. 
Complete Roswell Park Memorial Institute medium (cRPMI): cRPMI was used as a 
suspension growth medium for the human-derived cells in this study. RPMI 1640 was 
supplemented with penicillin (100U/ml) (PAA Laboratories, UK), streptomycin (100µg/ml) 
(PAA Laboratories, UK), 2 mM L-glutamine (PAA Laboratories, UK) and 10% (v/v) foetal 
calf serum (FCS) (PAA Laboratories, UK). 
Serum-free medium (sfRPMI): RPMI was supplemented with penicillin (100U/ml) and 2 
mM L-glutamine. 
Phagocyte interaction with AC assay medium: Serum-free medium (sfRPMI) 
supplemented with 0.2% w/v BSA.  
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Cell freezing medium: 5% (v/v) Dimethyl sulphoxide (DMSO) in FCS. The cell lines were 
frozen using the Cryo-freezing container (Fisher, UK) prior to storing in liquid nitrogen.  
MØ medium (Sigma Aldrich, UK): To study MØ migration using DUNN chamber the MØ 
medium was used as a negative control.  
Flow wash buffer: PBS containing 1% (w/v) BSA. 
Cell fixative: 1% (w/v) formaldehyde in PBS. 
PMA: 250µM stock made up in absolute ethanol (CEAC, UK). 
Dihydroxyvitamin D3 (VD3) (Enzo Life Sciences, UK): 100µM stock diluted using 
RPMI+10% FCS following solubilization in DMSO.  
2.3.2 Cell lines 
THP-1: A human monocytic leukaemia cell line. THP-1 cells can be differentiated into MØ-
like cells using a range of stimulants 36. 
Mutu: This EBV-positive Burkitt lymphoma cell line (B - cell line) were kindly provided by 
Professor Christopher D Gregory (University of Edinburgh, UK) 417  
All cell lines were routinely cultured by passaging them every 48-72h and maintained at 
37°C, 5% CO2 humidified incubator. Depending on the size of the Cell Culture 
EasYFlasks™ (Thermo scientific, UK), the required number of cells were left in the flask 
and resuspended in pre-warmed cRPMI.  
2.3.3 Freezing and thawing of cell lines 
Liquid nitrogen was used for storage of cells in cryovials. Before freezing, the cells were 
checked for viability. 5 X 106 cells were centrifuged (300xg for 5 min) from the suspension 
culture and the pellet resuspended in 1 ml of cell freezing medium (as described in section 
2.3). Before transferring the culture aliquots to cryovials, the cryovial was labelled with the 
cell line details, followed by the passage number and the date of freezing the cells. The 
cryovial was then placed in a cryo-freezing container (Fisher, UK) at -80°C for 24h and 
then transferred to liquid nitrogen vapour for long-term storage.  
Cell thawing was performed by placing the frozen cryovial of cells in a water bath at 37ºC.  
In a biosafety cabinet, the defrosted cells were transferred into a centrifuge tube 
containing cRPMI medium and cells were then centrifuged at 300xg for 5 min and the 
pellet resuspended in cRPMI media (as described above) prior to culturing. Cells were 
seeded in Cell Culture treated EasYFlasks™ and cultured at 37ºC, 5% CO2 in an 
incubator. 
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2.3.4 Culturing of cells 
THP-1 and B cell lines were cultured in cRPMI and maintained at 37ºC in 5% CO2 
humidified incubator.  Cells were passaged at an interval of 48-72h to avoid high levels of 
confluence and appropriate cells were counted using a graduated haemocytometer and 
maintained at a density of 2 x105 - 1 x 106 cells/ml by feeding the cells with the fresh pre-
warmed (37ºC) culture medium.  
2.3.5 THP-1 differentiation to MØ-like cells 
THP-1 cells were differentiated into MØ-like cells by treating cultures in fresh medium with 
either 100nM dihydroxy vitamin D3 (VD3) or 250 nM PMA or double-stimulated (DS) with 
both VD3 and PMA for 48-72h at 37ºC in 5% CO2 incubator 36. 
2.3.6 Immunofluorescence 
2.3.6.1 Indirect Immunofluorescence staining of cells 
VD3 or DS stimulated THP-1 differentiated MØ (1 X 106 cells/ml) or NØ (1 X 106 cells/ml) 
were washed in the flow wash buffer (as described in section 2.3) by centrifugation for 
300xg for 5 min and incubated with 100µl of primary antibodies anti-CD14 clones 
61D3/63D3 (1:100 made in house) or IgG1 k isotype- control MOPC 21 (20 µg/ml) for 20 
min on ice in the dark. Cell surface expression of ICAM-3 was detected with 100µl of anti- 
ICAM-3 clone MA4 (1:100 made in house) or the isotype control MOPC 21 (20 µg/ml) for 
20 min on ice in the dark. Following incubation, the cells were washed three times with 
flow wash buffer. 100µl of goat anti-mouse FITC was used as a secondary antibody at a 
dilution of 1: 100 for cells stained with the primary antibody and incubated again for 20 
min on ice in the dark and the cells were washed again three times with flow wash buffer. 
Cells were then fixed with 500µl of 1% w/v formaldehyde and analysed immediately using 
flow cytometry (as described in 2.1) or stored at 4°C until further analysis. 
2.3.6.2 Direct Immunofluorescence staining of cells 
Cell surface expression of the molecules CD31, CD91, CD47 and CD36 was determined 
using direct immunofluorescence assay as described in Table 3. To the VD3 or DS 
differentiated THP-1 MØ (as described in section 2.3.5) 5µl of appropriate primary 
antibody conjugated with the fluorochrome or 5µl of appropriate isotype control conjugated 
with fluorochrome was added and then incubated for 20 min on ice in the dark. Following 
incubation, the cells were washed three times with the flow buffer and fixed with 500µl of 
1% w/v formaldehyde and analysed immediately using flow cytometry or stored at 4°C 
until further analysis. 
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Receptor 
Antibodies conjugated with 
fluorochrome 
Isotype control 
conjugated with 
fluorochrome 
CD36 
anti- human CD36 conjugated with 
FITC (0.125 µg/ml) 
mouse IgM isotype control 
FITC (0.15 mg/ml), 
CD91 
anti- human CD91 conjugated with 
PE (0.06 µg/ml) 
mouse IgG1 K isotype 
control PE (0.5 µg/ml) 
CD31 
anti- human CD31 conjugated with 
PE (0.125 µg/ml) 
mouse IgG1 K isotype 
control PE (0.5 µg/ml) 
CD47 
anti- human CD47 conjugated with 
FITC (1 µg/ml) 
mouse IgG K isotype control 
FITC (1 µg/ml) 
 
Table 3: Direct immunofluorescence staining using flow cytometry 
List of primary antibodies conjugated with fluorochromes and their appropriate isotype 
control studied for direct immunofluorescent staining of cell surface receptor expression 
on MØ-like cells analysed using flow cytometry.  
2.4 Isolation of NØ from peripheral whole human blood using the Percoll 
gradient method 
2.4.1 Materials for isolation of NØ  
 Winged infusion set needle 21G X 0.75’’ X 12”, tourniquet, Vacuette holdex, BD 
Vacutainer EDTA, cotton balls, plasters were all purchased from Nu-Care 
Products, UK. 
 Percoll (GE Healthcare, UK) 
 RBC lysis Buffer: 8.3 g/L NH4Cl, 1 g/L KHCO3, 0.04 g/L Na2EDTA-2H2O and 
2.5g/L BSA to sterile water and stored at 4ºC 
 NØ medium: Freshly isolated NØ were seeded in 1 x 106 cells/ml in sfRPMI with 
0.15%BSA 
 GPBS: Glucose (1.5% v/v) supplemented with PBS, 1mM MgCl2 and 1.5mM CaCl2 
 Anti-Human CD66b, PE clone G10F5 (Affymetrix eBioscience, UK) 
2.4.2 Blood collection 
Healthy blood donors were selected and the nature of the study was explained prior to 
blood collection and written and signed consent was obtained.  A winged infusion set 
(21G X 0.75’’ X 12”) was used to collect 10ml of venous blood from healthy volunteers 
using 10ml EDTA BD Vacutainers and the collected fresh venous blood was used 
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immediately for NØ isolation. Blood handling was undertaken in accordance with ethical 
guidelines (Aston University Ethics Committee).  
2.4.3 Preparation of Percoll gradient 
Percoll was used to prepare two density media of 1.098g/ml and 1.079g/ml in 150mM 
NaCl solution. Percoll solutions were prepared according to the following Table 4. 
Density (g/ml) 1.079 (g/ml) 1.098 (g/ml) 
Percoll (ml) 19.7 24.8 
Distilled water (ml) 11.7 6.6 
1.5 M NaCl (ml) 3.5 3.5 
 
Table 4: Percoll density composition for isolation of NØ 
Preparation of Percoll gradients with compositions for two different densities used for NØ 
isolation.  
 
The entire NØ isolation procedure (section 2.4) was performed at room temperature 
immediately after blood collection. 8ml of 1.098g/ml Percoll was layered carefully beneath 
8ml of 1.079g/ml Percoll using a 10ml pipette in a 50ml universal tube (Sarstedt, UK). To 
the layered gradient, 10ml of whole blood was layered carefully using a sterile Pasteur 
pipette. The blood was centrifuged using a benchtop centrifuge at 150xg for 8min at 20°C 
and then immediately centrifuged again at 1200xg for 10 min at 20°C with the brake off. 
After centrifugation, the visible layers from top to bottom were plasma, lymphocytes, clear 
liquid or Percoll, NØ and red blood cells (RBC) (figure 10).  
 
 
 
 
 
 
Figure 10: Isolation of NØ from whole blood  
Image showing various stages in the NØ isolation procedure. The whole blood was 
collected at room temperature (A) and layered on the Percoll gradient (B) and centrifuged 
to obtain the resultant layers of cells (C).  
 
Using a plastic Pasteur pipette plasma, lymphocytes and most of the clear liquid Percoll 
were removed by aspiration and discarded. NØ and the majority of the red blood cells 
were subsequently extracted using a Pasteur pipette and transferred to a sterile centrifuge 
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tube (Sterilin Ltd, Newport, UK) containing 30ml of lysis buffer and incubated at room 
temperature for 20 min with gentle mixing until the solution became transparent, an 
indication of haemolysis. After centrifugation at 500xg for 10 min, the cell pellet was 
resuspended in 3ml of lysis buffer and incubated at room temperature for 5 min to lyse 
any remaining red blood cells. This mixture was then centrifuged at 500xg for 10 min and 
to the resultant pellet 3 ml of PBS was used for resuspension and to remove remaining 
cell debris. This mixture was further centrifuged (500xg for 10 minutes), and the 
supernatant removed and the pellet was resuspended in GPBS prior to assessment of NØ 
purity or in RPMI medium containing 0.15% (w/v) BSA (NØ medium) for generation of AC 
(AC) 418.   
Isolated cells were counted using a haemocytometer. The NØ count typically ranged from 
2 X 107 to 1 X 106 cells/ml and varied between each isolation and for each donor. Cell 
viability was analysed by trypan blue exclusion method (Sigma-Aldrich, UK) using 10µl of 
isolated NØ added to 10µl of 0.4% trypan Blue solution and incubated at room 
temperature for 1-2 min. This suspension was carefully loaded to a graduated 
haemocytometer chamber and the unstained viable cells and stained non-viable cells 
were counted using light microscopy and the percentage of viable cells was calculated.  
2.4.4 Confirmation analysis of NØ purity  
2.4.4.1 Direct Immunofluorescence  
1 x 106 /ml NØ were washed with flow wash buffer by centrifuging for 300xg for 5 min and 
to the pellet 5µl of anti-human CD66b conjugated with PE (0.06 µg/ml) or Mouse IgM 
Isotype Control - PE (0.125 µg/test) was added and incubated on ice in the dark for 20 
min and analysed using flow cytometry to detect the percentage of NØ purity. Cell surface 
expression of CD31, CD91, CD47 and CD36 were determined using direct 
immunofluorescence assay as described in section 2.3.6.2 
2.4.4.2 Indirect Immunofluorescence  
The cell surface expression of CD14 and ICAM-3 on NØ (1 x 106 /ml) was determined 
using indirect immunofluorescence assay as described in section 2.3.6.1 
2.4.4.3 4', 6-diamidino-2-phenylindole (DAPI) nuclear stain 
Prior to seeding on a multiwell glass slide, NØ (1 X 105 cells/ml) were fixed using 1% (v/v) 
formaldehyde in PBS for 15 min.  Glass slides containing cells were mounted with a hard 
fix using 100µl of DAPI stain (100ng/ml) (Vector Labs, UK) and incubated on ice for 5 min. 
The stained cells were analysed using fluorescence microscopy to image the nuclear 
morphology of viable and apoptotic NØ.  
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2.5 Induction and characterization of apoptosis 
2.5.1 Generation of AC (AC) 
2.5.1.1 B cells 
1 X 106 cells/ml of B cells were resuspended in cRPMI medium and apoptosis was 
induced using a Chromata-Vue C71 light box and UVX radiometer (UV-P Inc., Upland, 
CA, USA). The radiometer was used precisely to provide the UV dose which ranged from 
25-100mJ/cm2. Apoptosis was allowed to proceed overnight for 16h at 37ºC in 5% (v/v) 
CO2 in a humidified incubator 418.  
2.5.1.2 NØ  
Isolated NØ were either induced to apoptosis using Chromata-Vue C71 light box and UVX 
radiometer and incubated overnight for 16h at 37ºC in 5% (v/v) CO2 in a humidified 
incubator or incubated at 37ºC for 16 h in sfRMI with 0.15% BSA without induction.   
2.5.2 Generation of secretomes (AS) from AC  
AS from B cells and NØ were generated using whole AC culture (as described in section 
2.5.1) by centrifuging at 2000xg for 5 min. Supernatants containing the secreted factors 
and extracellular vesicles were considered as AS and were used in future studies.  
2.5.3 Identification and quantification of apoptosis 
2.5.3.1 Annexin-V FITC/Propidium Iodide Staining 
Reagents: 
1) Binding buffer: 150mM NaCl, 10mM HEPES pH 7.4, 2.5mM CaCl2 in dH2O.  
2) Annexin V-FITC (AxV) and propidium iodide (PI) kit (Bender MedSystems, Vienna, 
Austria). 
Procedure 
PS,  a well characterised marker for apoptosis “flips” from the inner leaflet of a membrane 
to the external leaflet which forms the basis of the AxV/PI assay analysed using flow 
cytometry. AxV binds to PS on exposure in the outer leaflet of the plasma membrane 
whilst PI specifically binds to DNA as cells lose their membrane integrity. Staining with 
AxV but not PI indicates apoptosis whilst double staining indicates necrosis and negative 
staining indicates viability 280.  
Briefly, 100µl of 1 X 106 cells/ml of AC (B cells or NØ) were resuspended in 900µl of 
binding buffer containing 2µl of AxV-FITC and incubated in the dark on ice for 15 min. 
Prior to analysis of samples by Beckman Coulter flow cytometry, 5µl of PI was added to a 
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final concentration of 20µg/ml and samples were analysed immediately to detect viable, 
apoptotic and necrotic cells. 
2.5.3.2 Nuclear stain  
Nuclear changes in AC were observed using DAPI staining as described in section 2.4.4.3 
or by acridine orange (Sigma, UK) added at a concentration of 10µg/ml to the cells and 
incubated for 10 minutes at 4ºC on dark and washed the cells with PBS to remove 
unbound stain. The Percentages of AC was scored. 
2.6 Assays of phagocyte interaction with AC 
2.6.1 Phagocytosis of AC by MØ through interaction assay 
To assess the interaction (i.e. tethering and phagocytosis) with AC (B cells or NØ) THP-
1/DS derived MØ were cultured in multi well glass slides (Hendley Essex PH-005, 
Loughton, England) for 48-72h according to the procedure described in section 2.3.5 
Untreated or gingipain (5µg/ml) -treated MØ (as described in section (2.7.11) (5 X 105) 
were co-cultured with AC (B cells or NØ) 1X 106 / well in multiwell glass slides for 1h at 
37ºC in the cRPMI medium. Care was taken not to mix the supernatant from different 
wells. After co-culture, the multiwell glass slides were washed with ice-cold PBS three 
times to remove unbound cells and the bound cells were fixed with methanol for 10 
minutes prior to standing with Jenner-Giemsa stain 36.  
Staining method for Jenner - Giemsa 
 Jenner and Giemsa stain (Oxoid, Basingstoke, UK). 
 Jenner Giemsa buffer (JG) (50X stock): Two solutions were prepared. Solution A 
200mM NaH2 PO4 and solution B: 200mM Na2 HPO4. To make a 1X working 
solution, 20ml of solution B was added to 190ml of solution A until the pH reached 
5.6 and then the volume was increased to 1 litre with distilled H2O. 
 Preparation of Jenner buffer (1:3): To avoid precipitates, the buffer was made 
fresh 1 part of Jenner stain was mixed with 3 parts of JG buffer. 
 Preparation of Giemsa buffer (1:10): 1 part of Giemsa stain was mixed with 10 
parts of JG buffer and used immediately for staining of cells.  
The co-cultured air-dried methanol fixed slides were stained by immersing the slides with 
Jenner buffer for 6 min. The unbound stains were removed by extensive washing with JG 
buffer and following this the slides were immersed in Giemsa buffer for 11 min and again 
washed with JG buffer three times with the final wash in distilled water. Slides were 
mounted with DePeX mounting medium and cells scored following visualisation under 
light microscopy for at least 200 MØ in each of the quadruplicate wells.  
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2.6.2 In vitro cell migration assay 
2.6.2.1 Horizontal migration  
 
 
 
 
 
 
 
 
 
 
Figure 11: The Dunn chamber model  
Diagram showing the Dunn chamber used for MØ migration towards a putative 
chemoattractant. A) The Dunn chamber used to study MØ chemotaxis. B) The design of 
the interior of the chamber. The chamber consists of two wells the inner well containing 
MØ medium and an outer well containing the putative attractant. The outer well and the 
inner well were separated by an annular bridge which is covered by a cover slip carrying 
MØ placed on the top of the chamber. C) MØ migration viewed from the top of the annular 
bridge at 0h where the MØ showed no or minimal movement and at 2h showing random 
or defined migration.  
2.6.2.2 Vertical migration  
MØ migration towards a chemoattractant was also studied using the vertical Cell-IQ live 
cell imaging and analysis platform system. To set up the experiment, 700µl per well of AC 
(1 X 106) (B cells or NØ) or AS were added to the lower chamber of a 24 well plate and a 
transwell with 8.0 µm pore polycarbonate membranes (Corning, Life Science, NY, USA) 
was subsequently placed in each well. To each transwell 300µl of THP-1/VD3 stimulated 
MØ (5 X 105) was added and the 24- well plate was covered by a Cell-IQ lid and sealed 
using adhesive paper tape (figure 12). The output connector from the Cell-IQ lid was 
connected to the Cell-IQ analyser with the gas (5% CO2) enabled on the system. Vertical 
migration of MØ towards AC or AS was recorded for up to 12h with an image captured 
every 20 minutes using the Cell-IQ tracking system and software. The migrated MØ found 
in the lower chamber of a 24 well plate were calculated and analysed using the Cell-IQ 
software.  
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Figure 12: The Cell-IQ model 
Diagram showing the Cell-IQ model set up to study MØ migration. The bottom chamber of 
a 24-well plate was loaded with a putative attractant (blue) and the transwell containing 
8µm porous filter membrane were placed on the top of each well in a 24-well plate. The 
MØ (green) were loaded on the transwell and analysed for their migration using the Cell-
IQ equipment. Adapted from 419. 
 
2.7 Isolation and characterisation of gingipains from P.gingivalis HG66 and 
W83 
2.7.1 Bacterial strains of P.gingivalis 
2.7.1.1 W83: P. gingivalis W83 was originally isolated from an undocumented human 
oral infection in Bonn, Germany in the 1950s 420-422 
2.7.1.2 HG66: P. gingivalis HG66 DSM-No: 28984, was isolated from the oral cavity and 
proven to produce gingipains in a soluble form unlike strain W83 which retained the 
enzymes on the cell surface 423  
Both the strains W83 and HG66 of P.gingivalis were provided by the Periodontal 
Research Group, School of Dentistry, University of Birmingham, United Kingdom. 
2.7.2 Materials and buffers for gingipain isolation 
2.7.2.1 Materials for bacterial growth 
Fastidious agar plate (Oxoid, Thermo Fisher Scientific, UK) 
Fastidious anaerobe broth (FAB) (LAB M, UK) 
2.7.2.2 Buffers for W83 
TLCK buffer: To 100ml of PBS, 100µl of Nα-p-tosyl-L-lysine chloromethyl ketone (TLCK) 
0.1mM, 1 ml of leupeptin (0.1mM) and 100µl of 0.5mM EDTA were added. 
Triton and MgCl2 buffer: To 100 ml of PBS, 1ml of Triton X-100, 20 mM of MgCl2 were 
added. 
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Dialysis buffer: 150 mM NaCl, 20 Mm Bis-tris (Bisiminotrismethane), 5 mM CaCl2 were 
added to a litre of sterile distilled water.  
2.7.2.3 Buffers for HG66 
Buffer A: 20 mM Bis-Tris-HCl, 150 mM NaCI, 5 mM CaCI2, 0.02% (w/v) NaN3, pH 6.8 
Buffer A for dialysis: 20 mM Bis-Tris-HCI, 150 mM NaCl, 5 mM CaCl2, 0.02% (w/v) 
NaN3, pH 6.8 with 1.5 M 4, 4’-dithiodipyridine disulphide (Aldrithiol) 
Buffer B: 50 mM Tris-HCl, 1 mM CaCl2, 0.02% NaN3, pH 7.4  
Buffer B with NaCl gradient: A step gradient of 500 mM NaCl was applied in buffer B 
Buffer B with arginine gradient: A gradient of 100 mM L-arginine was applied in buffer B 
Buffer B with lysine gradient: A gradient of 0-750 mM L-lysine was applied in buffer B 
Buffer C: 20 mM Bis-Tris- HCl, 1 mM CaCl2, 0.02% (w/v) NaN3, pH 6.4 
Enzyme activity buffer (pH 7.6): 0.2 M Tris-HCl, 0.1M NaCl, 5 mM CaCl2, 0.02% (w/v) 
NaN3, 10 mM L-cysteine were added to sterile distilled water. 
Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) running 
buffer: 3.03 g/L of Tris, 14.4 g/L of glycine (Alfa Aesar, UK) and 1 g/L of SDS (Fisher 
Scientific, UK) pH 8.3 
TBS (10x): 24.23 g/L Trizma HCl, 80.06 g/L NaCl, pH 7.6 
Destaining buffer: To 800 ml of distilled water 100 ml of methanol, 100 ml of acetic acid 
(17.5M) were added 
Pierce BCA Protein Assay Kit (Thermo Scientific, UK) 
LAL chromogenic endotoxin quantitation kit, Thermo Scientific Pierce, UK 
2.7.3 Bacterial strains and growth conditions:  Bacteria (W83 and HG66) were 
grown on fastidious agar plates containing 7% (v/v) sterile horse blood and incubated for 
24- 48h at 37°C in an anaerobic chamber of 10% H2, 10% CO2, and 80% N2. The bacterial 
colonies were transferred to the sterile fastidious anaerobe broth containing 10.0g yeast 
extract, 5 mg haemin, 0.5 mg vitamin K1, 500 mg L-cysteine and subsequently incubated 
at 37°C in an anaerobic chamber with gentle agitation overnight.  
2.7.4 Gram stain of W83 and HG66 
P. gingivalis strains W83 and HG66 were grown on horse blood agar fastidious plates to 
form distinctive black pigmented colonies. After 48h, these colonies were prepared for 
Gram staining by creating a slide smear of the bacterial culture 424. Based on the 
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composition of the cell wall of bacteria, the Gram stain procedure aids differentiation of 
Gram-positive from Gram-negative bacteria. In brief, on a clean microscope glass slide, a 
loopful of water was placed prior to addition of bacterial culture from the petri dish. Care 
was taken to add a small amount of bacteria culture. The culture mixed with water was 
spread on the glass slide surface creating a thin film on its centre. This smear was 
allowed to air dry for a few seconds and fixed over a gentle flame using a circular motion. 
To the fixed culture, crystal violet stain was added for 1 minute prior to rinsing with water. 
The crystal violet stains penetrates the cell wall of both Gram-positive and Gram-negative 
bacteria.  Following this, a mordant dye-iodine solution was added to the smear to 
enhance the interaction between the culture and the dye and was incubated for 1 minute 
prior to rinsing with water. Gram-positive bacteria resists the decolourisation because of 
their thick peptidoglycan layer while Gram-negative bacteria, due to their thin layer of 
peptidoglycan, the crystal violet-iodine complex was decolurised while washing with 
acetone  for a minute. Following this step, safranin, the positively charged counterstain 
dye was added and incubated for 1 minute and washed with running tap water. Since 
Gram-negative cells lose the purple colouration unlike Gram-positive bacteria they take up 
the safranin and they appear red or pink in colour upon visualisation under light 
microscopy (figure 13).  
                        
Figure 13: Culture and Gram staining of the P.gingivalis strains W83 and HG66  
Images show bacterial solid state culture of P.gingivalis strains and their corresponding 
Gram strains. On the top panel W83 is shown and the HG66 strain is shown on the 
bottom panel. The bacterial strains were grown on fastidious agar plates incubated for 24-
48h in an anaerobic chamber at 37°C (as described in section 2.7.3). The black 
pigmented colonies were analysed for purity by Gram stain procedure. The right-hand 
panels show pink rod-shaped bacilli confirming the purity of Gram-negative bacteria of 
both W83 and HG66.  
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2.7.5 Growth curve of bacterial culture W83 and HG66 
To study bacterial growth, the healthy viable bacterial culture were inoculated into FAB 
broth and incubated in an anaerobic chamber with gentle agitation for 72h. At a range of 
time points during the growth period, a sample of broth containing multiplying bacteria was 
removed for spectrophotometric analysis at 600nm. Gram staining (as described in 
section 2.7.4) was also undertaken to ensure purity. The degree of turbidity at 600nm 
relates to the absorbance value in a spectrophotometer and bacterial cell number. The 
growth curve plots determine the dynamics of the bacterial growth in four phases lag, 
exponential or logarithmic (log) phase, stationary phase, decline or death phase.  
2.7.6 Isolation of membrane-bound proteins from P.gingivalis strain W83: 
Bacterial cultures were centrifuged at 10,000xg for 30 min at 4° C to produce a pellet and 
cell-free culture supernatant. The cell pellet was used for isolating cytosol-derived 
fractions of gingipains as described 425. Briefly, the pelleted bacterial cells were 
resuspended in TLCK buffer (as described in section 2.7.2.2) and disrupted using 
sonication (Bandelin Sonopuls). The cells were disrupted at 65 MPa on 6 occasions with a 
time gap of 30 seconds to avoid the disruption of the proteins in the samples. The 
sonicated bacterial cells were centrifuged at 2,400Xg for 10 min in order to release the 
proteins into the supernatant. The resulting supernatant was subjected to 
ultracentrifugation (Beckman 70Ti rotor) at 100,000×g for 60 min at 4°C. The pellet, 
consisting of the outer membrane fragments, was resuspended in Triton and MgCl2 buffer 
(as described in2.7.2.2) and mixed gently for 30 min at 20 °C. These fragments were then 
ultracentrifuged at 100,000Xg for 60 min at 4°C and the pellet resuspended in dialysis 
buffer (as described in section 2.7.2.2) to recover the outer membrane proteins as a 
precipitate.  
2.7.7 Isolation and purification of soluble proteins from culture supernatant 
HG66:  
Gingipains were isolated according to the method described 426. Briefly, 24h bacterial 
cultures (1 litre) (optical density – 1.763 at 600nm) were centrifuged at 12,000xg for 45 
min at 4°C and to the cell-free-culture supernatant chilled acetone was added at a ratio 
40:60 (culture supernatant:acetone) slowly with gentle agitation and incubated for 2h at -
20°C. The resultant protein precipitate was centrifuged at 12,000xg for 30 min at 4°C and 
the pelleted precipitate was resuspended in 290ml of buffer A with aldrithiol (as described 
in section 2.7.2.3) for 4h and dialysed against buffer A without aldrithiol overnight. In order 
to concentrate the dialysed fractions, Amicon PM-10 membranes (Merck Millipore, UK) 
were used prior to application of the fractions to Sephadex G-150 columns (5 x 115 cm) 
equilibrated with buffer A at a flow rate of 0.5ml/min. Fractions were tested for activity 
against Bz-L-Arg-pNA (BAPNA) (Sigma-Aldrich, UK) and Z-L-Lys-pNA (Sigma-Aldrich, 
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UK) (as described in section 2.7.8.1) and were pooled and dialysed overnight against 
buffer B with 2 changes. Dialysed fractions were applied to a 10ml arginine-Sepharose 
column (GE healthcare, UK) (1.5 x 30 cm) equilibrated with buffer B (as described in 
section 2.7.2.3). Following the washes, buffer B with 500mM NaCl gradient was applied 
and the A280nm baseline decreased to zero. RgpB was eluted by equilibrating the column 
with buffer B containing an 100 mM arginine gradient (as described in section 2.7.2.3).and 
the Kgp eluted with Buffer B containing a 750 mM lysine gradient at a flow rate of 
0.5ml/min-1 (as described in section 2.7.2.3). The eluted fractions were concentrated again 
using Amicon PM-10 membrane at a speed 4000xg for 20 min at 4°C. The concentrated 
samples were resuspended in buffer C (as described in section 2.7.2.3) and centrifuged 
again at 4000xg for 20 min at 4°C to obtain a pure RgpB or Kgp protease. Eluted 
gingipains were stored at -80°C. 
2.7.8 Confirmatory analysis of gingipain purity 
2.7.8.1 Enzyme activity assay  
To measure the purified RgpB and Kgp activities, 100µl of enzyme buffer containing 1mM 
Bz-Arg-pNA for RgpB or 0.5 mM Z-L-Lys-pNA for Kgp were added to 100µl of eluted 
RgpB or Kgp fractions from W83 and HG66 and incubated for 1h at 37 °C. The reaction 
was stopped by adding 50µl of glacial acetic acid (Sigma-Aldrich, UK) and p-nitroaniline 
(pNA) released from the substrate was read at 405nm on a spectrophotometer. One unit 
of enzyme activity corresponds to 1 µmol of pNA released during 1h of incubation at 37°C. 
2.7.8.2 Determination of molecular weight using SDS-PAGE electrophoresis 
2.7.8.2.1 Protein determination using BCA assay 
The concentration of eluted protein fractions from the W83 and HG66 strains was 
determined using a protein assay kit (as described in section 2.7.2.3). In brief, the 
Bicinchoninic acid assay is based on the principle involving a temperature-dependent 
reaction, where Cu2+ ions are reduced from copper (II) to copper (I) sulphate by the 
peptide bonds present in the protein thereby resulting in purple colouration as BCA 
chelates Cu (I) ion. The colour correlates with the amount of protein present in the sample. 
The BSA standards were prepared in the same buffer as samples to avoid interference. 
Standards or samples were incubated with the BCA reagent for 30 minutes at 37°C prior 
to reading the absorbance at 562nm using a spectrophotometer. The samples were 
cooled for several minutes at room temperature to enable increased sensitivity.  
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2.7.8.2.2 Trichloroacetic Acid (TCA) precipitation of eluted proteins derived 
from the W83 and HG66 strains 
Once the known amount of protein was calculated in the eluted fractions from the W83 
and HG66 strains the protein samples were concentrated using the TCA method. The 
eluted protein fractions were treated with 0.15 % (w/v) sodium deoxycholate (DOC) at a 1: 
10 ratio and 72 % (v/v) TCA (1: 10 ratio) and centrifuged at 16,000xg for 10 minutes to 
precipitate the proteins. The resulting pellet was either used directly for SDS-PAGE (as 
described in section 2.7.8.2.3) or stored at –80°C until analysis. 
2.7.8.2.3 SDS-PAGE electrophoresis 
Separation of proteins based on the electric charge or mass is a common method of gel 
electrophoresis 427. Here, SDS was used to denature the proteins and to provide a net 
negative charge to all the proteins that have been denatured such that mass to charge 
ratio is equalised and proteins are separated simply based on their molecular mass. SDS-
PAGE was performed on a 10% resolving gel with a 4% stacking gel in Tris-glycine 
running buffer as detailed in Table 5 according to the manufacturer instructions (Mini-
protean II apparatus from Bio-Rad).  
Gel reagents 
Reagents 10% resolving gel 4% stacking gel 
Acrylamide solution (30%) 
(37.5:1) 
3.33 ml 666 µl 
1.5 M Tris- HCl 2.5 ml 1.25 ml 
dH2O 4.015 ml 3 ml 
10% SDS 100 µl 50 µl 
10% APS 100 µl 50 µl 
TEMED 10 µl 5 µl 
 
Table 5: Composition of reagents to prepare resolving and stacking gel 
The percentage of resolving and stacking recipes for preparation of one gel used for SDS-
PAGE electrophoresis for molecular weight determination of extracted proteins from the 
W83 and HG66 strains. 
 
The gel was prepared according to the details provided in Table 5 and depending on the 
number of gels needed the volume of individual recipes were calculated accordingly. 
Briefly, the 10% resolving gel was prepared (as detailed in Table 5) and added to cleaned 
gel plates and the gel was allowed to polymerise. The 4% stacking gel was prepared (as 
detailed in Table 5) and added to the top of the polymerised resolving gel. Gel set ups 
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were then placed in the buffer chamber containing the SDS-PAGE running buffer. To 
prepare the samples, 40µg of TCA-precipitated protein (as described in section 2.7.8.2.2) 
were mixed with 2 X Laemmlli buffer and denatured at 95°C for 5 min and incubated on 
ice for 1 minute prior to loading on the SDS- PAGE gel and electrophoresed using a 
Hoefer buffer chamber at 200V for 40 min. Electrophoresis was performed at 60V through 
the stacking gel and at 120V through the resolving gel until the marker standard reached 
the bottom of the resolving gel. The pre-stained protein ladder (Life Technologies, UK) 
was used alongside the samples to estimate the approximate size of separated proteins. 
The protein bands were visualized by staining with coomassie blue (GE Healthcare Life 
Sciences, UK) and destaining buffer (as described in section 2.7.2.3) and homogeneity 
was determined using laser densitometry by scanning the gel under gel imager (as 
described in 2.1).  
2.7.9 Mass spectrometry 
2.7.9.1 Sample preparation 
Purified samples of gingipains (x µg) were separated by SDS-PAGE, and  was subjected 
to mass spectrometry analysis after in-gel digestion of the gel band of the appropriate 
molecular size 428. Briefly, the Coomassie blue-stained gel was layered over a clean glass 
plate, and the protein band of interest (40-50 kDa) was excised using a clean scalpel 
blade. The excised gel was transferred into a 0.5 ml polypropylene Eppendorf tube and 
diced. Gel pieces were destained using 200 µl of 50 % aqueous ammonium bicarbonate 
in acetonitrile (50 mM) for 90 min on the orbital thermoshaker (550 rpm) at 37°C. After 
destaining was completed the supernatant was removed and gel pieces were repeatedly 
dehydrated with 100 µl of acetonitrile until the gel shrunk and turned white. Excess of 
acetonitrile was removed in the vacuum concentrator for 10 min and sample was stored at 
-20 °C prior to sending for further analysis at the University of Birmingham where trypsin 
in-digestion and nLC-MS/MS were carried out. 
2.7.9.2 LC-MS/MS 
The samples were trypsin digested using 40µl of 100mM ammonium bicarbonate (pH 8) 
added to 10µl of the protein samples (~1-100µg of protein). Following this, 50 µL 10 mM 
dithiothreitol (DTT) was added to the protein samples and incubated at 56°C for 30 mins. 
To the cooled protein samples, 50µl 50mM iodoacetamide, were gently mixed incubated 
for 30 mins at dark. In the final step, samples were incubated overnight at 37°C with 25 µl 
of trypsin gold (Promega, Southampton, Hampshire, UK, 6 ng/µl). 
Digested samples were analysed using-nLC-MS/MS (QExactiveTM Thermo Fisher, UK). 
The peptide concentration was carried out using UltiMate® 3000 HPLC series (Dionex, 
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Sunnyvale, CA USA). The gradients were performed for 30 mins using 3.2% to 44% 
formic acid (0.1%) in acetonitrile. LTQ Orbitrap Elite ETD mass spectrometer 
(ThermoFisher Scientific, Germany) was used to elute the peptides. 
Acquired data were searched against SwissProt database for Porphyromonas gingivalis 
taxomomy using Sequest search engine allowing for a maximum two trypsin mis-
cleavages and with the m/z confidence of 5 ppm.  
2.7.10 Limulus Amebocyte Lysate (LAL) assay for LPS detection 
To detect and quantify Gram-negative bacterial LPS in the eluted proteinase from W83 
and HG66 of the P.gingivalis strains, a LAL assay (as described in section 2.7.2.3) was 
performed. LAL, sourced from horseshoe crab’s blood cells reacts with bacterial 
endotoxins in the eluted samples by activating the proteolytic enzymes and catalyses pNA 
upon adding the chromogenic substrate resulting in a yellow colouration which is 
quantified by measuring the absorbance at 405nm (A405). Briefly, the microplate was 
equilibrated in a heating block for 10 minutes at 37°C prior to addition of 50µl of standard 
(BSA) or samples (10µg) and incubated for 5 minutes at 37°C. Following the addition of 
samples, 50µl of LAL reagent was added and incubated for 10 minutes at 37°C and 
subsequently 100µl of chromogenic substrate was added and incubated for 6 minutes at 
37°C prior to gently mixing the contents using a plate mixer. The reaction was stopped by 
adding 50µl of acetic acid (25%) and the plate was gently homogenised using a plate 
mixer for 10 seconds and measured for absorbance at 405nm. All reagents were prepared 
using the endotoxin-free water provided with the kit. A standard curve was established 
using LPS from 0.1 -1.0 EU/ml (endotoxin/mL) and 1EU/ml is equivalent to 0.1 to 0.2 ng 
endotoxin/ml of solution. 
2.7.11 MØ or NØ treatment with gingipains  
VD3 or DS THP-1 differentiated for 48h MØ (990µl) (1 X 106 cells/ml) or freshly isolated 
viable NØ (990µl) (1 X 106 cells/ml) were treated with 10µl of the eluted gingipains 
fractions of either RgpB or Kgp (5µg/ml) derived from HG66 P.gingivalis in sfRPMI 
medium for 1h at 37°C. Treated cells were used for further analysis to study MØ 
behaviour in response to AC. 
2.7.12 Inhibition of gingipains using Nα-p-tosyl-l-lysine chloromethyl ketone  
THP-1 VD3 or DS MØ (1 X 106 cells/ml) were treated with the cysteine protease inhibitor, 
TLCK (0.1mM) for 10 minutes at 37°C prior to treatment with gingipains (5µg/ml) as 
described in section 2.7.11. 
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2.8 LPS from P.gingivalis induced TNF-α response in THP-1 derived MØs 
VD3 or PMA stimulated THP-1 differentiated MØ were washed and seeded in 850µl of 
fresh cRPMI at 6 X 105 cells/well in a 24 well plate. The cells were challenged with a range 
of doses of 50µl of lipopolysaccharide (LPS -0-500ng/ml/assay) from Escherichia coli (Ec 
LPS) (positive control) or LPS (0-100µg/ml) from P.gingivalis (Pg LPS) (Invivo Gen, UK) in 
the presence of 100µl of 10% (v/v) normal human serum (NHS) to act as a source of LPS-
binding protein and incubated for 4h at 37°C.The reaction was stopped by freezing at -
20ºC until the TNF-α ELISA was performed. The supernatant was harvested and used for 
analysis of TNF-α release in the MØ using the anti-human TNF-α capture ELISA (R &D 
systems, Minneapolis, USA). 
Gingipains from P.gingivalis induced TNF-α response in THP-1 derived MØs 
Gingipains (5µg/ml) 10µl were used to induce TNF-α response in THP-1 derived MØ (both 
VD3 and DS) (990µl) (1 X 106 cells/ml) (as detailed in section 2.7.11) and incubated for 1h 
at 37ºC and either analysed immediately for TNF-α response or left at -20ºC until indirect 
ELISA was performed. The supernatant was harvested and used for analysis of TNF-α 
release in the MØ using the anti-human TNF-α capture ELISA (R &D systems, 
Minneapolis, USA). 
2.8.1 Measurement of TNF-α levels in MØ co-cultured with AC  
The effect of AC or their derived AS (from either B cells or NØ) on TNF-α production in 
LPS or gingipain-stimulated MØ were studied using ELISA. Briefly, 750µl of VD3 or DS 
THP-1 differentiated MØ (as described in section 2.3.5) were seeded (6x105 cells/well) in 
wells of a 24 well plate. As appropriate to each well, 100µl of AC (1 X 106) or AS (1 X 106) 
or NØ medium alone (control) (as described in section 2.4.1) were added to the MØ and 
incubated for 18-24h at 37ºC. After the incubation period, 50µl of Ec LPS (20ng/ml) or 
50µl of Pg LPS (1µg/ml) were added in the presence 100µl of NHS (10% v/v) and 
incubated for 4h at 37ºC or 10µl of gingipains (RgpB or Kgp) were added and incubated 
for 1h at 37ºC. The supernatants were harvested and stored at -20ºC until further 
analysis. 
2.8.2 ELISA 
Materials 
 Anti-human TNF-α capture ELISA from R &D systems, Minneapolis, USA 
 Recombinant TNF- α from R &D systems, Minneapolis, USA 
 TNF- α detection antibody from R &D systems, Minneapolis, USA 
 ELISA Diluent (PBS-T): 0.05% (v/v) Tween 20 in PBS (Fisher, UK). 
 ELISA wash buffer: 0.9% (w/v) NaCl, 0.05% (v/v) Tween 20 in PBS 
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 ELISA block buffer: 1% (w/v) BSA, 5% (w/v) sucrose and 0.05% (w/v) sodium 
azide in PBS 
ELISA plates were coated with 100µl of 2µg/ml of the TNF-α capture antibody diluted in 
PBS and incubated overnight at 4ºC.  Prior to experimentation, the antibody coated ELISA 
plate was washed with ELISA wash buffer three times and TNF-α ELISA block buffer 
(100µl/well) was added to the 96 well plate and incubated for 1h at 37ºC. The plates were 
washed for three times with ELISA wash buffer and 100µl of known concentrations of 
recombinant TNF-α (standard) or supernatant of the samples were added to the 
designated wells and incubated at 37ºC for 2h. The plate was washed again three times 
using ELISA wash buffer to remove unbound samples and 100µl of TNF-α detection 
antibody (200ng/ml) diluted in ELISA diluent was added to each well and incubated for 2h 
at 37ºC.  Prior to the addition of 100µl of streptavidin-Horseradish peroxidase (HRP) at 
1:2000 concentration in ELISA diluent, the plate was washed three times with ELISA wash 
buffer and incubated with HRP for 1h at 37ºC. Bound HRP was detected by addition of 
100µl of Ortho-Phenylenediamine (OPD) to each well and incubated at room temperature 
in the dark until the colour developed. The reaction was stopped by the addition of 50µl of 
1M HCl and the plate was read at a 490nm absorbance.  
2.9 Determination of anti-inflammatory cytokines (TGF-β and IL-10) mRNA 
levels using quantitative PCR 
2.9.1 Materials 
 RNA isolation kit includes TRK lysis buffer, RNA wash buffer I, RNA wash buffer II, 
DEPC treated water, HiBind RNA column (E.Z.N.A total RNA kit I, Omega bio-tek, 
VWR, UK) 
 RNase free TBE buffer (Geneflow, UK) 
 1kb RNA Ladder (Geneflow, UK) 
 Ethidium bromide (Fisher Scientific, UK) 
 Norgen 2x loading sample buffer (Geneflow, UK) 
 Reverse transcription (RT)-nanoScript2 (Primer design, UK) 
 Reverse transcription polymerase chain reaction (RT-PCR) primer kit  TGF-β 
(Primer design, UK) (forward primer: 5’ CAC TCC CAC TCC CTC TCT C 3’ and 
reverse primer: 3’ GTC CCC TGT GCC TTG ATG 5’) 
 RT-PCR primer kit  IL-10 (Primer design, UK) (forward primer: 5’ GCT GGA GGA 
CTT TAA GGG TTA C 3’ and reverse primer: 3’ TGA TGT CTG GGT CTT GGT 
TCT 5’) 
 Human β-actin forward primer (h ACT F) – 5’ CTG GAA CGG TGA AGG TGA CA 
3’ (ThermoFisher Scientific, UK) 
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 Human β-actin reverse primer (h ACT R) – 3’ AAG GGA CTT CCT GTA ACA ATG 
CA 5’ (ThermoFisher Scientific, UK) 
 SYBR (Syber green) (Primer design, UK) 
 RNase/DNase free water (Primer design, UK) 
2.9.2 Preparation of cells 
VD3 stimulated THP-1 MØ (1 X 106 /ml) (as described in section 2.3.5) were cultured with 
or without AC NØ (3 X 106) for 6h and treated with gingipains for 1h at 37°C or left 
untreated. Following the treatment, the cells were centrifuged at 2000xg for 10 min. The 
supernatant discarded and the pelleted cells were stored -80°C until RNA isolation was 
performed 429. 
2.9.3 RNA isolation 
RNA was isolated at room temperature from the VD3 MØ co-cultured with AC NØ, and 
treated with or without gingipains, according to the manufacturer’s instructions as 
described in section 2.9.1. In brief, 350 µl of TRK lysis buffer was added to the thawed 
pellet followed by 350 µl of ethanol (70%). This sample mixture was then vortexed and 
transferred to the HiBind RNA column (as described in 2.9.1). The column is inserted into 
a 2ml collection tube prior to addition of the sample mixture. The column was centrifuged 
at 10,000xg for 1 minute and the flow through was discarded. To the column 500µl of RNA 
wash buffer I was added and centrifuged at 10,000xg for 30 seconds. The resultant filtrate 
was discarded and 500µl of RNA wash buffer II was added and centrifuged at 10,000xg 
for 30 seconds and the washing step was repeated again with the centrifugation speed at 
16,000 x g for 2 minutes. The column was transferred to a 1.5ml microcentrifuge tube 
(Fisher Scientific, UK) and 50µl of DEPC-treated water was added and centrifuged again 
at 16, 000xg for 2 minutes. The resulting flow through was stored at -20°C until further 
analysis. 
2.9.4 Confirmatory analysis of RNA purity 
2.9.4.1 Nanodrop 
Isolated RNA was quantified by Nanodrop to determine the purity of the RNA samples. To 
the cleaned Nanodrop sample contact 1µl of the RNA sample was added to assess the 
purity of the RNA. The value above 2.0 within the 260/280 ratio indicates the purity of the 
RNA samples and analysed further using PCR. 100ng of isolated RNA was used for each 
PCR.  
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2.9.4.2 Agarose gel electrophoresis 
To test the integrity of the isolated RNA 1% (w/v) agarose was dissolved in RNase-free 
TBE buffer (as described in section 2.9.1) and microwaved until the agarose melted 
completely and, prior to addition of ethidium bromide (to give a final concentration of 
0.5µg/ml), the agarose gel was cooled and stained for RNA visualisation. 100ng of RNA 
samples (as described in section 2.9.3) were mixed with 2X sample buffer (as described 
in 2.9.1) and incubated for 5 minutes at 95°C. Samples were left on ice for one minute and 
then loaded on the agarose gels. Gels were electrophoresed at 60 Volts, 120 Watts 250 
mA for up to 1h and RNA profiles viewed using a UVP transilluminator. 
2.9.5 RNA reverse transcription 
2.9.5.1 Reverse transcribe RNA into cDNA 
Once the quality of RNA was determined the RNA was reverse transcribed to cDNA using 
the Primer design RT-nanoscript kit (as described in section 2.9.1). To 100ng of each 
RNA sample, 1µl of reverse transcription primer was added and made up to 10 µl using 
RNase/ DNase free water. Samples were incubated at 65°C for 5 mins in a heat block and 
were frozen immediately on ice. 
2.9.5.2 Extension step reaction mixture 
To the above mixture generated as described in section 2.9.5.1, 2µl of Nanoscript 2 4X 
buffer, 1µl of dNTP mix (10mM), 4µl of RNase/DNase free water and 1µl of Nanoscript 2 
enzyme were added to each sample or a master mix was prepared depending on the 
sample count and 10 µl of the master mix was added to each sample. The RNA samples 
were amplified using a thermocycler programmed for 42°C for 20 min followed by 75°C for 
10 min. The resultant cDNA samples were diluted 1:10 using RNase/DNase free water 
and stored at -20°C until further PCR analysis was performed.  
2.9.6 Quantification of TGF-β and IL-10 gene expression  
2.9.6.1 Housekeeping gene (Human β-actin) 
To 5µl of each cDNA samples (1:10) generated from RNA using RT-PCR, 3µl of 
RNase/DNase free water, 1µl of human actin forward primer (as described in section 
2.9.1), 1µl of human actin reverse primer (as described in section 2.9.1) and 10µl of Syber 
green were added to a PCR 96 well plate (Primer design, UK) or a master mix of the 
reagents were prepared and 15µl of the master mix were added to 5µl of cDNA sample. 
2.9.6.2 TGF-β and IL-10 gene expression 
To 5µl of each cDNA samples (1:10) generated from RNA using RT-PCR, 4µl of 
RNase/DNase free water, 1µl of human primers IL-10 or TGF-β (as described in section 
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2.9.1) and 10µl of SYBR were added to a PCR 96 well plate (Primer design, UK) or a 
master mix of the reagents were prepared and 15µl from the master mix were added to 
5µl of the cDNA sample. The plate was covered using PCR seal adhesive plates and 
gently mixed by spinning the plate for 10 seconds using a plate spinner (as described in 
section 2.9.1). The plate was amplified using a Stratagene Mx3000P thermocycler (as 
described in section 2.1) using the PCR program comprising 10 minutes at 95ºC, 15 
seconds at 95ºC and 1 minute at 60ºC for 40 cycles, 30 seconds at 95ºC, 30 seconds at 
55ºC and 30 seconds at 95ºC and results were analysed using qPCR software (as 
described in section 2.1).  
2.9.6.3 Quantification of mRNA 
The comparative method was used to interpret the cycle threshold (Ct) value of the target 
gene. First, Ct values of the gene of interest was subtracted from the house keeping gene 
to calculate the delta Ct (∆Ct). ∆Ct refers to the amount of target nucleic acid present in 
the given sample. Second, to the obtained ∆Ct value for each sample were compared with 
the ∆Ct  of the control (untreated MØ) to acquire ∆∆Ct. The resulting ∆∆Ct were powered 
by 2∆∆Ct to determine the fold-difference between the untreated and the treated samples. 
2.10 Statistical analysis 
Data were analysed using Instat (GraphPad prism v7, La Jolla, CA, USA) and general 
statistical analysis using mean ± Standard error of the mean (S.E.M) for independent 
replicates (n ≥3) and different test are used as appropriate. 
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Chapter 3 
Results 
Results 1: Establishing a model assay system for MØ interaction with 
primary apoptotic NØ 
3.1 Introduction 
Polymorphonuclear cells (PMNs), the most abundant leukocytes which are mostly 
involved in the innate immune response, are the main players to participate in the body’s 
fight against host-derived danger signals or pathogenic insult 430. Circulating NØ migrate 
towards encountered pathogens by using their specialised adhesion and migration 
qualities, and eradicate the culprit microorganism by producing primary antibacterial 
effectors such as azurophilic granules containing NØ elastase, serine protease and alpha-
defensins and secondary granules such as lysozyme, lactoferrin, NADPH oxidase and 
histaminase to combat infection 431. To facilitate NØ recruitment and migration, MØ upon 
receiving an inflammatory stimulus produce IL-8, a chemoattractant cytokine that elicits 
activation of NØ to participate in chemotaxis towards and phagocytosis of the pathogens. 
Thus NØ are important for the resolution of inflammation 432-434. Other chemoattractants, 
such as FMLP, leukotriene B4 and complement peptides (e.g. C3a, C5a), also recruit NØ 
to migrate towards the site of inflammation and stimulate clearance of the pathogens 
using anti-microbial molecules or by generating NETs, to trap and kill the invading 
pathogens. In order to prevent exacerbating inflammation timely removal and disposal of 
recruited NØ, which die by apoptosis at injury sites, is essential. Dysregulation of NØ has 
been linked with major chronic inflammatory diseases, causing significant disruption of 
normal physiology and influencing the behaviour of other cell types by inhibiting tissue 
homeostasis restoration 372, 435, 436.  
NØ influx, an important process in response to bacterial infection, results in phagocytosis 
and digestion of the pathogen via NØ toxic contents within their NØ phagosome 21. 
Phagocytosis-induced cell death is an important process. NØ is primed to undergo 
apoptosis so that they are cleared rapidly by resident tissue MØ and this critical step aids 
prevention of NØ necrosis, a potential inducer of tissue damage 437, 438. NØ apoptosis, is a 
tightly-regulated event that enables recognition of the dying cell by professional 
phagocytes such as MØ and thus prevents the release of toxic contents such as elastases 
to the surrounding tissues 439. Apoptotic NØ undergo cell surface modulation to enable 
their recognition. For example, flipping of phosphatidylserine from the inner to outer leaflet 
of the plasma membrane in order to expose ’eat me’ signals to local phagocytes allowing 
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phagocytosis of apoptotic NØ whilst also triggering anti-inflammatory responses 266, 324, 329, 
440.  
To fully understand inflammatory diseases such as periodontitis, it is important to 
understand the process of cell death to produce apoptotic NØ, the mechanism by which 
they are removed by MØ and how they stimulate anti-inflammatory cytokines that promote 
resolution of inflammation. The aim of this chapter, therefore was to establish an in 
vitro model of primary apoptotic NØ and study how well they interact with and are 
recognised by THP-1 MØ. 
3.2 Phenotypic characterisation of primary NØ isolated from peripheral 
blood 
Human NØ apoptosis has been widely studied to understand the critical molecular 
mechanisms behind inflammation resolution 24. NØ accumulated at a site of bacterial 
infection have the potential to damage the surrounding tissue if the timely elimination of 
activated NØ fails, leading to NØ necrosis and thus exacerbating inflammation. Here, NØ 
were isolated by a Percoll gradient method and purity of the isolated cells was confirmed 
by analysis of specific surface receptor expression and nuclear staining for NØ. Following 
successful isolation, NØ were induced to apoptosis by various methods to identify the 
optimal AC death induction method. The subsequent interaction and phagocytosis by MØ 
was then assessed.  
3.2.1 Characterisation of primary NØ 
In order to separate NØ from other white and red blood cells present within donor blood, 
fresh human venous blood was collected from healthy volunteers and layered onto a 
Percoll density column which was centrifuged to separate different cell populations, 
including NØ (figure 10, Materials & Methods). Following NØ harvesting from columns and 
red blood cell lysis, the purity of NØ was estimated. The presence of CD66b expression, a 
surface marker of NØ, was determined both in whole blood and isolated NØ by immuno-
fluorescence and flow cytometry (figure 14). The results demonstrate high CD66b 
expression as shown by the mean fluorescence intensity (MFI) (figure 14A) of isolated NØ 
as MFI=703 compared to isotype control MFI = 51.  Coupled with the percentage of cells 
positive by flow cytometry (figure 14B) confirming the purity of NØ as 96%±2 (figure 14B). 
Additionally, nuclear (DNA) staining reveals characteristic polymorphic nuclei with two-
lobed or three-lobed segmented nuclei connected by a strand or filament (figure 14C) as 
assessed by DAPI staining, again confirming the purity of isolated NØ. Depending on the 
nature of the NØ the shape of the nucleus changes 441. Normal healthy NØ nuclei have a 
3-5 lobed shape, however, NØ are very sensitive and tend to become activated quickly. 
Activated NØ appear more amorphous and lose their natural shape and adapt to an 
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amoeba-like structure inducing NØ chemotaxis 442.  These data support the successful 
approach adopted for NØ isolation from whole blood. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Phenotypic analysis of isolated NØ  
NØ were isolated from healthy donor blood using Percoll-mediated fractionation. Isolated 
cells were assessed for activation marker CD66b (highly expressed on the surface of NØ 
cells) using flow cytometry and nuclear morphology by DAPI staining. A) Histogram 
showing MFI of CD66b incubated with whole blood or isolated NØ. B) Flow cytometric 
frequency histograms of cells stained with isotype control antibody (solid grey line) or anti-
CD66b (solid black line) confirming that 96.2% of isolated cells are NØ. The MFI of both 
isotype and NØ are shown. C) Representative fluorescent image displaying (60X) DAPI 
stained isolated viable NØ cells (arrows) showing mature segmented nuclei with 3 -5 
lobes connected by a filament. Data shown are representative of three independent 
experiments. 
3.3 Generation of AC  
3.3.1 B cells  
The Mutu Burkitt’s lymphoma (B) cell line, is an important AC model used for much of the 
current study as this cell line has been highly characterised within the Devitt research lab 
over many years and will play an important role as a control for many assays in this study 
37, 282, 324, 384, 418. Various doses (25, 50, 75, 100 mJ/cm2) of UV were used to induce 
apoptosis in B cells. Following overnight incubation at 37°C, which allowed apoptosis to 
proceed, the cells were washed with binding buffer and stained with annexin V- FITC and 
propidium iodide (PI) to assess exposure of PS and membrane integrity (i.e. apoptotic and 
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necrotic cell presence) and accordingly the cells are sorted on the flow cytometric 
quadrant plot (figure 15A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Induction and analysis of apoptosis by UV in B cells  
B cells were induced to undergo apoptosis by exposing to the indicated doses of UV 
ranging from 0 to 100 mJ/cm2. Following 16h incubation at 37°C, cells were stained with 
annexin-V FITC and PI to reveal the levels of cell death in B cells via flow cytometry. A) 
An example of flow cytometric AxV/PI quadrant plot showing gated regions of stained 
cells. B) Representative flow cytometric analysis of AxV and PI showing untreated B cells 
(left) and UV (50mJ/cm2) induced cells (right). C) The percentage of viable and AC of UV-
induced B cells was quantified. The data shown are representative from three 
independent experiments for (B) and the mean ± S.E.M of three independent experiments 
for (C).  
 
The data in figure 15 suggest that exposure to 50mJ/cm2 UV and 16h incubation allows 
death to proceed which is confirmed by 87.6% of cells stained positive for AxV when 
plotted against PI (fgure 15B) while untreated cells remained mostly negative for AxV/PI 
stain (figure 15B). Analysis of cell death at various UV doses indicate that 50mJ/cm2 at 
16h incubation provides maximum apoptosis in B cells (figure 15C) in agreement with the 
published kinetics of cell death in B cells  418. These data confirm UV as a useful method 
for the rapid induction of apoptosis in B cells and for future studies 50mJ/cm2 UV was 
used to induce apoptosis in B cells. 
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3.3.2 Primary NØ  
Being the primary responder to bacterial infection, NØ help to resolve an infection by 
phagocytosis and inflammation, and then by silently triggering the ‘self–destruct switch’ 
called apoptosis to remove inflammatory cells that are no longer required. It was important 
to undertake the present study to determine the methods required to trigger the execution 
phase of apoptosis in isolated NØ so that apoptotic NØ could be used in future 
experiments. Here various methods of inducing apoptosis were developed and tested to 
allow further studies to employ the method that produced a high level of apoptosis with 
minimal necrosis or lysis (autolysis) of NØ. 
Isolated NØ were resuspended in RPMI/ BSA medium (section 2.4.1) and used 
immediately as healthy viable control cells. Similar to B cells, the isolated NØ were 
induced to undergo apoptosis by exposing cells to UV at a range of doses prior to allowing 
apoptosis to proceed before staining with AxV-FITC and PI. The results are shown in 
figure 16A.  
The data indicate that freshly isolated NØ show little staining with AxV (figure 16A & B) 
and that UV at 50mJ/cm2 induces an increase in PS exposure at 16h incubation marking 
approximately 82% of cells as apoptotic with further higher doses of UV failing to increase 
the apoptosis level in NØ (figure 16B). DAPI nuclear dye was used to detect characteristic 
nuclear changes in NØ undergoing apoptosis by fluorescence microscopy. Figure 16C 
displays representative fluorescence images at time point’s 0h post-UV showing viable 
NØ (V) and 16h post-UV showing condensed chromatin as a sign of AC death for a UV 
dose of 50 mJ/cm2. Higher doses of UV induced necrosis and loss of cells as shown by 
AxV/PI stain (figure 16D).  
NØ exposed to various doses of UV showed wide-ranging levels of apoptosis, however, it 
was noted that there was a low cell count following higher doses of UV analysed by flow 
cytometry. On further study, it was observed that cells were lost, presumably through 
lysis, as the number of events (i.e. number of cells) was reduced. Where possible, 10,000 
events were analysed per condition but in some cases this was not possible due to cell 
loss. Table 6 shows the level of apoptosis and the number of cells analysed per second 
by spontaneous ageing at 4°C or 37°C at various time points. While the spontaneous 
ageing at 37°C showed an increased number of cells analysed per second with higher 
percentage for apoptosis, the UV-induced NØ revealed a higher NØ apoptosis however 
lower cell count per second.  This can be seen with 50 mJ/cm2 induced increased level of 
apoptosis in NØ at 16h however the cell count was lower indicating loss of cells (Table 6). 
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Figure 16: Induction and analysis of apoptosis by UV in primary NØ  
Freshly isolated NØ were irradiated with UV at the indicated doses of UV (mJ/cm2) 
followed by incubation for 16h before quantification of cell death via staining cells with 
AxV/PI and analysis by flow cytometry. A) Histogram showing level of fluorescence for NØ 
stained of AxV-FITC plotted against PI. B) Histogram showing the percentage of apoptotic 
and viable cells in NØ cultures exposed to different doses of UV. C) Nuclear morphology 
was studied using DAPI stained NØ at 0h showing viable (V) cells and 16h showing 
condensed nuclei or bleb nuclei, a marker for apoptosis (A). Magnification 60X. D) 
Histogram shows the percentage of necrotic cells (i.e. cells stained positive for PI). The 
data shown are mean and ± SEM from three independent experiments (B and D) and flow 
cytometric and microscopic image (A and D) are representative of three independent 
experiments. 
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Table 6: Induction and analysis of various forms of apoptosis on primary NØ 
analysed using flow cytometry  
Freshly isolated NØ were induced to apoptosis either by UV followed by culturing at 37ºC 
for 16h (as described in section 2.5.1.1 and 2.5.1.2) or by the spontaneous ageing in 
culture at 4ºC or 37ºC at various time points (as described in section 2.5.1.2). Cells were 
analysed for apoptosis by AxV/PI staining (as described in section 2.5.3.1) at the indicated 
time by flow cytometry. The table on the left shows the percentage of apoptosis induced 
by spontaneous ageing at 4°C, 37°C and the table on the right shows percentage of 
apoptosis by UV-induced NØ at indicated doses cultured for 16h at 37°C. Time (seconds) 
taken to analyse the indicated number of cells (events) (maximum 10000) using flow 
cytometry were also shown. The data shown are mean ± SEM from three independent 
experiments.  
3.3.3 Temperature dependent apoptosis in NØ 
Since the UV method of apoptosis induction failed to give a large yield of AC, temperature 
dependent apoptosis was analysed by culturing isolated NØ at 37ºC or 4ºC in NØ medium 
(as described in 2.5.1.2) and monitored for AC death over 40h using flow cytometry. To 
assess cell death, NØ at various time points post-isolation were stained with AxV and PI 
to detect apoptosis and necrosis. Time points observed were 0h, 4h, 16h, 20h, 24h and 
40h post-isolation with incubation at 4°C or 37°C (figure 17A). NØ incubated at 37°C 
showed increased apoptosis at 8h of culture and beyond while NØ incubated at 4°C 
demonstrated much lower levels of apoptosis that even after 40h of culture did not reach 
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the levels seen with 37°C (figure 17A). Overall, the levels of necrosis remained low 
(<0.5%) in cells cultured at either 4°C or 37°C (figure 17B). The results were consistent 
with analysis of nuclear morphology shown by DAPI staining (figure 17C) where classical 
apoptosis was only noted at 16h following incubation at 37°C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Quantification of spontaneous NØ cell death incubated at 4°C and 37°C  
NØ were isolated from healthy donor blood using Percoll-mediated fractionation. Freshly 
isolated NØ were incubated at 4ºC or 37ºC in sfRPMI with 0.2% BSA and analysed for AC 
death by staining the cells with AxV/PI using flow cytometry (as described in section 
2.5.3.1) at the indicated time points. A) The percentage of AC (AxV+/PI-) in NØ cultured at 
4ºC or 37ºC at various time points. B) The percentage of total necrotic cells (PI+) in NØ 
cultured at 4ºC or 37ºC at various time points. C) Representative fluorescent image of 
DAPI stained NØ cultured at 4ºC or 37ºC showing viable (V) and AC (A) at time points 4h 
and 16h. Magnification 60X. Data shown is mean ± SEM from three independent 
experiments (A and B) and the images are representative of three independent 
experiments (C).  
 
The results in figure 17 suggest that 37ºC culturing of NØ induces robust spontaneous 
apoptosis at maximal levels with minimal necrosis compared to the UV-induction method. 
Additionally, the number of cells analysed per second were comparatively higher to the 
UV-induced method (Table 6). For future studies, to induce apoptosis in NØ, cells were 
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cultured at 37ºC for 16h to allow spontaneous apoptosis to proceed and then were used 
to study the interaction assays with THP-1 MØ.  
3.4 THP-1 differentiated MØ model 
Tissue MØ are multifunctional cells that are widely distributed in connective tissue and 
organs e.g. bone marrow, lungs, liver, nervous system 443. To understand the MØ host 
defences it is important to study the interaction between MØ and immune challenges 
(invading pathogens and AC) because MØ are considered as a professional scavenger of 
AC and their function has a vital role in tissue homeostasis 35. In order to allow these 
studies, a MØ model system was developed from THP-1 cells, a human monocytic 
leukaemia cell line which was used to study the ability of THP-1 differentiated MØ to 
migrate towards dying cells, to tether and remove AC and to mediate pro-/anti-
inflammatory cytokine responses. Similar models have been used previously 36, 444.  
3.4.1 THP-1- derived MØ model system 
The THP-1 cell line derived from peripheral blood of a 1-year-old human male with acute 
monocytic leukaemia was stimulated with VD3 or PMA or DS for 48h at 37ºC to produce 
MØ-like cells (as described in section 2.3.5). MØ produced from THP-1 cells treated with 
different stimulants (VD3 or PMA or DS) have been assessed for their role in AC 
clearance and these models will be used for further assay in characterising the role of MØ 
in interaction with apoptotic NØ 36 
Depending on the environmental stimuli (e.g. bacterial signals, PAMPs) the functional 
phenotype varies from monocyte to MØ. This includes the development of characteristics 
such as specialised functions (e.g. cell adhesion), or cell features (e.g. nuclear-
cytoplasmic ratio, increased cell size, granularity, surface receptor expression, 
mitochondrial organelle number and secretory vesicles) as differentiated tissue MØ 
prepare to live longer to maintain tissue homeostasis 445. To asses THP-1 changes in 
response to differentiation with VD3, PMA or DS cells were treated for 48h and their 
morphological appearance recorded (figure 18).  
The results in figure 18 show clear morphological changes analysed using microscopic 
analysis of monocytes differentiating to MØ. MØ differentiated from THP-1 /VD3 and 
untreated THP-1 cells were semi-adherent and no consistent difference was observed in 
the cell morphology whereas THP-1 cells induced with PMA or DS appeared to be 
strongly adherent and elongated unlike VD3 stimulated THP-1 cells which appeared 
relatively small and spherical in morphology.  
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Figure 18: Morphology of THP-1-derived MØ induced to differentiation with various 
stimulants  
THP-1 (1 X 105) cells were seeded in a 24 well plate with various stimulants VD3 (100 
nM), PMA (250nM) or DS or left untreated. Monolayer formation of THP-1 cells was 
analysed for phenotypic variation after 48h microscopically. The microscopic images in 
the top row are 10X magnification and the bottom row images are 60X. The images are 
representative of three independent experiments.   
3.4.2 Cell surface receptor expression  
3.4.2.1 CD14 
The glycosylphosphatidylinositol-linked plasma membrane glycoprotein CD14, is an 
innate immune PRR and a feature of differentiated MØ.  It has been established as a 
receptor for multiple ligands including PAMPs (e.g. LPS) and AC 324. To study the CD14 
receptor expression as a measure of MØ differentiation, cell surface CD14 levels were 
assessed using indirect immunofluorescence staining on THP-1 monocytes and 
differentiated MØ using the established anti-CD14 mAb (63D3) by flow cytometric analysis 
(figure 19). Analysis of the function of CD14 in mediating inflammatory responses and 
taking up and phagocytosing apoptotic NØ, an anti-inflammatory event, is key to the 
current study. This will allow analysis of pathogen factors and AC present in chronic 
inflammatory diseases such as PD to understand the impact on CD14 and MØ function. 
Flow cytometric results in figure 19 suggest that nearly 100% of VD3-stimulated MØ 
express CD14 compared to THP-1 monocytes and that these cells are highly positive for 
CD14, as assessed by the MFI.  This indicates a clear differentiation from monocytes to 
MØ. The MFI value is higher on all the stimulated THP-1 cells except the PMA stimulated 
compared to unstimulated cells indicating CD14 levels are increased as a marker for 
Untreated VD3 PMA DS 
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differentiation into MØ in agreement with previous studies 446. However of all the 
stimulants, VD3 showed the highest positive fluorescence for CD14, across all cells 
compared to PMA or DS which showed lower levels of CD14 in a sub-population of cells, 
with 40-60% of cell being positive for CD14. For PMA stimulated cells, they showed a 
detectable level of CD14 compared to DS culture suggesting VD3 presence is essential to 
enhance the CD14 surface receptor 447. These findings are supported by previous work 
demonstrating a similar difference on CD14 expression level on myeloid cells i.e. 
monocytes and MØ 36. 
 
 
 
 
 
 
 
 
 
Figure 19: CD14 surface expression on THP-1-derived MØ  
THP-1 cells were stimulated to differentiate with VD3, PMA or DS for 48h and the cells 
were stained with anti-CD14 (63D3) to assess the CD14 levels using immunofluorescence 
and flow cytometry. A) Histogram showing percentage of cells positive for CD14 staining 
B) The MFI of the stained population is shown. The data shown are of mean ± S.E.M of 
three independent experiments. Statistical analysis was conducted using AVOVA with 
Dunnetts post-test (*P<0.05, ***P<0.001) compared to THP-1. ns- Non significant. 
3.4.2.2 CD36 
CD36, a class B scavenger receptor expressed on human monocytes, is found to be 
increased on the plasma membrane of HMDM cells upon differentiating from monocytes 
at mRNA levels 448. Additionally, CD36 is proven to be involved in PS recognition and AC 
clearance. It acts as a scavenger receptor for uptake of oxidised low-density lipoprotein 
(Ox-LDL) and is essential for MØ activation to initiate inflammatory signalling associated 
with the gingival epithelial cell inflammation 329, 449-451.  Here, CD36 surface receptor was 
assessed on THP-1 stimulated MØ using anti-CD36 or isotype control. The MFI and cells 
positive for fluorescence were measured using flow cytometry analysis. The results are 
shown in figure 20. 
 
A B 
Results 
91 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: CD36 surface expression of THP-1-derived MØ  
THP-1 cells were stimulated to differentiate with VD3, PMA or DS for 48h and the cells 
were stained with anti-CD36 to assess the CD36 levels using immunofluorescence and 
flow cytometry. A) Histogram showing percentage of cells positive for CD36 staining B) 
The MFI of the stained population is shown. The data shown are mean and ± S.E.M of 
three independent experiments. Statistical analysis was conducted using AVOVA with 
Dunnett’s post-test. (**P<0.01) compared to THP-1. ns- Non significant. 
 
Flow cytometric results in figure 20 suggest that each cell type irrespective of stimulant 
(VD3, PMA and DS) expressed CD36 on its surface with between 55% and 80% of cells 
positive for CD36. However, VD3 and DS stimulated THP-1 MØ expressed significantly 
higher CD36 compared to THP-1 monocytes and PMA differentiated THP-1 MØ as 
assessed by the MFI (level of CD36 per cell). While 55% of THP-1 monocytes and PMA 
MØ were positive for CD36, PMA showed a trend towards more CD36 per cells (MFI 
increased). For both VD3 and DS, the percentage of positive cells increased (to nearly 
80%), as did the MFI suggesting more cells are positive for CD36.  
3.5 MØ chemotaxis to AC 
3.5.1 Dunn chamber model-horizontal chemotaxis 
Introduction 
Chemotaxis, is the active locomotion of cells guided by various signals in the form of 
extracellular chemical gradients.  These signals may be released either by a pathogen 
(e.g. FMLP) or by immune cells on detecting microbes (e.g. IL-8), thus aiding cells to 
reach pathogen-infected tissue 452. Chemotaxis has been widely studied in physiological 
processes such as in embryogenesis for normal development of organs, in repairing 
infected tissue and healing wounds, and more recently reprogramming chemotaxis 
A B 
Results 
92 
 
pathways has been suggested as a model to study the dissemination of tumour cells and 
also proposed as therapy for cancer treatment 453-456. 
Upon injury or bacterial invasion, circulating monocytes are recruited from the blood and 
differentiate into MØ as they migrate towards toxic components released by pathogenic 
bacteria 44. Classic examples are the potent chemotactic microbial peptide FMLP or the 
chemokine IL-8 (CXCL8) that recruit NØ to the injured sites via chemotaxis 457, 458. Upon 
infection, tissue resident leukocytes migrate to the endothelium of the infected tissue via 
histamine mediated recruitment. Once the NØ reach the endothelium, the NØ initiate 
adhesion through adhesion proteins such as β2-integrins to prevent cell detachment by 
the flow of blood. Following adhesion, NØ will roll along the endothelium using low-affinity 
binding selectins (i.e. L-selectins) towards the chemotactic gradient.  Binding of 
chemokines to specific NØ receptors strengthens the interaction between lymphocyte 
function associated antigen-1 (LFA-1) on the NØ and ICAM-1 expressed by the 
endothelium, which arrests NØ rolling. This immobilisation allows NØ to extravasate 
through the endothelium and migrate towards sites of inflammation 459. Defective 
activation or migration of phagocytes may contribute to poor AC clearance and a 
consequent failure to resolve inflammation. This has been suggested as a target for 
translational therapy in chronic inflammatory disorders such as PD 460.  
Chemotactic factors create a chemical concentration gradient along which cells might 
migrate. Factors such as ICAM-3 shed from apoptotic B cells, and CX3CL1 released from 
apoptotic lymphocytes promote attraction of monocytes, MØ and dendritic cells leading to 
efficient clearance of dying cells 37, 461, 462.  
Based on the gradient of chemotactic factors released during apoptosis MØ migration 
towards dying cells may differ. Numerous assay systems have been developed to study 
chemotaxis including capillary movement 463, Boyden chambers 464, collagen or fibrin gels 
465 and recently microfabrication 466. Due to the long term stability of the established 
gradient, Dunn chemotaxis chambers are used which operate on a ‘true’ linear 
concentration gradient making them an excellent model system to track cell movement by 
velocity, distance and the degree of angle traveled towards the chemoattractant 467, 468. 
This section aims to study the recruitment of phagocytes by dissecting THP1-derived MØ 
migration towards apoptotic B cells and primary NØ.  
The chemoattractive abilities of AC (B or NØ) were assessed using the low throughput 
Dunn chamber model. The Dunn chamber was set up according to methods described in 
section 2.6.2.1. Preliminary work suggests that VD3 stimulated MØ showed suitable 
adhesion capacity using PDL coated coverslips and efficient migration towards the 
chemoattractant compared to PMA or DS-derived MØ showing adhesion was too strong 
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to allow migration due to the firm anchoring phenotype.  Consequently, VD3 stimulated 
THP-1 cells were used as the preferred model for the MØ migration assays. Additionally, 
various cell concentrations ranging from 4 X 105 to 6 X 105 cells/well in a six-well plate 
containing the cover slip were assessed to standardise the most appropriate 
concentration of MØ for migration assay.  A density of  4 X 105 cells/well was too low to 
locate 40 cells for scoring (as recommended by the Ibidi chemotaxis tool) on the Dunn 
chamber viewing bridge to track migration;  while 6 X 105 cells/well caused either crowded 
or clumped cells that were also difficult to track.  Therefore, a density of 5 X 105 cells/well 
was used as standard, demonstrating a simple and clear migration phenotype of individual 
cells. 
3.5.1.1 MØ chemotaxis to AC B cells 
MØ migration towards serum-free medium serves as an essential negative control 
compared to migration towards apoptotic B cells (figure 21). This control reflects the 
medium in which the B cells were induced to apoptosis. The control checks were analysed 
to assess the level of MØ migration in the absence of AC and to confirm that there were 
no putative attractants contaminating the reusable Dunn chamber to stimulate MØ 
migration. THP-1/VD3 MØ were also assessed for their migration towards either AC B 
cells or their derived AS (figure 21). The data were analysed using 13 images taken every 
6 minutes for 2h at 37ºC using Zeiss automated microscope. To obtain the normalised 
plots shown in figure 21, 40 cells were tracked using the manual tracking plugin from 
Image J and the generated data were uploaded to the Chemotaxis and Migration Tool 
V2.0.  This generated the plots shown in figure 21 where all cells are mapped at the start 
to the cross hairs, with the relative position of the putative attractant at the top of the plot 
(black diamond).  Each plot is 400X400µm (figure 21).   
Figure 21 shows MØ migration towards sfRPMI showed less migration or chemokinesis of 
THP-1 MØ confirming no chemotactic factors present in the gradient to trigger the 
migration. However directional migration of MØ was observed in MØ moving to apoptotic 
B whole culture or their derived AS indicating that B cells serves as an chemoattractant for 
MØ (figure 21B &21C), this is in agreement with previous studies using vertical chambers 
37, 469. 
To describe fully the migration of MØ, other measures were taken from the plots (e.g. 
accumulated distance travelled, Euclidean distance (direct distance between start and end 
points), velocity, directness, and angle of multiple chemotaxis assays using the 
Chemotaxis and Migration Tool as described below. 
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Figure 21: THP-1- derived MØ migration towards AC B cells and their derived AS 
THP-1 cells were stimulated with VD3 in cRPMI and cultured on a coverslip for 48h at 
37ºC. B cells were induced to apoptosis with UV (50mJ/cm2) and cultured for 16h at 37ºC 
for apoptosis to proceed and used either directly as an apoptotic whole culture or 
centrifuged (2000xg for 20 minutes) and the resultant supernatant (AS) used as an 
attractant. MØ migration from their starting point at the cross hairs towards the putative 
attractants on the top of plot (black diamond) were recorded. The putative attractant was 
sfRPMI- medium (control) (left panel) or AC B cells whole culture (middle panel) or AS B 
(right panel). Migration was monitored using time-lapse video microscopy (images were 
taken every 6 min for 2h) and analysed using image J to obtain the normalised plots. The 
plots are standardised such that all 40 MØ (as recommended by chemotaxis and 
migration tool) start at the centre of the cross showing their migration towards or away 
from the attractants. The plots shown are representative of three replicates.  
3.5.1.2 Determination of efficiency of migration 
To analyse cell migration, chemotactic effects were extracted from Ibidi Chemotaxis and 
Migration Tool software, examined and analysed using appropriate statistical tests. The 
migrated MØ were assessed for forward migration index, velocity, distance travelled 
(Euclidean and accumulated), and angle of cell movement towards the attractive gradient.  
3.5.1.2.1 Forward migration index (FMI) 
To quantify the movement of a cell in a direction parallel to the attractive gradient, yFMI 
data was extracted from the software (figure 22A).  Similarly, movement in a direction 
perpendicular to the attractant gradient, xFMI data was extracted. The FMI data indicate 
the distance travelled by a single cell, here a MØ, from the starting point to the endpoint 
(after 2h) along both the axes (figure 22). An effective chemotactic migration is a high 
positive yFMI value which corresponds to parallel movement of cells towards the gradient 
(figure 22A) while low xFMI value corresponds to perpendicular movement of cells (figure 
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22B) towards the chemoattractant. The values that are closer to 1 are directional and the 
values that are closer to -1 corresponds to indirect migration.  
 
 
 
 
 
 
 
 
Figure 22: Schematic representation of forward migration index calculated from cell 
migration Dunn chamber assay using Chemotaxis and Migration Tool software  
The picture shows FMI of MØ migration, starting at the centre of the plot (cross hairs) 
towards the attractive gradient at the top of the plot (red spot), calculated using parallel 
(yFMI) and perpendicular (xFMI) measures representing the directionality of cell migration. 
A) The plot shows strong chemotaxis effect with a high yFMI value and a low xFMI value. 
B) The plot shows poor chemotaxis effect with a high xFMI value and a low yFMI value, 
indicating the cells are moving either in a random direction or with limited directionality 
towards the attractant gradient. Adapted from 470. 
3.5.1.2.2 Measurement of distance, directness and velocity 
Two types of distance were measured (figure 23), Euclidean distance which measures the 
direct distance between the start and end points of a migrated cell, and the accumulated 
distance which measures the total distance travelled by the cell (i.e. the sum 
measurement of all incremental movements).  
Directness demonstrates the straightness of migration or a cell’s affinity to travel straight 
in a given direction however, directness fails to show the true MØ chemotaxis response as 
it does not take direction into account, only the distance. Directness is calculated by 
dividing the Euclidean distance by the accumulated distance for each cell. However, 
plotted separately, the accumulated and Euclidean distances of 40 cells describe the 
trajectories used to measure the distance and velocity of movement the cell undertakes in 
the 2h.  
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Figure 23: Schematic representation of the distance travelled by the phagocytes 
calculated using the Chemotaxis and Migration Tool software  
The picture depicts the measurement of accumulated (A) and Euclidean distance (B) of 
cell migration from starting to end point of in a 2h assay performed in Dunn chamber 
model. A) The plot shows the measurement of accumulated distance by calculating the 
total distance travelled by a MØ from the centre of the plot (cross hairs) considering all the 
routes taken to reach the chemoattractants on the top of the plot (red spot) in a 2h time 
period. The arrow indicates all the incremental movements taken by the cell to reach the 
endpoint. B) The plot shows the measurement of the Euclidean distance by calculating the 
start (arrow) and the end point (arrow) location of a migrated cell. The arrow indicates the 
start of the MØ at the centre of the plot (cross hairs) and the endpoint. Adapted from 470. 
3.5.1.2.3 Angle 
In addition to the yFMI index, the uniformity of cell movement was determined using angle 
measurements extracted using the Chemotaxis and Migration Tool. Based on the location 
of the end points, the uniformity of each cell was tracked upon their migration to the 
attractants without taking into account the distance or direction of the migrated cells. The 
angle was calculated for 40 cells in each assay by normalising all cells to the starting point 
in the centre of the circle in a migration plot. The uniformity of phagocytes’ migration was 
measured towards the attractant. Higher angle values indicate higher variability on the 
end points of the cell indicating deviation from the other endpoints of the cell (figure 24A). 
A lower angle displays low variability on the end points of the cell indicating most of the 
MØ were travelling closer towards the chemoattractant (figure 24B). While the angle 
measurement demonstrates the uniformity of all 40 cells’ end points, the yFMI index 
shows the uniformity only in the cells that were moving towards the attractants. 
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Figure 24: Schematic representation of angle measurement of phagocyte migration 
calculated from Chemotaxis and Migration Tool software  
The diagram depicts the uniformity of cell migration towards the attractants using angle 
measurement of individual cell endpoints of all 40 cells migrated in a specified time period 
performed in a Dunn chamber model. A) The plot shows schematic representation of the 
endpoints of the MØ (black dots) migrated to the chemoattractant at the top of the plot 
(red spot) with a higher angle measurement indicating higher variability of cell endpoints. 
B) The plot shows schematic representation of the endpoints of the MØ (black dots) 
migrated to the chemoattractant present at the top of the plot (red spot) with a lower angle 
measurement indicating lower variability of cell endpoints. The angle measurement 
ensures only the variability of the movement of phagocytes but it does not grade whether 
the migration is strong or poor towards the chemoattractant. Adapted from 470. 
 
These different measures of migration were extracted from the assays of MØ migration 
towards AC B or AS B (e.g. figure 21) and are presented in figure 25. The data in figure 
25 show no significant differences in accumulated distance migrated towards control 
medium and AC B or AS B (figure 25A); Euclidean distance (figure 25B) or velocity (figure 
25C) though a trend was observed in each case for increased migration towards AC B 
and again to AS B. However, AC B showed a significant difference (P<0.05) in yFMI of 
MØ migration (figure 25D) compared to control indicating AC B as a stronger attractant 
compared to AS B cells (figure 25D). 
To quantify the uniformity and direction of MØ migration, angle and directness were 
assessed using the Chemotaxis and Migration Tool. The data in figure 26A show 
significant difference (P<0.05) between migration towards the attractants (AC B or AS B) 
and control indicating that MØ migration towards the attractants was in a uniform manner 
compared to the control, as a lower angle represents lower variability in cell movement. 
To characterise the migration directness (D) Euclidean distance was divided by the 
accumulated distance. If the D value is equal to 1, then cells migrate from their starting to 
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their end point in a perfect straight line. The data in figure 26B show no significant 
difference between the directness of migration to putative attractants and control, however 
directness values are always positive and do not take into account the direction (towards 
or away from the gradient) indicating that the directness is not a definite measure of 
chemotaxis. 
Though VD3 stimulated THP-1 MØ were treated with two different components of 
apoptotic B cell culture (AC or AS) the migration of MØ was found to be stronger towards 
AC B (figure 25D) compared to AS B. Yet AS B showed a greater trend in distance and 
velocity travelled (figure 25A, B & C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Quantitative measurement of MØ migration towards AC B and AS B  
VD3 stimulated THP-1 MØ were allowed to migrate to either sfRPMI (control) or AC B 
cells whole culture (AC) or their derived secretomes, using a DUNN chemotaxis chamber 
for 2h at 37°C.  Migration was monitored using time-lapse video microscopy. The data 
were extracted using image J by tracking 40 MØ per assay and standardised in a 
normalised plot. The plot obtained in figure 21 was used to extrapolate the measurements 
using Ibidi Chemotaxis and Migration Tool (V2.0). The figure shows A) accumulated 
distance B) Euclidean distance C) velocity and D) yFMI of MØ movement towards AC B 
cells or their derived AS or sfRPMI on its own. Data show the mean ± SEM of three 
independent experiments. Statistical test conducted using AVOVA with Bonferroni post-
test (*P<0.05).  
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Figure 26: Angle and directness of MØ migration towards AC B or AS B  
VD3 stimulated THP-1 MØ were allowed to migrate to either sfRPMI (control) or AC B or 
AS B using a Dunn chemotaxis chamber for 2h at 37°C and monitored using time-lapse 
video microscopy. The data were extracted using image J by tracking 40 MØ per assay 
and standardised in a normalised plot. The plot obtained in figure 21 were used to 
extrapolate the measurements using Ibidi Chemotaxis and Migration Tool (V2.0). The 
figure shows A) Angle in degrees B) Directness in units of MØ migration towards AC B AS 
B or sfRPMI on its own. Data show the mean ± SEM of three independent experiments. 
Statistical test conducted using AVOVA with Bonferroni post-test. (*P<0.05).  
3.5.1.3 MØ chemotaxis to AC NØ 
Similar to B cells, VD3 stimulated THP-1 MØ migration towards apoptotic NØ or their 
derived AS was assessed using the Dunn chamber model. The data in figure 27, obtained 
by tracking 40 cells using imageJ, shows non-directional movement of MØ to serum-free 
medium (control) indicating some limited chemokinesis of phagocytes (figure 27). 
However, MØ movement towards AC NØ or AS NØ was higher suggesting directional 
migration of MØ (figure 27).  
Different measures of migration were extracted from the assays of MØ migration towards 
AC NØ or their AS (e.g. figure 27) and are presented in figure 28. The data in figure 28 
show no significant difference between the MØ accumulated distance, Euclidean distance 
and velocity of MØ migration to putative attractants (AC NØ or AS NØ) (figure 28A, B & 
C). However, significant differences were observed in yFMI of MØ migrating to both AC 
NØ (P<0.001) and AS NØ (P<0.05) compared to the control (figure 28D), moreover, 
stronger attraction was seen towards AC NØ compared to AS NØ (figure 28D).  
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Figure 27: THP-1-derived MØ migration towards AC NØ or AS NØ 
THP-1 cells were stimulated with VD3 in cRPMI and cultured on a coverslip for 48h at 
37ºC. Primary NØ were induced to apoptosis by culturing the cells for 16h at 37ºC and 
used either directly as an apoptotic whole culture or centrifuged (2000xg for 20 mins) and 
the resultant supernatant (AS) was used as an attractant. MØ migration towards the 
putative attractants on the top of the plot (black diamond) showing sfRPMI +0.2% BSA-
medium (control) (left panel) , AC NØ whole culture (middle panel), AS NØ (right panel) 
was monitored using time-lapse video microscopy (images were taken every 6 min for 2h) 
and analysed using image J to obtain the normalised plots. The plots are standardised 
such that all 40 MØ (as recommended by chemotaxis and migration tool) start at the 
centre of the cross showing their migration towards or away from the attractants. The plots 
shown are representative of four experiments. 
 
Similar to AC B cells and their derived AS, the angle of MØ migration towards the AC NØ 
and their derived AS shows a significant difference compared to control (figure 29A), 
where the control indicates higher deviation suggesting less uniform movement by MØ 
towards the sfRPMI. However, the measure of directness fails to show any significant 
difference in migration towards either attractant or control (figure 29B), similar to AC B 
cells.  
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Figure 28: Quantitative measurement of MØ migration towards AC NØ  
VD3 stimulated THP-1 MØ were allowed to migrate to either sfRPMI (control) or AC NØ or 
their derived AS using a Dunn chemotaxis chamber for 2h at 37°C and monitored using 
time-lapse video microscopy. The data were extracted using image J by tracking 40 MØ 
per assay and standardised in a normalised plot. The plot obtained in figure 27 were used 
to extrapolate the measurements using Ibidi Chemotaxis and Migration Tool (V2.0). The 
figure shows A) accumulated distance B) Euclidean distance C) velocity and D) yFMI of 
MØ movement towards the putative attractants or control medium. Data show the mean ± 
SEM of four independent experiments. Statistical test conducted using AVOVA with 
Bonferroni post-test (*P<0.05, ***P<0.001).  
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Figure 29: Angle and directness of THP-1 differentiated MØ migration towards the 
AC NØ or AS NØ 
VD3 stimulated THP-1 MØ were allowed to migrate to either sfRPMI with 0.2% BSA or AC 
NØ or their derived AS using a Dunn chemotaxis chamber for 2h at 37°C and monitored 
using time-lapse video microscopy. The data were extracted using image J by tracking 40 
MØ per assay and standardised in a normalised plot. The plot obtained in figure 27 was 
used to extrapolate the measurements using Ibidi Chemotaxis and Migration Tool (V2.0). 
The figure shows A) Angle in degrees B) Directness in units of MØ migration towards AC 
NØ or their derived AS or control medium. Data show the mean ± SEM of four 
independent experiments with two internal replicates. Statistical test conducted using 
AVOVA with Bonferroni post-test (***P<0.001).  
 
While both AC NØ whole culture and their derived AS recruited MØ (yFMI) (figure 28D) 
the AC NØ whole culture appears to have stronger attractive abilities compared to AS NØ 
(figure 28D). 
3.5.2 Cell-IQ model – Vertical chemotaxis 
Next, to complement the horizontal migration assays, the impact of THP-1 differentiated 
MØ migration using a vertical chemotaxis model was studied. The migration of MØ differs 
depending upon the gradient or linearity of the chamber used during the establishment of 
any migration assay 419. Gradients of biomolecules (e.g. cytokines) play an essential role 
in the migration of phagocytic immune cells in vivo but also provides directional cues 
involved in guiding immune cells towards chemical gradients released from the wounded 
tissue environment 419. To understand MØ migration in vivo, various in vitro gradient 
methods have been established for a better understanding of MØ transendothelial 
migration in pathogen-exposed environment.  
From the Dunn chamber studies presented here, it is clear that the horizontal migration 
assay method reveals migration of MØ to AC chemoattractants, based on the linear 
concentration gradient. Here, the transwell-based Cell-IQ assay, a vertical migration 
assay of phagocytes to potential attractants as a step-gradient was studied. Unlike the 
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Dunn chamber model, this method allows a multitude of kinetic assays to be carried out 
simultaneously in a single experiment and thus provides a significant advantage to allow 
more replicates to be carried out. The experiment was established using a transwell-
based system and a Cell-IQ tracking system to observe and capture data (detailed in 
section 2.6.2.2). Briefly, VD3 stimulated THP-1 MØ were placed inside the transwell, 
which serves as an upper compartment per well of a 24 well plate, and the transwell is 
directly placed into the bottom well containing AC cultures. The plate is sealed and loaded 
into the Cell-IQ instrument for cell imaging. Images were routinely collected every 20 
minutes over a 12h period. Representative results are shown in figure 30. 
 
  
 
 
 
 
 
 
Figure 30: Representative Cell-IQ image of THP-1-derived MØ migration to putative 
attractants using a vertical chemotaxis model  
VD3 stimulated THP-1 MØ migration towards the AC B cells or AC NØ was analysed 
using the Cell-IQ tracking system (as described in section 2.6.2.2). The transwell (8.0µm 
pore polycarbonate membrane) containing THP-1-derived MØ (8 X 105/well) were placed 
over a bottom well of a 24 well plate containing putative attractants (1 X 106/well) (either 
AC B cell whole culture or AC NØ whole culture) and imaged for every 20 minutes for 12h 
using cell IQ imaging system. The picture shows the Cell-IQ images (magnification 20X) 
of the bottom well of a 24-well plate containing AC B or AC NØ at 0h and migrated MØ 
(circled) at 12h from the top transwell. The images shown are representative of three 
independent experiments.   
 
The data in figure 30 shows the microscopic images of the bottom well of a 24-well plate 
containing attractants (AC B or AC NØ) imaged at 0h and 12h. A clear difference in 
number of MØ is observed at 0h displaying no MØ however many MØ (highlighted as 
circle) can be viewed at 12h indicating that MØ have migrated from the transwell to the 
bottom well of a 24-well plate in response to the attractants  present in the AC cells (AC B 
or AC NØ).  
Results from microscopic image (figure 30) were extracted using the cell-IQ software and 
analysed by Graph Pad Prism. The results are shown in figure 31. 
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Figure 31: THP-1-derived MØ migration to AC B or AS B using Cell IQ tracking 
system   
VD3 stimulated THP-1 MØ migration towards the AC or AS B cells was analysed using 
the Cell-IQ tracking system (as described in section 2.6.2.2). THP-1 MØ were placed in 
the upper transwell (8.0µm pore polycarbonate membrane; 8 X 105/well) and AC or AS B 
(1 X 106/well) in the bottom well of a 24 well plate.  Where indicated AC B cells were also 
included in the upper well to destroy the gradient.  Wells were imaged for every 20 
minutes for 12h using cell IQ imaging system. A) The graph shows numbers of migrated 
MØ in the lower well over time for 12h. B) The table shows cells present in the top and 
bottom well. C) The tables shows the statistical test conducted between the groups. The 
results shown are the mean ± SEM of three independent experiments with 2 replicates in 
each experiment. Statistical test conducted using AVOVA with Bonferroni post-test 
(**P<0.01).  
 
The data in figure 31 show a significant difference (P<0.01) in MØ migration towards AC B 
or AS B compared to control. However, to check whether the MØ count was true 
chemotaxis and not simply the result of cell movement influenced by gravity, the 
experiment was repeated to add the putative attractant (AC B) to both the top and bottom 
wells to destroy the gradient. However, no significant difference was seen in MØ migration 
between lower well containing AC or AS B cells compared to the upper well containing 
attractant (AC B). Since the AC B cells appear similar in size to MØ the experiment was 
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repeated using the AC NØ, which appear smaller in size compared to MØ (figure 30). The 
results are shown in figure 32.    
 
 
Groups Groups 
Statistical test P 
value 
Control MØ + AC NØ ns 
Control AC NØ ns 
Control AS NØ ** 
AC NØ AS NØ ns 
MØ + AC NØ AC NØ * 
MØ + AC NØ AS NØ *** 
 
Figure 32: THP-1-derived MØ migration to AC NØ or AS NØ using Cell IQ tracking 
system   
VD3 stimulated THP-1 MØ migration towards the AC or AS NØ was analysed using the 
Cell-IQ tracking system (as described in section 2.6.2.2). THP-1 MØ were placed in the 
upper transwell (8.0µm pore polycarbonate membrane; 8 X 105/well) and AC NØ or AS 
NØ cells (1 X 106/well) in the bottom well of a 24 well plate. Where AC NØ indicated were 
also included in the upper well to destroy the gradient.  Wells were imaged for every 20 
minutes for 12h using cell IQ imaging system. A) The graph shows numbers of migrated 
MØ in the lower well over time for 12h. B) The table shows cells present in the top and 
bottom well. C) The tables shows the statistical test conducted between the groups. The 
results shown are the mean ± SEM of three independent experiments with 2 replicates in 
each experiment. Statistical test conducted using AVOVA with Bonferroni post-test 
(*P<0.05, **P<0.01, ***P<0.001).  
 
A significant difference (P<0.001) was observed in the MØ migration to AS NØ compared 
to control (sfRPMI +0.15% BSA). However, no difference was observed in migrated MØ 
towards AC NØ compared to control indicating AS NØ as a stronger attractant. 
Additionally, significant difference was observed in the migrated MØ towards AC NØ 
(P<0.05) or AS NØ (P<0.001) compared to MØ with putative attractant (AC NØ) indicating 
the true directional migration was occurring. Moreover, unlike the Dunn chemotaxis 
assays (figure 28D), AS NØ were highly attractive compared to whole AC NØ culture 
(figure 32).  
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3.6 Phagocyte interaction with AC 
3.6.1 MØ-AC Interaction assay  
The ability of MØ to recognise and remove AC is a crucial step in promoting the resolution 
of inflammation 4. It is also a step that may be disrupted in inflammatory disease and the 
effect of periodontal pathogens on this step will be assessed later. From the migrational 
assay, it is understood that AC (B or NØ) may act as a chemoattractant for THP-1 MØ. 
Therefore the next logical step was to assess the interaction abilities i.e. tethering and 
phagocytosing of AC by THP-1 MØ by establishing an in vitro interaction assay model. 
Similar to the chemotaxis assays, B cells were used as a positive control in this 
experiment as it is a well-established model system to study MØ interaction with AC 37, 282, 
418, 469. Savill et al. found that MØ use CD36 and αvβ3 as bridging molecules to interact with 
aged apoptotic NØ. As this assay requires extensive washing of unbound AC from MØ on 
glass slides, the ability of THP-1/DS differentiated MØ to interact with NØ was assessed 
as they showed a strong adherent phenotype to the glass slides (figure 18). The AC 
bound or eaten by MØ were assessed following Jenner-Giemsa staining to study the level 
of MØ interaction with AC NØ by scoring the percentage of MØ interacting with AC. Here, 
a MØ interacting with an AC(s) is defined as a MØ that is binding and/or phagocytosing at 
least one AC. The results are shown in figure 33. 
 
 
 
 
 
 
 
 
Figure 33: Interaction of apoptotic B cells and apoptotic NØ with THP-1-derived MØ  
THP-1 DS differentiated MØ were cultured in the absence (control) or presence of AC B 
or AC NØ at 37ºC for 1h at a ratio of 20 AC per MØ. Cells were fixed with methanol after 
washing with cold PBS to remove unbound AC and stained for Jenna-Giemsa. Slides 
were mounted and assessed by light microscopy and values scored as the percentage of 
phagocytes interacting with AC (at least 200 MØ per well were counted). A) Graph shows 
the percentage of MØ that have interacted with AC B or AC NØ. B) Representative 
photomicrograph of THP-1-derived MØ (light blue) and their interaction with AC B and AC 
NØ (intense blue). Magnification 40X. The results shown are the mean ± SEM of three 
independent experiments. Statistical analysis was conducted using AVOVA with Dunnett’s 
post-test. (***P<0.001) compared to control. 
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The result in figure 33A indicates a significant difference was observed between MØ 
interaction with AC B cells and AC NØ. However, the interaction of MØ with apoptotic NØ 
shows a lesser percentage (20%) of interaction compared with apoptotic B cells (80%). 
Moreover, the percentage of cell death in all the groups (figure 33A) is not 100% 
indicating there are viable cells present which will not engulfed by MØ. This is in 
agreement with previous work suggesting that viable cells do not bind to MØ 281, 324. 
Microscopy images show elongated MØ (light blue) and engulfment of apoptotic B cells 
(intense blue) (figure 33B bottom left image) and NØ (intense blue) (figure 33B bottom 
right image) scored using a light microscope.  
3.7 Discussion 
The aim of this chapter was to establish an in vitro working model of THP-1 differentiated 
MØ interaction with AC NØ. AC B were used as a positive control in this study as they 
have been well established in earlier studies 36, 37, 324. In this section, the role of primary 
AC NØ recognition and phagocytosis by THP-1 differentiated MØ was studied. MØ 
differentiated from the THP-1 monocyte cell line were used as an important immune cell to 
understand the mechanism by which phagocytes trigger efficient clearance of AC and 
subsequently secrete anti-inflammatory cytokines to achieve tissue homeostasis, which 
has been hypothesised in this study to be inhibited in PD patients. 
One of the main in vivo events involved in AC clearance is how well MØ recognise signals 
from dying cells 471. This in vivo event has been modelled in vitro by isolating peripheral 
NØ from venous blood and inducing them to apoptosis. These apoptotic NØ have then 
been studied for their interaction with the THP-1 MØ cells. NØ help decide the result of an 
injury, either by helping heal the tissue by, undergoing apoptosis to enable their 
phagocytosis by MØ and release of anti-inflammatory mediators, or by, turning necrotic 
and worsening the inflammation by secreting their toxic contents. One of the major 
challenges involved in PD is to understand the role of NØ in the inflamed tissue. Many 
studies have assessed the function and characterisation of NØ in juvenile to generalised 
periodontal patients and proposed that hyperactive NØ worsen the gingival bleeding by 
accumulating in the biofilm region and producing increased reactive oxygen intermediates 
and enzymes causing tissue damage and bone loss 133, 472. However, only a few studies 
have addressed the role of phagocytes in chronic inflammatory disease through a 
bacterially-mediated environment. Hence the in vitro model proposed in this study is a 
THP-1-derived MØ interaction with apoptotic human NØ, to study the mechanisms 
involved in recognition and interaction of MØ with apoptotic NØ and the release of 
cytokines in the presence of factors from P.gingivalis.  
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3.7.1 Characterisation of human NØ 
NØ isolated from peripheral blood were confirmed for their purity using CD66b surface 
receptor expression and the nuclear stain DAPI (figure 14). CD66b, is a glycosylated GPI-
anchored protein expressed on both human NØ and eosinophils 473, 474. Lakschevitz et al. 
also reported that CD66b was expressed at higher levels on healthy segmented NØ 
suggesting CD66b as a marker for mature NØ 474. Moreover, CD66b on NØ regulates 
CD11/CD18 signals to mediate NØ interaction with endothelial surfaces thereby 
contributing to leukocyte migration 475. 
Nuclei of NØ vary depending on their lifespan 441. Generated from hematopoietic cells, 
immature NØ are seen with two lobe-shaped nuclei compared to matured nuclei 
displaying three lobed to six lobed nuclei 442. It is unclear whether, depending on the 
nature of NØ nuclei, the function of their immunity varies in relation to  tissue 
homeostasis. However, activated NØ vary in nuclear lobe shape and each lobe has a 
diameter of around 2µm connected by a thin segment of nuclear material ranging from 
0.2-0.5 µm 476, 477. Indeed NØ were considered to be active even if their nucleoli size is 
reduced. NØ undergo structural differentiation from a round nucleus to segmented lobe-
shaped nucleus which is considered to be healthy in conducting chemotaxis and 
phagocytosis of the pathogens and to stimulate the cytokines essential to repair the 
wounded tissue 478. The data presented in figure 14 confirms the purity of the NØ by 
phenotype CD66b expression as 96.2% and mature segmented nuclei of NØ by nuclear 
DAPI stain.  
3.7.1.1 Induction of apoptosis in NØ by UV and spontaneous method 
The characteristic structural and functional changes seen in viable cells on intiating 
apoptosis include alterations in the cell surface, cell shrinkage, nuclear fragmentation, 
plasma membrane blebbing and finally release of apoptotic bodies.  The molecular and 
biochemical variations at the cell surface include modifications of lipid, carbohydrate and 
protein levels and most important PS exposure 47. PS, a traditional marker for apoptosis 
has been widely studied for its necessity for effective cell clearance by MØ 479. Studies 
have however shown that exposure of this anionic phospholipid alone is not sufficient for 
recognition by phagocytes and innate immune receptors and ligands such as CD14, 
CD36, CD91 and ICAM-3 are required along with the presence of PS 329. Furthermore 
annexin proteins secreted following caspase activation are released from interacellular 
domains of AC. The secreted annexins such as annexin A5 (annexin V) bind to PS, 
identifying the translocation of PS from the inner leaflet to the outer leaflet of the plasma 
membrane 266. This knowledge has been used here to detect cell death of NØ or B cells, 
induced either by UV or spontaneously, using AxV-FITC and PI.  The data in figure 15B 
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show an example of non-induced cells that stained mostly negative for both AxV and PI, 
revealing the presence of viable cells.  After UV induction of apoptosis, a defined 
population of AC stained positive for AxV and negative for PI and a lesser number of 
necrotic cells stained positive for AxV and positive for PI. 
Apoptosis-associated genes play an important role in regulating and controlling apoptosis 
in multicellular organisms 233. Caspase-3, a frequently activated protease has been linked 
with DNA fragmentation in cell death by apoptosis 480. Also characterised as an 
executioner caspase of apoptosis, caspase-3  degrades the nuclear lamina through 
DNase enzymes resulting in condensed shrinkage of the cell, another characteristic 
feature of apoptosis 255. This correlates with the data presented here in figure 16C and 
17C showing condensed chromatin in NØ following either UV or spontaneous apoptosis at 
37°C. A study showed that procaspase-3, the inactive form of caspase-3 turned active 
only after 22h at 37°C in freshly isolated PMN while another study explained that low-
temperature arrests apoptosis in NØ, however, warming the NØ to 37ºC triggers a 
synchronous burst of apoptosis 481, 482. Taken together, the data presented here in figure 
17 suggest that spontaneous aging culture at 4°C might have inhibited the proteolytic 
cleavage of pro-caspase-3 while higher temperature i.e. at 37°C the active form of 
caspase 3 might have developed. An earlier report states that cold shock treatment of 
Burkitt lymphoma cells protected the cell viability for a prolonged period compared to cells 
at 37°C which enter apoptosis within a few hours 483. Weinmann et al.  also observed that 
on inhibiting caspase-3 in PMN cells a down-regulation is seen in the expression of Bcl-
XL, a Bcl-2 family member that inhibits apoptosis suggesting that caspase-3 regulates Bcl 
protein expression. Similarly, another study explained that cleavage of Bcl-2 protein 
contributes to amplification of caspase cascades 484. These studies highlight the close link 
between the activation of caspases to induce death and the expression of Bcl-2 family 
members to inhibit death.   
Dunkern et al. have shown that UV-irradiation triggers apoptosis through degradation of 
Bcl-2 via caspase and proteasome enzyme activation 485. The data in figure 15 suggests 
that B cells underwent effective apoptosis, possibly through Bcl-2 degradation and 
execution of caspases cascades. Additionally, P53, a major regulator of apoptosis has 
been shown to be activated by UV-irradation via mitochondria-dependent apoptosis 
through interaction with apoptosis-regulating proteins 486. Though, UV-induced NØ 
developed apoptosis at 16h a lower cell count (number of cells analysed per second) was 
noticed from 50mJ/cm2 UV dose compared to spontaneous ageing at 37°C (Table 6). This 
might be because UV-induced NØ have been shown to express increased level of p38 
MAP kinase in an activated form, which has been linked with TNF-α induced NØ  
apoptosis stimulating the release of soluble cytoplasmic proteins and triggering apoptosis-
Results 
110 
 
induced autolysis 487, 488. In contrast, freshly isolated NØ  or spontaneous aged NØ in 
culture at 37°C displayed a reduced level of p38 MAP kinase 487. This correlates with the 
data presented in figure 16 and 17 showing UV-induced apoptosis resulted in a lower cell 
count persumably as cells underwent frequent autolysis compared to spontaneous aged  
NØ culture at 4°C or 37°C (Table 6). 
Other than caspases, TLRs have been shown to have a modest effect during NØ 
apoptosis 489. TLR4 signals stimulate endogenous or exogenous mediators in order to 
maintain the survival of NØ. Indeed TLR2 has been proven to mediate the pro- and anti-
apoptotic signals in NØ and both TLR2 and TLR4 are effective mediators in the presence 
of monocytes/MØ 490. On the other hand, LPS delays apoptosis in NØ in vivo in septic 
peritonitis patients revealing inflammatory cells’ involvement in the host immune system 
491. GM-CSF has been stated to reduce the apoptosis on NØ in chronic periodontitis 
patients by an unknown mechanism 190. This suggests that delayed apoptosis in NØ might 
also prevent the recruitment of MØ to phagcoytose the AC, which in turn inhibit the 
release of anti-inflammatory mediators.  
The lifespan of circulating NØ in vivo has been extensively studied in recent years. A 
recent study measured the life span of NØ in vivo and revealed an average life span of 
NØ in the peripheral blood as 5.4 days under normal conditions 492. However, a recent 
study demonstrated that based on the turnover rate the life span of circulatory and tissue-
resident NØ were estimated as 8–12h in the blood and 1–2 days in tissues 493. The data in 
figure 17 showed the apoptotic death of NØ isolated from peripheral blood from 8-40h at 
37°C and around 40h at 4°C suggesting the viability of NØ might be upto 4h regardless of 
the temperature in vitro. Nevertheless, for the effective regulation of inflammation 
resolution timely clearance of apoptotic NØ is essential to prevent the secretion of toxic 
intracellular contents from necrotic NØ 15.  
3.7.2 Phenotypic characterisation and function of THP-1-derived MØ  
Monocytes and MØ are a key cell type in the immune system and enable the host defense 
against pathogenic insults as well as contributing to the prevention of chronic inflammation 
through phagocytosis of AC and control of pro-inflammatory mediators 494. Generation and 
activation of HMDM has been widely studied for their in vivo role in regulating 
inflammation resolution. Their differentiation from human monocytes takes several days 
and therefore it is a challenge to maintain the viability of these cells following stimulation. 
THP-1-derived MØ was produced using different stimulants (VD3 or PMA or DS) in this 
current study as the cell density were easy to maintain and importantly the role of THP-1 
MØ like cells in AC clearance is well established 418, 445, 495, 496. Hence, THP-1 differentiated 
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MØ were used in characterising the resolution of inflammatory mechanisms which may be 
involved in periodontal disease.  
Morphological changes were analysed using microscopic analysis through monocyte 
differentiation to MØ. Untreated THP-1 cells and VD3 stimulated MØ were similar in 
appearance (round shaped, semi-adherent) with no consistent differences in cell 
morphology (figure 18). However, THP-1 cells induced with PMA or double stimulated 
(VD3 and PMA) were strongly adherent, with a more flattened morphology and elongated 
(figure 18). These findings are in agreement with previous work 445. However, depending 
on the experimental need, different stimulants were selected to differentiate the THP-1 
cells to MØ. Notably, the profound effect on cell density of the THP-1 cells depending on 
the stimulants was also increased using light microscopy. In VD3 stimulated THP-1 cells 
the density of cells was observed upto 72h. However, in THP-1 cells stimulated with THP-
1/PMA or THP-1/DS the cell number remained relatively constant, likely due to their 
strong adherent capacity. Previous work has reported cell fusion in PMA treated BeWo 
cells resulting in larger multinucleated cells 497. Additionally, MØ have been reported to 
fuse with neighbouring MØ to form a giant mutli-nucleated MØ during chronic 
inflammation, but their role in inflammatory mechanism is yet to be elucidated 498. 
However, PMA-induced THP-1 MØ have been widely studied due to their similarities with 
HMDM cells. Indeed they have been shown to share similar upregulated lysosomal and 
mitochondrial staining which is broadly distributed in the cytoplasm of PMA stimulated 
THP-1 cells 445. 
CD14, an AC clearance and LPS receptor, has been widely used as a marker for 
differentiated MØ both in in vivo and in vitro conditions 142, 288, 326, 418, 447, 499-501. THP-1 
monocytes express a measurable level of CD14 before differentiation into MØ and upon 
incubation, the stimulants resulted in increased CD14 expression, except for PMA (figure 
19). Of all the stimulants used, VD3 stimulated THP-1 MØ expressed the highest level of 
CD14; THP-1/DS MØ expressed considerable levels and PMA stimulated MØ expressed 
noticeable levels of CD14 (Figure 19) in agreement with a previous study 445. 
Nevertheless, all stimulants, except for PMA were capable of inducing MØ-like cells as 
analysed via CD14 surface receptor expression.  
CD36, another expression marker for MØ differentiation was observed in THP-1 
monocytes following exposure to any of the  three stimulation methods 502. Unlike CD14, 
CD36 was expressed to a high level on the THP-1 monocytes. Upon stimulation, with VD3 
or with DS the percentage of cells expressing CD36 elevated to 80%. On the other hand, 
CD36 levels on PMA differentiated MØ remained similar to undifferentiated THP-1 
monocytes (Figure 20). These data suggest that the three methods of stimulation create 
MØ-like cells that have different adhesion properties. So these may be of different value in 
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subsequent assays presented here. For e.g., in those experiments where strongly 
adherent MØ are to be used PMA or DS MØ may be most appropriate. 
3.7.3 Modelling of AC clearance in vitro 
3.7.3.1 Chemotaxis and interaction of MØ with AC 
Recruitment of MØ in response to highly expressed chemokines in an inflamed tissue is 
vital for normal host defence to fight against the initiator of inflammation and to resolve the 
inflammation 33. Healthy tissue is susceptible to damage if inappropriate recruitment of 
phagocytes occurs 503. To guide phagocytes to a site of infection or inflammation, 
directional cues are sent in the form of chemoattractants from the inflamed site.  These 
signals can be detected by phagocytes which migrate up the chemoattractant gradient. A 
lack of directional migration will impair clearance of AC as phagocytes will not be in a 
position to clear the dying cells. A MØ exhibits a spindle-body shape followed by 
protruded edges to lead the migration directionally in addition to increased attachment and 
spreading towards the chemical gradients 504, 505. Loss of directional cues or modulation in 
the phagocytes results in an oscillating swing causing random movement in the cell body 
506.  
In this study, directional MØ migration towards dying cells was assessed using horizontal 
(Dunn chamber) and vertical (Cell-IQ) chemotaxis assays. The Dunn chamber method 
measures not only the chemotactic cell behaviour but also adds precise information on the 
proportion of analysed cells moving towards or away from the attractants under controlled 
gradient conditions (yFMI) thereby aiding calculation of the true chemotaxis movement. 
Other measurements such as Euclidean distance, accumulated distance, velocity, and 
angle contributes knowledge to the speed, directness and uniformity of the phagocytes’ 
migration towards putative attractants. yFMI is a measure of the parallel movement of MØ 
for each experiment and indicates the defined and consistent direction of MØ permitting 
analysis of the strength and level of chemotaxis in a stable chemoattractant environment. 
The data presented here in figure 25D and 28D suggests that AC B or AC NØ had a 
stronger MØ chemotaxis effect compared to their derived AS based on the yFMI. These 
data suggest that perhaps a combination of cells and secreted factors may be important in 
maximising MØ migration. It is established that AC B cells release AS (containing 
vesicles) which can be attractive to MØ 37. However, also could be that MØ release 
cytokines in response to the AC aiding in chemotaxis of other MØ cells 507.   
Both forms of AC (AC B or AC NØ or AS B or AS NØ) were inducers of chemotaxis for 
MØ compared to control (figure 25D and 28D). Moreover, lower variability in the 
movement of the migrated phagocytes’ end points (angle measurement) suggests that 
MØ travelled in a uniform manner to the chemoattractant AC and AS (B cells and NØ) 
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compared to their own control showing higher variability in migration (figure 26A and 29A). 
However, the angle of measurement fails to show the true chemotaxis effect as all MØ 
were taken into account irrespective of the direction taken. The uniformity of the cell 
movement is essential to grade the strength of chemoattractant guiding MØ through 
directional cues.  
While the Dunn chamber migration system is based on a true linear concentration 
gradient, the transwell migration assay using the Cell-IQ is based on a vertical step-
gradient and as such is influenced by gravity due to the nature of the experimental setup. 
This means that once cells have left a transwell they can’t change direction (unlike in the 
Dunn system). The MØ contained in the transwell were tracked for migration by counting 
the number of MØ reaching the bottom well containing putative attractants in a 24-well 
plate over a 12h period (figure 30). Similar to the Dunn chamber assay (figure 25D), the 
transwell system showed AC B cells as a strong attractant whilst AS B also showed 
chemoattractive abilities using the Cell-IQ (Figure 31). In contrast to the Dunn chamber 
system (figure 28D), the Cell-IQ model shows that MØ responses to AS NØ was stronger 
than to whole AC NØ culture (figure 32). These difference may be due to the gradients, 
the level of response of MØ towards the attractants might vary and in the Cell-IQ an 
excess of MØ is used leading to higher cell counts using the Cell-IQ software. 
However, to confirm the true migration of phagocytes in a vertical assay, the experiment 
assay included two controls 1) No gradient: i.e. MØ migration towards a bottom well 
containing serum free medium alone; 2) Destroyed gradient: MØ co-cultured with the 
attractant i.e. AC in the transwell and the bottom well. Based on the above controls the 
migration of MØ towards the putative attractants was standardised and determined. In 
each case, where the gradient was absent, the migration of MØ was reduced (figure 31 
and 32). In the case, where the attractant was added both on the top and bottom well to 
destroy the gradient the MØ migration was reduced towards AC or AS NØ (figure 32) but 
not in AC or AS B cells (figure 31), as they appeared similar in appearance to MØ under 
microscope (figure 30). All this ruled out the possibility that chemokinesis may be 
responsible for the MØ appearing in the lower well.  Overall, these experimental results 
show that it is possible to measure MØ migration to AC and this allows analysis of how 
periodontal relevant factors may influence this process.   
During inflammatory responses, MØ produce IL-8 and other chemokines to recruit NØ to 
the site of inflammation. However, upon turning apoptotic, NØ secrete a wide variety of 
intermediate factors to opsonise themselves with attractive components recognised by 
phagocytes. While factors such as ICAM-3 have been found to be key mediators involved 
as chemoattractants for MØ, the mediators that are released by AC NØ in recruiting MØ 
are unknown 37. However, annexin-1 and it’s peptide fragments are proposed to act as a 
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pro-phagocytic signals in recruiting THP-1 differentiated MØ 508. Also other known factors 
that promote the migration of phagocytes are stated to be CXCL1, CXCL2, CXCL5, 
CX3CL1, ATP, UTP and LPC 258, 461, 509 
While molecular mediators regulate the bridge between the phagocytes and AC, innate 
immune surface receptors are reported to facilitate the clearance mechanisms through 
tethering and tickling to uptake the AC 280, 479. Many receptors have been reported to be 
involved in the recognition and tethering of AC such as PS-R 510, integrins 511 and lectins 
512, 513, scavenger receptors 514 and receptors like CD14 324, CD36 294, 295, CD91 515 and 
ICAM-3 281. Once bound, the tethered AC are later ingested by MØ to suppress pro-
inflammatory mediators through the release of anti-inflammatory cytokines to resolve the 
inflammation. 
The ability of THP-1 DS-derived MØ to interact with AC was studied here using Jenner-
Giemsa staining (figure 33). The data in figure 33 suggests that MØ succesfully interact 
(i.e. tether and/or phagocytose) with AC B or AC NØ. Moreover, the data (figure 33B) 
indicates that MØ do not ingest viable cells. Brown et al. reported that viable cells tether to 
MØ initially due to the presence of unmodified CD31 and detach later. However on AC the 
CD31 undergoes an undefined variation at the cell surface which helps them to be 
tethered to phagocytes for a longer time and later to be engulfed 338. However, the data 
(figure 33B) also indicates that THP-1-derived MØ show more efficient interaction with AC 
B cells compared to AC NØ. Though the induction of apoptosis in both of these cells 
varied, the percentage of cell death remained similar in both B and NØ at around 80% 
apoptotic (figure 15C and 17A). This suggests that in vitro, primary NØ may be less likely 
to be taken up by the THP-1 differentiated MØ. Devitt et al. also showed, using HMDM 
and primary AC NØ, lower interaction levels of ~20% ruling out the possibility that the 
effect is limited to the THP-1 MØ 418. A further study also demonstrated that primary NØ 
isolated from venous blood showed limited capacity to be ingested by primary AC NØ 516. 
Alternatively, participation of IgG autoantibodies present in the human serum have been 
stated in opsonising AC for the clearance 517. Subsequently, human neutrophils exhibited 
adhesion and phagocytosis of IgG opsonised zymosan in the presence of serum 
proposing that IgG mediated-cell target interaction recruits immune cells 518. Together, 
serum with other bridging molecules might be the missing factors in the attractants 
released by the apoptotic NØ that might make ingestion by MØ.  
Alternatively, viable NØ might be present in the culture and being a phagocytic cell viable 
NØ might have phagocytosed AC NØ leading to a lower percentage of interaction with 
MØ. This is in line with previous work that has shown that viable NØ can phagocytose AC 
NØ in chlamydia cultures 516.  
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3.8 Conclusion 
Results from this chapter confirm the purity of isolated NØ isolated from peripheral human 
blood as in excess of 96%. Additionally, THP-1 cells differentiated using various 
stimulants (VD3, PMA or DS) confirmed the expression of important receptors for AC 
clearance e.g. increased level of CD14 expression on the surface of the differentiated MØ. 
The apoptotic NØ and their derived AS recruited MØ as confirmed by the chemotaxis 
assay (both vertical and horizontal) and the recruited MØ efficiently interacted with 
apoptotic NØ through tethering and phagocytosing the AC. Additionally, AC B or AS B 
cells function as an effective attractant by recruiting and interacting with THP-1 MØ, acting 
as a positive control for the study. These established in vitro models will be further used to 
study the AC clearance mechanism in PD by analysing THP-1 differentiated MØ 
behaviour following exposure to periodontal pathogens and their ability to phagocytose 
the AC NØ will be elucidated in the following chapters. 
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Chapter 4 
Result 2: Purification of gingipains from P.gingivalis 
4.1 Introduction 
Gingipains are cysteine proteases expressed by the key periodontal pathogen P. 
gingivalis and have been implicated in PD pathogenesis due to their ability to degrade 
cytokines, and complement components and anti-bacterial peptides, thereby facilitating P. 
gingivalis survival in the host by modulating the innate immune response 180, 519. P. 
gingivalis is a major causative agent for adult periodontitis, and gingipains predominantly 
exhibit 85% general proteolytic activity and 100% trypsin-like cysteine protease activity 202. 
From the onset of inflammation, P. gingivalis gingipain activity is documented as being 
able to attack and disarm professional phagocytes either by cleaving C1q and C3. These 
complement components are key to the amplification of the complement cascade and 
their digestion subsequently results in non-functional fragments, or inactivation of the 
production of cytokines such as membrane bound TNF-α 520-522. The multiple pathogenic 
effects of gingipains also include downregulation of CD31 expression on endothelial cells. 
CD31 downregulation disrupts vascular barrier function causing intercellular gaps 
resulting in increased permeability for entry of pathogens 204, 523. Another possible 
mechanism by which gingipains might contribute to the pathogenesis of PD is via their 
production of inflammatory mediators such as kinins. These molecules are high-
molecular-mass kininogens similar to bradykinin and other related peptides, which can 
interfere with homeostasis mechanisms within the infected tissue 524.  
In the work reported here, two major clinical strains (W83 and HG66) of P.gingivalis were 
studied. Strain W83 expresses membrane-bound gingipain activity, while, HG66 
synthesises soluble forms 525, 526. Several studies indicate that of all virulence factors 
produced by P.gingivalis, such as LPS, fimbriae, hemagglutinins and other metabolites, it 
is the cysteine proteases that are recognised as the major virulence factors necessary for 
disrupting the host innate immune response 157, 202. The aim of this chapter, therefore, 
was to purify and characterise the cysteine proteases from the HG66 strain of 
P.gingivalis. In this chapter, the isolation of arginine (ARG or RgpB) and lysine (LYS 
or Kgp) specific proteases is reported. 
4.2 Establishment of appropriate growth conditions for P.gingivalis strains 
W83 and HG66  
Evidence indicates that P.gingivalis secretes major trypsin-like enzymes classified as 
cysteine proteases 429. Isolation of these cysteine proteases from the strains W83 and 
HG66 was attempted as these strains play a predominant role in periodontal tissue 
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destruction 420, 423. In order to establish laboratory cultures of these anaerobes P.gingivalis 
strains W83 (ATCC 33277) and HG66 (DSM 28984) were grown and cultured as 
described in sections 2.7.3 and 2.7.5. Briefly, fastidious agar plates containing 7% sterile 
horse blood were used to culture the bacterial strains with incubation for 24-48h at 37°C in 
an anaerobic chamber. They were checked for purity by Gram staining as is shown in 
figure 13 in the Materials and Methods.  
To enrich for gingipain activity, it is necessary to culture the P.gingivalis strains (W83 or 
HG66) to a high density. In order to do this, the black pigmented colonies obtained from 
anaerobic growth on agar plates for 48h were further cultured in fastidious anaerobe broth 
(FAB) containing vitamin K, haemin, and L-cysteine and monitored for bacterial growth by 
measurement of absorbance over a 72h period. Growth curve profiles are presented in 
figure 34.  
 
 
 
 
 
 
 
 
 
 
 
 
                                
 
Figure 34: Growth curves of W83 and HG66 strains of P.gingivalis 
W83 and HG66 bacterial strains were grown anaerobically in 7% horse blood agar 
containing haemin and vitamin K1 at 37°C in 10% H2, 10% CO2, and 80% N2. The 
resultant black pigmented colonies of P. gingivalis were checked for purity by Gram 
staining. The bacterial colonies were inoculated into FAB broth in the anaerobic chamber 
with gentle agitation and were monitored for growth spectrophotometrically at O.D 600nm. 
The graph showing the growth curves for P.gingivalis strains A) W83 and B) HG66 for 72h 
are shown. Data are mean ± SEM from three independent experiments. 
 
The data in figure 34A show that W83 exhibits a log phase of growth up to 32h and slowly 
progressed towards the stationary phase by 72h. Additionally, HG66 exhibits rapid 
multiplication of bacteria between 8 and 24h followed by a stationary bacterial growth 
phase at 48h and a subsequent decrease in the number of bacteria by 72h (figure 34B). 
These data indicate successful growth of both strains of P.gingivalis. 
4.3 Characterisation of cysteine proteases from P.gingivalis strains W83 and 
HG66  
Bacterial cultures grown from W83 and HG66 were fractionated to determine the 
presence of enzyme activity for gingipains, either the RgpB or Kgp types, according to 
methods described in section 2.7.8.1. Initially, the bacterial cultures of W83 and HG66 
A B W83 HG66 
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were centrifuged to separate the cell-bound bacterial proteins in the pellet and soluble 
proteins in the culture supernatants (as described in sections 2.7.6 and 2.7.7). The cell-
bound and soluble fractions were then analysed for the presence of RgpB and Kgp protein 
activity using their specific substrates Bz-L-Arg-pNA and Z-L-Lys-pNA, respectively. The 
activity for the gingipains (RgpB or Kgp) were measured as p-nitroanilide (pNA) released 
from the Bz-L-Arg-pNA and Z-L-Lys-pNA substrates and assayed by reading absorbance 
at 405nm and expressed as a percentage of total enzyme activity. The data from this 
analysis are presented in figure 35. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: Determination of the amidolytic activity of P.gingivalis strains W83 and 
HG66 following culture fractionation.  
Strains W83 or HG66 were cultured according to the methods described in sections 2.7.3 
and 2.7.5. The log-phase bacterial cultures, grown for 32h for W83 and 24h for HG66 
(O.D 600nm), were centrifuged to separate the bacterial pellet and supernatant and 
analysed for amidolytic activity. The histogram shows total amidolytic activity (%) 
assessed for A) RgpB activity against Bz-L-Arg-pNA and, B) for Kgp activity, against Z-L-
Lys-pNA for cell-bound cell extract (black bars), cell-free culture supernatant (white bars) 
for both W83 and HG66 strains. Statistical analyses were conducted using ANOVA 
followed by a Bonferroni post-test, ***P<0.001. Statistical tests compared differences 
between strains.  Data shown are means ± SEM of three independent experiments. 
 
The data in figure 35 show the amidolytic activities tested for the presence of RgpB and 
Kgp in the bacterial pellet (black bars) and culture supernatant (white bars) of W83 and 
HG66. The RgpB enzyme activity was found to be significantly greater in the bacterial 
pellet of W83 compared with the HG66 pellet while the culture supernatant of HG66 
exhibited significantly increased activity for RgpB compared with the W83 supernatant 
(figure 35A). Additionally, Kgp activity was significantly increased in the HG66 culture 
supernatant compared with both the W83 bacterial pellet and the culture supernatant 
indicating that HG66 secretes the soluble form of proteins specific for Kgp (figure 35B). 
Overall, HG66 demonstrates higher activity for both RgpB (figure 35A) and Kgp (figure 
35B) over strain W83 which showed higher activity for RgpB (figure 35A) but weaker 
activity for Kgp (figure 35B) in the bacterial pellet. This indicates that RgpB and Kgp were 
B A 
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abundant in the cell-bound form in W83 while HG66 secretes soluble forms. These data 
are consistent with previous studies 526-529.  
In order to determine the molecular weights specific for RgpB (~50kDa) and Kgp (~60-
70kDa) present in the bacterial pellet and culture supernatant of W83 and HG66, SDS-
PAGE analysis was performed according to the method described in section 2.7.8.2.3. 
The separated protein bands were stained with Coomassie blue and the results are 
shown in figure 36. 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
Figure 36: Characterisation of molecular weights of proteases from P.gingivalis 
strains W83 and HG66 using SDS-PAGE  
Strains W83 or HG66 were cultured according to the methods described in sections 2.7.3 
and 2.7.5. The log-phase bacterial cultures were grown for 32h (W83) or 24h (HG66), 
centrifuged to separate the bacterial pellet and supernatant. The SDS-PAGE analysis of 
proteins present in the cell pellets and the culture supernatants of P.gingivalis strains 
show the presence of RgpB (~50kDa) and Kgp (~60kDa) in strains W83 (A) and HG66 
(B). The histograms (C) show the densitometry analysis of the gel images for the W83 and 
HG66 proteins obtained from A and B performed using ImageJ software. Densitometry 
values were expressed as % of relative density. SDS-PAGE gel profiles shown in A and B 
are representative of three different independent experiments. 
 
In agreement with the patterns of proteolytic activity shown in figure 35, the SDS-PAGE 
analysis in figure 36 shows the presence of clear protein bands in the bacterial pellet of 
W83 compared with the supernatant which has relatively weak bands at ~50kDa and 
~100kDa (figure 35A). In contrast, HG66 expressed cysteine protease activity both on the 
cell pellet and in the culture supernatant with protein bands between ~50kDa to ~100kDa, 
however, intense molecular weight bands were present only in the supernatant derived 
from the HG66 strain (figure 36B). Total protein levels were measured from the 
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representative image of SDS-PAGE gel (figure 36A&B) and relative densitometry was 
expressed as a percentage of the total activity (figure 36C). The relative densitometry 
analysis obtained from the P.gingivalis strains W83 and HG66 show the intensity of the 
proteins present in the pellet of W83 and supernatant of HG66 (figure 36C). Data 
indicating that most of the activity in W83 was cell-bound whilst in the HG66 strain activity 
was present in the soluble form. 
The amidolytic enzyme activity (figure 35) and the SDS-PAGE analysis (figure 36) showed 
that W83 and HG66 released proteases in the form of cell-bound and soluble forms, 
respectively. In order to determine whether the proteins present in the bacterial pellet of 
W83 and culture supernatant of HG66 belong to the group of cysteine proteases, cysteine 
(50mM) was added to the substrates Bz-L-Arg-pNA and Z-L-Lys-pNA as a stimulating 
agent to fully activate the proteolytic activities of RgpB or Kgp, respectively. The results of 
this analysis are shown in figure 37.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37: Determination of amidolytic activity in the presence or absence of 
cysteine derived from P.gingivalis strains W83 and HG66  
Strains W83 or HG66 were grown according to the methods described in sections 2.7.3 
and 2.7.5. Log-phase bacterial cultures were grown for 32h (W83) or 24h (HG66), 
centrifuged to separate the bacterial pellet and supernatant and analysed for amidolytic 
activity. The bacterial pellet of W83 and culture supernatant of HG66 were used to test for 
amidolytic activity in the presence or absence of cysteine. The histograms show the 
percentage of total enzyme activity against Bz-L-Arg-pNA assessed for RgpB (A) and Z-L-
Lys-pNA assessed for Kgp (B) with and without cysteine. Statistical analyses were 
conducted using ANOVA followed by a Bonferroni post-test, **P<0.01, ***P<0.001. 
Statistical tests compared differences between cysteine-treated and untreated samples. 
Data shown are means ± SEM of three independent experiments. 
 
The data in figure 37 show that a significant difference in amidolytic activity was detected 
between the cysteine-treated W83 cell-bound proteins or HG66 culture supernatants 
compared with untreated W83 or HG66 proteins assayed for RgpB (figure 37A) and Kgp 
(figure 37B) enzyme activities. These data indicate that cysteine was necessary to 
activate the total amidolytic activity in both the protease samples and this is consistent 
with previous studies to indicate the actvity rises from cysteine proteases 426. 
Cysteine treated Cysteine Untreated 
A B 
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4.4 Purification of gingipains from P.gingivalis HG66 
In line with previous work, the amidolytic activity (figure 35) and SDS-PAGE analysis 
(figure 36) confirmed the presence of enzymatically active proteins present in the bacterial 
pellet of the W83 strain and the culture supernatant of the HG66 strain. However, the W83 
sample showed reduced Kgp activity (figure 35B) and a weaker protein band at the Kgp 
molecular weight (~60kDa) compared with the HG66 Kgp presence. Additionally, W83 
activity was mostly cell-bound (figure 35 and 36) and this might result in the presence of 
LPS contaminants and other proteins. For this reason, the bacterial culture supernatant 
from HG66 was further fractionated as this strain appeared the more promising source of 
gingipains for use in further study. The presence of gingipains was tested according to the 
methods described in section 2.7.7. Briefly, acetone precipitated proteins from the culture 
fluid of HG66 were fractionated by gel filtration chromatography. One of the challenges 
involved in the isolation of purified gingipains by gel filtration was to remove haemin, 
added as a source of iron nutrient for the survival of bacteria from the bacterial culture 
medium. In order to avoid the interference of haemin in the gingipain isolation, gel filtration 
chromatography was coupled with Sephadex G-150 on an arginine-Sepharose column 
(figure 38). This process was performed as recommended by a previous successful 
gingipain purification method 426.  
 
The acetone-precipitated proteins from the HG66 culture supernatant were applied to a 
Sephadex G-150 column equilibrated in and eluted with buffer containing NaCl, Bis-Tris, 
and CaCl2 (pH 6.8) (as described in section 2.7.7). Fractions containing 280nm-absorbing 
material in the 50-100 kDa range were collected and applied to an arginine-Sepharose 
column which was previously equilibrated with loading buffer containing CaCl2 and Tris-
HCl (pH 7.4) (as described in section 2.7.7). Unbound proteins were removed from the 
column by washing with loading buffer until the absorbance at 280 nm reached a baseline 
value of 0. Once the baseline was achieved, the column was eluted sequentially with 
loading buffer containing NaCl (500 mM), followed by lysine (750 mM in loading buffer), 
loading buffer alone and finally arginine (100 mM in loading buffer). Material eluted from 
the affinity column was monitored at 280 nm for protein content and by conductivity. The 
results of this analyses are presented in figure 38. 
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Figure 38: Representative chromatogram of a gel chromatography column 
performed on Sephadex G-150 fractions followed by arginine sepharose affinity 
chromatography  
Strains W83 or HG66 were grown according to the methods described in sections 2.7.3 
and section 2.7.5. Log-phase bacteria cultures grown for 24h for HG66 were used to 
isolate proteins according to methods described in section 2.7.7.  The gel chromatography 
column analysis performed shows the 50-100 kDa material collected from a Sephadex G-
150 column which was applied to an arginine sepharose column by washing the column 
with 500 mM NaCl prior to elution of fractions exhibiting proteinase activity against Z-L-
Lys-pNA (LYS) and Bz-L-Arg-pNA (ARG) sequential elution with lysine (750 mM) and 
arginine (100 mM). The peaks in the chromatogram show (from left to right) gradient 
equilibrated with NaCl, 750 mM lysine gradient to elute Kgp and 100 mM arginine gradient 
to elute RgpB from P.gingivalis strain HG66. The blue line indicates absorbance at 280 
nm. The brown line indicates conductivity. A representative chromatogram from three 
different runs by gel filtration chromatography is shown. 
 
The data in figure 38 shows a representative image of Sephadex G-150 column applied 
on arginine sepharose chromatography to elute the proteins specific for RgpB and Kgp 
derived from P.gingivalis HG66. The chromatogram shows the NaCl elution profile used to 
wash the column and remove unwanted proteins at the beginning of the flow. Followed by 
the buffer wash and sequential elution with lysine, showing a peak for the eluted proteins 
specific for lysine (Kgp) and RgpB was eluted exhibiting a larger peak for proteins specific 
for arginine. The chromatogram was plotted for volume (ml) against absorbance 280nm.  
The fractions collected for arginine and lysine eluted proteins (figure 38) were pooled and 
concentrated using an Amicon PM-10 filtration column as described in section 2.7.7. 
Amidolytic activity was determined using the specific substrates Bz-L-Arg-pNA for RgpB 
and Z-L-Lys-pNA for Kgp. The results of this analysis are shown in figure 39. 
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Figure 39: Determination of the amidolytic activity of gingipains purified from 
P.gingivalis strain HG66  
Strain HG66 was grown according to the methods described in sections 2.7.3 and 
cultured in FAB broth as described in section 2.7.5. Log-phase cultures grown for 24h for 
HG66 were used to isolate proteins according to methods described in section 2.7.7. The 
isolated fractions ARG and LYS eluted from arginine-Sepharose using 100 mM arginine 
and 750 mM lysine (figure 38) were analysed for amidolytic activity. The histogram shows 
total enzyme amidolytic activity in percentage assessed for RgpB activity against Bz-L-
Arg-pNA and Kgp activity against Z-L-Lys-pNA for the isolated fractions of HG66. 
Statistical analyses were conducted using ANOVA followed by a Dunnett’s post-test, 
***P<0.001 compared to control (enzyme buffer on their own). Data shown are mean ± 
SEM from three independent experiments. 
 
The data in figure 39 show RgpB activity against Bz-L-Arg-pNA and Kgp activity against 
Z-L-LYS-pNA from HG66 and this exhibited 75% of recovered enzyme activity. 
The ARG and LYS fractions collected using Sephadex G-150 fractions on arginine-
Sepharose chromatography for HG66 of gingipains were assessed for molecular weight 
using SDS-PAGE according to the method described in section 2.7.8.2.3. The results of 
this analysis are shown in figure 40.  
The data presented in figure 40A shows distinct intense double bands with the upper band 
presumed to represent mature RgpB at ~50kDa and the lower band revealing weaker 
expression for the presumed RgpB catalytic domain (~48kDa). The presumbed Kgp 
protein appeared as a single major band (~60kDa) suggesting the presence of some 
additional gingipain activity in the final eluted proteins using gel filtration chromatography 
in agreement with previous studies 530-532. The absence of other bands compared with the 
supernatant of HG66 (figure 36B) indicates the successful isolation of purified gingipains 
without the contamination of other proteins or proteolytic enzymes. Additionally, data 
(figure 40B) shows the percentage of protein expression of RgpB as 89% and Kgp as 
72.3% compared with the total dialysed proteins before separating them into RgpB and 
Kgp. The densitometric values shown demonstrate the intensity of RgpB and Kgp bands 
distinctly.  
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Figure 40: Determination of molecular weights using SDS-PAGE analysis for the 
final purified proteins from the HG66 strain of P.gingivalis  
Strain HG66 was grown according to the methods described in sections 2.7.3 and 2.7.5. 
Log-phase cultures grown for 24h were used to isolate proteins according to methods 
described in section 2.7.7. The ARG and LYS fractions eluted from arginine-Sepharose 
using 100 mM arginine and 750 mM lysine (figure 38) were analysed by SDS-PAGE. A) 
SDS-PAGE gel showing the molecular weight for RgpB revealed double bands at ~50kDa 
and ~48kDa while Kgp showed a single band at ~60 - 70kDa. Densitometry values were 
obtained by using ImageJ and compared the purified protein bands with the dialysed 
culture fluid before separating them as RgpB and Kgp. B) The graph shows the area of 
surface positive for a protein expressed as a percentage using ImageJ analysis compared 
with the total dialysed and concentrated protein, which was used as a control. Data shown 
are representative of three independent experiments. 
 
 
To check whether the isolated fractions from HG66, as shown in figure 38, were 
gingipains, assays were performed in the presence of the cysteine protease inhibitor, 
TLCK. The results of this analysis are presented in figure 41. 
 
                                                
Figure 41: Inhibition of purified proteins from P.gingivalis HG66 using TLCK  
Strain HG66 was grown according to the methods described in sections 2.7.3 2.7.5. Log-
phase cultures grown for 24h were used to isolate proteins according to methods 
described in section 2.7.7. The isolated fractions specific for RgpB and Kgp from HG66 
acquired using Sephadex G-150 and arginine-Sepharose chromatography (figure 38) 
were analysed for amidolytic activity in the presence of TLCK (100µM), as a measure of 
cysteine protease activity in the purified proteins (as described in section 2.7.12). The 
histogram shows the total enzyme activity (%) of the isolated fractions against L-BAPNA 
in the presence or absence of TLCK inhibitor. Statistical analyses were conducted using 
ANOVA followed by Bonferroni post-test, ***P<0.001. Data shown are mean ± SEM of 
three independent experiments. 
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The data in figure 41 show a significant difference between TLCK treated protein fractions 
compared with untreated samples and indicating that TLCK inhibits the gingipain activity 
within the isolated fractions, findings which are consistent with a previous study 426. 
A major contaminant in the purification products of Gram-negative bacteria is LPS and this 
may have significant effects in downstream inflammation assays. Therefore, to assess the 
level of LPS contamination in the purified HG66 supernatant isolated gingipains, Limulus 
Amoebocyte Lysate tests were undertaken according to the methods described in section 
2.7.10. These studies revealed that the LPS contamination levels were 2.9U/ml (RgpB) 
and 1.9U/ml (Kgp) from isolated gingipains of HG66. 
The yield of the enzyme in the final eluted protein measured as described in section 
2.7.8.2.1 and was estimated at approximately 0.5 mg/ml of protein starting from 1-litre of 
culture fluid. 
 
4.5 Characterisation of isolated proteins using mass spectrometric analysis 
The data presented in the previous section indicate that the proteins isolated using a 
strategy to purify gingipains exhibit appropriate molecular weights (figure 40) and carry 
appropriate cysteine protease activity (figure 41). However, to more robustly identify the 
presence of gingipains within the isolated fractions mass spectrometry analyses were 
undertaken. Subsequently isolated SDS-PAGE gel bands of ≃ 50kDa and ≃60kDa which 
correspond to the molecular weights for RgpB and Kgp, respectively, were subject to 
further analysis. Isolated bands were extracted cleaved via in-gel digestion according to 
the method described in section 2.7.9, and the released peptides were analysed by mass 
spectrometry. The data obtained were subjected to proteomic analysis using Swiss-Prot, a 
protein sequence database, followed by Sequest search engine analysis, a data tool used 
for protein identification. The likely identity of the proteins excised from the gel is shown in 
Table 7. 
The results (Table 7) show analysis for the excised bands from the gel. More than 30 
proteins with at least two unique peptide sequences were identified, thereby assuring at 
least 28% of total protein coverage and providing the highest identification scores 
(XCorr>1000) for RgpB and Kgp. Based on the XCorr values the top 6 likely identified 
abundant proteins were gingipains and this confirms the formal presence of arginine and 
lysine gingipains within the sample preparations. The presence of other contaminating 
proteins such as major fimbrium subunit and peptidyl arginine deiminase enzyme show 
significantly lower scores than gingipains. Given this characterisation of the gingipains 
within the isolated fractions and the clear cysteine protease activity along with the 
appropriate molecular weight banding, data indicates the successful isolation of RgpB and 
Kgp from P.gingivalis HG66. 
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Table 7: Characterisation of purified proteins from P.gingivalis HG66 using mass spectrometric analysis: The table shows the numbers of proteins identified as a result of the Sequest 
search against the SwissProt database, using P. gingivalis taxonomy, trypsin as a proteolytic enzyme and allowing up to two miss-cleavages. Oxidation of the methionine residue, 
carbamidomethylation on the cysteine thiol, and deamidation of asparagine and glutamine were used as variable post-translational modifications. Only the high confidence, rank 1 and unique 
peptides were used for the identification, with at least two different sequences identified per protein. 
Accession Description Score Coverage # Proteins 
# Unique 
Peptides 
# Peptides 
MW 
[kDa] 
B2RM93 
Gingipain R1 OS=Porphyromonas gingivalis (strain ATCC 33277 / DSM 
20709 / CIP 103683 / JCM 12257 / NCTC 11834 / 2561) GN=RgpB A 
PE=3 SV=1 - [CPG1_PORG3] 
1833.17 37.29 2 3 52 185.2 
B2RKU0 
Gingipain R2 OS=Porphyromonas gingivalis (strain ATCC 33277 / DSM 
20709 / CIP 103683 / JCM 12257 / NCTC 11834 / 2561) GN=RgpB B 
PE=3 SV=1 - [CPG2_PORG3] 
1522.05 52.58 1 1 30 80.9 
P28784 
Gingipain R1 OS=Porphyromonas gingivalis GN=RgpB A PE=1 SV=2 - 
[CPG1_PORGN] 
1448.00 45.21 1 1 38 108.7 
P95493 
Gingipain R2 OS=Porphyromonas gingivalis (strain ATCC BAA-308 / W83) 
GN=RgpB B PE=1 SV=2 - [CPG2_PORGI] 
1206.98 34.92 1 1 23 80.9 
B2RLK2 
Lys-gingipain OS=Porphyromonas gingivalis (strain ATCC 33277 / DSM 
20709 / CIP 103683 / JCM 12257 / NCTC 11834 / 2561) GN=kgp PE=1 
SV=1 - [KGP_PORG3] 
1082.04 28.50 1 2 33 187.1 
P72197 
Lys-gingipain HG66 OS=Porphyromonas gingivalis GN=kgp PE=1 SV=1 - 
[KGP66_PORGN] 
1076.46 30.88 2 2 35 186.7 
Q9RQJ2 
Peptidylarginine deiminase OS=Porphyromonas gingivalis (strain ATCC 
BAA-308 / W83) GN=PG_1424 PE=1 SV=1 - [PAD_PORGI] 
344.40 68.35 1 29 29 61.7 
Q51845 
Hemagglutinin A OS=Porphyromonas gingivalis GN=hagA PE=3 SV=1 - 
[HAGA2_PORGN] 
146.89 14.80 1 6 10 283.1 
B2RH57 
Major fimbrium subunit FimC OS=Porphyromonas gingivalis (strain ATCC 
33277 / DSM 20709 / CIP 103683 / JCM 12257 / NCTC 11834 / 2561) 
GN=fimC PE=1 SV=2 - [FIMC_PORG3] 
132.26 34.22 1 13 13 50.1 
B2RH59 
Major fimbrium tip subunit FimE OS=Porphyromonas gingivalis (strain 
ATCC 33277 / DSM 20709 / CIP 103683 / JCM 12257 / NCTC 11834 / 
2561) GN=fimE PE=1 SV=1 - [FIME_PORG3] 
103.50 49.27 1 20 20 60.6 
B2RH54 
Major fimbrium subunit FimA type-1 OS=Porphyromonas gingivalis (strain 
ATCC 33277 / DSM 20709 / CIP 103683 / JCM 12257 / NCTC 11834 / 
2561) GN=fimA PE=1 SV=3 - [FIMA1_PORG3] 
81.91 34.46 3 8 8 41.3 
P0C934 
NAD-specific glutamate dehydrogenase OS=Porphyromonas gingivalis 
(strain ATCC BAA-308 / W83) GN=gdh PE=1 SV=1 - [DHE2_PORGI] 
63.10 37.98 1 14 14 49.2 
B2RHG1 
Minor fimbrium subunit Mfa1 OS=Porphyromonas gingivalis (strain ATCC 
33277 / DSM 20709 / CIP 103683 / JCM 12257 / NCTC 11834 / 2561) 
GN=mfa1 PE=1 SV=1 - [MFA1_PORG3] 
21.66 11.19 1 5 5 60.7 
Q9S3R8 
Outer membrane protein 40 OS=Porphyromonas gingivalis (strain ATCC 
BAA-308 / W83) GN=PG_0694 PE=1 SV=1 - [OMP40_PORGI] 
19.83 18.95 1 5 5 42.4 
B2RLL7 
Enolase OS=Porphyromonas gingivalis (strain ATCC 33277 / DSM 20709 / 
CIP 103683 / JCM 12257 / NCTC 11834 / 2561) GN=eno PE=3 SV=1 - 
[ENO_PORG3] 
19.01 16.24 2 5 5 45.8 
B2RHG3 
Minor fimbrium tip subunit Mfa3 OS=Porphyromonas gingivalis (strain 
ATCC 33277 / DSM 20709 / CIP 103683 / JCM 12257 / NCTC 11834 / 
2561) GN=mfa3 PE=1 SV=1 - [MFA3_PORG3] 
18.10 20.40 1 5 5 50.0 
Q9S3R9 
Outer membrane protein 41 OS=Porphyromonas gingivalis (strain ATCC 
BAA-308 / W83) GN=PG_0695 PE=1 SV=2 - [OMP41_PORGI] 
13.12 14.58 1 5 5 43.4 
B2RHV8 
Phosphoenolpyruvate carboxykinase [ATP] OS=Porphyromonas gingivalis 
(strain ATCC 33277 / DSM 20709 / CIP 103683 / JCM 12257 / NCTC 
11834 / 2561) GN=pckA PE=3 SV=1 - [PCKA_PORG3] 
12.82 10.65 2 4 4 59.4 
B2RJM1 
Hydroxylamine reductase OS=Porphyromonas gingivalis (strain ATCC 
33277 / DSM 20709 / CIP 103683 / JCM 12257 / NCTC 11834 / 2561) 
GN=hcp PE=3 SV=1 - [HCP_PORG3] 
12.39 8.00 2 4 4 60.4 
B2RH58 
Major fimbrium tip subunit FimD OS=Porphyromonas gingivalis (strain 
ATCC 33277 / DSM 20709 / CIP 103683 / JCM 12257 / NCTC 11834 / 
2561) GN=fimD PE=1 SV=1 - [FIMD_PORG3] 
10.40 5.97 1 4 4 75.8 
B2RGR2 
Serine hydroxymethyltransferase OS=Porphyromonas gingivalis (strain 
ATCC 33277 / DSM 20709 / CIP 103683 / JCM 12257 / NCTC 11834 / 
2561) GN=glyA PE=3 SV=1 - [GLYA_PORG3] 
6.29 7.75 1 3 3 46.6 
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4.6 Discussion 
The aim of the studies presented here were to purify and characterise the cysteine 
proteases from P.gingivalis. These enzymes, gingipains, are considered to be a major 
virulence factor in advanced PD 157. Indeed several virulence agents such as 
collagenases, serine proteinase, trypsin-like enzymes and other forms of proteases from 
P.gingivalis are also involved in the hydrolysis of tissue factors, e.g. fibrin, fibrinogen, 
fibronectin, collagen, lysozyme, as well as complement factors such as C3, C5 and 
plasma coagulation factors 533-541. However, gingipains are proposed to be the major 
virulence factors due to their ability to invade the host system by contributing at least 85% 
of proteolytic activity compared to other components in P.gingivalis 156. Therefore, 
P.gingivalis cleave key molecules and interfere with the host immune system which can 
cause severe destruction of the gingival and periodontal tissues 94.  
Previous studies report that many forms of proteolytic enzymes exist in P.gingivalis. 
These are in the range of 29-110kDa molecular masses, of which two are serine 
proteases and the rest are classified as cysteine proteases with a specificity for ARG and 
LYS residues. These enzymes are known as arginine gingipains (RgpB) or lysine 
gingipains (Kgp) and are capable of cleaving the synthetic substrates Bz-L-Arg-pNA and 
Z-L-Lys-pNA respectively as was utilised in this study 542. Chen et al. described the first 
enzymes classified as cysteine proteases from P.gingivalis. These were 50kDa in size 
and were termed gingipains which show specific cleavage at arginine residues 525. 
Subsequently, Pike et al. demonstrated an enzyme associated with the ability to cleave 
Bz-L-Arg-pNA using SDS-PAGE. This enzyme gave a single SDS-PAGE band of high 
molecular mass at 95kDa in size in the absence of sample boiling. However, upon 
denaturation by heat, protein bands were seen at 50, 44, 27 and 17kDa, with 50kDa being 
accepted as the source of the arginine-specific activity 426. Another form of gingipain has 
been identified which cleaves following lysine residues. This enzyme is known as Kgp. It 
has been identified as a single 105 kDa band on SDS-PAGE prior to denaturation by heat 
however, after boiling, it yields bands at 60, 44, 27 and 17 kDa. Since both gingipains 
produce smaller size protein bands following heat denaturation the main difference 
between the gingipains is represented by their highest molecular weight upon heating, i.e. 
~50kDa for RgpB and ~60kDa for Kgp. The study presented here focused on these 
highest molecular weight bands thought to contain the enzymatically active components 
426, 526, 543, 544.  
4.6.1 Comparison of P.gingivalis W83 and HG66 derived cysteine proteases 
Identification of microorganisms associated with PD has been the focus of significant 
research. While 500 species of bacteria have been identified in the oral cavity, only a 
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relatively small number of bacteria have been classified as virulent based on their strong 
relationship with periodontitis. Notably, these virulent strains show a strong relationship 
with diseases phenotypes characterised by periodontal pocket depth and bleeding on 
probing 52, 107. The virulence of periodontal bacteria has been proposed to be based on 
three characteristics: i) adherence capacity 545; ii) the ability to evade the host immune 
system by producing proteolytic enzymes, 546; and iii) inhibition of phagocyte functions by 
degrading complement factors or inactivating cytokine secretions 520, 521. The work 
presented in this thesis will be highlighting ii) and iii). When considering bacterial species 
associated with periodontal disease, P.gingivalis was identified as the species which 
satisfied all three of these criteria. Belonging to the family of Porphyromonadaceae, 
P.gingivalis is known to invade gingival epithelial cells following their colonisation in the 
subgingival region. Notably, these gingival epithelial cells modulate oral health by 
adapting and responding to the infection by regulating the local inflammatory response 60, 
547. The main effect of this bacterium, however, is to disrupt tissue homeostasis within the 
gingival environment resulting in advancement from gingivitis to more generalised 
periodontal disease which ultimately leads to alveolar bone loss 200. Many diverse strains 
of P.gingivalis have been identified from orally infected patients including W50, A7A1, 
381, ATCC 33277, and ATCC 49417 548. However, it is unclear to what extent strain 
variability is associated with bacterial virulence in periodontal disease. It is also unclear as 
to what degree genetic variation within the host or other factors may be involved in driving 
PD responses. 
 
The wild-type strain, W83, is the most frequently studied P.gingivalis strain and it has 
been used in earlier studies to extract membrane-associated proteolytic enzymes 171, 549. 
However, strain HG66 is known to secrete soluble forms of proteolytic enzymes into the 
GCF 94, 164. When studied here both strains, W83 and HG66, showed similar appearance 
of black pigmented colonies and a characteristic malodour following anaerobic growth on 
blood agar (figure 13, Materials and Methods). The proto-heme present in erythrocytes in 
blood agar enables the bacteria to grow by forming black pigmented colonies, due to 
deposits of heme - µ- oxo dimers present in the bacterial cell surface 550. Depending on 
the strain, the colour and virulence of the bacterial colonies vary in appearance 550. 
However, most P.gingivalis strains or variants are known to produce volatile sulphur 
compounds (VSCs), such as hydrogen sulphide (H2S), methyl mercaptan (CH3SH), and 
dimethyl sulphide which initiate the metabolism of the sulphur amino acids causing the 
oral malodour 551. Furthermore, the absence of black pigmented colonies in P.gingivalis 
was observed in heme-deprived blood agar medium indicating that the presence of heme 
plays a major role in colony pigmentation 552-554. The growth and the virulence of the 
P.gingivalis bacteria are dependent upon the ability to acquire iron and protoporphyrin IX 
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from the host system and these function as essential nutrients. Notably, earlier studies 
have indicated that RgpA, RgpB, and Kgp from both the strains W83 and HG66 bind to 
iron or heme-containing compounds in the host system 555.  
At 48h, black pigmented colonies were inoculated into FAB broth to enable generation of 
bacterial growth curves for the W83 and HG66 strains. HG66 demonstrated faster growth 
compared with the W83 strain under anaerobic conditions (figure 34). However, both of 
the bacterial strains cultured generated a dark brown fluid, indicating the presence of 
haemin, though, this was comparatively low in strain HG66 at the 24h log-phase bacterial 
culture point. One of the possible means by which haemin can be eliminated is by using 
gel filtration chromatography, which was used in this study. Additionally, dialysis was 
undertaken overnight to remove the majority of the haemin.  
Preliminary experiments measured cysteine protease activity for both the W83 and HG66 
strains. During the purification process, amidolytic activity and SDS-PAGE analysis were 
performed. Analysis of the cell pellets and culture supernatants obtained from strains W83 
and HG66 enabled identification of the most productive strain based on the level of 
proteolytic activity. The data presented in figures 35 and 36 demonstrated that both 
strains produced cell-bound and extracellular enzyme activity. However, cell-bound 
activity was higher in strain W83 while HG66 secreted more activity in soluble forms. This 
observation is in agreement with earlier studies which reported that major cysteine 
protease proteins were present in the outer membrane of the W83 bacteria strain 556. 
Previous studies report that different strains of P.gingivalis express multiple proteolytic 
enzymes and all of them differ in their molecular mass and specificity for peptide bonds202, 
526. Eight different endopeptidases and numerous exopeptidases have been documented 
with molecular weights ranging from 29 to 110kDa. Two of these proteins belong to the 
group of serine and metallopeptidases enzymes while the rest are cysteine proteases with 
specificity for Bz-L-Arg-pNA 525. The data presented (figure 35) demonstrate that the W83 
strain produced RgpB-specific aminopeptidase activity with a weaker expression for Kgp-
specific aminopeptidase activity (figure 35A). Notably the HG66 strain expressed both 
RgpB and Kgp-specific aminopeptidase activity (figure 35B). Additionally, figure 36B 
highlighted data demonstrating that proteins with a wide range of molecular weights were 
present in both the cell pellet and culture supernatant derived from HG66. However, W83 
extracts showed distinct bands at ~50kDa and at ~100kDa (figure 36A), which were 
presumed to be RgpA (~95kDa). Studies on comparison of W83 and HG66 reports that 
both strains express identical Rgp and Kgp protein sequence 94, 185. 
Existing literature presents conflicting views on the various forms of cysteine proteases 
from P.gingivalis with different molecular masses and specificity for peptide bonds being 
Results 
130 
 
reported 94. To date, it is understood that there are 3 forms of gingipain, each of which can 
be distinguished on SDS-PAGE gels by the pattern of lower molecular mass bands 
produced. RgpA can exist in different molecular masses depending on the domains 
present. For RgpB this is ~50kDa due to the absence of hemagglutinin adhesion domains. 
However, when the hemagglutinin adhesion domains are present the size is reported to 
be 90~110kDa, which is comparable to RgpA 94, 557. Lysine gingipain has been shown to 
have a molecular mass of ~60 kDa with hemagglutinins (HA1, HA2, HA3, and HA4) 
present 160. Currently, there is a consensus of opinion that RgpB has a 50kDa molecular 
mass with some smaller molecular weight bands, while Kgp tends to be present from ~ 
60-70kDa.  
The variation of the molecular masses is notable for different isoforms of gingipains 549. It 
is unclear where the variation in molecular mass of the different forms is derived from and 
whether this is affected by or related to the growth kinetics of the different clinical strains 
of P.gingivalis. However research has demonstrated that gingipains are produced by most 
strains of P.gingivalis 179, 193, 558, 559. The gingipains are classified as cysteine proteases 
containing an N-terminal C25 (catalytic cysteine residue) domain. Gingipains exhibit 
unique primary protein structures when compared with other cysteine proteolytic enzymes 
present in the databases, suggesting that gingipains comprise a distinct group of 
proteolytic enzymes. However further study is needed to better understand their 
biochemical properties and their specialised functions in causing periodontal tissue 
destruction 560.  
In addition to amidolytic activity (figure 35) and SDS-PAGE (figure 36) size determination, 
the isolated proteins were tested for cysteine protease activity (figure 37). Cysteine acts 
as a reducing agent for the activation of both gingipains (RgpB and Kgp) 561. This is in 
agreement with the data presented here (figure 37) showing that cysteine was necessary 
for complete activation of the amidolytic activity in both gingipains (RgpB or Kgp). Indeed 
in the absence of the cysteine, the enzyme activity decreased, indicating their absolute 
dependence for full activity. These data are consistent with a previous study which has 
shown that increasing concentrations of cysteine stimulate higher levels of total gingipain 
enzyme activity 426. Notably 50mM of cysteine has been proposed as the highest 
concentration required for the total activation of gingipains, and this amount was applied 
here (figure 37). Above this concentration of cysteine, enzyme denaturation may occur 
resulting in no further activation 426. Notably, Chen et al. reports that in the absence of 
cysteine in the lysine gingipain, enzyme stability was maintained at the pH range 5-9 
however in the presence of cysteine the activity rapidly decreases 525. While cysteine 
activates gingipain activity the report suggests that cysteine prepares the lysine gingipain 
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to lose activity rapidly. For this reason, gingipains were used in the absence of cysteine in 
order to avoid loss of stability of the proteolytic activity during experimental assays. 
Additionally, the presence of calcium was shown to be essential for stabilisation of the 
enzyme at 4°C within a pH range 4.5 to 7.5 whilst in the absence of calcium the activity 
decreased 525. Calcium (5mM) was used in this study in the enzyme buffer when 
measuring the amidolytic activity, in addition, it was added to the dialysis buffer to 
eliminate unwanted salts from the purified gingipains from HG66. The physiological level 
of calcium concentration in GCF of normal adults is reported to be 2.5mM 562. It is 
interesting to note that at 37°C the stability of the enzyme is maintained in the presence of 
calcium as most of the studies performed here were undertaken at this temperature 525.  
Given the amidolytic activity and molecular weight of cysteine proteases present in W83 
and HG66, W83 exhibited increased levels of proteins in the cell-bound form, making 
further isolation of gingipains from this strain difficult. Notably, isolating cell-bound proteins 
from Gram-negative bacteria can result in significant LPS contamination from the outer 
membrane which may hinder the activity of cysteine proteases and this can interfere with 
downstream analysis.   
It was therefore important to remove LPS from cysteine protease preparations especially 
as previous reports have shown that LPS from P.gingivalis has a significant impact on 
gingival cells and causes elevated inflammatory responses 327. While the LPS 
contamination used by previous study report 5pg/ml the study here, shows 0.2ng/ml using 
the same method 563. The results in chapter 6 shows that Pg LPS induced TNF-α in 
macrophages only at 1µg/ml indicating that LPS contamination had no effect on the 
macrophages. A key aspect of this study was to analyse whether cysteine proteases in 
isolation have the ability to inhibit the resolution of inflammation and to test this hypothesis 
it was therefore necessary to obtain relatively pure preparations of gingipains. For this 
reason, it was decided that isolation of proteins from HG66 culture supernatant would be 
preferable for application in downstream studies. Additionally, data obtained here indicate 
that both amidolytic activity (figure 35) and SDS-PAGE (figure 36) detectable proteins 
were released from HG66 indicating that this strain represents an appropriate source of 
extracellular cysteine proteases. Taken together these factors suggested that strain HG66 
would be the more appropriate strain for gingipain isolation for use in the subsequent 
studies which were undertaken as part of this thesis.  
4.6.2 Purified gingipain activity from the strain HG66 
Affinity chromatography on arginine-Sepharose was preferred over other modes of 
purification, e.g. anion exchange, as this approach separates enzymes based on selective 
binding and subsequent elution of intact functioning proteins from the column. Here 
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arginine was used to elute fractions exhibiting activity for Bz-L-Arg-pNA and lysine was 
used to elute fractions exhibiting activity for Z-L-Lys-pNA (figure 38).  Additionally, NaCl 
was used as a preliminary elution step to remove other proteins that might be bound non-
specifically to the affinity column. The net effect of these sequential elution steps resulted 
in the isolation of separate fractions containing protein specificity for ARG and LYS. 
Notably, the yield of the desired enzyme obtained from 1-litre of culture medium was 
concentrated to ~1.5 ml in the final eluted protein step, generating ~0.5 mg of protein per 
ml. Additional purification steps might have removed further traces of other proteins 
however this might also have reduced the overall yield of the enzyme and was therefore 
not undertaken. Interestingly, Pike et al. further purified the gingipain proteins using anion-
exchange chromatography to remove lower molecular mass molecules and reported the 
recovery of gingipain activity as 18% in the final eluted protein 426.  
 
The data presented here show that proteins recovered from the culture medium of strain 
HG66, purified by gel filtration on Sephadex G-150 followed by affinity chromatography on 
arginine-Sepharose exhibit relatively high levels of RgpB and Kgp activity (figure 39) as 
demonstrated by the cleavage of substrates Bz-L-Arg-pNA and Z-L-LYS-pNA specific for 
Rgp and Kgp, respectively. In order to differentiate between RgpB from RgpA, molecular 
weight analysis was undertaken using SDS-PAGE. The data presented in figure 40 reveal 
the presence of 50kDa and 60kDa molecular weight bands indicative of RgpB and Kgp 
gingipains isolated from the soluble fractions of the culture supernatant of HG66. Though 
HG66 reported to express RgpA here (figure 36) and elsewhere the activity appeared to 
be lost on further purification steps 94, 185. These data are in agreement with previous 
studies demonstrating similar molecular weight profiles 426, 525, 526, 532. RgpA and Kgp have 
been shown to be the most potent virulence factors of P.gingivalis due to their 
hemagglutinin adhesion domains which enable the organism to colonise periodontal 
pockets and the gingival sulcus 564, 565. These molecules also enable the organisms to 
acquire iron from erythrocytes 177. Notably, inactivation of RgpB has been shown to affect 
RgpA function via post-translational modification events causing aberrant glycosylation 
processing of the arginine gingipains 566. 
Having established appropriate molecular weights for the isolated proteins the presence of 
cysteine protease activity was confirmed using specific inhibitors (figure 41). These data 
strongly supported the notion that the isolated proteins were the relevant cysteine 
proteases sought, i.e. the gingipains. Various inhibitors have been used in previous 
studies, such as iodoacetamide, E-64, leupeptin, EDTA, p-aminobenzamidine, and all of 
these agents showed inhibition only for RgpB activity. TLCK was used here as this 
molecule has been shown to inhibit both of the enzymes, effectively suggesting that many 
active-cysteine sites might be expressed in the HG66 P.gingivalis strain 426. These data 
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are in agreement with that presented in figure 41, as the addition of TLCK reduced total 
enzyme activity to 50%, suggesting that the isolated proteins were indeed gingipains, i.e. 
cysteine proteases. While TLCK inhibited only 50% of cysteine protease activity, the 
inhibition is not complete indicating that either the presence of active-cysteine groups in 
the eluted proteases are less reactive to TLCK or different forms of cysteine groups exist. 
Inhibitors of Papain, superfamily of cysteine proteases show to inhibit only Rgp but not 
Kgp indicating that active-cysteine residues present in the Kgp were less reactive to 
depending on the inhibitors 426. Interestingly, the inhibition of both arginine and lysine 
gingipain by TLCK were also reported to prevent apoptosis in endothelial cells by 
inactivating caspase-3 enzymes 567. Additionally, TLCK was shown to inhibit the cleavage 
of CD99 on RgpA or Kgp-treated human umbilical vein endothelial cells 204. 
The final confirmatory test used to identify the presence of gingipains from the isolated 
fractions from the P.gingivalis strain HG66 used here was mass spectrometry following in-
gel digestion of the purified proteins. Data confirmed that both RgpB and KgpA were 
present within the isolated bands as they exhibited the highest identification score of cross 
correlation (XCorr>1000) (Table 7). This outcome was regarded as being definitive proof 
that the most abundant proteins within the bands were identified as gingipains, with 
coverage for the presence of both RgpB and Kgp being 28 %.  
Interestingly, the presence of the major fimbrium subunit FimC and peptidylarginine 
deiminase enzyme activity were also observed in the Mass Spectrometry analysis 
(identification scores of XCorr <500 (table 7). Their role reported in the literature has been 
in mediating bacterial and host interactions as well as protein citrullination production 
which may be involved in rheumatoid arthritis pathogenesis. Hence they may also play a 
role in any downstream effects detected when studying the final eluted proteins 568, 569. 
Furthermore, the analysis of the gel bands for protein identification also reported the 
presence of serine hydroxymethyltransferase, phosphoenolpyruvate carboxykinase, 
hydroxylamine reductase and other outer membrane proteins, albeit at very low amounts. 
Combined, these results confirm that the proteins isolated by gel filtration and affinity 
chromatography were enriched for cysteine proteases identified as gingipains specific for 
ARG and LYS amino acids.  
4.7 Conclusion  
Gingipains have been identified as principal components of the proteolytic enzymes 
produced by P.gingivalis and have been widely studied for their direct involvement in 
periodontal tissue destruction and modulation of host immune responses. Reportedly they 
may also play causative roles in other chronic inflammatory diseases associated with PD 
such as rheumatoid arthritis. Given the potential importance of gingipains in disease 
Results 
134 
 
pathogenesis, it is necessary to isolate them relatively purely to enable mechanistic 
studies, such as in determining their involvement in AC clearance. Indeed, while many 
studies have analysed the impact of P.gingivalis on phagocytic immune cells such as on 
NØ, monocytes, and MØ few studies have thus far reported on the effects of gingipains on 
AC clearance. Subsequently, the gingipains purified here can be analysed for their 
involvement in triggering inflammatory mediators, affecting chemotaxis and inflammation 
resolution. Outcomes from these studies might aid our understanding of the 
pathophysiology of periodontal diseases and their link to other systemic diseases.  
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Chapter 5 
Result 3: Gingipain selectively cleaves CD14 leading to MØ hypo-
responsiveness towards AC 
5.1 Introduction 
For phagocytes to discriminate a viable cell from an AC, the presence of specific AC 
ligands that are bound by MØ receptors are required in order to decide whether they have 
to be eaten by professional phagocytes or left to perform cellular functions in the biological 
system 570. The discovery of phospholipid asymmetry and translocation from the inner 
leaflet to the outer leaflet of the plasma membrane is one of the early cell surface 
modulations undertaken by a dying cell. This translocation of phospholipids in AC guides 
the phagocytes to recognise and engulf them thereby preventing the activation of the 
adaptive immune system 510, 571, 572. AC clearance receptors are therefore critical players in 
innate immunity as they aid in the uptake of AC, which is a non-inflammatory process and 
results in resolution of inflammation and promotion of wound healing 336.  
This study addresses how P. gingivalis gingipains interferes with the host immune system 
by modifying AC clearance receptors on MØ and thereby reducing MØ uptake of dying 
cells. The first step in disturbing tissue homeostasis is to cleave essential receptors 
specific for the ‘tether and tickle’ mechanism of AC clearance 280, 479. A wide range of 
receptors (Table 8) has been suggested to be involved in the clearance of dying cells, 
acting either directly or through bridging molecules recognised by the phagocytes. 
In addition to the receptors discussed, factors such as pro-resolving lipid mediators, 
nucleotides, fractalkine (CX3CL1), tRNA synthetases and ribosome components are also 
said to participate in mediating the clearance of dying or dead cells 460, 573, 574. The 
clearance of apoptotic NØ has been widely studied due to their role in infection and 
causing chronic inflammatory diseases 21, 471, 575, 576. Here, the study address how AC NØ 
are cleared by gingipain-treated MØ when exposed to periodontal pathogens. Hence, the 
aim of this chapter was to analyse whether gingipains inhibit the clearance of AC 
by modifying MØ migration towards dying cells and reducing their interaction with 
primary AC NØ and whether this is dependent on specific AC receptors present on 
MØ.  
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Receptors References 
Phosphatidylserine receptors 510, 577, 578 
Class A scavenger receptor 514, 579 
CD14 324, 325, 418 
CD31 337, 580 
CD47 339, 581, 582 
CD91 300, 301 
CD68 583, 584 
αvβ5 and αvβ3 585-587 
ATP-binding cassette transporter 1 588, 589 
Complement receptors 40, 590 
 
Table 8: List of receptors that participate in AC clearance  
The above-listed receptors present on the surface of phagocytes have been suggested to 
act as bridging molecules important in the uptake and phagocytosis of dying cells. 
5.2 Gingipains fail to induce apoptosis in primary NØ and THP-1 MØ 
Apoptosis is prevalent in periodontal tissues and in the gingival sites infected with 
complex polymicrobial organisms 107. Upon constant exposure to bacterial biofilm, 
inflammation is induced causing bleeding and, in advanced stages of disease, alveolar 
bone destruction 591-594. AC death within the inflamed periodontal tissue contributes to the 
inflammatory environment either by modulating phagocyte function or by inhibiting their 
cell death resulting in the perpetuation of the chronic inflammatory lesion and frustrated 
healing 595. 
To check whether P.gingivalis gingipains influence apoptosis in phagocytes (MØ and NØ), 
THP-1 MØ were exposed to either RgpB or Kgp for 1h at 37°C. One hour incubation was 
chosen as most of the experiments performed in this study utilised phagocytes (THP-1 
differentiated MØ) that were pre-treated with protease for 1h prior to the analysis of 
phagocyte function. E.g. in recognition and interaction with AC. Consequently, cell viability 
studies were performed in either MØ (Figure 42 & 43) or primary human NØ (Figure 44 & 
45).  The phagocytes were exposed to gingipains prior to assessment of cell death with 
annexin V FITC (to determine apoptotic death) and PI (to measure cell necrosis) using 
flow cytometry. The results for gingipain-treated THP-1 MØ are shown in figure 42. 
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Figure 42: Measurement of cell viability, size, and granularity of gingipain-treated 
THP-1 MØ  
THP-1 VD3 differentiated MØ were treated with RgpB or Kgp (5µg/ml) (as described in 
section 2.7.11) or left untreated for 1 h or 16 h at 37°C. Untreated or treated MØ were 
washed and stained with annexin V FITC or PI to assess cell viability using flow cytometry 
(as described in section 2.5.3.1). A) Flow cytometry plots showing MØ stained for annexin 
V FITC and PI to reveal the viability of cells following 1h treatment. B) Histogram showing 
percentage of cells negative for annexin V (i.e.viable) stain in 1h treatment. C) Flow 
cytometry plots showing forward (FS) and side (SS) scatter of MØ to reveal the size and 
granularity of cells following 1h treatment. D) Histogram showing the mean of forward and 
side scatter for untreated and treated MØ following 1h. E) Histogram showing percentage 
of cells negative for annexin V (i.e. positive for viable) stain following 16h treatment. Data 
shown are mean ± SEM for three independent experiments. Statistical analysis was 
conducted using ANOVA followed by Dunnett’s post-test: no significant (ns) differences 
were noted between treated and untreated cell. Data shown in A and C are representative 
whilst data shown in B, D and E are mean ± SEM of three independent experiments. 
 
As shown in figure 42, MØ remain negative for annexin V and propidium iodide (i.e. viable 
– figure 42 A&B) following gingipain treatment indicating that gingipains do not induce 
apoptosis within one hour of treatment. Size and granularity were also measured (forward 
scatter and side scatter respectively) using flow cytometry. Untreated MØ, show large 
cells with low granularity (figure 42C) as revealed by high forward scatter and low side 
scatter.  Gingipain-treated MØ remain similar to untreated MØ based on their size and 
granularity (figure 42 C&D).  MØ were also incubated with gingipains for extended time 
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periods and checked for viability using AxV and PI after 16h (figure 42E). The data figure 
42E shows that gingipains do not induce apoptosis with longer incubation times on MØ. 
To confirm this finding using alternative method, nuclear morphology of untreated or 1h 
gingipain (RgpB or Kgp) treated THP-1 VD3 stimulated MØ were assessed by confocal 
microscopy following cell nuclear staining with acridine orange (10µg/ml). The results are 
shown in figure 43. 
 
 
                                                                                  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43: Confocal analysis of cell and nuclear morphology of gingipain-treated 
MØ  
THP-1 VD3 MØ were either treated with RgpB or Kgp (5µg/ml) (as described in section 
2.7.11) or left untreated (control) for 1h or 12h at 37°C. Cells were washed with PBS and 
stained with acridine orange (10µg/ml) (as described in section 2.5.3.2) and observed 
using confocal microscopy to detect nuclear changes in the MØ. Top panel shows the 
microscopic image of untreated or gingipain-treated MØ for 1h with the fluorescence stain 
(scale bar 50µm). Below panel shows the microscopic image of untreated or gingipain-
treated MØ for 12h with the fluorescence stain (scale bar 10µm). Data shown are 
representative of three independent experiments.  
 
Careful analysis to detect any nuclear changes in the gingipain-treated cells revealed that 
cells remained healthy and viable exhibiting intact cell membranes and nuclei with all 
nuclei emitting a similar pattern of green fluorescence indicating that gingipain treatment 
of cells does not alter the morphology of MØ (figure 43).  
NØ are the most recruited immune cells in patients with PD and have been widely studied 
for their pathogenic role in causing advanced lesions in humans 351, 435, 596-598. With a short 
life span, NØ are classically characterised as phagocytic cells contributing to the 
inflammation induced by extracellular pathogens by producing antimicrobial mediators 
leading to acute inflammation and NØ death promotes the resolution of this acute 
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inflammation 33, 599, 600. However, in PD if the response of NØ to biofilm formation in the 
subgingival microorganism-infected regions is either prolonged or the resolution inhibited, 
the NØ may cause extended local inflammatory response triggering amplification of 
inflammation leading to chronic diseases 191, 601, 602. Delayed NØ apoptosis has been 
reported in chronic periodontitis patients, which is linked with disturbance of the extrinsic 
apoptotic pathway contributing to systemic inflammation 190. Additionally, increased GM-
CSF and TNF-α in the gingival tissue of adult periodontitis patients are reported to inhibit 
NØ apoptosis by modulating BAX expression 190. Here, NØ viability was observed after 
treating cells with purified gingipains to assess the impact of NØ viability. NØ were treated 
with either RgpB or Kgp, for 1h at 37°C and stained with annexin V FITC (figure 44) for PS 
exposure and PI for nuclear morphology. The results are shown in figure 44 and 45. 
 
                                                                                            
                           
 
  
 
 
 
Figure 44: Measurement of cell viability, size, and granularity of gingipain-treated 
primary NØ  
Primary NØ were treated with RgpB or Kgp (5µg/ml)  or untreated for 1h at 37°C (as 
described in section 2.7.11). Untreated or treated NØ were washed and stained with 
annexin V FITC or PI to assess cell viability using flow cytometry (as described in section 
2.5.3.1). A) Flow cytometry plots showing NØ stained for annexin V FITC and PI to reveal 
the viability of cells. Data shown are representative of three independent experiments B) 
Histogram showing percentage of cells negative for annexin V (i.e. positive for viable) 
stain. Data shown are mean ± SEM for three independent experiments Statistical analysis 
was conducted using ANOVA followed by Dunnetts post-test: ns- not-significant compared 
to untreated.  
 
The data in figure 44 shows that similar to THP-1 MØ, NØ maintained their viability after 
1h treatment with either of the gingipains incubated at 37°C. Though Kgp-treated MØ cells 
remained negative for both annexin V and propidium iodide, RgpB treatment however, 
showed a trend with a shift of cells staining positive for annexin V (i.e. apoptotic) 
compared to untreated NØ (Figure 44A). However, no significant difference was observed 
in RgpB-treated NØ compared to untreated NØ. 
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To further support this work, nuclear morphology (figure 45) of untreated or 1h gingipain 
(RgpB or Kgp)-treated primary NØ was assessed by confocal microscopy following 
staining of cells with DAPI (100ng/ml). The results are shown in figure 45. 
 
  
 
 
 
 
 
Figure 45: Fluorescent images of gingipain-treated primary NØ 
Primary NØ were either treated with RgpB or Kgp (5µg/ml) (as described in section 
2.7.11) or left untreated for 1h at 37°C. Cells were washed with PBS and stained with 
DAPI (as described in section 2.4.4.3) and observed using fluorescent microscopy to 
detect nuclear changes in the NØ. The microscopic image shows untreated or gingipain-
treated NØ with the fluorescence stain (scale bar 50µm). Arrow indicates the formation of 
NETs in RgpB treated NØ. Data shown are representative of three independent 
experiments.  
 
The data in figure 45 shows representative fluorescent images of DAPI stained NØ either 
treated with gingipains or left untreated for 1h at 37°C in a sfRPMI medium with 
0.15%BSA (control). RgpB treated cells appear to show the formation of NETs following 
gingipain-tretament whereas Kgp treatment does not appear to induce NETs formation. 
Nevertheless, viable nuclei were noticeable in Kgp-treated NØ, similar to untreated NØ. 
Compared to untreated NØ, RgpB-treated NØ lacked prominent shaped nuclei in order to 
produce NETs.  
5.3 Gingipain cleaves CD14, an AC clearance receptor 
CD14, is an important innate immune receptor expressed as a membrane-associated 
CD14 (mCD14) and soluble form (sCD14). mCD14 is a protein anchored 
glycosylphosphatidylinositol (GPI) and is highly-expressed on differentiation of circulating 
monocytes to mature MØ 328, 603. sCD14 is synthesised either from the intracellular pools 
or via proteolysis of mCD14 604. Both forms of CD14 mediate responses to LPS, from 
Gram-negative bacteria and can initiate shock 143, 604, 605. Traditionally, the mCD14 
receptor was considered as an LPS receptor. LPS-LBP complexes induce immune 
responses by transferring LPS monomers to cell surface receptors such as CD14 and 
TLRs 142. Conversely, cells that lack mCD14 such as endothelial and epithelial cells use 
sCD14 to respond to LPS by binding to additional surface receptors (e.g. integrin) to 
generate inflammatory responses in the host 141.  
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Preliminary experiments were conducted to assess if P.gingivalis LPS stimulation of THP-
1 differentiated MØ leads to loss of CD14 through shedding. Initial experiments involved 
two models of THP-1 monocytes i) THP-1 VD3 MØ or ii) THP-1 DS MØ for 48h. These 
models were used to determine cell viability (using Annexin V-FITC and PI) and CD14 
expression using immunofluorescence and flow cytometry following LPS-stimulation (1h at 
37°C). The results are shown in figure 46. Earlier experiments show that VD3 stimulated 
MØ expressed higher CD14 levels compared to DS MØ (figure 19). However, CD14 
expression on DS MØ was detected also. They responded strongly to LPS producing 
increased cytokine levels 36 and also in future experiments (chapter 6).  
 
                              
 
 
 
 
 
 
Figure 46: Quantification of CD14 expression on P.gingivalis LPS treated THP-1 MØ  
THP-1 cells were differentiated either with VD3 or DS for 48h at 37°C. MØ were either 
treated with LPS from P.gingivalis or untreated for 1h at 37°C. Cells were stained with 
mouse anti-human CD14 mAb 63D3 and analysed using flow cytometry. A) Histogram 
showing MFI of CD14 expression on differentiated MØ (VD3 and DS). B) Histogram 
showing percentage of cells negative for annexin V staining (i.e. viable cells). Data shown 
are mean ± SEM for three independent experiments. Statistical analysis was conducted 
using ANOVA followed by Dunnett’s post-test: no statistical significance (ns) was noted in 
CD14 expression after LPS treatment. 
 
The results shown in figure 46 demonstrate that, following LPS stimulation, there was no 
reduction in CD14 receptor expression in either of the MØ models used (VD3 alone or 
DS). In addition, cells stained negative for Annexin V indicates cell viability (Figure 46B) 
compared to untreated MØ. These data indicate that CD14 receptor levels and cell 
viability are unaffected by LPS treatment.  
Having observed that LPS stimulation of THP-1 MØ does not reduce levels of CD14 
expression, MØ expression of CD14 following treatment with purified gingipains was 
assessed. The results are shown in figure 47. 
 
 
A B 
Results 
142 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47: CD14 surface expression on THP-1 MØ treated with gingipains  
THP-1 VD3 MØ were treated 5µg/ml with Kgp for 1h or with RgpB with 12h (as described 
in section 2.7.11 ) or untreated at 37°C prior to indirect immunofluorescence staining for 
CD14 using the the established mAb 63D3 and flow cytometry (as described in section 
2.3.6.1). A) Histogram showing the percentage of cells positive for CD14 expression and 
B) MFI after 1h of either RgpB or Kgp treatment. C) Histogram showing the percentage of 
cells positive for CD14 expression at various time points 0, 1, 12h and D) their MFI after 
1h of RgpB treatment. Flow data shown are collected from at least 10000 events.  Data 
presented are mean ± SEM of at least three independent experiments. Statistical analysis 
was performed using ANOVA followed by Dunnett's post-test. *P<0.05, ***P<0.001, not 
significant (ns) compared with untreated cells. 
 
The flow cytometry-based analyses (figure 47) confirm a significant decrease (P<0.001) in 
CD14 receptor levels on VD3 stimulated MØ treated with Kgp, but not Rgp, compared to 
untreated cells in 1h treatment at 37°C. These data suggest that Kgp treatment of MØ 
decreases CD14 expression detected either as percentage of cell positive for CD14 
(figure 47A) or MFI of CD14 expression on all cells (figure 47B). RgpB treated cells do not 
appear to show reduced CD14 expression after 1h of treatment (figure 47A &B). However, 
an extended treatment of MØ  with RgpB causes a slower decrease in CD14 expression 
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at 12h compared to untreated (figure 47C, D), with reduced percentage of cells positive 
for CD14 and a trend towards reduced MFI (i.e. CD14 levels per cell). 
Previous studies show that CD14 expression on human monocytes differs greatly from 
that on NØ. Monocytes have approximately 45,000 – 110,000 CD14 surface receptors per 
cell as compared to NØ which express significantly lower levels, estimated to be below 
5000 receptors per cell 304, 305, 501, 606, 607. In a manner similar to that seen in MØ, NØ CD14 
mediates binding of LPS through LBP forming a complex that triggers the innate immune 
inflammatory responses in humans 305. Given the ability of gingipains RgpB and Kgp to 
reduce CD14, most likely by cleaving CD14 receptor from MØ cells, the CD14 expression 
on gingipain-treated primary NØ was also studied. The results are shown in figure 48. 
 
 
                                
 
 
 
 
 
 
 
Figure 48: CD14 surface expression on primary NØ treated with gingipains  
Primary human NØ were treated with either RgpB or Kgp (5µg/ml) (as described in 
section 2.7.11) or untreated for 1h at 37°C prior to indirect immunofluorescence staining 
for anti-CD14 using established mAb 63D3 using flow cytometry (as described in section 
2.3.6.1). A) Histogram showing the percentage of cells positive for CD14 expression and 
B) mean fluorescence intensity (MFI). Data presented are mean ± SEM of three 
independent experiments. Statistical analysis was performed using ANOVA followed by a 
Dunnett’s post-test. **P<0.01, not significant (ns) compared with untreated cells. 
 
The data reveal that NØ express relatively low CD14 (figure 48B) compared to MØ (figure 
47B). The data also reveal that both RgpB and Kgp cleave CD14 from the surface of 
primary NØ compared to untreated cells (figure 48). A significant effect of gingipain 
treatment (P<0.01) can be observed in the percentage of NØ expressing CD14 with NØ 
treated with either of the gingipains compared to untreated cells. However, no significant 
effect was observed in the MFI of the untreated and treated NØ.  
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5.4 TLCK inhibits CD14 cleavage in THP-1 MØ  
To assess whether the reduction in MØ CD14 noted above was due to cleavage by 
gingipains, TLCK, a cysteine protease inhibitor, was used. MØ were stained for CD14 
expression following Kgp treatment in the presence or absence of TLCK and cell surface 
receptor expression was determined by immunofluorescence staining and flow cytometry. 
The results are shown in figure 49.  
 
 
 
 
 
 
 
 
Figure 49: TLCK inhibits CD14 reduction on Kgp gingipain-treated THP-1 MØ  
THP-1 VD3 MØ were treated with Kgp (5µg/ml) (as described in section 2.7.11) in the 
presence or absence of TLCK, cysteine inhibitor (as described in section 2.7.12) or left 
untreated for 1h at 37°C. Treated or untreated MØ were studied by indirect 
immunofluorescence staining with anti-CD14 and analysed using flow cytometry (as 
described in section 2.3.6.1). A) Representative overlay plots showing CD14 expression 
on MØ either untreated (light blue) or Kgp-treated for 1h (black) or Kgp and TLCK-treated 
for 1h (dark blue) and MØ stained with MOPC21 isotype negative control (red). B) 
Histogram showing MFI for the anti-CD14 stained cells. Data shown are mean ± SEM of 
three independent experiments. Statistical analysis was performed using ANOVA followed 
by a Bonferroni post-test (*P<0.05). Data shown in A and B are representative. 
 
The MFI extracted from the flow cytometric plots (figure 49A) suggests that CD14 
expression was preserved on MØ treated with Kgp in the presence of the TLCK (figure 
49B). Whereas compared to untreated cells, Kgp-treated MØ without TLCK treatment 
exhibited a rapid decrease (P<0.05) in CD14 expression (figure 49B) in line with previous 
experiments (figure 48). 
5.5 Expression of AC clearance receptors on gingipain-treated THP-1 MØ 
and primary NØ  
Emerging research suggests that a wide range of receptors participate in the clearance of 
dying cells 35, 608, 609. The extracellular matrix glycoprotein, thrombospondin-1 (TSP-1) 
synthesized by both MØ and NØ binds to mediator αVβ3 integrin to form a complex with 
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MØ CD36 to clear AC 294. Additionally, calreticulin, an endoplasmic reticulum protein 
which is highly expressed on AC, signals to phagocytes to uptake dying cells using CD91 
and involving other mediators such as collectins and low-density lipoprotein receptor-
related protein present on phagocytic cells 275, 300. Additionally, ICAM-3, another well-
described ligand facilitates MØ migration to AC and binding to phagocytes 37, 281, 384. These 
important receptors and ligands were studied for their expression on gingipain-treated 
phagocytic cells to assess whether their expression was altered in response to the 
proteases from P. gingivalis. The results are shown in figure 50. Alterations in expression 
of these receptors may affect AC clearance. 
 
 
  
 
 
 
 
 
 
Figure 50: Gingipain treatment of MØ does not alter the expression of CD36, ICAM-3 
or CD91  
THP-1 MØ (VD3 or DS) were incubated with RgpB or Kgp for 1h (as described in section 
2.7.11) at 37°C and stained with antibody to the indicated antigen (CD36, ICAM-3 or 
CD91) followed by secondary antibody FITC/PE and analysed using flow cytometry to 
determine receptor expression (as described in section 2.3.6.1 and 2.3.6.2). Data shown 
are A) percentage of cells positive for antigen and B) their MFI. Data presented are mean 
± SEM of three independent experiments. Statistical analysis was performed using 
ANOVA followed by Dunnett's post-test; no significant difference in antigen expression 
was noted with gingipain treatment. 
 
The results in figure 50 suggest 1h treatment of gingipain (RgpB or Kgp) on THP-1 MØ 
fails to reduce significantly the percentage of cells expressing CD36, ICAM-3 or CD91 
compared to untreated cells. Additionally, the MFI measure (figure 50B) shows that CD91 
was expressed at low levels, ICAM-3 showed moderate expression compared to CD36 
with the highest expression on MØ. 
These receptor and ligand molecules were also studied for their expression on gingipain-
treated human NØ to assess for the modulation of receptors in response to the proteases 
from P.gingivalis. The results are shown in figure 51. 
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Figure 51: Gingipain treatment of primary NØ does not alter the expression of 
CD36, ICAM-3 or CD91  
Primary NØ were incubated with RgpB or Kgp (5µg/ml) for 1h at 37°C (as described in 
section 2.7.11) and stained with antibody to the indicated antigen (CD36, ICAM-3 or 
CD91) followed by secondary antibody FITC/PE and analysed using flow cytometry to 
determine receptor expression (as described in section 2.3.6.1 and 2.3.6.2). Data shown 
is A) percentage of cells positive for antigen and their B) MFI respectively. Data presented 
are mean ± SEM of three independent experiments. Statistical analysis was performed 
using ANOVA followed by Dunnett's post-test; no significant difference in antigen 
expression was noted with gingipain treatment. 
 
These studies with primary human NØ, suggest higher ICAM-3 expression compared to 
CD36, CD91 appeared poorly expressed with only weak fluorescence on primary NØ 
(figure 51B). However similar to THP-1 MØ, no cleavage of receptors was observed on 
gingipain-treated NØ compared to untreated cells.  
To prevent uptake by phagocytes, viable cells use ‘don’t eat me’ signals in order to avoid 
ingestion by phagocytes. CD31 (PECAM-1), is one such signal vital for leukocyte motility 
and cell-cell adhesion molecule.  However due to inactivation of CD31 ‘don’t eat me’ 
signals on AC, CD31 initiates binding of AC to phagocytes and phagocytosis 338. To 
assess gingipains’ ability to cleave the CD31, MØ were treated with either RgpB or Kgp 
for 1h or 16h at 37°C and assessed for cell surface receptor using anti- CD31 and 
analysed via flow cytometry. The results are shown in figure 52.  
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Figure 52: CD31 expression on gingipain-treated THP-1 MØ at various time points  
THP-1 VD3 MØ were incubated with RgpB or Kgp (5µg/ml) for 1h (as described in section 
2.7.11) or 16 h at 37°C and stained with anti- CD31 and analysed by flow cytometry for 
cells positive for receptor expression (as described in section 2.3.6.2). Data shown is A) 
The percentage of cells positive for CD31 at 1h incubation B) The percentage of cells 
positive for CD31 at 16 h incubation. C) MFI for CD31 at 16 h. Data presented are mean ± 
SEM of three independent experiments. Statistical analysis was performed using ANOVA 
followed by a Dunnetts post-test; **P<0.01 compared with untreated cells.  
 
The results in figure 52 suggest that RgpB fails to cleave CD31 on MØ even with 
extended time incubation. However, Kgp reduces CD31 expression only following 16h 
incubation (figure 52B) though no significant difference was observed in the MFI (figure 
52C).  
An identical approach was taken to study the effect of gingipains on another ‘don’t eat me’ 
signal, CD47 is also expressed on viable cells to prevent uptake by phagocytes. CD47 is 
an integrin-associated protein and is a receptor for SIRPα, expressed mainly on 
phagocytes such as MØ and dendritic cells 585. AC lose CD47 during the process of 
programmed cell death. Viable cells losing CD47 are unable to serve as a ligand for 
SIRPα leading to reduction of tyrosine phosphorylation of SHP-1 allowing the phagocytes 
to remove AC by engulfment 16, 275, 341. To assess gingipains’ ability to cleave the CD47, 
THP-1 differentiated MØ were treated with gingipains (RgpB or Kgp) for 1h at 37°C and 
assessed for cell surface receptor using anti-CD47 and analysed via flow cytometry. The 
results are shown in figure 53.  
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Figure 53: CD47 expression on gingipain-treated THP-1 MØ at various time points  
THP-1 VD3 MØ were incubated with RgpB or Kgp (5µg/ml) for 1h (as described in section 
2.7.11) or 16 h at 37°C and stained with anti-CD47 and analysed by flow cytometry for 
cells positive for receptor expression. Data shown is A) The percentage of cells positive 
for CD47 at 1h incubation B) The percentage of cells positive for CD47 at 16h incubation. 
C) MFI for CD47 at 16h incubation. Data presented is mean ± SEM of three independent 
experiments. Statistical analysis was performed using ANOVA followed by a Dunnett's 
post-test; no significant differences were noted compared with untreated MØ. 
 
The results in figure 53 reveal that viable MØ express CD47 and no reduction in the CD47 
receptor is observed after treatment with gingipains (either RgpB or Kgp) even at 
extended time points (16h) (figure 53B &C). Previous work has found that LPS from 
P.gingivalis induce enhanced production of TSP-1 on THP-1 cells 610. TSP-1 has shown 
earlier to interact with CD47 on MØ inducing osteoclastogenesis and bone resorption via 
an unknown mechanism thereby modulating the inflammatory responses resulting in 
damage of alveolar bone in periodontitis patients 611.  
CD31 is reported to bind homotypically i.e. CD31 on MØ binding to CD31 on AC. AC NØ 
have been shown to exhibit reduced CD31 in order to differentiate them from viable NØ 
and to allow this phagocytosis by MØ 338.  In order to assess if CD31 levels may be 
altered on viable and AC NØ, and in response to gingipains, flow cytometry was used. 
The level of CD31 expression was analysed in viable and AC NØ in addition to gingipain-
treated NØ for 1h at 37°C and assessed for cell surface receptor using anti- CD31 and 
analysed via flow cytometry. The results are shown in figure 54.  
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Figure 54: CD31 expression on gingipain-treated primary viable and AC NØ 
treatment at different time points  
Human viable NØ were incubated either with RgpB or Kgp (5µg/ml) for 1h or 16h at 37°C 
(as described in section 2.7.11) or allowed to undergo spontaneous apoptosis for 16h at 
37°C (as described in section 2.5.1.2), NØ were stained with anti-CD31 and analysed by 
flow cytometry for CD31 expression. Data shown is A) Representative flow cytometric 
plots of NØ stained for anti-CD31 detected using indirect immunofluorescence, showing 
overlay plots of CD31 surface expression for untreated viable NØ (red) or RgpB treated 
NØ (blue) or Kgp-treated NØ (purple) at 16h and their matched isotype control (grey). B) 
The percentage of cells positive for CD31 at 1h incubation C) MFI of CD31 at 1h time 
point. D) The percentage of cells positive for CD31 at 16h incubation E) MFI of CD31 at 
the 16h time point. Data shown are representative of three independent experiments for 
(A) and mean ± SEM of three independent experiments for (B, C, D, and E). Statistical 
analysis was performed using ANOVA followed by a Dunnett’s post-test. ***P<0.001 or 
not significant (ns) compared with untreated viable NØ (control). 
 
The flow cytometric plots in figure 54 reveal that untreated viable NØ express a higher 
level of CD31 on their surface (figure 54A- red line) compared to RgpB (figure 54A- blue 
line) or Kgp-treated NØ at 16h (figure 54A- violet line). No significant difference was 
observed in the percentage of viable NØ positive for CD31 (figure 54B) or their MFI (figure 
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54C) following gingipain treatment despite a trend of reduced CD31, compared to 
untreated NØ at 1h and 16h (figure 54D).  However, the MFI of CD31 of spontaneous AC 
NØ and gingipain-treated NØ after 16h exhibited a tremendous reduction compared to 
untreated viable NØ (figure 54E).  
Another inhibitor for ‘eat me’ receptors, CD47 was also analysed in viable and AC NØ and 
gingipain-treated NØ for 1h at 37°C. The resulting cells were assessed for CD47 cell 
surface receptor levels using anti- CD47 using flow cytometry. The results are shown in 
figure 55.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55: CD47 expression on gingipain-treated primary viable and AC NØ 
treatment at different time points  
Human viable NØ were either incubated with RgpB or Kgp (5µg/ml) for 1h or 16h at 37°C 
(as described in section 2.7.11) or allowing to undergo spontaneous apoptosis for 16h at 
37°C (as described in section 2.5.1.2) NØ were stained with anti-CD47 and analysed by 
flow cytometry for CD31 expression. Data shown is A) the percentage of cells positive for 
CD47 at 1h incubation B) MFI of CD47 at 1h time point C) The percentage of cells positive 
for CD47 at 16h incubation and D) MFI of CD47 at the 16h time point. Data shown are 
representative of three independent experiments for (A) and mean ± SEM of three 
independent experiments for (B, C, D, and E). Statistical analysis was performed using 
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ANOVA followed by a Dunnett’s post-test. Not-significant (ns) compared with untreated 
cells.  
The result in figure 55C indicate that CD47 was expressed at both viable and AC NØ. 
Additionally, no significant difference was observed in CD47 levels on NØ treated (1h or 
16h) with the proteases compared to untreated NØ (figure 55B&D). 
5.6 Gingipains inhibit the directional migration of phagocytes to AC 
Having characterised a panel of ‘eat me’ and ‘don’t eat me’ receptors important for AC 
clearance, the THP-1 derived MØ were used to assess for their migrational abilities in 
gingipain-exposed environments using an in vitro migration mode system. Phagocyte 
migration in response to the attractive mediators released by the AC is considered to be 
an essential step in the removal of dying cells. The prompt clearance of AC induces 
immunological tolerance and subsequent biological responses in the infected tissue of the 
host 609. The impact of gingipains on this is unknown. Preliminary results suggest that 
THP-1 VD3 MØ demonstrate efficient migration towards both AC B and AC NØ using an 
established Dunn chemotaxis chamber assay (figure 25D & 28D). To determine whether 
gingipains can inhibit phagocyte migration to AC, possibly through cleavage of receptors 
CD14, THP-1 VD3 MØ were treated with gingipains and analysed for migrational abilities. 
Kgp was chosen over RgpB to treat the MØ due to the rapid reduction of CD14 levels on 
Kgp-treated MØ (figure 47).  THP-1 VD3 MØ grown on glass slides were treated with Kgp 
gingipain for 1h and sealed in a Dunn chamber prior to addition of AC as an attractant. 
The migration of the protease-treated MØ was recorded for 2h at 37°C using time-lapse 
video microscopy. The results are shown in figure 56. 
The results in figure 56 show MØ migration towards AC B and this appears reduced for 
gingipain-treated MØ. The chemotaxis plots (figure 56A) shows the migration of 40 
selected MØ, the count recommended by the chemotaxis and migrational tool assay V2.0 
were standardised at the centre of the plot 469. MØ migration in the absence of a gradient 
(i.e. medium alone in the outer well) serves as a negative control and non-protease MØ 
migration towards AC B serves as a positive control 37. Kgp-treated MØ appear to show 
some directional movement towards AC B, similar to untreated MØ. However, using the 
measure yFMI, as a measure of directional migration for all cells, the data suggest Kgp 
treatment of MØ causes a significant decrease in the directional migration of MØ towards 
dying cells (P<0.01) compared to non-protease treated MØ. These data suggest that 
gingipains may cause the delayed clearance of dying cells and their debris resulting in 
prolonged inflammation and tissue destruction. 
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Figure 56: Gingipains inhibit MØ migration towards AC B cells  
THP-1 cell-derived VD3 MØ were exposed to AC B in a horizontal migration assay.  MØ 
were seeded on glass coverslips and treated or untreated with gingipains before loading 
to a Dunn horizontal chamber and exposed to putative attractants (as described in section 
2.6.2.1).  MØ migration was monitored for 2h at 37°C using time-lapse video microscopy. 
Migration of 40 cells per assay was measured using Image J and Ibidi Chemotaxis and 
Migration Tool (V2.0). The MØ route of travel is shown by a line from the starting point 
(set at the cross hairs of the plots) to the final MØ position after 2h (black dot). The 
relative location of AC was at the top of the plot (black diamond). (A) Representative plots 
showing:  Left panel: Untreated MØ migration with control, cell-free medium as a putative 
attractant to reveal basal levels of MØ migration. Centre panel: Untreated MØ migration 
with AC B as an attractant. Right panel: Kgp-treated MØ (Kgp-MØ) migration with AC B 
cells as an attractant. (B) Forward migration index (yFMI) to quantify MØ migration in the 
direction of the AC B. Data shown are representative of three independent experiments 
for (A) and mean ± SEM of three independent experiments for (B). Statistical analysis was 
conducted using ANOVA followed by a Bonferroni post-test **P< 0.01, ***P< 0.001 
compared to MØ + B cells.  
 
From the data plots (figure 56A), other measurements of migration were extracted using 
image J and chemotaxis and migration tool. Parameters measured included Euclidean 
and accumulated distance, velocity, and angle. The results are shown in figure 57. 
 
 
 
 
 
 
 
400 
400 
0 
Outer well attractant 
Medium AC B AC B 
MØ MØ Kgp-MØ 
Migrating cell 
D
is
ta
n
c
e
 (
µ
m
) 
A B 
Results 
153 
 
 
 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 57: Gingipain treatment of THP-1 MØ does not affect distance, velocity or 
angle of migration towards AC B cells  
THP-1 VD3 MØ with or without gingipain treatment were exposed to AC B in a horizontal 
migration assay (as described in section 2.6.2.1). MØ migration was monitored for 2h at 
37°C using time-lapse video microscopy. Quantitative measurement of migrated MØ was 
analysed using Image J and Ibidi Chemotaxis and Migration Tool (V2.0). 40 cells per 
assay were tracked for their migration towards the chemoattractant and extrapolated the 
measurements from the data plots in figure 56. Data shown is A) Accumulated distance B) 
Euclidean distance C) velocity and D) angle measurement of Kgp-treated and untreated 
MØ moving towards AC B or medium alone. Data shown are the mean ± SEM of three 
independent experiment. Statistical analysis was conducted using ANOVA followed by 
Bonferroni post-test; *P<0.05, **P<0.01, ***P<0.001 or not significant compared to MØ + 
AC B. 
 
The results in figure 57 show that other than angle of migration, the other measures were 
unaffected, while the angle travelled alone suggests a significant difference (P< 0.01) 
between Kgp-treated MØ compared to untreated MØ. This indicates that the Kgp-treated 
MØ travelled in a less uniform manner compared to untreated MØ. Taken together, these 
data suggest that gingipain-treated MØ can be stimulated by AC such that the distance 
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and speed migrated by MØ are not significantly different to that of non-protease treated 
MØ, suggesting that chemokinesis is unaffected. However, directionality is reduced by 
gingipain treatment (figure 56B). 
The VD3 stimulated THP-1 MØ were similarly used to assess for their migrational abilities 
in gingipain-exposed environment towards AC NØ using a Dunn chemotaxis chamber. 
The results are shown in figure 58. 
 
 
 
 
 
 
 
 
 
 
 
Figure 58: Gingipains inhibit MØ migration towards AC NØ 
THP-1 VD3 MØ with or without gingipain treatment were exposed to AC NØ in a 
horizontal migration assay (as described in section 2.6.2.1). MØ migration was monitored 
for 2h at 37°C using time-lapse video microscopy. Migration of 40 cells per assay was 
measured using Image J and Ibidi Chemotaxis and Migration Tool (V2.0). The MØ route 
of travel is shown by a line from the starting point (set at the cross hairs of the plots) to the 
final MØ position after 2h (black dot). The relative location of AC was at the top of the plot 
(black diamond). (A) Representative plots showing: Left panel: Untreated MØ migration 
with control, cell-free medium as a putative attractant to reveal basal levels of MØ 
migration. Centre panel: Untreated MØ migration with AC NØ as an attractant. Right 
panel: Kgp-treated MØ (Kgp-MØ) migration with AC NØ as an attractant. (B) Forward 
migration index (yFMI) to quantify MØ migration in the direction of the AC NØ. Data 
shown are representative of 4 distinct experiments for (A) and mean ± SEM of three 
independent experiments for (B). Statistical analysis was conducted using ANOVA 
followed by Bonferroni post-test *P< 0.05, **P< 0.01 compared to MØ + AC NØ. 
 
Similar to previous experiment with AC B, migrational movement of gingipain-treated MØ 
towards AC NØ appeared similar to that of untreated MØ (figure 58A) however, a reduced 
yFMI for Kgp-treated MØ (P<0.05) was noticed compared to untreated cells (MØ + AC 
NØ) (figure 58B).  
The data plots in figure 58 were used to extract other quantitative measurements to 
assess further the migrational abilities of MØ towards AC NØ. The results are shown in 
figure 59. 
200 
200 
0 
D
is
ta
n
c
e
 (
µ
m
) 
Outer well attractant 
Medium AC NØ AC NØ 
Migrating 
cell 
MØ MØ Kgp-MØ  
A B 
Results 
155 
 
 
 
 
                             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 59: Gingipain treatment of THP-1 MØ does not affect distance, velocity or 
angle of migration towards AC NØ  
THP-1 VD3 MØ were exposed to AC NØ in a horizontal migration assay.  MØ were 
seeded on glass coverslips and treated or untreated with gingipains before loading to a 
Dunn horizontal chamber and exposed to AC NØ (as described in section 2.6.2.1). MØ 
migration was monitored for 2h at 37°C using time-lapse video microscopy. Quantitative 
measurement of migrated MØ was analysed using Image J and Ibidi Chemotaxis and 
Migration Tool (V2.0). 40 cells per assay were tracked for their migration towards the 
chemoattractant and extrapolated the measurements from the data plots in figure 58. Data 
shown is A) Accumulated distance B) Euclidean distance C) velocity and D) angle 
measurement of treated and untreated MØ movement towards AC NØ or medium on its 
own. Data shown are the mean ± SEM of 4 distinct experiments. Statistical analysis was 
conducted using ANOVA followed by Bonferroni post-test. Not-significant (ns) compared 
to MØ + AC NØ. 
 
The results in figure 59 suggest no significant difference in any of the quantitative 
measurements (Euclidean distance, accumulated distance, velocity or angle). Failed 
clearance of apoptotic NØ has been previously reported in periodontitis resulting in 
necrotic cell death of NØ and a consequent release of toxic intracellular contents into the 
periodontal tissues causing local tissue damage characteristic of PD 356. Moreover, GCF 
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samples from chronic periodontitis patients’ have been shown to contain hydrolytic 
enzymes from NØ 612, 613. Together, these data suggest that gingipain-treated MØ can be 
stimulated by AC NØ such that the distance and speed migrated by MØ are not 
significantly different to that of non-protease treated MØ, suggesting that chemokinesis is 
unaffected. Though, directionality is reduced by gingipain treatment. 
5.7 Rgp and Kgp inhibits MØ migration towards AC NØ in a vertical cell 
migration assay 
THP-1 MØ were also studied for their migration towards AC NØ following gingipain-
treatment within an automated vertical Cell IQ-based assay. Since the Cell-IQ allows 
tracking of cells over a longer time period, MØ migration following RgpB treatment was 
also studied here as Rgp showed cleavage of CD14 at later time points (figure 47). This 
model assays MØ migrated from an upper well (the transwell) to a lower well, across a 0.8 
µm pore membrane, performed in a 24 well plate. Throughout the assay and up to the end 
of the assay, the number of MØ migrated to the lower well, containing putative 
chemoattractant, was counted in an automated fashion using the Cell-IQ software. This 
vertical model is strongly influenced by gravity (cells can only move down) and the 
gradient is a ‘step’ gradient (i.e. no attractant in the top well and all attractant in the bottom 
well).  Thus, in order to study true migration, in some cases AC NØ were also added to 
the upper transwell, to destroy the step gradient. This is shown in earlier results (figure 32) 
demonstrating that migration of MØ was reduced when the attractant was added to both 
upper and lower wells (i.e. the gradient was destroyed). This revealed true migration of 
MØ. 
Two forms of AC were extracted and used 1) whole culture apoptotic B cells (AC B) or 
apoptotic NØ (AC NØ) where, after inducing apoptosis, the culture was used directly as a 
source of attractants; 2) whole culture AC (either B or NØ) centrifuged (2000xg for 20 
minutes) to remove whole cells and their debris, leaving only the supernatant containing 
cell secretomes termed apoptotic B cell-derived AS (AS B) or apoptotic NØ-derived AS 
(AS NØ). This is performed in order to determine the effective recruitment of MØ and the 
2000xg supernatant provides an attractant that is easier to apply to the Cell-IQ automated 
assays. The earlier result (figure 32) showed that AS NØ were more attractive than the 
whole culture apoptotic NØ using the vertical cell-IQ model.  
Initial experiments were carried out for 4h to observe any effect in the gingipain-treated 
MØ migration towards AC B or AS B cells using the vertical migration model. The results 
are shown in figure 60. 
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Figure 60: Gingipains does not inhibits vertical migration of MØ migration towards 
AC B or AS B cells  
THP-1 VD3 MØ were either treated with gingipains (5µg/ml) (as described in section 
2.7.11) or left untreated for 1h at 37°C and were seeded to a transwell (as described in 
section 2.6.2.2) placed over a lower well containing either AC B or AS B (as described in 
section 2.5.1.1) or medium in a 24-well plate. MØ migration from transwell to the lower 
chamber was assessed at the end of 4h by Cell-IQ software. (A) The graph shows the 
number of MØ migrated towards AC B or (C) AS B at different time points. (B) The 
histogram shows number of MØ migrated towards AC B or (D) AS B at 4h. Data shown 
are the mean ± SEM of three independent experiments with three replicates in each 
experiment. Statistical analysis was conducted using ANOVA followed by Dunnett's post-
test. Not-significant (ns) compared to untreated. 
 
The result in figure 60 shows that no significant difference was observed on gingipain-
treated MØ migration compared to untreated MØ at the end of the 4h assay period (figure 
60B and D). However, RgpB-treated MØ showed a trend towards reduced migration 
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towards AS B cells (figure 60C) though no significant difference was observed with 
untreated MØ (figure 60D). 
Since the earlier experiment (figure 60) showed no inhibition of MØ migration towards AC 
B or AS B cells the ability of protease-treated MØ migration towards AC NØ or AS NØ 
was observed by extending the assay to 12h. The results are shown in figure 61. 
 
 
 
 
 
 
 
 
 
 
 
Figure 61: Gingipain treatment of MØ inhibits MØ migration towards AC NØ using 
vertical assay 
THP-1 VD3 MØ were either treated with gingipains (5µg/ml) (as described in section 
2.7.11) or left untreated for 1h at 37°C and were seeded to a transwell (as described in 
section 2.6.2.2) placed over a lower well containing either AC NØ (as described in section 
2.5.1.2) or medium in a 24-well plate. MØ migration from transwell to the lower chamber 
was assessed at the end of 12h by cell-IQ software. (A) The graph shows the number of 
MØ migrated at different time points. (B) The histogram shows a number of MØ migrated 
at 4h time points. Data shown are the mean ± SEM of three independent experiments with 
three replicates in each experiment. Statistical analysis was conducted using ANOVA 
followed by Dunnett’s post-test. *P<0.05 compared to untreated. 
 
Here, MØ treated with either Rgp or Kgp exhibited reduced migration to AC NØ at the end 
of the 12h period compared to untreated MØ migration towards whole culture AC NØ 
(figure 61). Untreated MØ were rapidly recruited to the lower well containing attractant, 
demonstrating significantly increased migration over gingipain-treated MØ. These 
differences were noticeable from 1-2h and for the duration of the assay.  
The result in figure 61 demonstrates the RgpB or Kgp gingipain-treated MØ showed 
reduced migration to AC NØ compared to untreated MØ. The effects were similarly 
assessed for gingipain-treated MØ migration towards AS NØ. The results are shown in 
figure 62. 
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Figure 62: Gingipain does not inhibit vertical migration of MØ migration towards AS 
NØ  
THP-1 VD3 MØ were either treated with gingipains (5µg/ml) (as described in section 
2.7.11)  or left untreated for 1h at 37°C and were seeded to a transwell (as described in 
section 2.6.2.2)  placed over a lower well containing either AS NØ (as described in section 
2.5.1.2) or medium in a 24-well plate. MØ migration from transwell to the lower chamber 
were assessed at the end of 12h by cell-IQ software. (A) The graph shows the number of 
MØ migrated at different time points. (B) The histogram shows a number of MØ migrated 
at 4h time points. Data shown are the mean ± SEM of three independent experiments. 
Statistical analysis was conducted using ANOVA followed by Dunnett’s post-test. Not-
significant (ns) compared to untreated. 
 
The results in figure 62A show similar trends to MØ migration towards AC NØ. However, 
no significant difference was observed between the protease-treated and untreated MØ 
migration at the 4h time point (figure 62B). The AS NØ served as a stronger attractant 
with more MØ recruited (figure 62) comparison to whole culture AC NØ (figure 61).  
5.8 Gingipains inhibit interaction of MØ with AC 
Given the implication that gingipain-treated MØ are less able to migrate towards AC 
(either B or NØ) (figure 56 and 58), the effect of MØ interaction with phagocytes treated 
with gingipains was also assessed as a key point in the AC clearance process. Earlier 
results show (figure 33) that THP-1-derived MØ are able to interact with AC NØ or AC B 
individually. Additionally, the result also showed that MØ do not interact with viable MØ in 
the control, where only weaker interaction can be seen (figure 33). 
Of all the receptor assessed, only a reduction in CD14 expression was noted on gingipain-
treated MØ where Kgp was rapid in cleaving CD14 receptors from the MØ surface at 1h of 
treatment compared to RgpB which required an extended (12h) period (figure 47). Taking 
into account, which is CD14 is cleaved by the gingipains and the established importance 
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of CD14 as a tethering receptor for AC 418 the impact of gingipains on the ability of MØ to 
interact with AC was determined. THP-1 MØ or gingipain-treated MØ were co-cultured 
with AC B (used as a positive control) for 1h at 37°C and stained with Jenner–Giemsa 
staining and scored by microscopy for MØ interaction with AC. In this assay, interaction is 
defined as a MØ that has bound or phagocytosed an AC.  The results are shown in figure 
63. 
 
                           
 
                
 
 
 
 
 
 
 
 
 
 
 
 
Figure 63: Gingipain treatment of MØ inhibits the interaction of MØ with AC B  
THP-DS MØ (as described in 2.3.5 section) were treated or untreated with gingipains 
(5µg/ml) for 1h at 37°C (as described in section 2.7.11) prior to co-culture with apoptotic B 
cells for 1h (as described in section 2.6.1). A) Photomicrographs of Jenner-Giemsa 
stained untreated or gingipain-treated THP-1 DS MØ interacting with AC B cells. 
Untreated THP-1 MØ showing tethering and phagocytosing of AC B (left panel) and 
gingipain-treated (RgpB/Kgp) THP-1 MØ showing interaction with fewer AC B (middle and 
right panel). THP-1 MØ can be seen in light blue and AC are stained with intense blue. 
The arrow indicates the AC B cells that are not up taken by MØ. Magnification 40X. B) 
Histograms showing the percentage of MØ (with or without gingipain treatment) 
interacting (binding or phagocytosing) with AC B. C) The mean number of AC B cells 
interacting per MØ with or without gingipain treatment. Data shown are mean ± SEM of 
three independent experiments. Statistical analysis was conducted using ANOVA followed 
by Dunnett’s post-test: ***P<0.001 or not significant (ns) compared to untreated. The 
photomicrographs are representative of three independent experiments. 
 
The results in figure 63 suggest that many apoptotic B cells (arrow) are not taken up by 
the gingipain-treated (either RgpB or Kgp-treated) MØ compared to untreated MØ where 
AC can be seen internalised by the MØ (figure 63A). However, the percentage of MØ 
Untreated 
 RgpB Kgp 
A 
C B  
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interacting with AC remains unaffected by gingipain treatment (figure 63B). However, it 
was clearly visible under the microscope that many AC were left without uptake by MØ 
and that the numbers of AC per MØ appeared to be reduced. The nature of the scoring 
method used was not initially designed to detect the level of AC binding. So, the number 
of AC interacting per MØ was scored and the mean number of AC per MØ presented 
(figure 63C). As a result of the alternative scoring method, scoring the mean number of 
AC interacting per MØ exhibits a robust decrease in the level of interaction by gingipain-
treated MØ (figure 63C). This may suggest that a reduction in CD14 or other receptors 
may lead to reduced AC clearance.  Perhaps surprisingly, RgpB treatment reduced AC 
clearance after only 1h of treatment – a time when CD14 is not significantly cleaved by 
RgpB-perhaps suggesting that CD14 is not the sole mediator responsible for this effect.  
RgpB treated MØ show reduced CD14 only at 12h time point (figure 47D) however a trend 
to reduced MFI was noticed in 1h treatment (figure 47B). 
Next, using a similar experimental approach, the ability of gingipain-treated MØ to interact 
with AC NØ in co-culture was assayed to determine the level of interaction with 
phagocytes. The results are shown in figure 64. 
The results in figure 64 show a similar effect to that seen with AC B. Both RgpB and Kgp-
treated MØ showed significantly reduced uptake of AC NØ (figure 64A).  However, unlike 
with AC B,  gingipain-treated MØ showed both a decreased percentage of interaction with 
apoptotic NØ (figure 64B) and a significant decrease in the mean number of AC NØ 
interacting per gingipain-treated MØ (figure 64C).  
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Figure 64: Gingipain treatment of MØ inhibits interaction of MØ with AC NØ 
THP-1-DS MØ (as described in 2.3.5 section) were treated or untreated with gingipains 
(5µg/ml) for 1h at 37°C (as described in section 2.7.11) prior to co-culture with apoptotic 
NØ for 1h (as described in section 2.6.1). A) Photomicrographs of Jenner-Giemsa stained 
untreated or gingipain-treated THP-1 DS MØ interacting with AC NØ. Untreated THP-1 
MØ showing tethering and phagocytosing of AC NØ (left panel) and gingipain-treated 
(RgpB/Kgp) THP-1 MØ showing interacting with fewer AC NØ (middle and right panel). 
THP-1 MØ can be seen in light blue and AC are stained with intense blue. The arrow 
indicates the AC B cells that are not up taken by MØ. Magnification 40X. B) Histograms 
showing the percentage of MØ with or without gingipain treatment interacting (binding or 
phagocytosing) with AC NØ C) The mean number of AC NØ interacting per MØ with or 
without gingipain treatment. Data shown are mean ± SEM of three independent 
experiments. Statistical analysis was conducted using ANOVA followed by Dunnett’s post-
test: ***P<0.001 compared to untreated. The Photomicrographs are representative of 
three independent experiments. 
  
5.9 Discussion  
A wide range of receptors associated with phagocytes, AC, and soluble bridging 
molecules are involved in recognition and engulfment of AC 570. Before phagocyte 
recognition of an AC takes place, the AC undergoes several morphological changes 
resulting in the release of factors and alterations to the dying cell surface which ultimately 
lead to receptor-mediated recognition 609. The released signals enhance phagocyte 
migration, and subsequent recognition of, interaction with and engulfment of the dying 
cells. In addition, AC- derived vesicles have also been reported to recruit phagocytes and 
promote anti-inflammatory cytokines 37, 614, 615. 
Untreated  RgpB Kgp 
A 
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‘Find me’ signals secreted in the form of soluble factors such as nucleotides ATP and UTP 
can promote recruitment of microglial cells 616. Also, the lipid LPC secreted from dying 
MCF7 breast cancer cells attracts THP-1 monocytes suggesting that ‘find me’ signals act 
also to promote MØ recruitment 258. If phagocytes and dying cells are in close proximity, 
the need for ‘find me’ signals may be reduced when compared to phagocytes that are 
some significant distance from the dying cell. It may also be that different ‘find me’ signals 
act over different distances.  Sphingosine 1-phosphate (S1P), a sphingolipid metabolite is 
proposed to be another ‘find me’ signal, acting via sphingosine 1-phosphate receptors 
(S1PRs), recruiting lymphocytes through various receptors 617. The chemotaxis of immune 
cells is reported to be regulated by S1PR1 via phosphoinositide (PI) 3-kinase- and Rac 
enzymes. Additionally, S1PR4 induces NØ chemotaxis towards FMLP from the blood to 
tissue 618. 
Once phagocytes are recruited to dying cells, ‘eat me’ signals come into play. The most 
studied ‘eat me’ signal is PS, found in the outer leaflet of the plasma membrane of an AC, 
it has been shown to bind soluble proteins such as GAS6, protein S and MFGE8 in order 
to facilitate AC uptake by phagocytes 46, 47, 332, 619. Additionally, annexin I released from 
dying cells binds to PS marking them as apoptotic 620.  The ‘Tether and tickle’ mechanism 
proposed by Hoffman et al. is an important complex relationship as several ligands 
expressed by AC bind to appropriate phagocyte receptors for direct recognition and to 
stimulate uptake 280.  Specific antibodies used to block the exposed PS result in the 
decreased AC uptake, suggesting a key role for PS in the engulfment process 47. 
Conversely, treatment of healthy viable NØ with gingipain R were reported to enhance the 
uptake by MØ  in a non-dependent PS exposure 188. However, it is unclear whether PS-R 
present on the phagocytes recognised PS as a naked molecule which is on its own or in 
combination with other soluble proteins 621. However, Park et al. identified that BAI1 
expressed on the phagocytes can stereo-specifically bind to PS on AC suggesting that 
BAI1 act as a PS-R molecule to facilitate clearance 276.  
Inhibitory signals are also necessary to prevent clearance of viable cells.  CD31 
expressed by both viable and AC, functions to enable phagocytes to discriminate a viable 
target cell from a dying cell. The engulfing phagocyte also expresses CD31 receptors 
which bind CD31 on the target cell to tether to the surface. Viable cells initially tether and 
switch to a repulsive mode whereas dying cells tether and fail to repulse, instead switch 
on the adhesive mode until engulfed by the phagocytes 338.  
Once recognised, AC are taken via engulfment in two ways: (1) phagocytes engulf whole 
AC, if the encountered AC size is similar to phagocyte (e.g. professional phagocytes 
engulf AC NØ or apoptotic thymocytes as intact whole cells) 235, 236;  (2) If the target AC 
varies is large relative to the phagocytes, then engulfment occurs in ‘’bite-size’’ fragments. 
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In inflamed adipose tissue multiple phagocytes, have been reported to ingest smaller 
fragments of single apoptotic adipocytes 609, 622. In situation 2, the dismantling of AC into 
apoptotic bodies enables this to happen.   
To explore potential therapeutic approaches to the treatment of chronic inflammatory 
diseases, such as periodontitis, it is necessary to understand how AC clearance is 
affected by pathogens and disease.  The work in this chapter studied how P. gingivalis 
derivatives –gingipains interfere with AC clearance.   
5.9.1 Gingipain modulation of CD14 on MØ  
CD14 is a receptor for multiple ligands including endotoxin, PAMPs and also identified as 
an AC clearance receptor. It is involved in stimulating both pro-inflammatory responses to 
PAMPs and anti-inflammatory responses to AC through phagocytosis and 
immunosuppressive process 142, 329, 418, 440, 623. Expressed in myeloid cells, CD14 is well 
documented for its role in monocytes, MØ, and NØ 324, 418. However, recently a CD14 role 
on non-myeloid cells was reported in a range of cells (HELA, MCF-7, H400, B-2B, HPF, 
and Calu-3) which were studied for their ability to rapidly bind dying cells mediating 
clearance 36. This work also suggests a primary role for CD14 in regulating airway 
inflammation e.g. inhibition of AC clearance by airway cells in smokers causing respiratory 
infections 624.  
In light of the established CD14 receptor role in AC clearance, from our laboratory 36, 418, 
469 and elsewhere 281, 326, 625, here, CD14 function was studied in AC clearance and the 
influence of gingipains was assessed. A panel of cell clearance receptors was studied 
here and of those studied (CD14, ICAM-3, CD36, and CD91), CD14 was the only 
molecule cleaved by gingipains. This was cleaved rapidly from THP-1 VD3 MØ by Kgp 
(1h) and more slowly by Rgp (12h) (figure 47) without inducing apoptosis (figure 42 and 
43). This is in agreement with previous studies which report that CD14 cleavage is 
apparent from gingipain-treated mouse peritoneal MØ 626;  human monocytes 627 and from 
gingival fibroblasts 628. However, gingipains have been shown to induce apoptosis in 
human gingival epithelial cells by activating mitochondria, FAS, TNFR and IL-R apoptosis 
signals suggesting that gingipain affects both intrinsic and extrinsic pathways in gingival 
epithelial cells 187. Apoptosis by gingipain was also observed in endothelial cells and 
lymphocytes 629, 630. Yet, the work presented here show that the gingipain does not induce 
apoptosis in MØ and NØ. 
CD14 cleavage on THP-1 VD3 MØ was rapid on treatment with Kgp compared to Rgp 
(figure 47). This could be due to the presence of hemagglutinin/adhesion domains in Kgp 
that are lacking in RgpB. The hemagglutinin/adhesion domains have been reported to 
bind to the phospholipids and activating factor X in the blood coagulation system to 
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stimulate thrombin, an activating factor which has been associated with periodontitis 
infection by binding with haemoglobin and haem present in the host 164, 183. This suggests 
that the hemagglutinin/adhesion domains might be responsible for binding to the immune 
cells and thereby aiding bacterial attachment to immune cells to promote CD14 cleavage.  
The gingipain-mediated reduction in CD14 on MØ, without inducing apoptosis, 
demonstrates the potential inflammatory nature of these proteases carried by the bacteria 
at the infected gingival sites. Whilst the data here suggest that gingipains cleave CD14 
(figure 47) it is also possible that gingipains might simply have cleaved the epitope of the 
mAb that recognises CD14 leaving CD14 still on the surface of MØ. Potential future work 
may address this by staining gingipain-treated MØ with a range of CD14 antibodies that 
bind elsewhere on the CD14 molecule, and if the CD14 reduction was still observed, the 
chances are that gingipains actually cleaved CD14. Additionally, detection of released i.e. 
soluble CD14 by ELISA analysis might further confirm the cleavage of CD14 by 
gingipains. Increased levels of sCD14 are observed in the sera of periodontitis patients 
compared with the healthy controls, it seems likely that the reduction in CD14 is due to 
cleavage and that this is relevant to disease in patients 631. 
Additionally, a previous study showed on human monocytes stained with the anti-CD14 
mAb, MY4, that following exposure to gingipains MY4 binding was reduced and CD14 
fragments were detected in the culture medium by western blot analysis. This resulted in 
downregulation of LPS-induced TNF-α production 627. Furthermore, CD14 cleavage is also 
detected in human gingival fibroblasts, a dominant cell type in periodontal connective 
tissue, on exposure to arginine-specific cysteine proteinases. This led to LPS 
hyporesponsiveness (i.e. decreased IL-8 production) 628. Reduced IL-8 production has 
been linked with inhibitory NØ phagocytosis function 432, 632. Additionally, increased CD14 
levels were reported in the serum and saliva of P.gingivalis induced adult periodontitis 
patients suggesting that gingipains might contribute to the cleavage of CD14 631, 633. Whilst 
these results might suggest cleavage of CD14 would be anti-inflammatory, this doesn’t 
consider the consequence of reduced CD14 on AC clearance as studied here and the 
impact this has on generating inflammation seen in periodontal disease. 
The concentration of gingipains within the GCF in chronic periodontitis patients has been 
determined to be ≤1.5 μM and the concentration of gingipains used in this study was 
5µg/ml which is therefore highly efficient in cleaving the CD14 on MØ and NØ 634. An 
earlier study reported that using the same method used here to isolate gingipains in 
addition to anion-exchange chromatography 5mg of gingipain was isolated from 1 litre 
HG66 bacterial culture. The difference of concentration might be due to alteration in 
growth of the bacteria or the purification steps used here might be the reason for the 
variation in gingipain concentration. 
Results 
166 
 
However, within in vivo conditions, P.gingivalis secretes gingipains both as a membrane-
bound and soluble form and as vesicles from bacterial outer membranes. It is therefore 
conceivable that higher concentrations of gingipains are released, from bacteria residing 
at the gingival sites or in the periodontal pocket to the circulating or recruited phagocytic 
cells leading to a local reduction of CD14 expression on MØ 426, 526, 635-637. Soluble 
gingipains from HG66 or W83 supernatants have been used previously for studying CD14 
levels on phagocytes 626, 627. This raises the question whether cell membrane-bound 
gingipains interact with CD14 on monocytes/MØ but this remains unclear. However, 
vesicles from the outer membrane of P.gingivalis promote shedding of CD14 from the 
surface of human U937 MØ-like cells 638 implying that membrane-associated cysteine 
proteases might participate to evade the host immune system.  
Various gingipain inhibitors have been proposed to inhibit, to various degrees, all three 
gingipains 202. Here, TLCK, a cysteine protease active inhibitor was used to help confirm 
the gingipain role in CD14 cleavage. As mentioned earlier, TLCK is reported to inhibit both 
Rgp and Kgp proteases activity 426. The data presented here (figure 49B) shows that 
TLCK blocked the loss of CD14 after treatment with Kgp, indicating that the isolated 
proteases were gingipains and that they were responsible for the CD14 cleavage seen. 
TLCK also inhibits thrombin in the blood coagulation defence system reported being 
associated with bone resorption by osteoclasts through a prostaglandin-dependent 
pathway this could be one of the reasons for alveolar bone resorption at periodontal sites 
544, 639. Other inhibitors such as FPR-cmk and Z-FK-cmk specific for Rgp and Kgp 
respectively have shown to inhibit IL-8 production in human monocytic THP-1 cells treated 
with gingipains. This suggests that gingipains were the causative agent for the production 
of pro-inflammatory cytokines and their dependency on stimulating the enzyme activities 
on initiating destruction within periodontal region 202, 640.  
5.9.2 CD14 on NØ  
Having mentioned the importance of CD14 on monocytes/MØ in the inflammatory 
response, the ability of gingipain to cleave CD14 on primary NØ was also assessed. AC 
NØ have been used as a model for their participation in AC clearance in chronic 
inflammatory disease such as periodontitis 190, 357, rheumatoid arthritis 641, 642, 
cardiovascular disease 643, 644 and other systemic diseases 645, 646. Before viable NØ 
become apoptotic, the efficiency of NØ to assist in clearance of microbial components will 
decide the nature of the inflammatory response. The action of gingipains to modulate NØ 
receptor levels as seen in MØ may impact pathogen or AC clearance in the infected 
tissue. The data presented here shows that both forms of gingipains (Rgp and Kgp) 
cleave CD14 on viable NØ in 1h of treatment (figure 48) without inducing apoptosis (figure 
44). This is in agreement with a previous study showing that gingipains do not induce a 
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high level of apoptosis on NØ at 1h treatment 188. However, RgpB treated primary NØ 
showed viability only 60% (figure 44) which is correlated with the presence of NETs seen 
in figure 45. This might be a reason for the presence of NET’s found in crevicular 
exudates of periodontitis patients indicating that NET’s might be flushed out from the 
periodontal pocket to the GCF 374. 
It is interesting to note that the cleavage of CD14 observed with RgpB-treated NØ is much 
more rapid (1h) (figure 48A) compared to that in THP-1 MØ where RgpB cleaved after 
12h (figure 47C). Though intermediate time points for Rgp treated THP-1 MØ were not 
analysed to detail the exact time point of cleavage, however, it is clear that Rgp fails to 
cleave CD14 on MØ in 1h treatment (figure 47A). This may be explained as data here 
shows that NØ express CD14 (figure 48) though to a lesser degree than MØ (figure 47). 
Previous studies agree that the GPI-anchored CD14 receptor is expressed on primary NØ 
501, 647. Haziot et al. further demonstrate the presence of CD14 on NØ by digesting with PI-
PLC, an enzyme that specifically cleaves the GPI anchor, suggesting that NØ express 
membrane-bound CD14 647. Moreover, the same work demonstrates active participation of 
CD14 in releasing TNF-α upon interaction with LPS-LBP complexes indicating the direct 
participation of CD14 NØ in the acute inflammatory response. CD14 has been studied as 
a marker for inflammation on NØ for pulmonary infection in asthmatic children 
demonstrating reduced CD14 levels suggesting a poor response to bacterial components, 
such as LPS 648. Inflammatory stimuli such as LPS and FMLP have been shown to 
increase the level of CD14 on the plasma membrane of NØ with an argument being made 
that the newly expressed CD14 is released from intracellular stores of the receptor 649. 
Additionally, the same study showed that CD14 is expressed in vesicles secreted by the 
NØ and also in the azurophilic granules. 
Again, the loss of CD14 from NØ might suggest that immune responses will be reduced 
following bacterial challenge.  However, the impact of CD14 loss on the total immune 
response has not been considered i.e. the net effect of blocking responses to bacteria and 
reduced AC clearance. 
5.9.3 Possible receptor modulation in periodontal disease 
While CD14 levels are reduced on gingipain-treated THP-1 VD3 MØ here (figure 47), 
other studies have reported that TLR4 and TLR2 (co-receptors for CD14) are unaltered by 
gingipains on murine MØ 146, 500, 626, 650-652. Additionally, CHO reporter cells expressing 
CD14 and TLR2 respond to gingipain-deficient P.gingivalis through NF-kB activation 
indicating that gingipains have no effect on TLR2 signaling pathways 653. Gingipains’ 
ability to cleave other GPI-anchored proteins, such as CD40, CD59, and CD157, suggests 
that CD14 is not the only GPI- anchored molecule cleaved by gingipains. However, 
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Sugawara et al. show that gingipains reduced CD59 by only 40% compared to a CD14 
reduction of 80% on the surface of human gingival fibroblasts indicating CD14 as an 
efficient substrate for gingipains 627, 628.  
The study here suggests that neither gingipain (RgpB or Kgp) cleave the AC clearance 
receptors CD36, ICAM-3, or CD91 from the surface of THP-1 MØ nor on primary NØ 
(figure 50 and 51) perhaps suggesting that the cleavage by gingipains doesn’t affect all 
cell surface molecules. It remains possible that these other molecules are cleaved but that 
the mAB epitope remains unaffected. However, MØ and primary NØ exhibit very low 
levels of CD91 and primary NØ show low CD36 expression (figure 50B and 51B). Both 
cells (MØ and NØ) do however display significant ICAM-3 expression on their surface 
(figure 50B and 51B) and this remains unaffected by gingipain treatment. Interestingly, 
ICAM-3 shows high expression on both the phagocytes (MØ and NØ) confirming its role 
as a marker of leukocytes and this may suggest that this molecule could be important in 
facilitating AC clearance. Though the level of antigen does not necessarily correlate with 
its participation in AC clearance, earlier research shows that leukocytes undergoing 
apoptosis release ICAM-3 within their microparticles to promote recruitment of MØ and 
tethering to MØ 37. In both phagocytic cells (i.e. MØ and NØ) CD91 expression appeared 
weak and this might be a limitation of using THP-1 as a model for CD91, as primary 
human monocytes and their derived dendritic cells have been reported to express 
considerable amount of CD91 654-656. However, work by Shaw et al. reported that freshly 
isolated NØ do not express CD91 but on turning apoptotic carry ecto- calreticulin to 
induce phagocytosis in a CD91- dependent mechanism on MØ 657, 658. THP-1 
differentiated MØ and HMDM cells were reported to express increased amount of CD36 
on their surface and use CD36 as a mediator to phagocytose apoptotic NØ 288, 659, 660. 
Further work could seek to assess the effect of gingipains on a broader range of AC 
clearance receptors and this could be perhaps addressed on a range of different cells 
including, for example, gingival fibroblasts that express CD14. 
To avoid uptake and ingestion by MØ, viable cells express anti-phagocytic signals such as 
CD31, CD47 in order to differentiate them from the AC 338, 582. The data here show that 
both MØ and NØ express CD31 on viable cells (figures 52 and 54) and reduced CD31 
was found on apoptotic NØ (figure 54E). This is in agreement with previous study 
explaining that NØ  apoptosis disables CD31 switching off the repulsive mode which is 
active on viable NØ 338. The same study explained that phagocytes, expressing CD31, 
use the disarmed CD31 signals on their target AC to tether and engulf dying cells. 
However, on exposure to Kgp, MØ CD31 was reduced compared to untreated cells at 16h 
(figure 52B) suggesting that gingipains may reduce CD31 which is otherwise essential to 
recognise AC. This would reduce the removal of dying cells. Additionally, both Rgp and 
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Kgp reduce CD31 on viable NØ at 16h (figure 54E). Possibilities that gingipain might have 
cleaved CD31 to a greater extent due to their weaker expression of CD31.This is in 
agreement with the previous study that demonstrated that RgpB cleaves CD31 on the NØ 
surface 188.   
Spontaneous AC NØ and gingipain treatment both reduce CD31 NØ (figure 54E) which 
might promote the clearance by MØ. However, it is not clear whether gingipain cleaved 
CD31 or spontaneous apoptosis developed on NØ at 16h is responsible for CD31 
cleavage. Earlier work shows NØ shed CD32 and CD16 receptors on turning apoptotic 661. 
Although CD31 is cleaved by gingipains, future experiments are needed to analyse 
whether the viable cells with cleaved CD31 are engulfed by the phagocytes and this would 
further address the bacterial clearance inhibition and promoted inflammation. 
Whilst CD31 is cleaved by gingipains, CD47 expression was unaltered on the surface of 
the MØ and NØ by either of the gingipains over short time frames (figure 53 and 55). 
However, reduced CD47 expression was reported earlier in AC NØ but not other AC types 
such as apoptotic Jurkat T cells or apoptotic murine thymocytes 275, 581.  
5.9.4 Gingipain-mediated alterations in MØ response in the migration to AC  
The very first activity of phagocytes on sensing the pathogens is migration. Impaired NØ 
chemotaxis is well documented in chronic periodontitis patients 662-668. Abnormal NØ 
chemotaxis was first recorded in the 1980s in localised juvenile periodontitis due to 
decreased chemotactic peptides such as C5a and FMLP found on the surface of NØ 669. 
This might be one of the reasons why, despite the presence of numerous NØ numbers in 
the periodontal sites, elimination of pathogens or dead cells is ineffective 667, 670.  
Gingipain modulation of IL-8, a potent NØ chemoattractant, has been shown to result in 
impaired NØ recruitment 193.  The same study further explained the cleavage of 5- and 11-
amino acids peptides by Rgp and 8-amino acids peptides by Kgp from the N-terminal 
portion of IL-8 resulted in a three-fold increase in priming and chemotactic abilities of IL-8 
affecting directly NØ chemotaxis and thereby causing local tissue degradation. This has 
been proposed as one possible mechanism involved in P.gingivalis pathogenesis 193.  
While these studies report mainly on defective NØ chemotaxis, here defective MØ 
chemotaxis was studied based on their migrational abilities following exposure to 
gingipain proteases. Based on the effect of the rapid cleavage of CD14 on Kgp-treated 
MØ compared to RgpB (figure 47), Kgp was chosen initially to study MØ chemotaxis 
assay using horizontal chemotaxis. The plots in figure 56 and 58 show that migrational 
activities of gingipain (Kgp)-treated MØ towards AC (either AC B cells or AC NØ) appear 
similar to untreated MØ (figure 56A and 58A). However, if the directional migration was 
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assessed quantitatively the yFMI measure shows a significant decrease on pre-treated 
MØ moving towards AC B cells (P<0.01) (figure 56B) or AC NØ (P<0.05) (figure 56B) 
compared to untreated MØ. Additionally, angle measures depict significant differences 
(P< 0.01) between Kgp-treated MØ compared to untreated cells moving towards AC B 
cells indicating less uniformity of movement by Kgp-treated MØ (figure 57D).  
Though no significant difference was observed in various other measures of MØ migration 
to AC NØ (e.g. accumulated distance, Euclidean distance, velocity, and angle - figure 59), 
a significant variation was observed in the yFMI of Kgp-treated MØ compared to untreated 
MØ (figure 58B). This is in correlation with a previous study demonstrating defective 
directional accuracy on NØ migration, using another horizontal chemotaxis system: the 
Insall chamber, from PD patients 662. Moreover, the same study also observed a 
significant difference in the velocity of NØ from PD patients’ displaying lower migration 
speed compared to healthy NØ migration towards CXCL8 and fMLP. It is unclear why the 
velocity showed no significant difference in gingipain-treated and untreated MØ using 
Dunn chamber. Taken together, the yFMI is considered as a true chemotaxis effect of all 
the measurements as explained in section as the 3.5.1.2 as the yFMI takes into account 
only these cells moving towards the putative chemoattractant while other measurements 
account all the cells in spite of their direction travelled. 
For the effective MØ migration determination, gingipain-induced MØ were assessed for 
their migration abilities over a longer time frame using a vertical chemotaxis transwell 
system. This enabled counting over time to provide additional measures of migration.  
This system does not include a true gradient but it is a higher throughput assay which 
enables 24 well plates to be used. Initial experiments were observed for 4h using AC B or 
AS B as a positive control which has been used previously37. The data in figure 60 shows 
that no significant difference was observed in gingipain (either RgpB or Kgp)-treated MØ 
compared to untreated MØ migrating towards AC or AS B cells. Though RgpB showed 
CD14 cleavage at later time points (figure 47) no effect in MØ chemotaxis was observed. 
This is interesting as in the Dunn chamber model, Kgp-treated MØ were inhibits yFMI, but 
not the distance travelled nor the speed of the MØ towards AC B. One of the limitations of 
using the Cell-IQ model is that other measurements cannot be extracted as the system is 
designed to count only cells on the transwell or bottom of a 24-well plate. It is possible that 
the movement of cells is sufficient for them to move through the transwell and, once 
through the transwell, they cannot ever move back up, so directionality is more difficult to 
measure in the vertical assay. 
Conversely, a significant difference was seen in RgpB or Kgp-treated MØ migration 
towards AC NØ but not AS NØ compared to untreated MØ at 4h and extended later time 
points (figure 61 and 62). Additionally, Kgp-treated MØ performed better at the end of 12h 
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compared to RgpB-treated MØ migration towards AC NØ (figure 61). This indicates that 
CD14 might be not the only molecule involved in the defective migration as Kgp caused 
rapid CD14 cleavage compared to RgpB (figure 47) suggesting that other molecules might 
have undergone modulation for this migrational effect on MØ towards AC NØ. 
Additionally, increased levels of NØ elastase are correlated with increased gingipain 
secretion from P.gingivalis 184. NØ elastase has been reported to participate in inhibiting 
the clearance of apoptotic lymphocytes by cleaving CD14 370. Hence the gingipains and 
the NØ elastase together may increase the inhibitory effects and drive inflammation in 
periodontitis patients. However, future experiments are required to directly assess any 
role for CD14 in migration by using anti-CD14.  
NØ have been reported to use CD31 for directional migration through homotypic 
interaction with CD31-expressing human umbilical vein endothelial cells by guiding them 
for transmigration into the tissues 671. Perhaps not surprisingly, the same study observed 
that using anti-CD31 blocking antibodies impaired directional migration of NØ towards the 
chemoattractant. Alternatively, complement factors C5a and proteins molecules CXCL8, 
integrin β1 were shown to regulate directional migration of the phagocytes. However, 
gingipains have been described to modulate C5a, CXCL8 and integrin β1 expression on 
the immune cells 179, 194, 567. C5a enhances directional migration by acting as a 
chemoattractant protein for mouse MØ (J774A) and alveolar MØ 672, 673. On the other 
hand, IL-8 mediated NØ chemotaxis into the tissues through both phosphatidylinositol 3-
kinase (PI3K)-γ- pathways, which has shown to be dysregulated by gingipain proteases 
674. Loss of integrin beta 1 signalling was observed on gingipain-treated endothelial cells 
and this degradation of integrin β1 has been associated with upregulation of Bcl-2 
expression in CHO cells preventing the cells from undergoing apoptosis 567, 675. Due to 
their adhesion functions, integrins mediate cell motility and aid in the directional migration 
of cells that have the flexibility to use either integrin-dependent and independent pathways 
and due to this mechanisms integrins have been proposed as a therapeutic strategy in the 
treatment of tumour invasion and metastasis mediated disease 676. Similar approaches 
may be of use in the treatment of chronic inflammatory disease where cell recruitment is 
driving disease. 
Aside from the above receptors, cytoskeletal actin filaments have been linked to MØ 
directional migration where actin proteins concentrate themselves at the edge of the MØ 
guiding them through filopodia - long parallel bundles form movements and lamellipodia -
the branching filamentous networks like shape promoting flattening form of chemotaxis on 
MØ 506, 677. Gingipains-mediated degradation of actin filaments, observed in oral epithelial 
cells, suggests gingipains ability to reorganise the cytoskeleton by degrading the 
directional proteins 678, 679.  Formation of actin filaments signals through a series of 
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molecules and receptors, such as guanosine triphosphate (GTP)-binding proteins 
(GTPases) and Cdc42, to activate Wiskott-Aldrich syndrome protein (WASP) to aid in the 
regulation of MØ by promoting directional migration towards various chemoattractants 680, 
681. Additionally, PI3K and Protein Kinase B were also involved in directional sensing of 
phagocytes moving towards AC by regulating numerous phosphatidylinositol molecules 
506, 682. PI3K activation mediates cell directional migration through WASP and Cdc42 
molecules so inactivation of phosphatidylinositol 3-Kinase/Akt signalling, which has been 
observed in gingipain-induced gingival epithelial cells, might downregulate WASP and 
Cdc42 activation thereby affecting phagocyte chemotaxis 683, 684.  
5.9.5 Gingipain-mediated alterations in MØ response in the clearance of AC 
GPI- anchored CD14 (mCD14) has been widely researched for the uptake of AC however 
the involvement of the shed, soluble form of CD14 in the AC clearance process is unclear. 
Rey et al. showed that sCD14 binds to surface molecules of activated T cells isolated from 
PBMC and regulates negatively the activation and function of T lymphocytes by producing 
IL-2, IL-4, and IFN- suggesting that sCD14 might control the level of host inflammatory 
response by interacting with other negative regulators 685. Also, a previous study showed 
that sCD14 binds to AC however, it is unknown whether sCD14 participates in promoting 
the clearance of AC 418, 686. Studies have found that treatment of human MØ with the 
CD14-specific monoclonal antibody 61D3 blocked the uptake of lipid-symmetric 
erythrocytes through PS-dependent mechanisms to inhibit the uptake the apoptotic 
lymphocytes indicating that CD14 might serve as a ligand for the anionic phospholipid 
phosphatidylserine on AC 687. In contrast, Devitt et al. proposed CD14 as an unlikely 
receptor for PS on the AC by demonstrating PS-expressing liposomes showed no 
preferential blocking of apoptotic NØ clearance 418. Additionally, CD14 blocked by mAbs in 
human MØ or by genetic knockout in mice MØ, showed impaired binding (tethering) of 
apoptotic lymphocytes suggesting CD14 as a non-redundant tethering receptor for AC 282. 
This correlates with the data presented here shown in figure 63 and 64 that gingipain-
treated MØ reveal an inability to bind to AC B or AC NØ and this is likely due to the 
reduction of CD14 receptors shown on Kgp-treated MØ at the 1h time point (figure 47). 
Subsequently, a previous study reported that gingipains cleave CD14 from gingival 
fibroblasts implying that gingipains might impair clearance of AC by CD14 expressing 
human fibroblast, as seen here in MØ (figure 63 and 64) 628. However, RgpB-treated MØ 
also displayed defective interaction with AC B or AC NØ even when cleavage of CD14 
was observed only at 16h (figure 47). These data suggest that CD14 can be made non-
functional by gingipains long before it is removed from the cell surface or that other 
molecules that can be cleaved rapidly by gingipains, might be involved in the apoptotic 
clearance. Future work could seek to identify these other cleaved receptors. 
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Additionally, P.gingivalis gingipains can modify immune responses in other ways.  They 
regulate the subversion of complement system through degradation of C3 components 
which are essential for mediating phagocytosis using effector molecules 520. Furthermore, 
all three gingipains have been shown to digest and activate C1q component 520. C1q 
components are demonstrated to be abnormal in patients suffering from lupus and failure 
of C1q to bind to AC resulted in impaired phagocytosis by monocytes 688, 689. Gingipains 
have also been reported to cleave C5a complement component which is involved in the 
recruitment and activation of inflammatory cells by inactivating C5a interaction with the 
anaphylatoxin receptor (C5aR) to form complex with TLR2 214. TLR2 on NØ has been 
shown to recognise P.gingivalis and regulates MYD88 ubiquitylation and degradation 
thereby inhibiting antimicrobial secretion by activated NØ 690, 691. Taken together, the 
above studies suggests that gingipains attack the phagocytosis process by degrading the 
complement factors essential to recognise and mediate the clearance mechanism. 
5.10 Conclusion  
Uptake of apoptotic NØ within acute inflammatory responses establishes a most important 
protection against inflammation188, 692. If apoptotic NØ cells are not removed in an 
appropriate and timely manner, exacerbation of inflammation occurs as a result of cell 
necrosis. Taken together the data presented here reveal that gingipains may impact 
inflammation by interfering with the clearance of AC and that this may be mediated by at 
least two methods: 1. Inhibition of phagocyte migration towards AC, and 2. Inhibition of 
removal of AC at the level of tethering and engulfment. The net effect of these two points 
of inhibition would result in delayed AC removal that would be responsible for cell necrosis 
and associated prolonged inflammation. This work, therefore, raises the possibility that 
inhibition of gingipain activity may be a useful strategy for preventing or interrupting the 
chronic inflammation seen in periodontitis. 
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Chapter 6 
Result 4: Regulation of pro and anti-inflammatory cytokines in RgpB and 
Kgp induced THP-1 MØ  
6.1 Introduction 
To protect the host from surgical trauma, sudden injury or from invading foreign organisms 
the host triggers an immune response in the form of release of mediators necessary for 
defence from the noxious agents 33. The nature of the inflammatory mediators released 
during the “war” between the phagocytic cells and microorganism are self-limiting, to 
ensure there is no significant damage caused to the host 336. However, the released 
mediators, e.g. due to failed clearance of NØ in the later stages of an inflammatory 
response, can cause severe damage to local tissue due to the unintentional release of 
their destructive contents. Timely removal of AC therefore has to be controlled tightly 5, 693. 
MØ, the main producer of endogenous modulators on exposure to inflammatory stimuli, 
produce protein mediators such as cytokines, which decide the nature of the downstream 
response 694. Usually the removal of AC generates an anti-inflammatory response. 
Phagocytosis of AC NØ is known increase production of anti-inflammatory mediators such 
as TGF-β and PGE2 329. However if the uptake or ingestion of AC is delayed, pro-
inflammatory mediators dominate 264, 460, 575, 695. It is currently not clear whether, depending 
on the receptors that mediate the AC clearance, the level and type of the inflammatory 
mediators varies. However, Fadok et al. demonstrated that PS-mediated uptake of AC 
was similar to VnR and CD36 receptor-mediated recognition of AC which inhibit pro-
inflammatory cytokine production. Additionally, β-glucan treated MØ, which utilised FcR or 
CR3 for the uptake of AC, also inhibited GM-CSF, IL-8, IL-10 and TNF-α expression and 
increased TGF-β production 329, 696, 697.  
The inflammatory cytokines elicited from microorganism infected immune cells have been 
widely studied and used as a model for destructive tissue damage and defective 
resolution of inflammation 193, 327, 329, 698. Here, the oral microbiota serves as an excellent 
model system to study the inflammatory response provoked by bacteria residing in tissues 
surrounding the tooth during periodontitis. Therefore, the aim of this chapter was to 
study gingipain-induced pro–inflammatory (TNF-α) and anti-inflammatory (TGF-β 
and IL-10) cytokine levels during protease-treated MØ phagocytosis of AC NØ. 
6.2 LPS-induced TNF- α production 
TNF-α is the most commonly used marker of the pro-inflammatory response and is 
produced by monocytes or MØ treated with stimuli, such as LPS 310, 699. However, 
clearance of AC has been shown to inhibit pro-inflammatory signals and trigger an anti-
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inflammatory response, increasing levels of cytokines such as TGF-β via 
autocrine/paracrine mechanisms 329, 697. Conversely, following LPS stimulation, the 
phagocytosis process has been studied widely for the immunosuppressive effects by AC, 
turning off the inflammation induced by LPS stimuli on MØ 440.  
Preliminary assays were established to assess the dose of E.coli LPS (Ec LPS) (positive 
control) required to generate TNF-α production in MØ. To determine the immune 
suppressive effect of AC B or AS B cells, preliminary experiments were conducted to 
establish an Ec LPS-induced inflammatory response in the THP-1 derived MØ model. 
VD3 differentiated THP-1 MØ were co-cultured with AC B or AS B cells for 18h. This was 
followed by Ec LPS stimulation for 4h. The TNF-α production was measured using ELISA 
analysis and results are presented in figure 65. 
 
 
 
 
 
 
 
 
 
 
Figure 65: AC B or AS B cells fail to inhibit E.coli LPS -induced TNF-α production by 
MØ   
A) Titration of Ec LPS-induced TNF-α response of THP-1- derived VD3 MØ. B) VD3 
differentiated MØ were either co-cultured with AC B or AS B cells (as described in section 
2.5) for 18h at 37ºC or were untreated and stimulated with or without LPS (4ng/ml) from 
Ec for 4h at 37ºC to induce TNF-α production (as described in section 2.8.1.1 and 
2.8.1.2). TNF- α release was quantified using ELISA (as described in section 2.8.3). Data 
shown are mean ± SEM of three independent experiments. Statistical analysis was 
conducted using ANOVA followed by a Bonferroni post-test. **P< 0.01 not significant (ns) 
compared with untreated cultures. 
 
The data in figure 65A shows that MØ respond to Ec LPS at a range of doses by 
producing TNF-α. Following titration, 4ng/ml Ec LPS was chosen to induce TNF-α 
production for future experiments as this dose showed a significant response for TNF-α 
while below 4ng/ml less response for TNF-α can be seen (figure 65A). Figure 65B shows 
that AC B or AS B cells fail to inhibit TNF-α production induced by 4ng/ml Ec LPS. No 
significant differences were observed in MØ stimulated with LPS in the presence or 
absence of AC B or AS B. However a significant difference (P< 0.01) was observed in the 
LPS stimulated TNF-α response in MØ compared with basal level (no LPS) MØ 
A B 
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demonstrating the ability of the THP-1 model to respond by induction of inflammatory 
cytokine production. This data is in contrast to previous work which has shown that in the 
presence of AC B cells the LPS-induced inflammation was reduced compared with MØ 
that were stimulated with LPS alone 36. 
The immune suppressive effects of primary AC NØ or AS NØ were also studied in Ec 
LPS-induced inflammatory response in the THP-1 derived MØ model. The results are 
shown in figure 66. 
 
Figure 66: AC NØ or AS NØ cells fail to inhibit E.coli LPS -induced TNF-α 
production by MØ   
VD3 differentiated MØ were either co-cultured with AC NØ or AS NØ (as described in 
section 2.5) cells for 18h at 37ºC or were untreated and stimulated with or without LPS 
(4ng/ml) from Ec for 4h at 37ºC to induce TNF-α production (as described in section 
2.8.1.1 and 2.8.1.2). TNF-α release was quantified using ELISA (as described in section 
2.8.1.3). Data shown are mean ± SEM of three independent experiments. Statistical 
analysis was conducted using ANOVA followed by a Bonferroni post-test. **P< 0.01 or not 
significant (ns) compared with untreated. 
 
The data in figure 66 shows similar effects to that observed for AC B or AS B cell 
treatments. A significant difference (P< 0.01) was observed on LPS elicited TNF-α 
responses on MØ compared with untreated MØ indicating successful induction of TNF-α 
by LPS. However, again AC NØ or AS NØ failed to inhibit the inflammation induced by Ec 
LPS. Additionally, phagocytosis of AC NØ or AS NØ did not elicit significant TNF-α 
production compared with untreated MØ alone indicating that the phagocytosis response 
is generally an anti-inflammatory process, findings in agreement with 329. 
The P. gingivalis LPS (Pg LPS)-induced signalling pathways remain unclear as conflicting 
evidence indicates that cell activation occurs through either TLR2 and/or TLR4 120, 147, 150, 
327, 700. Notably however, Ec LPS responses are predominately mediated through TLR4 146, 
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701, 702. The LPS isolated from Pg used in this study was ultra-pure and obtained from 
InvivoGen and is reported as a TLR4 agonist 703-705. 
Due to potential differences in the signalling pathways, two models of MØ were initially 
tested to determine the most appropriate model to elicit a robust TNF-α response in THP-
1 derived MØ cells. The models studied were: i) THP-1 VD3 differentiated MØ; and ii) 
THP-1 DS MØ. The results of these analyses are shown in figure 67. 
 
Figure 67: TNF-α response in an LPS (P.gingivalis) induced THP-1 derived MØ 
model  
THP-1 cells were washed and suspended in cRPMI and seeded in 24 well plates (1x106). 
Cells were induced with stimulants either VD3 or DS for 48h (as described in section 
2.3.5). Following this, Pg LPS (1µg/ml) were induced at a range of concentrations for 4h at 
37°C and the supernatants were collected and stored at -20°C until TNF-α response were 
quantified using ELISA (as described in section 2.8.1). Data shown are mean ± SEM of 
three independent experiments with each experiment. Statistical analysis was conducted 
using ANOVA followed by a Bonferroni post-test. ***P< 0.001 or not significant (ns) 
compared with no (0) LPS. 
 
VD3 stimulated MØ showed undetectable TNF-α response to Pg LPS stimulation (no 
significant difference compared with untreated MØ) for 4h (figure 67). However, DS MØ 
exhibited more robust responses to Pg LPS from 1µg/ml by producing increased TNF- α 
(P< 0.001) compared with untreated DS MØ (figure 67). Hence 1µg/ml of Pg LPS was 
chosen as an appropriate dose for use in further studies. Notably Thomas et al. showed 
detectable levels of TLR4 were expressed in DS stimulated THP-1 MØ compared with 
THP-1 VD3 derived MØ indicating that Pg LPS response could be mediated through TLR4 
in this model 706. 
Having observed that DS MØ expressed an enhanced response to Pg LPS (figure 67) the 
presence of AC (either B cells or primary NØ) in suppressing the pro-inflammatory 
cytokine response was assessed. The results of these studies are shown in figure 68. 
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Figure 68: AC inhibit Pg LPS-induced TNF-α production  
THP-1-derived DS MØ (VD3/PMA) were co-cultured with AC (B or NØ) or their derived AS 
(as described in section 2.5) for 18h prior to the addition of Pg LPS (1µg/ml). After 4h 
stimulation, TNF-α production was assessed using ELISA. Data shown were mean ± SEM 
of three independent experiments. Statistical analysis was conducted using ANOVA 
followed by a Bonferroni post-test. ***P< 0.001 or not significant (ns) compared with 
untreated cultures. 
 
ELISA data (figure 68) confirmed a significant difference (P< 0.001) in TNF-α production 
detected between Pg LPS-induced MØ compared with untreated MØ. Additionally, the 
presence of AC (AC B or AS B or AC NØ or AS NØ) significantly (P< 0.001) inhibited the 
inflammatory response induced by Pg LPS in MØ cultures. These data are in contrast to 
Ec LPS (figure 65 and 66) exposure where neither of the AC (B cells or NØ) inhibited the 
inflammatory response induced by Ec LPS (figures 65 and 66). Additionally, these results 
indicate that the phagocytosis of AC does not trigger further TNF-α release. Both the AS 
as well as the AC of both NØ and B cells reduced the inflammatory response equally. 
Previously AS from phagocytic cells have been shown to exhibit anti-inflammatory 
properties 614, 615. These data therefore suggest that Pg LPS-induced inflammation can be 
switched off by AC or their released factors (AS). 
6.3 Gingipain induced TNF-α production  
A possible mechanism used by pathogens to evade the host defence system is to 
dysregulate the cytokine networks 214. Gingipains are known to degrade cytokines such as 
membrane-bound and the soluble form of TNF-α 521, 626. This process can contribute to 
deleterious effects such as bone resorption by activating osteoclasts and recruiting NØ 
causing inflamed periodontal tissues and apoptosis in gingival fibroblast 707, 708. Increased 
levels of TNF-α have been reported at the sites of gingival inflammation indicating that this 
cytokine might be an indicator for periodontal disease. Notably all forms of gingipains 
(HRGP, RgpB, and Kgp) have been demonstrated to cleave TNF-α 522.  
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Whilst attempting to address the effect of gingipain treatment on MØ during inflammatory 
responses, significant unexpected TNF-α production was noted from MØ that were 
otherwise untreated. Initial experiments of gingipain treatment were performed in the two 
MØ model systems (similar to the LPS-induced TNF-α response shown in figure 67) to 
assess the ability of gingipains to elicit pro-inflammatory cytokine responses. The two 
models used were i) THP-1 VD3 differentiated MØ; and ii) THP-1 DS MØ. The 
differentiated MØ (VD3 or DS MØ) were incubated with either of the two gingipains (RgpB 
and Kgp) and assessed for TNF-α production. Results are shown in figure 69. 
 
 
 
 
 
 
 
 
Figure 69: TNF-α release from gingipain-treated MØ   
THP-1 derived MØ (VD3-differentiated THP-1 or DS-differentiated THP-1-Yellow) were 
treated with the gingipains (5µg/ml) (RgpB-Green and Kgp-Pink) for 1h at 37°C in a 
serum-free medium (as described in section 2.7.11) immediately prior to ELISA to 
measure TNF-α production (as described in section 2.8.1). Data shown are mean ± SEM 
from three independent experiments. Statistical analysis was conducted using ANOVA 
followed by a Bonferroni post-test. ***P< 0.001 or not significant (ns) compared with 
untreated samples. 
 
Both models (VD3 and DS MØ) produced increased TNF-α inflammation upon stimulation 
with gingipains following a 1h incubation at 37°C. 
The data in figure 69 show that RgpB induces greater TNF-α release compared with Kgp 
treatment, in both MØ models. RgpB treated VD3 or DS MØ triggered higher TNF-α 
production (P< 0.01) compared with untreated MØ (controls in both model systems). 
However, no significant differences were observed between Kgp-treated and untreated 
MØ. This outcome could be due to the CD14 cleavage observed in Kgp-treated MØ which 
occurred within 1h of treatment at 37°C compared with RgpB which showed cleavage only 
at 16h (figure 47, chapter 3). Notably the results presented in figure 69 correlate with a 
previous study demonstrating that arginine gingipains were efficient in producing higher 
TNF-α compared with Kgp gingipains 521.   
Having observed that both models of MØ released TNF-α in response to RgpB, the highly 
adherent DS MØ were used further to study the ability of AC (both B cells and NØ) to 
inhibit this inflammatory response. Since P.gingivalis LPS only induced a response to DS 
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MØ (figure 67) the same model was used to study gingipain inflammation to enable 
comparison. This is the first time that the impact of AC on gingipain-induced inflammation 
has been assessed.  
THP-1 DS MØ were incubated with both types of AC (B cells or NØ) for 18h at 37°C. 
Following incubation, MØ were stimulated with gingipains (either RgpB or Kgp) at 37°C for 
1h and the supernatants were collected and assayed for TNF-α measurement using 
ELISA.  The results are shown in figure 70 and 71. 
 
Figure 70: AC B or AS B cells fails to inhibit gingipain-induced TNF-α production  
DS THP-1 MØ (VD3/PMA) were co-cultured with AC B or AS B (as described in section 
2.5) for 18h prior to treatment with gingipain from P. gingivalis to induce TNF-α. Produced 
TNF-α levels were assessed using ELISA analysis. Data shown were mean ± SEM of 
three independent experiments. Statistical analysis was conducted using ANOVA followed 
by a Bonferroni post-test. ***P< 0.001 or not significant (ns) compared with untreated 
samples. 
 
The results presented in figures 70 and 71 suggest that both AC types (B cells or NØ) fail 
to inhibit the inflammation induced by RgpB in MØ alone. Data presented in figure 69 
indicate that Kgp failed to induce significant TNF-α levels. Together, these data (figure 70 
and 71) indicate that the clearance of AC in the absence of gingipains can be anti-
inflammatory in nature, however, the addition of RgpB alone induced inflammation in MØ 
and they are resistant to the effects of AC. Moreover, Pg LPS-induced inflammation is 
abrogated by AC (both B cells and NØ) and their derived AS (figure 68) whilst gingipain-
induced inflammation is not. These data suggest that gingipains are significant pro-
inflammatory modulators which may be key to driving chronic PD pathogenesis.  
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Figure 71: AC NØ or AS NØ cells failed to inhibit gingipain-induced TNF-α 
production  
DS THP-1 MØ (VD3/PMA) were co-cultured with AC NØ or AS NØ (as described 
insection 2.5) for 18h prior to treatment with gingipain (5µg/ml) (as described in section 
2.7.11) from P.gingivalis to induce TNF-α production. TNF-α levels were assessed using 
ELISA analysis (as described in section 2.8.1). Data shown were mean ± SEM of three 
independent experiments. Statistical analysis was conducted using ANOVA followed by a 
Bonferroni post-test. **P< 0.01 or not significant (ns) compared with untreated samples. 
 
6.4 Inhibition of gene expression of TGF-β and IL-10 anti-inflammatory 
cytokines on gingipain-treated MØ  
Clearance of AC is an immunologically silent process which activates anti-inflammatory 
cytokines via autocrine/paracrine mechanisms resulting in reduced pro-inflammatory 
mediators 440, 709. Notably engulfment of AC promotes the release anti-inflammatory 
mediators such as TGF-β 279, IL-10 710 as well as other cytokines 329. AC themselves have 
also been reported to secrete IL-10 711 and TGF-β 712 prior to them encountering MØ. 
Additionally, the AC use these secreted mediators to promote the activated MØ to engulf 
them 713, 714. 
Having shown that RgpB gingipain increased the release of TNF-α from MØ with no 
apparent inhibitory effects of AC, (figures 70 and 71), the response of anti-inflammatory 
cytokines TGF-β and IL-10 was assessed at the mRNA level in MØ co-cultured with 
apoptotic NØ analysed using RT-PCR. VD3 stimulated THP-1 MØ were either co-cultured 
with apoptotic NØ or cultured alone for 6h at 37°C prior to incubation with gingipains 
(either RgpB or Kgp) for 1h at 37°C. Subsequently, supernatants were collected at 
2000Xg for 10 minutes and the cell pellet was stored at -80°C until RNA isolation was 
performed. 
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6.4.1 Quality assessment of isolated RNA 
Pelleted cells were treated using the E.Z.N.A total RNA kit I to isolate RNA (as described 
in the section 2.9.3). Table 9 shows quantified RNA from MØ or co-culture of MØ with AC 
NØ using the NanoDrop spectrophotometer. A 260/280 ratio was obtained to determine 
the RNA quality and to estimate the quantity isolated. Samples showing a 260/280 ratio of 
above 2 were further processed for PCR analysis. The 260/280 ratio was the primary 
measure for the purity of the nucleic acid and the 260/230 as the secondary measure. 
Subsequently, cDNA synthesis was performed using 100ng of RNA. 
Samples A260/A280 A260/A230 Concentration, ng/µl 
MØ 2.18 1.88 217.8 
MØ- RgpB 2.24 1.69 165.9 
MØ-Kgp 2.14 2.06 338.8 
MØ + AC NØ 2.17 1.84 336.7 
MØ –RgpB + AC NØ 2.21 0.95 112.1 
MØ –Kgp + AC NØ 2.20 1.71 172.4 
 
Table 9: Quantification of RNA for PCR analysis using the NanoDrop 2000c  
RNA was isolated using the E.Z.N.A total RNA kit from VD3 stimulated THP-1 MØ or MØ 
co-culture of with AC NØ. Isolated RNA was quantified using the NanoDrop 
spectrophotometer. 1µl of the RNA sample was added to the cleaned NanoDrop sample 
contact apparatus. The 260/280 ratio was determined to assess the purity of RNA. 
Samples showing 260/280 ratio of above 2 were further processed for PCR. 100ng of 
RNA was used to perform the downstream PCR analysis. Data shown are representative 
of three independent experiments. Data shown are mean of ± SEM of three independent 
experiments. 
 
Having shown the purity of RNA samples using the NanoDrop, agarose gel 
electrophoresis was implemented as a secondary measure to assess the quality of the 
RNA. RNA integrity of the ribosomal RNA was evaluated in cells including gingipain-
treated MØ and with the co-cultured AC NØ. To check for any signs of degradation of the 
total RNA, 1% denaturing agarose gel were stained with ethidium bromide (as described 
in section 2.9.4.2). RNA samples were treated according to the manufacturer’s 
instructions. Samples were viewed under a UVP transilluminator at the end of the 
electrophoresis period.  Results are presented in figure 72. 
Intact total RNA was assumed when the rRNA bands were viewed clearly as in figure 72, 
as distinct 28S and 18S rRNA bands in all the RNA samples. The results presented in 
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figure 72 also indicate that gingipain treatment of cells did not result in degradation of the 
integrity of the RNA in the samples.  
 
 
 
 
 
 
Figure 72: Quality assessment of isolated RNA using agarose gel electrophoresis  
RNA was isolated from the VD3 stimulated THP-1 MØ or from MØ co-cultured with AC 
NØ (as described in section 2.5.1.2) and incubated for 6h at 37°C followed by gingipain 
treatment for 1h at 37°C. The isolation of RNA was carried out according to E.Z.N.A total 
RNA kit I (as described in section 2.9.3). Isolated RNA samples were mixed with 2X 
sample buffer and incubated for 5 mins at 95°C. Samples were incubated on ice for 1-
minute prior to loading in 1% agarose gels (as described in section 2.9.4.2). Gels were 
electrophoresed for 30 minutes at 60 Volts, 120 Watts at 250 mA and viewed using a UVP 
transilluminator. Data shown are representative of three independent experiments. 
 
6.4.2 Relative mRNA expression level of TGF-β and IL-10 
To assess the level of anti-inflammatory cytokine gene expression at a transcriptional 
level, purified RNA samples were reverse transcribed to cDNA and the resulting 
synthesized cDNA were then amplified using specific primers for TGF-β or IL-10 using 
Syber Green as a fluorescent nucleic acid stain to enable detection of amplified DNA. The 
housekeeping gene assay used for comparison was β-actin. The amplified DNA 
represents threshold cycle (Ct) values in the amplification curve obtained from the MxPro-
Mx3000P SYBR Green software. The obtained fluorescence Ct values were standardised 
by setting the baselines and thresholds at the same level to remove background noise 
from the analysis.  
Using a comparative ∆Ct method, (as described in section 2.9.6.3) co-cultured untreated 
MØ with AC NØ were compared with gingipain-treated (either RgpB or Kgp) co-cultured 
cells. Results are shown in figure 73. 
The data presented in figure 73 show that interaction phagocytosis of AC NØ by MØ 
provokes increased TGF-β expression (P<0.001) compared with MØ on their own 
indicating that AC promote anti-inflammatory cytokine expression. These data are in 
agreement with previous findings 329. The results in figure 73 also suggest that a threefold 
reduction in TGF-β mRNA expression (P<0.001) occurred in gingipain (either RgpB or 
Kgp) treated-MØ co-cultured with AC NØ compared with untreated co-cultured cells.  
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Figure 73: Relative gene expression of TGF-β in gingipain-treated MØ using PCR 
analysis  
VD3 stimulated THP-1 MØ or MØ co-cultured with AC NØ (as described in section 
2.5.1.2) incubated for 6h at 37°C followed by gingipain (5µg/ml) treatment for 1h at 37°C. 
RNA was isolated according to E.Z.N.A total RNA kit I (as described in section 2.9.3). 
Isolated RNA was transcribed to cDNA using the primer design RT-nanoscript. The 
synthesised cDNA was amplified using specific primers for TGF-β (10µM) with human β-
actin (100µM) used as an internal control (as described in section 2.9.5 and 2.9.6). The 
histogram shows the mRNA expression of TGF-β in fold change for untreated MØ alone 
and MØ either treated with gingipain (5µg/ml) or untreated and co-cultured with AC NØ for 
18h (as described in section 2.7.11). Data shown are mean ± SEM of three independent 
experiments. Statistical analysis was conducted using ANOVA followed by a Bonferroni 
post-test. ***P<0.001 compared to untreated. 
 
IL-10, another anti-inflammatory cytokine-triggered by AC clearance by MØ also 
participates in enabling tissue homeostasis 715. In vivo studies performed in IL-10-deficient 
mice show that IL-10 regulates the suppression of pro-inflammatory mediators by 
restricting the inflammatory responses generated by the host defence system 716.  The 
level of the IL-10 anti-inflammatory cytokine was also assessed at a transcriptional level 
using the purified RNA samples. These were reverse transcribed to cDNA and the 
resulting synthesized cDNA then amplified using specific primers for IL-10. The results are 
shown in figure 74. 
The data in figure 74 show that AC NØ, in addition to TGF-β, were also able to induce IL-
10 expression (P<0.001) in MØ compared with MØ alone. The results also show that 
gingipains (both RgpB and Kgp) prevent the induction of IL-10 mRNA similar to that 
observed for TGF- β in the treated MØ (figure 73). Both gingipains exhibited less than a 
five-fold change in IL-10 expression (P<0.001) compared with untreated MØ with AC NØ 
exerting a 20 fold-change. 
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Figure 74: Relative gene expression of IL-10 in gingipain-treated MØ using PCR 
analysis  
VD3 stimulated THP-1 MØ or MØ co-cultured with AC NØ (as described in section 
2.5.1.2) incubated for 6h at 37°C followed by gingipain (5µg/ml) treatment for 1h at 37°C. 
RNA was isolated according to E.Z.N.A total RNA kit I (as described in section 2.9.3). 
Isolated RNA was transcribed to cDNA using primer design RT-nanoscript. The 
synthesised cDNA was amplified using specific primers for IL-10 (10µM) with human β-
actin (100µM) used as an internal control (as described in section 2.9.5 and 2.9.6). The 
histogram shows the mRNA expression of IL-10 in fold change for untreated MØ alone 
and MØ either treated with gingipain (5µg/ml) or untreated and then co-cultured with AC 
NØ for 18h (as described in section 2.7.11).  Data shown are mean ± SEM of three 
independent experiments. Statistical analysis was conducted using ANOVA followed by a 
Bonferroni post-test. ***P<0.001 compared to untreated samples. 
6.5 Discussion 
The classically activated MØ, i.e. M1 phenotype MØ, have been reported to be associated 
with several systemic diseases compared to M2-anti-inflammatory MØ phenotype 41, 717-
723. The role of MØ phenotypes at the mRNA level was investigated in the mouse gingival 
tissues for their participation in PD and studies found that excess generation of M1 
markers (nitric oxide synthase, TNF-α, IL-1β, IL-6 and C-reactive protein) were 
upregulated while M2 markers (CD206 and IL-10) were downregulated 406, 724, 725. 
Activation of monocytes/MØ in the periodontitis rat model was found to elevate TNF-α 
receptors in MØ, thereby triggering the initial pathogenesis of atherosclerosis causing 
aortic inflammatory responses 406.  Here, the work aimed to dissect whether gingipains 
inhbit the production of pro- and anti-inflamamtory cytokines at the protein and mRNA 
levels. 
6.5.1 TNF-α production by LPS and gingipains from P.gingivalis 
Ingestion of AC by MØ has been reported previously to result in decreased TNF-α and IL-
8 at the transcription level indicating that removal of AC inhibits pro-inflammatory 
mediators 674. This correlates with the findings presented here (figure 68) which show that 
AC prevent the inflammation by suppressing TNF-α protein production.  
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To discuss in detail, firstly, the model used for Ec LPS was VD3 differentiated MØ (figure 
65) which have been shown earlier in this study to express higher CD14 levels (figure 19) 
and reported elsewhere to express very low TLR4 levels and detectable TLR2 levels 445, 
706. Additionally, the model used here for Pg LPS studies was DS MØ as LPS from Pg did 
not induce responses in VD3 MØ (figure 67). DS MØ showed clear expression of CD14 
(figure 19) and a detectable level of TLR4 706. The similarity between these MØ models is 
that both models show increased CD14 expression (figure 19) compared to THP-1 cells, 
though DS MØ show stronger expression of detectable levels of TLR4 while VD3 MØ 
revealed marked TLR2 receptors 445, 706. Whilst studies have shown that TLR4-deficient 
mice are hyporesponsivene to Ec LPS, TNF-α production has also been shown to be 
regulated through TLR-2 receptors in MØ treated with Ec LPS suggesting that TLR2 might 
also be a signalling component for Ec LPS endotoxins 146, 726.  
Sadeghi et al. showed, using RT-PCR analysis, the VD3 upon differentiating THP-1 
monocytes diminish the TLR4 and TLR2 levels whilst CD14 remained unaltered 446. This 
raises the possibility that Pg LPS might require either TLR4 or TLR2 presence to stimulate 
the pro-inflammatory TNF-α production in MØ. This might be a reason for Pg LPS 
inducing responses in DS MØ (which have been reported to express TLR4) but not VD3 
MØ. Additionally, a recent study explained that of all the THP-1 differentiated models, 
PMA-differentiated MØ and DS-MØ, expressed higher TNF-α responses and this might be 
a consequence of PMA-induced differentiation 36. Taken together, the above studies 
suggest that CD14 and TLR’s regulate LPS-associated responses and that cellular 
differences in receptor expression may explain the different ability of Pg and Ec LPS to 
induce inflammatory responses 500, 700. 
Previously published research investigated two different isoforms of Pg LPS, based on 
their lipid A mass ions, Pg LPS1435/1449 and Pg LPS1690 and characterised the TNF-α 
protein levels in the serum of mice stimulated with Pg LPS (1435/1449 and 1690) showing 
variability in the TNF-α response 727. Additionally, the same study found that Ec LPS 
induced higher TNF-α levels compared to these two Pg isoforms suggesting that Ec LPS 
is more potent compared to Pg LPS. This strength of response could be one reason why 
AC were able to turn off the inflammation induced by Pg LPS but remained resistant to Ec 
LPS (figure 65, 66, 68). Both human monocytes and gingival fibroblasts are reported to 
express both TLR2 and TLR4 and Pg LPS acts both as an agonist and antagonist in both 
these cells for the secretion of inflammatory cytokines 728, 729. Subsequently, another study 
found that Pg LPS and Ec LPS regulate differentially the production of IL-6 by human 
gingival fibroblast which expresses both TLR2 and TLR4 suggesting that, depending on 
the presence of TLR, the LPS from Pg or Ec controls the production of inflammatory 
mediators in the gingival tissues 700.  
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In LPS, the lipid A core is a highly conserved amphipathic molecule linked to a hydrophilic 
phosphorylated D-glucosamine disaccharide by hydrophobic fatty acid chains (C12-C14). 
It is the biologically potent component of LPS. It is also responsible for LPS’ non-specific 
interaction with host cells via fusion with the phospholipid membrane which has been 
considered as a possible mechanism of action in activating immune cells 730-732. Pg lipid A 
contains fatty acids composed of 16–17 carbon atoms however, the absence of an ester-
linked phosphate group at the 4’ position and fatty acids at positions 3 and 3’ and 
differences in the core sugar composition marks them as a unique structure compared to 
Ec lipid A structure (figure 75) 733, 734. For this reason, low endotoxic activity is reported for 
Pg LPS compared to Ec LPS in human monocytes 138, 735. This is consistent with the study 
shown here (figure 65 and 67) revealing maximal TNF-α production from MØ stimulated 
with only 4ng/ml for Ec LPS but at 1µg/ml for Pg LPS.  
 
 
 
 
 
 
 
 
 
Figure 75: Structure of Pg LPS and Ec LPS 
The diagram depicts the major components of, LPS. Pg LPS is composed of three main 
subunits, O-antigen, core oligosaccharides that attaches to lipid A through sugars, which 
has been varied in the Pg LPS compared to Ec LPS. Followed by sugars, Lipid A 
components in Pg LPS varies in fatty acids at 3 position along with absence of phosphate 
group at 4 position compared to Ec LPS. While Ec LPS displays all the major components 
without missing sugars, fatty acids and phosphate groups. Adapted from 733 
 
The amino-terminal region of CD14 on MØ provides several different locations for Ec LPS 
binding sites 736. In human CD14, three leucine-rich domains are reported to be 
responsible for Ec LPS binding and activation of host cells 737. Additionally, highly 
hydrophilic regions of four CD14 proteins in addition to region 3 and 4 of CD14 were 
reported to participate in Ec LPS binding which was characterised by mAb epitope 
mapping using multiple alanine replacement mutations 738-740. Notably, region 1 of CD14 
was described to be involved in Ec LPS signaling 737.  
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Studies have revealed the binding sites of Pg LPS in CD14 differs from Ec LPS CD14 
binding sites 736. Pg LPS fails to elicit E-selectin expression on non-myeloid cells such as 
human endothelial cells due to reduced or no expression of CD14. However, Ec LPS 
facilitates E-selectin expression both on myeloid and non-myeloid cells 741. This is 
explained by CD14-dependent pathways theory that CD14 uses electrostatic interactions 
to capture different microbial ligands using their charged residues (hydrophilic region) on 
their surface. Also, to support the explanation that Pg LPS and Ec LPS binds to different 
regions of CD14 a series of CD14 proteins were analysed 736. The outcome of the studies 
identified that residues E11K of CD14 partially reduced and D59K of CD14 completely 
inhibited the Pg LPS binding compared to wildtype CD14 confirming Pg LPS have 
moderate affinity towards E11 residues of CD14. However no difference in Ec LPS 
binding to both E11 and D59 were observed compared to wildtype CD14 suggesting that 
Ec LPS have higher affinity towards both residues 736.  
Subsequently, studies using anti-CD14 mAbs on MØ showed prevention of AC binding to 
CD14 324, 418. Earlier, the same mAbs MEM-18 was shown to inhibit LPS recognition of 
CD14 739. Taken together, Devitt et al. proposed that the binding sites for LPS and AC on 
CD14 were either identical or close 324. Later, Thomas et al. investigated the binding of 
apoptotic lymphocytes to HeLa cells expressing CD14 mutants 36. These studies also 
revealed glutamic acid residue 11 (E11) as an apoptotic recognition site on CD14. Earlier 
studies suggested that E11 may bind Pg LPS but perhaps not Ec LPS 736. 
Together, the above theory supports the data presented here, that AC NØ were able to 
prevent the inflammation induced by Pg LPS (figure 68) but not from Ec LPS (figure 65 
and 66). This may be the result of competition for CD14 as both Pg LPS and AC might 
have similar CD14 binding patterns. However, Ec LPS may have a different binding site 
on CD14 and so may be unaffected. 
The results presented here in figure 69 suggests that low TNF-α was found in Kgp- 
compared to RgpB-induced MØ cells. This might be due to the cleaved CD14 
demonstrated in VD3 MØ (figure 47) within 1h by Kgp and later time points (16h) by RgpB 
at 37°C (figure 47) perhaps suggesting a requirement for CD14 in regulating TNF-α 
production. Additionally, Pg LPS induced TNF-α inflammation only in the DS MØ (figure 
67) while RgpB induced TNF-α both on VD3 and DS MØ (figure 69) suggesting that 
gingipain-induced inflammation is not as a result of LPS contamination.  
The possible CD14 cleavage sites for Rgp and Kgp are reported to be 21 Arg-X and 9 
LYS-X bonds respectively and for TLR4 29 Arg and 35 Lys amino acid sequence 627, 628, 
742, 743. Moreover, deletion of amino acids 9-12 and 35-39 both singly, or in combination, 
within the N-terminal 65 amino acid region of CD14 have been demonstrated to eliminate 
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the binding of the mAb MY4 which blocks LPS binding and therefore has been used as an 
indicator of the LPS binding site 627, 744. Followed by this, Sugawara et al. proposed that 
gingipains might cleave CD14, eliminating MY4 binding and hence resulting in reduced 
LPS-induced TNF-α response. 
Interestingly, AC NØ, which were able to turn off the TNF-α inflammation induced by LPS 
from Pg (figure 68), failed to prevent the inflammation induced from gingipains both RgpB 
and Kgp (figure 70 & 71). Though the same MØ model (DS differentiated MØ) was used 
to induce TNF-α responses by LPS or gingipains, the difference in inhibiting the 
inflammation, by AC NØ or their derived AS, suggests that gingipains may be the most 
potent mediators of inflammation and that this may be resistant to usual mechanisms of 
control (e.g. by AC). This also suggests that gingipains may be more significant in causing 
or driving PD than LPS. It is also important to note that, despite RgpB treatment of DS MØ 
being only 1h and Pg LPS treatment was for 4h, the level of released TNF-α response 
induced by the Pg LPS (figure 67) and RgpB (figure 69) was similar, again supporting the 
idea that RgpB may be an extremely potent driver of inflammation in periodontal disease.  
6.5.2 Role of anti-inflammatory cytokines in PD 
Enhanced anti-inflammatory and immunosuppressive cytokines are reported to be 
produced from monocytes cultured with AC and following LPS stimulation, AC reduce pro-
inflammatory responses 440. Interaction of MØ with apoptotic NØ for 1h increased by 40% 
the release of TGF-β1 cytokine and when left for 18h this increased to three times the 
expression of TGF-β compared to control 329. These correlate with the results shown in 
figure 73, where MØ fed with AC NØ produced increased TGF-β1 mRNA compared to 
untreated MØ indicating that AC may stimulate the expression of anti-inflammatory 
cytokines. Additionally, MØ treated with gingipains, either Rgp or Kgp, did not increase 
TGF-β mRNA in response to AC NØ (figure 73).  This reduced TGF-β mRNA level 
correlates with the reduced AC clearance seen following gingipain treatment. Together, 
these suggest that TGF-β induction is linked closely to AC binding and uptake. Future 
work could seek to address that gingipains might have destabilised TGF-β mRNA in the 
phagocytes.  
Additionally, upregulated TGF-β expression was found in Pg LPS- induced human gingival 
fibroblasts compared to Pg LPS-induced periodontal ligament suggesting that gingival 
fibroblasts might be the likely source 745. Consequently, it was reported that greater 
production of TGF-β stimulates the release of IL-6 from T helper cells and together these 
cytokines produce massive amounts of IL-17 which have been associated with alveolar 
bone loss in chronic periodontitis patients 597, 746. Moreover, Pg has been reported to 
regulate human aortic smooth muscle cells through activation of TGF-β and stimulating 
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the human aortic smooth muscle cells to bind to LDL thereby causing cardiovascular 
disease 747.  
Similar to TGF-β, mRNA for IL-10, another significant anti-inflammatory cytokine, was 
downregulated in the gingipain-stimulated MØ phagocytosing AC NØ (figure 74). This 
correlates with previous findings that reduced IL-10 is found in periodontal lesions 
compared to healthy gingival tissues 748. In contrast, IL-10 levels were found to be 
significantly higher in gingivitis patients compared to those who progressed to periodontitis 
749. This suggests that in initial stages of inflammation IL-10 may be induced. However, on 
progressing to advanced PD the bacterial factors such as gingipains may modulate IL-10 
expression leading to reduced effects. Together, reduction in the mRNA levels of TGF-β 
and IL-10 indicates that gingipain might have affected the transcription of the phagocytes 
inhibiting mRNA stability thereby affecting the production of these cytokines. 
Studies addressing cytokine levels in PD have demonstrated that no difference in IL-10 is 
observed in human gingival fibroblasts or periodontal ligament cells treated with LPS 
(P.gingivalis) compared to untreated cells 745. This suggests that LPS is a weaker 
stimulant compared to the gingipains (both RgpB and Kgp) which reduced IL-10 mRNA 
expression in MØ (figure 74). In vivo studies using IL-10 knockout mice reveal severe 
bone loss suggesting that IL-10 could be an important mediator of alveolar bone 
homeostasis 750-754. Moreover, IL-10 has been proposed as a potential therapeutic 
strategy for bone resorption to improve osteoporosis by dental implantation in osteoporotic 
periodontitis patients 754.  
The uptake and ingestion of the AC NØ by MØ are important, as they may be sufficient to 
induce protective anti-inflammatory responses. However, the data presented here (figure 
73) suggests that impaired clearance might lead to reduced TGF-β expression. Previous 
study stated that in in vivo CD14-/- mice showed reduced AC clearance but no evidence 
of inflammation suggesting that the AC even when not eaten are enough to induce anti-
inflammatory cytokine production 418.  Additionally, a knock out study demonstrated that 
dendritic cells derived from the bone marrow of IL-10 deficient mice on stimulation with 
LPS inhibited ingestion of AC suggesting that the presence of IL-10 is essential to mediate 
efficient phagocytosis 755. 
Taken together, these data suggest gingipains inhibit both TGF- β and IL-10 gene 
expression at the mRNA level (figure 73 and 74) and increase, in the case of RgpB, pro-
inflammatory cytokines (TNF-α) as shown in this chapter (figure 67) suggesting that 
gingipains evade the host immune system by inhibiting the production of anti-inflammatory 
mediators. This could be a possible underlying mechanism contributing to the 
pathogenesis of chronic periodontal disease.  
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6.5.3 Other cytokine levels in periodontal diseases 
While this work has focused on TNF-α, TGF- β and IL-10, alterations in other cytokines 
may also affect PD. Studies show that IL-1β, a primary pro-inflammatory cytokine was 
found to be elevated in the GCF of periodontitis patients compared to healthy controls 756. 
Human gingival epithelial cells challenged with live Pg induced increased IL-1β 757.  
Additionally, the same work investigated gingipain–deficient Pg mutant bacteria (lacking 
both Arg and Lys) and revealed that they were unable to induce IL-1β, IL-6 and IL-8 
degradation Lys-gingipain–deficient Pg (Kgp-) mutants completely lacked the ability 
compared to Arg-gingipain-deficient (Rgp-) Pg mutant. These data indicate that Kgp is a 
potent inflammatory activator in Pg compared to Rgp. However, the study presented here 
show that RgpB as a potent inducer of TNF-α inflammation compared to Kgp suggesting 
that modulation in cytokines level might have varied depending on the stimulants. 
Previous work has shown that IFN-γ and GM-CSF are activators of MØ in response to 
bacterial infections, playing an important regulatory role in mediating innate and adaptive 
immunity 758. Fitzpatrick et al. investigated the cDNA array of human MØ exposed to 
gingipains and found increased levels of IFN-γ and GM-CSF in addition to IL-1β cytokines 
429. The activation of phosphorylated p38α MAPK has been linked to increased TNF-α and 
IL-8 on human MØ stimulated with gingipains, resulting in modulation of chemokines 563, 
759. Other components of Pg, such as fimbriae, have been shown to participate in 
contributing to IL-1β, IL-6, and TNF-α production in murine peritoneal MØ, and have been 
shown to be responsible for forming resorption pits on the dentine slices 760.  
6.6 Conclusion  
Overall, the work in this chapter suggests that MØ fed AC NØ have suppressed 
production of pro-inflammatory cytokines (TNF-α) in response to LPS from Pg.  This may 
be mediated by the AC-induced anti-inflammatory cytokines (TGF-β and IL-10), which are 
increased at the mRNA levels. However, on gingipain treatment, the cytokine levels were 
altered. The role of cleaved CD14 has been suggested for LPS hypo responsiveness 
shown in Kgp-mediated MØ while, RgpB-treated MØ showed hyper responsiveness to 
produce TNF-α suggesting that CD14 might be a mediator responsible for TNF-α 
production. Additionally, AC NØ are able to prevent the inflammation induced by Pg LPS 
but not from gingipains. This needs further analyses to elucidate the factors released by 
AC, by determining the presence of other immune modifying factors (e.g. presence of lipid 
mediators produced by MØ fed AC) and their level of contribution in inhibiting gingipain-
mediated or LPS-mediated inflammation. 
Taken together, the above findings may suggest that, along with gingipains other 
components of Pg bacteria might also promote aberrant inflammation in PD and thereby 
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contributing to the inflamed gingival crevice. Importantly, the work in this chapter suggests 
that RgpB appears to be a strong driver of inflammation (TNF-α). Perhaps providing Rgp 
inhibitors locally might help to break the significant pro-inflammatory responses such that 
the normal anti-inflammatory mechanisms associated with normal AC clearance might 
function to resolve the inflammation. 
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Chapter 7 
7 Discussion 
Following tissue injury and activation of the inflammatory cascade, there is a rapid effort to 
resolve inflammation by eradicating the pathogens, infected cells and the resultant AC by 
professional phagocytes. This is undertaken through a rapidly changing pro-inflammatory 
to anti-inflammatory response which promotes normal healing 608. Thus the inflammatory 
response is a vital protective mechanism that regulates complex defence factors in the 
host, allowing them to gain access to infected or damaged sites and finally to restore 
tissue homeostasis. It is a collective response of white blood cells, cytokines, chemokines 
and other soluble factors to establish a healed and repaired milieu.  
A central event in this is the apoptotic death of inflammatory cells. Clearance of dying and 
dead cells is regarded as a nonphlogistic phenomenon associated with the 
immunomodulatory and anti-inflammatory process and this promotes the turning off of 
pro-inflammatory responses 35, 329. Indeed the importance of this process can be seen 
when it fails.  Deficient or failed clearance of AC by MØ leads to necrosis and this is 
connected with pro-inflammatory consequences resulting in auto-immune disease 43, 286. A 
series of PRRs recognise both PAMPs and AC, identified by innate immune receptor 
ligation studies 282 and knockout mice work 284, 285, 761 demonstrating that inefficient 
clearance of AC promote secondary necrosis contributing to the progression of chronic 
inflammatory diseases in the host system. One such inflammatory disease is periodontitis. 
Though initiated by oral pathogens, aberrant inflammatory responses occur in susceptible 
individuals and this is the key to the progression to PD 8. Thus PD provides an interesting 
model in which it is possible to try to understand the complex relationships between host-
pathogen interaction, inflammation, and resolution of inflammation, as studied here. It also 
serves as a model to understand systemic diseases initiated by the inflammatory 
mediators.  
P.gingivalis is a major microorganism strongly associated with chronic PD and it promotes 
advanced periodontal lesions by proliferating to a high cell number within the gingival 
region resulting in bone resorption and ultimately in tooth loss 107. The components of 
P.gingivalis that promote this pathogenesis have been studied recently in regard to 
evasion of the immune system 118, 121, 147, 172 and this research underlines that the 
proteases, gingipains, synthesised by P.gingivalis are responsible for inhibition of the 
immune system and exacerbating the inflammatory response  in the host 94, 202, 526.  
Due to the enormous number of NØ present at the gingival crevice/epithelium, it is clear 
that these cells play a major role in the pathogenic mechanisms in PD by deciding the fate 
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of inflammation (chronic inflammation or resolution). Increased amounts of necrotic NØ 356 
and destructive hydrolytic enzymes indicate that their timely removal is essential to 
chronic periodontitis disease resolution 190. However, this process has never been fully 
studied thus far and hence the work presented here sought to address this knowledge 
gap. It is known that various chemoattractants, such as CXCL12, IL-8, IL-1β, C5a, and 
exogenous signals recruit NØ to the crevicular region leading to an unwanted and 
continued infiltration of cells that subsequently become necrotic 351, 358. Indeed impaired 
NØ chemotaxis 662 or reduced NØ phagocytic activity have also been suggested as a 
cause for tissue destruction at periodontal sites 762. While a number of studies have 
examined NØ function and their chemotaxis ability, there has not been a strong focus on 
MØ clearance of AC NØ in a periodontal inflammation context. As such, this study also 
provides new and additional insights into MØ clearance of AC, including studies on their 
migration and interaction with AC NØ, in addition to the ability of AC NØ to turn off the 
inflammation by stimulating the release of anti-inflammatory mediators in a gingipain-
affected environment. This thesis therefore builds on and contributes to work in the field of 
AC clearance within the PD context.  
7.1 MØ phagocytosis mechanisms in human periodontal disease 
Differentiated tissue MØ are activated in response to an infection and have been 
simplistically viewed as a professional scavenger of pathogens and AC.  However, they 
use a cascade of molecules and biochemical reactions to rapidly eradicate unwanted cells 
and restore homeostasis 35. The appearance of AC and their released apoptotic bodies 
within MØ is a sure indication that MØ are the professional “eaters” 763. While MØ 
clearance of AC is regarded as non-inflammatory 329, the persistence of AC due to 
defective uptake by MØ in vivo can result in the absence of pro-inflammatory 
consequences however this is likely a consequence of a specific clearance defect 282. 
Notably, clearance of necrotic cells is associated with pro-inflammatory and an immune-
stimulatory response 764-766 and failure of AC clearance is widely linked with autoimmunity 
and chronic inflammatory diseases 43, 348, 471, 576, 767. Currently it is not clear as to whether 
periodontitis pathogenesis is associated with autoimmune mechanisms, however, its 
relationship with rheumatoid arthritis suggests that the immunological and pathological 
links are identical in both diseases 768. Inflammatory NØ are regarded as one of the main 
drivers of the destruction seen in the periodontal tissues and a deficiency in AC clearance 
mechanisms has recently been suggested as a major reason for the persistent 
inflammation in PD 190, 191, 356, 662. However, the precise defects in AC clearance remain ill-
defined. 
The THP-1 model used previously within the Devitt Laboratory provides an excellent 
model for studying the clearance of AC cells and AC B cells acted as a positive control in 
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this study with clearance of human AC NØ as a primary target 36, 37, 444. The data 
presented here demonstrated that the differentiated THP-1 MØ migration towards, and 
interaction with, human AC NØ, a novel effect were comparatively lower than to AC B 
cells. This latter limitation has also been previously shown in HMDM 418. Additionally, 
THP-1 differentiated MØ responses to microbial stimuli (i.e. LPS and gingipains) showed 
higher cytokine expression suggesting their ability to generate pro-inflammatory and 
suppress anti-inflammatory responses. Collectively, the data presented indicate that the 
THP-1 MØ model system provides a good model system for studying AC NØ clearance. 
This thesis tested the hypothesis: In the presence of P. gingivalis factors, MØ lose 
their ability to migrate and phagocytose the AC due to the cleavage of AC clearance 
receptors prompting a dominant pro-inflammatory response that may contribute to 
chronic inflammation and tissue destruction in periodontal disease. The data 
presented support the premise that defective AC clearance might be a mechanism 
underpinning the pathophysiology of the periodontal disease. 
Evidence 1 - CD14 is a preferred substrate for gingipains 
Hoffman et al. proposed a ‘’tether and tickle’’ hypothesis to describe the interaction 
between phagocytes and AC suggesting a two-part model whereby the initial binding of 
AC (tether), induced (tickled) a phagocytoic response and anti-inflammatory signalling, 
that was essential for successful clearance of AC. Furthermore, the study explained that 
PS exposure alone is not sufficient for the uptake of AC, with additional receptors on the 
phagocytes (e.g. CD14, CD68, CD36, and αvβ3 integrin) being required for the binding to 
promote the engulfment process 280. In order to study the AC clearance in PD, here, a list 
of AC clearance receptors on the MØ exposed to gingipains was studied.  
Of the gingipains RgpB and Kgp, Kgp elicited rapid cleavage of CD14 on MØ compared 
with RgpB which demonstrated CD14 degradation only at 16h. This might be due to the 
presence of hemagglutinin/adhesion domain in Kgp which is absent in RgpB. Notably, the 
adhesion and binding capacity of the hemagglutinin/adhesion domain for haemoglobin 
and haem, might underpin the ability to lyse the epithelial cell barrier causing bleeding and 
swelling in the gums 164, 183, 544. This adhesion and binding capability of Kgp might also be 
the reason for the rapid action of Kgp targeted against MØ by degrading CD14 compared, 
with RgpB which lacks these domains.  
In addition to CD14, CD31 cleavage has also been noticed on MØ and NØ. Nevertheless, 
CD14 cleavage was rapid compared to CD31 suggesting that CD14 might be a crucial 
substrate for gingipains in driving PD. Though Kgp reduced CD31 on MØ it is not clear 
whether reduction of CD31 in NØ is due to spontaneous apoptosis or to the effect of 
gingipains. However, previous findings suggests that RgpB cleaves CD31 on the cell 
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surface of both viable and AC NØ 188 . It is also important to note that that cleavage of 
these receptors i.e. both CD31 and CD14 were reduced on both the phagocytes i.e. MØ 
and NØ at same time points. Taking into consideration that gingipains cleaved CD14 and 
CD31 on the MØ and NØ their role on promoting migration and engulfment has been 
discussed further.  
Evidence 2 - Impact of gingipains on MØ migration and phagocytosis 
The initial activity after MØ sensing the chemoattractants is to migrate to AC. Based on 
the data obtained in this study suggests that both RgpB and Kgp affects the phagocytes 
directionality resulting in poor recruitment to AC, which is seen in using horizontal 
chemotaxis assays. It is not clear whether CD14 participates in regulating directional 
migration of phagocytes. Though CD14 knock out studies propose that CD14 acts as an 
important tethering receptor to AC, yet to date no study confirmed CD14 role on promoting 
migration 324.  
However, in vivo studies studying immune cells from calves revealed higher expression of 
CD14 on monocytes recruited to lymph nodes at the onset of inflammation suggesting that 
CD14 might be responsible for sensing the inflammatory mediators and thereby enabling 
prompt transmigration activities of monocytes 769. However, it is unclear whether CD14 
increased expression is a consequence of the transmigration. Furthermore, CD31 is 
known to participate in the directional migration of viable NØ via homotypic interaction of 
CD31-CD31 between NØ and endothelial cells. CD31 blocking antibodies are known to 
reduce directional NØ migration but not velocity towards the chemoattractant 671. Studies 
using CD31-deficient mice demonstrated overall normal transmigration activity of NØ 
however, NØ were specifically trapped between the endothelium and basement 
membrane signifying the non-directional movement of CD31 lacking NØ 770, 771 
Following migration, the macrophages tether and uptake the AC. Devitt et al. observed 
that CD14-deficient mouse MØ showed reduced binding and phagocytosis of AC B cells 
and subsequently proposed that CD14 acts as a tethering receptor facilitating the uptake 
of AC 282. Similarly, CD14-dependent phagocytosis of Gram-negative bacteria by human 
monocytes and THP-1 cells, reveals a requirement for CD14 in not only clearing AC but 
also bacterial compounds 772, 773. Data presented here show poor interaction and 
phagocytosis of AC B cells or AC NØ in gingipain-treated MØ (both RgpB and Kgp-
treated) suggesting that cleavage of CD14 inhibits the tethering capacity which, in turn, 
prevents the phagocytosis by MØ. Additionally, CD31, ‘don’t eat me’ signals are also 
proposed as a tethering receptor essential to discriminate a viable from an AC, switching 
from a repulsive mode (on viable cells) to an adhesion mode (on AC) 338. Kgp cleaved 
CD31 on MØ at 16h suggesting that gingipain dysregulates CD31 signals by inhibiting 
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homotypic interactions essential for tethering to AC through their CD31-adhesive mode 
signals. Also, reduced CD31 by Kgp on viable MØ might be the reason for poor 
recruitment to AC NØ seen in vertical chemotaxis assay.  However, a previous study 
reported that the cleavage of CD31 alone might not be sufficient for cell uptake but may 
also require exposure of PS at the surface of AC NØ 188.  
Collectively these data correlate with those presented here, which have been validated 
using a series of established AC clearance receptors CD14, CD36, ICAM-3 and CD91.  
Though the presence of other AC clearance receptors was found on MØ, the absence of 
CD14 due to the gingipain cleavage might be an explanation for poor AC clearance 
reported in PD patients. In addition, CD31 might have also participated in migrational 
events of the phagocytes with some of the previous studies specifically underscoring 
CD31 for the ability to regulate directional migration. Together, these receptors might have 
played a possible mechanism for the presence of relatively high number of necrotic NØ 
compared with AC NØ reported in the gingival crevice and periodontal pockets in PD 
patients 356. Of course, it is possible that gingipains also cleave other receptors that have 
not yet been identified but which function in apoptotic cell clearance. 
Evidence 3 – Impact of gingipains on MØ inflammatory mediators 
The data presented here suggest that both LPS and gingipains from P.gingivalis induce 
similar levels of TNF-α, however, LPS from P.gingivalis only induces responses in THP-1 
DS MØ whereas gingipains induced responses in both the THP-1 VD3 and THP-1 DS MØ 
models. This might be due to a difference in expression pattern recognition receptors 
present in the THP-1 models.  For example, TLR4 is more readily detectable in DS MØ 
compared with THP-1 or THP-1 VD3 MØ and this may explain why P.gingivalis LPS 
induces responses only in those models expressing TLR4. However similar levels of 
CD14 expression were previously observed in both the differentiated MØ models 706. 
Interestingly, multiple reports have proposed that TLR2 rather than TLR4 may be critical 
for host response to infection with P. gingivalis 119, 774. Furthermore, due to the highly 
heterogeneous nature of the lipid A of P.gingivalis LPS, activated primary bone marrow 
cells obtained from both TLR2 and TLR4 knockout mice suggest a functional interaction of 
P.gingivalis LPS with both TLR2 and TLR4 147. In addition previously it has been reported 
that TLR2 is downregulated on both VD3 and PMA alone differentiated MØ derived from 
THP-1 cells 445. Collectively, these data may indicate that P.gingivalis LPS-mediated 
responses may be regulated through TLR4 rather than TLR2 in the THP1-derived MØ 
used in this study. 
Previous studies confirm that both TLR4 and TLR2 levels are unaffected on gingipain-
treated murine MØ and for TLR4 levels on human monocytes 626, 627. These previous 
Discussion 
198 
 
finding may support with the data presented here which suggests that gingipains elicit 
TNF-α expression in both THP-1 MØ models indicating the effect might be both TLR4- 
and TLR2-independent. Notably, gingipain responses might be dependent on CD14 for 
inducing inflammation, as Kgp-treated MØ exhibit a lower production of TNF-α compared 
with RgpB-treated MØ suggesting a rapid clearance of CD14 proteolytically by Kgp might 
downregulate synthesis of TNF-α. This may agree with previous findings that indicate a 
CD14 reduction on human monocytes treated with gingipains also induced lower TNF-α 
production following LPS stimulation 627. Taken together, the data here further support the 
hypothesis that MØ CD14 cleavage by gingipains attenuates cellular recognition of 
bacterial components in addition to reducing the tethering and migration capacity of 
phagocytes compelling them to mediate a dominant inflammatory response in the host 
immune system.  
7.2 Mechanistic differences in AC NØ response to LPS and gingipains  
MØ ingestion of AC NØ inhibits production of pro-inflammatory mediators and enhances 
anti-inflammatory cytokine production through autocrine/paracrine mechanisms 329. This is 
in agreement with the findings presented in this study which suggest that AC NØ ingested 
by MØ mediate increased TGF-β and IL-10, at the mRNA level, and reduced TNF-α at the 
protein level. Interestingly, AC NØ inhibit TNF-α levels induced by Pg LPS but not 
gingipains. Similar results were seen using LPS/gingipain-induced TNF-α inflammation in 
MØ ingesting AC B cells. This highlights that gingipains being inflammatory the AC fails to 
turn off the inflammation unlike in LPS-induced MØ. Subsequently AC might act 
differentially in regulating the modulation of pro-inflammatory cytokines in LPS compared 
with gingipain-induced inflammation in MØ.  
Persistence of AC in CD14-deficient mice fails to elicit a pro-inflammatory response, 
however, the study also suggested that anti-inflammatory ticking is still present in spite of 
reduced tethering and removal of AC 282. This suggests that AC binding can be separated 
from the ability of AC to exert anti-inflammatory effects (i.e. it is possible to separate the 
“tether” and “tickle”).  However, the data obtained here indicate that CD14 cleaved 
gingipain-treated MØ ingestion of AC NØ lose anti-inflammatory cytokines. This suggests 
that gingipains may inhibit the production of anti-inflammatory cytokines through CD14 or 
other receptors cleavage on MØ in response to AC and thus results in the persistence of a 
pro-inflammatory condition. Taken together, the data presented here suggest that AC NØ 
may regulate MØ responses through CD14 for triggering both pro- and anti-inflammatory 
properties to prevent the inflammation induced by P.gingivalis components and that this 
might be a reason for the dominant TNF-α response in periodontitis patients which is 
reported. 
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Figure 76 summarises the function of MØ in a gingipain-exposed environment where 
phagocytes are either altered, through modifying their AC clearance receptors or their 
phagocytic activity, thereby governing aberrant inflammatory response in PD patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 76: Possible defective AC clearance mechanism involved in PD  
1. Gingipains from P.gingivalis cleave CD14 from MØ. 2. The cleavage of CD14 receptor 
together with degradation of other chemokine (e.g. IL-8) receptors on MØ modulates MØ 
migration towards AC. 3. Reduction of CD14 inhibits tethering and phagocytosis of AC by 
MØ resulting in AC becoming necrotic. 4. Failure of clearance of AC together with the 
inflammation induced by LPS and gingipains might contribute to enhanced and chronic 
inflammation within the PD patients’. 
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7.3 Conclusion 
This thesis originally proposed the hypothesis that in the periodontitis tissue 
microenvironment, MØ are defective for migration, tethering and phagocytosing AC via 
cleavage of receptors associated with recognition and phagocytosis by MØ, leading to a 
dominant inflammatory response in PD patients. This study used an in vitro AC clearance 
model utilising THP-1 differentiated MØ and primary AC NØ to study the effect of the 
P.gingivalis virulent proteases, gingipains, on MØ function. This was to model the context 
of destructive PD. The data presented here suggest that among a panel of AC clearance 
receptors gingipains preferentially cleaved CD14 at the surface of MØ as well as CD31, a 
‘don’t-eat me’/tethering receptor. Additionally, gingipain-treated MØ demonstrate poor 
directional migration and phagocytosis activity (i.e. tethering and uptake) towards AC NØ. 
This might be due to the lack of CD14 on MØ exposed to gingipain regulating the 
tethering capacity on MØ though the reason for defective migration is still not clear. 
Furthermore the findings are in agreement with previous work which indicate that CD14 
acts as a tethering receptor for AC. Notably the dominant inflammatory response in 
gingipain-treated MØ fails to be turned off by AC even though AC NØ prevent LPS-
induced inflammatory responses in phagocytes. In an inflammatory capacity, AC NØ 
might regulate anti-inflammatory responses in MØ through CD14-dependent ingestion of 
AC. Hence the work done here contributes to the literature of defective AC clearance in 
chronic inflammatory PD and advances current knowledge of the pathophysiology of the 
periodontal disease. The profound effect of CD14 degradation by Kgp on MØ migration is 
also a route by which in vivo gingipains may support defective AC clearance.    
The findings from this work are of interest in the study of the complex process of CD14-
mediated inflammation and CD14-mediated resolution of inflammation in physiology and 
pathophysiology. Future work will build on the data obtained here to apply this knowledge 
to understanding various inflammatory and autoimmune diseases and, in so doing, may 
contribute to the development of new therapeutic strategies. 
7.4 Future work 
Whilst the work presented here extends significantly the knowledge in the field, there are 
a number of areas where additional research may address gaps in knowledge that 
remain.   Further research could be conducted in the following areas: 
1) The discovery that anti-CD14 blocking antibodies (MEM-18 and 61D3) applied to 
phagocytes inhibit MØ ligand-binding responses of AC and also LPS binding 
suggests that both LPS and AC binding patterns share the same epitopes or 
neighbouring sites on CD14 324. Additionally, using a panel of anti-CD14 blocking 
antibodies or point mutations has identified the crucial CD14 regions involved in 
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the AC binding to MØ 36. With this knowledge in mind, a direct analysis can be 
performed to study whether gingipains bind CD14 and, if so, do they share 
identical or nearby epitopes on MØ CD14. The work presented here and previous 
work suggest that gingipain cleaved CD14 MØ caused hyporesponsivity for the 
production of pro-inflammatory cytokines 626. Therefore, gingipain effects on CD14 
signalling partners to induce cellular responses could be further characterised.  
2) The data presented here indicate that TLCK inhibits the proteolytic activity of 
gingipains in CD14 cleavage. Furthermore, the knowledge from previous studies 
predicts that 21 Arg and 9 Lys bonds are the possible cleavage sites in CD14 627, 
628, 742. Therefore, proteomic studies using mass spectrometry might provide an 
understanding of the specific cleavage sites in CD14. If the identification of the 
cleaved peptides confirms the specific cleavage sites, investigation of this peptide 
region in MØ chemotaxis and related biological activity could be undertaken. 
3) The work within this study indicates that Kgp induces less TNF-α compared with 
RgpB treatment and that AC NØ fail to prevent the inflammation induced from 
either of the gingipains. This is despite CD14 presence in RgpB treated MØ 
compared with Kgp at 1h. Earlier studies have shown that CD14-deficient mice, 
despite the chronic presence of AC, exhibited no overt TNF-α production 282. 
Therefore, CD14–mediated inflammatory signalling should be further explored to 
determine the role of CD14-dependent stimulation on inflammatory mediators in 
response to AC. 
4) While mCD14 has been studied widely for its clearance role, CD14 proteolysis by 
gingipains might also function to release the sCD14. The participation of sCD14 in 
triggering or blocking the clearance of AC is unknown. However previous studies 
have shown that gingipains degrade both mCD14 and sCD14 from human 
monocytes. Notably, sCD14 acts as a soluble mediator in AC tethering to enable 
their uptake by MØ282, 627. Another study also demonstrated that on exposure to 
P.gingivalis fimbriae, human gingival epithelial cells failed to stimulate cytokines 
due to the weaker expression of mCD14 and their inability to utilise sCD14 775. 
Therefore, sCD14 detection in the culture supernatant of MØ treated with 
gingipains would be valuable. Further, it would be important to analyse whether 1) 
sCD14 promotes AC clearance and 2) if gingipains bind to sCD14 and whether 
this acts as an anti-inflammatory or pro-inflammatory strategy mediating AC 
clearance.  
5) Similar to AC NØ, the AS derived from apoptotic NØ also inhibit the inflammation 
induced by P.gingivalis LPS on MØ in this study. Characterisation of the pro-
resolving mediators derived from AC NØ or their AS which modulate inflammation 
might provide a broad view of the mechanisms involved in achieving the resolution 
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phase of inflammation for application in periodontal therapy and other NØ related 
pathologies.  
6) In vivo studies using P.gingivalis-infected mice with specific gingipain inhibitors 
resulted in improved periodontal health with reduced bone resorption and tissue 
destruction776-779. Therefore, using a combined CD14-mediated therapy along with 
the existing gingipain treatment might act as a possible approach which targets the 
reprogramming of the inflammatory cascade in periodontal disease. Indeed it 
would also be useful to ensure that gingipain inhibitors restore effective AC 
clearance in vivo and potentially clinical trials in this area could be undertaken.
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